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ABSTRACT 
Background 
Quitting smokers gain weight, this offsets some advantages of quitting and may 
increase risk of type 2 diabetes above that of continuing smokers. The extent of 
weight gain, the associated characteristics, and management that will not hinder quit 
success are unclear. 
 
Method 
Examination of weight gain in an 8year prospective cohort. 
 
Feasibility trial of smoking cessation combined with a very low calorie diet(VLCD) or 
individualised diet and physical activity planning(IDAP) with usual care.  
 
Results 
Abstainers gained 9kg, 7kg more than smokers over 8years. Underweight and obese 
smokers gained most.  Less weight gain (1.7kg) was associated with higher baseline 
alcohol consumption (14units/week vs. none).  
 
Recruitment from general practices was difficult and limited by VLCD 
contraindications.  Following training, primary care nurses competently delivered 
specialist dietary interventions.  The control condition was generally unacceptable. 
Half those on the VLCD were non-adherent.  Mean weight change was 
+0.7kg(control), -1.3kg(IDAP), -7.1kg(VLCD) and +0.4kg for abstinence. We found 
 
 
lower cigarette cravings in the VLCD than control arm, but no difference in IDAP and 
unrelated to hunger. Relapse was greatest in the VLCD and least in the control.  
Conclusion 
Weight gain after cessation is important and IDAP but not VLCD is a feasible 
approach for tackling this.  
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1. BACKGROUND: WHY AND HOW 
SHOULD WE ADDRESS THE PROBLEM 
OF WEIGHT GAIN ASSOCIATED WITH 
SMOKING CESSATION? 
This thesis begins with a review of the literature on post cessation weight gain, its 
causes and consequences. It then presents original analysis of weight gain from a 
prospective eight year cohort of continuous abstainers, smokers and „relapsers‟. It 
describes the protocol and presents the results of a randomised controlled feasibility 
trial designed to test dietary interventions to prevent smoking cessation related 
weight gain.  
 
1.1. The undisputed benefits of smoking cessation 
In the year 2000, 4·83 million premature deaths worldwide were attributable to 
smoking.  Cardiovascular disease (1·69 million deaths), chronic obstructive 
pulmonary disease (0·97 million deaths), and lung cancer (0·85 million deaths) were 
the leading causes of death from smoking (Ezzati & Lopez, 2003).  
 
The causal relationships between smoking and numerous diseases have been 
established in the 2004 US Surgeon General‟s review (Table 1). This clearly defined 
criteria for causality (Table 2) and incorporated 1600 key articles. Where evidence 
was insufficient to infer causality three further categories were defined on the 
strength of evidence. These were „suggestive but not sufficient to infer a causal 
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relationship‟, „inadequate to infer the presence or absence of a causal relationship‟ 
and „suggestive of no causal relationship‟.  
 
Causality is bolstered by the removal of the factor of interest resulting in reduced risk 
of or improvement in a disease. In 1990, the US Surgeon General reviewed a large 
body of observational studies and clinical trials with respect to the health benefits of 
stopping smoking. The conclusions were as follows:  
 Smoking cessation has major benefits for men and women of all ages, with 
and without smoking related diseases, 
 Former smokers live longer than continuing smokers, those quitting before the 
age of 50 have half the risk of dying in the next 15 years,  
 Smoking cessation decreases the risk of lung cancer, other cancers, heart 
attack, stroke, chronic lung disease and low birthweight babies.  
Since then, evidence of the benefits of smoking cessation has continued to mount. A 
50 year prospective cohort of British male doctors showed stopping smoking at age 
60, 50, 40, or 30 years resulted in a gain of approximately three, six, nine and 10 
years of life expectancy respectively. Among the men born around 1920, cessation at 
age 50 halved the risk of premature death, and cessation at age 30 avoided almost 
all of it (Doll et al., 2004). 
 
A systematic review of smoking cessation in patients with coronary heart disease 
showed a 36% reduction in all cause mortality (relative risk (RR) 0.64, 95% CI (0.58, 
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0.71)) in quitting smokers compared to continuing smokers (Critchley & Capewell, 
2003). However, this review only included studies where follow-up was 2 years or 
more so risk during the first two years of quitting was not assessed. 
 
The increased risk of non fatal acute myocardial infarction in current smokers 
compared to never smokers (odds ratio (OR) 2·95, 95% CI (2·77, 3·14)) fell to 1·87 
(1·55, 2·24) within three years of quitting. An excess risk remained 20 or more years 
after quitting (1·22 (1·09, 1·37)). In light smokers (1-9 cigarettes/day) the risk was 
elevated at one to three years post quit beyond that of current smokers, but reduced 
after 3 years (Teo et al., 2006). 
   
Data from national statistics and case control studies showed the risks of developing 
lung cancer by the age of 75 were reduced from 16% in continuing smokers to 10%, 
6%, 3%, and 2% for men who stopped at ages 60, 50, 40, and 30 respectively. In 
women, they reduced from 10% to 5% and 2% in those who stopped at age 60 and 
50 respectively (Peto et al., 2000).  The risk of lung cancer in a prospective cohort of 
women reduced with increasing duration of abstinence (Ebbert et al., 2003). Death 
from lung cancer reduced in those who quit smoking (Anthonisen et al., 2005).  
 
The impact of smoking cessation on lung function was first clearly demonstrated in 
an eight year prospective study of 792 working men recruited in 1961, Fletcher and 
Peto found that forced expiratory volume in 1 second (FEV1) gradually falls over a 
lifetime. In most non smokers and in many smokers, clinically significant airflow 
obstruction never develops. However, in those susceptible to chronic obstructive 
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pulmonary disease (COPD), smoking causes permanent obstructive airway changes. 
Fletcher and Peto found that if susceptible smokers quit smoking, although their 
current reduced lung function was permanent, the average rate of decline in FEV1 
thereafter, reverted to follow a normal trajectory (Fletcher and Peto, 1977). More 
recently, a prospective cohort in those with COPD who quit 11 years previously 
showed FEV1 declined by 30.2ml/year in men and 21.5ml/year in women. Whereas 
in those who continued to smoke, FEV1 declined by 60.1ml/year and 54.2ml/year, in 
men and women respectively (Anthonisen et al., 2002). 
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Table 1. Causal relationships between smoking and disease established in 2004 by the US Surgeon General‟s review  
Evidence sufficient to infer causality Suggestive but not sufficient to infer a 
causal relationship 
Inadequate to infer the presence or absence 
of a causal relationship 
Suggestive of no causal relationship 
Chronic Obstructive Pulmonary disease 
(COPD) 
Ischaemic heart disease 
Stroke 
Aortic aneurism 
Atherosclerosis 
Peptic ulcer (Helicobactor (H.) Pylori 
positive) 
Pneumonia  
Osteoporosis (post menopausal) 
Hip fracture 
Periodontitis  
Cataract 
Reduced fertility 
Premature rupture of membranes 
Placenta previa 
Placental abruption 
Preeclampsia 
Foetal growth restriction 
low birth weight 
Sudden infant death syndrome 
Surgical complications 
Cancers:  
– Lung  
– Oral cavity/pharyngeal  
– Laryngeal  
– Oesophagus  
– Bladder  
– Kidney  
– Stomach  
– Pancreas  
– Cervical  
– Endometrial 
– Myeloid leukaemia 
 
Acute respiratory infections 
Chronic respiratory disease in offspring 
(maternal smoking during pregnancy) 
Erectile dysfunction 
Ectopic pregnancy 
Peptic ulcer complications 
Oral clefts 
Dental caries (root surface) 
Macular degeneration 
Graves disease opthalmology 
Low bone density in older men 
Cancers:  
– Colorectal  
– Liver  
– Non cardia gastric cancers 
 
Asthma  
Glaucoma 
Dental caries (coronal) 
Peptic ulcer (H. Pylori negative) 
Idiopathic pulmonary fibrosis 
Poor sperm quality 
Congenital malformations 
Childhood growth (maternal smoking) 
Childhood neurocognitive 
development (maternal smoking) 
Reduced bone pre-menopausal bone 
density 
Fractures at sites other than the hip 
Cancers: 
– Ovarian 
 
Diabetic retinopathy  
Cancers: 
– Prostate 
– Adult brain  
– Breast 
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Table 2. Definition of causality used by US Surgeon General, 2004 
 
 
1.2. Weight gain as a consequence of smoking 
cessation 
The 1990 US Surgeon General‟s review also showed that approximately 80% of 
those who stop smoking will gain weight, but concluded that: 
  
 “The health benefits of smoking cessation far exceed any risks of the average 
 5-pound (2-3kg) weight gain or any adverse psychological effects that may 
 follow quitting.” 
 
However, while there continues to be overwhelming evidence that smoking cessation 
reduces morbidity and mortality despite weight gain, more recent evidence 
demonstrates post cessation weight gain may be considerably greater than this early 
estimate. This presents us with a challenge which needs addressing for several 
reasons which I will elucidate in detail in this chapter. Firstly, for some this weight 
gain presents a barrier to making a quit attempt and is a reason to relapse. Secondly, 
those who gain weight receive less health benefit from smoking cessation than those 
who do not. Thirdly, there is emerging evidence of some increased medium term 
health risks in those who quit compared to that those who continue to smoke. For 
some diseases there appears to be an adaptation period before the full benefits of 
cessation become apparent, when ill health and health risk may in fact increase 
Criteria for causality (USDHHR, 2004) 
1. Consistency of evidence, 
2. Strength of association,  
3. A high degree of specificity,  
4. Temporality (cause must precede effect) 
5. Coherence, plausibility, and analogy such that a claim can be supported or refuted by plausible biological 
mechanisms,   
6. A biological gradient or dose-response relationship  
7. Evidence from conditions which might imitate a randomised ‘natural’ experiment 
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beyond that of continuing smokers. This may be due to weight gain. If this proves to 
be the case, strategies to prevent weight gain, provide treatment and reduce risk 
during this period of heightened susceptibility may maximise the benefits of quitting 
and help more smokers to quit.  
 
The rest of this chapter discusses these issues more fully and provides the rationale 
for our investigations, a cohort analysis and a randomised controlled feasibility trial, 
during this period of doctoral study. These contribute to addressing the problem of 
smoking cessation related weight gain.  
 
1.2.1. How much weight is gained? 
To obtain a more recent estimate of the amount of weight typically gained on 
smoking cessation we searched Medline, Embase and PsycINFO from 1989 to 
present day for review articles. We did a title search and used the terms „weight‟ AND 
(„smoking cessation‟ OR „smoking‟). We limited our search to articles in English. We 
excluded reviews where authors made no attempt to describe how they searched the 
literature or selected articles. We identified three eligible review articles and 
appraised them, together with the 1990 US Surgeon‟s General report. We used the 
critical appraisal skills programme (CASP) tool for systematic review articles.   
 
We found that none of these reviews assessed the validity of included studies or 
addressed the heterogeneity between them adequately (Table 3). For example, in 
the Klesges review (Klesges et al., 1989) estimated mean weight gain was derived 
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from studies reporting it at anything from four days to 40 years post quit. Weight gain 
does not reach its full extent after four days and so this combined estimate is hard to 
interpret.  In addition, estimates included both studies that measured abstinence by 
point prevalence (abstinence verified at a single point in time) and continuous 
abstinence (reported continuous abstinence verified at follow-up).  A prospective 
cohort study has shown that continuously abstinent participants gained significantly 
more weight at one year (5.9kg compared to 3.0kg respectively) than those who were 
point prevalent abstinent at one year (Klesges et al. 1997). Estimates of weight gain 
that include variable length of abstinence and point prevalence abstinence may 
include those quit for too short a time to demonstrate the full extent of weight gain.  
 
Therefore, we sought prospective cohort studies using continuous abstinence criteria 
to define smoking status from a common time point of abstinence. We searched the 
databases described above using terms: (weight gain AND smoking cessation) AND 
(cohort OR prospective). We also searched our own reference library that contained 
randomised controlled trials reporting on weight change during smoking cessation. 
For another project we had conducted a meta-analysis of weight gain at follow up in 
randomised controlled trials using continuous abstinence criteria, this showed weight 
gain after one year to be 4.8kg (Aubin et al. 2011, unpublished). We only found two 
longer term studies since the Klesges et al. review in 1989 which met these criteria. 
They showed four and five years post cessation weight gain to be 8.9kg (Daughten et 
al., 1999) and 8.1kg (O‟Hara et al., 1998) respectively. A further analysis of the Lung 
Health Study (O‟Hara et al., 1998) was done using an instrumental variable approach 
which takes into account unmeasured confounders between smokers and quitters, 
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raised this estimate to 9.7kg ( Eisenberg &  Quinn, 2006). Therefore, recent 
prospective studies over 4-5 years show a weight gain in quitters of 8-10kg, 
compared to 1.6kg in continuing smokers (O‟Hara et al., 1998).  However, these are 
the only long term prospective cohort studies which we found that reported weight 
gain in continuously abstinent smokers. 
 
1.2.2. Does this weight gain continue indefinitely? 
The Klesges review found reasonably consistent evidence from 24 out of 29 cross 
sectional studies that smokers weigh less than non smokers. Eight out of nine cross 
sectional studies showed smokers weigh less than ex-smokers. However, whether 
ex-smokers weigh more than non smokers is less clear (2 out of 3 cross sectional 
studies show that they do) (Klesges et al., 1989). Therefore, debate exists over 
whether weight gain in quitters is permanent or temporary.  It has been hypothesised 
that weight gain in quitters only continues until it catches up with that of the never 
smoking population (this could be explained by the „set point‟ theory of weight gain, 
which is discussed later in the section 1.3 of this chapter).  
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Study Klesges et al.,1989 US Surgeon General., 1990 Froom et al.,1998 Pistelli et al, 2009 
Was the question 
addressed? 
Yes. Although the article did seek to answer 
several questions at once. We have taken 
the ones relevant to our discussion 
separately  
Yes. Although other questions were 
addressed method for this question was 
clear 
Yes. Article tried to answer several different 
questions 
Yes. Article tried to answer 
several different questions 
Is it likely that important 
relevant studies were 
missed? 
Unclear. No method was described, although 
a large number of studies were identified 
Unclear. Method of searching not 
described 
Yes. Only searched medline, no attempt to 
obtain data from unpublished studies. Not 
all relevant MeSH terms were used i.e. used 
‘smoking’ but this did not cover ‘smoking 
cessation’  
Yes. No systematic selection 
procedure was 
applied. Large, population 
studies or large clinical trials 
from United 
States and Europe were 
preferably selected. 
Was inclusion criteria for 
studies appropriate? 
Not defined Yes. Prospective cohorts after 1970, with 
control of continuing smokers, at least 1 
month of follow up and 10 participants. 
Excluded studies where weight loss 
interventions were used or relapsed 
subjects were included in analysis  
Not defined As above 
Was validity of included 
studies addressed? 
To a degree. Narrative discussion mostly as 
an explanation for those which did not 
provide consistent results. No evidence of 
each study being formally assessed or 
excluded on the basis of its validity 
Not beyond inclusion/exclusion described 
above 
No No 
Were the results 
homogeneous or was 
heterogeneity adequately 
addressed? 
Discussed but not adequately addressed e.g. 
no sub-analysis 
Variable length of follow up not addressed, 
but means adjusted for sample size 
Not addressed No.  Cross sectional and 
longitudinal studies were 
considered with equal merit. 
Some different methodological 
issues were discussed 
What were the results? 41 prospective studies involving 110,000 
participants were included. 76% show 
smokers who quit gain weight.  
Studies ranged in follow-up from 4 days to 
40 years, mean follow up 2 years 11 months. 
Mean weight gain 2.9kg (range 0.3kg – 8kg) 
19% of these studied relied of self reported 
smoking status 
46% were in a select sample 
37% either had small samples or high 
attrition rates 
15 prospective studies, median follow up 
of 2 years.  
 
Weight gain among smokers who quit was 
2.1kg (range 0.7-5kg) compared to 0.4kg 
(range 0-1.6kg) in continuing smokers.  
 
Relative risk of weight gain 1.45, 95% CI 
[1.31, 1.75]. 
  
Weight gain >9kg is rare 
Narrative cited nine prospective studies and 
concluded sustained quitters gain on 
average 5kg more than continuing smokers, 
although how this figure was reached and 
over what period of time this refers to is 
unclear. 
No attempt was made to 
combine findings into a mean 
estimate of weight gain. Authors 
concluded “most smokers who 
quit experience a weight gain, 
particularly within one year, and 
it may persist up to 8 years after 
smoking cessation”.  
 
 
Table 3. Critical appraisal of systematic reviews addressing the amount of post cessation weight gain 
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The Froom review (Froom et al., 1998) attempted to answer this question concluding 
evidence was conflicting.  However, the authors of this review did not appraise the 
validity of the studies or consider methodological differences between then. We 
considered the relevant studies cited in the Froom review and searched for recent 
ones in the databases described above. We did a keyword search, using the MeSH 
terms “weight AND (never-smokers OR non-smokers) AND (abstainers OR 
abstinence OR former OR ex-smokers OR quit*) AND (cross sectional) OR 
(prospective OR cohort OR longitudinal OR follow-up)”. 
 
We found six large cross sectional studies with relevant data (Table 4). Five 
examined gender differences, four examined differences according to duration of 
abstinence and three provided combined data of their whole sample. 
 
Two out of three of the studies reporting on combined data found BMI was similar in 
ex-smokers and never smokers (Klesges et al., 1991, Mizoue et al., 1998) one study 
found it was higher in ex-smokers than never smokers (Chen et al, 1993).     
 
In three out of the five studies examining gender, women had a similar BMI to never-
smokers, whereas men had a higher BMI (Klesges et al., 1991, Molarius et al., 1997, 
Travier et al, 2009).  Although in one of these studies women who had been 
abstinent for less than one year, and only men who had been abstinent for more than 
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one year, had a higher BMI than never smokers. Men who had been abstinent for 
less than one year had a lower BMI than never smokers (Klesges et al., 1991). 
 
One study showed that women who had been abstinent for less than 10 years had a 
higher BMI than never smokers, and women abstinent for more than 10 years had a 
lower one. The same study showed the opposite was true for men. Those abstinent 
for more than 10 years had a higher BMI, and those abstinent for less, had a lower 
BMI than never-smokers (Flegal et al., 1995). 
 
The three studies showing a higher BMI in male ex-smokers compared to male 
never-smokers showed that this difference was between 0.4-0.6kg/m2, which is 
clinically important (Klesges et al., 1991, Molarius et al., 1997, Travier et al, 2009). 
 
Therefore, cross-sectional data suggests that the BMI of women who have been 
abstinent for a relatively long period is similar to that of never-smokers, but in short 
term abstainers it may be higher. Whereas men who have been abstinent for a long 
time have a BMI that exceeds never-smokers and those abstinent for a shorter period 
have a lower BMI than never-smokers.   
 
Some of the inconsistencies in these cross sectional studies, in particular those that 
show BMI in abstainers does not exceed former smokers, may be due to the 
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inclusion of shorter periods of abstinence. Prospective studies that track change in 
BMI from a specific quit date may be more accurate. 
 
We found five prospective studies, all of which gave consistent evidence that 
increase in weight and BMI during the first five years post cessation exceeds that of 
never smokers. In one study (Munafo et al., 2009) the increase in BMI after five years 
of abstinence was not statistically different to that of never smokers over the same 
period of time. However, the mean difference was 0.3kg/m2, which is clinically 
relevant.  
 
Two studies (Williamson et al., 1991, Munafo et al., 2009) reported on BMI at 
baseline and at the end of study. They both found that quitters at baseline had lower 
BMIs than never smokers, but BMIs after 13 years were not statistically significantly 
different but the study by Munafo, in men only, did show a clinically relevant mean 
difference of 0.6kg/m2 (Table 5).  
 
Therefore, findings from prospective studies suggest initial rapid weight gain may 
eventually, after a decade or more, result in a BMI which is not statistically different to 
never-smokers, but sufficiently different to be of clinical relevance. This is consistent 
with the cross-sectional evidence of long term male abstainers. Observational data, 
at least for men, does not substantiate the set-point hypothesis.
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Cross-sectional study Klesges et al., 1991 Chen et al., 1993 Flegal et al., 1995 Molarius et al., 
1997 
Mizoue et al., 1998 Travier et al, 2009 
Was the study sample 
clearly defined? 
 
Yes. Second National 
Health and Nutrition 
Examination Survey 
(NHANES II) 
Yes Yes. NHANES III Yes. 42 
populations in the 
WHO MONICA 
project 
Yes Yes. European 
Prospective 
Investigation into 
Cancer and Nutrition 
(EPIC) 
Was a representative 
sample achieved (e.g. 
was the response rate 
sufficiently high)? 
Yes. 10,778 over 18 
years old nationwide 
1633 white Canadian 
men and women 
Yes n=5837 69 000 men and 
women between 
35 and 64 years 
7324 working 
population of men 
469, 543 men and 
women 
Was exposure (smoking 
status) measured 
accurately? 
Self reported recall 
 
Self reported recall 
 
Self reported recall up 
to 10 years previously 
 
Self reported 
recall 
 
Self reported recall 
 
Self reported recall 
 
Was outcome 
measured accurately? 
Measured BMI Measured BMI Measured BMI Measured BMI Measured BMI Measured BMI 
Were confounders 
adjusted for? 
Yes Yes Yes Yes Yes Yes 
What were the results 
and precision of these? 
BMI in never smokers 
men: 25.5, women: 
25.8 
Quit< 1 year men: 25.2, 
women: 26.6 
Quit >1year men 25.9, 
women: 25.8  
Never and long term 
quitters BMI not 
significantly different.  
Ex smokers (>6months) 
weighed more than 
never smokers.  
BMI less in women with 
greater duration of 
abstinence (significant 
association) 
BMI in never smoker 
men: 29.6 (0.35) 
women: 27.2 (0.26) 
Quit <10years men: 
27.9 (0.27) women: 
27.7 (0.48) 
Quit>10years men: 
27.3 (0.24) women: 
26.7 (0.26) 
Mean difference 
in BMI (95% CI) 
between never 
smokers and ex-
smokers men: 0.5 
(0.4, 0.6) women: 
0.1 (-0.1, 0.3) 
BMI of former 
smokers and never 
smokers not 
significantly 
different, 2-4 year 
quitters higher BMI 
than never smokers 
Mean difference in BMI 
(95% CI) between never 
smokers and ex-
smokers men: 0.55 
(0.44, 0.65) women:   
-0.02 (-0.24, 0.19) 
Table 4. Critical appraisal of cross sectional studies comparing BMI in quitters with never smokers 
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Cohort study Williamson et al., 1991 Froom et al., 1999 Janzon et al., 2004 Reas et al., 2009 Munafo et al., 2009 
 
Representative 
sample? 
 
Yes 
N=9332 
Males only 
N=1338 
Females only 
All participating in the 
case control  Malmo diet 
and cancer study 
N=10902 
Yes 
N=1300 
Males only 
N=2512 
Common 
starting point? 
For weight but not for smoking i.e. not 
from a set quit date 
For weight but not for 
smoking i.e. not from a set 
quit date 
Yes, actively smoking or 
never smoker 
For weight but not for smoking 
i.e. not from a set quit date 
For weight but not for smoking i.e. 
not from a set quit date 
Adequate 
follow up             
(mean)? 
13 years 2.6 years 11 years 11 years 13 years 
Objective 
exposure? 
Self report recall Self report recall Self reported recall Self reported recall Self report recall 
Objective 
outcome?  
Measured weight Measured weight Measured weight Self reported BMI Measured weight 
Adjustment for 
confounding? 
Yes Yes Not adjusted for case or 
control 
 
yes Yes 
Results & 
precision of 
results? 
Mean difference (95%CI) between weight  
gain (kg) in continuing smokers and: 
 men women 
Recent 
quitters 
(<1yr)  
2(0.6-3.4) 1.1(-0.4, 2.6) 
Sustained 
quitters > 1 
year 
2.8 (2, 3.6) 3.8(2.9, 4.7) 
Former 
smokers 
>12 years 
1.2(0.3, 1.6) 1.6(0.8, 2.4) 
Never 
smokers 
0.9 (0.3, 1.5) 1.4(0.9, 1.9) 
Smoking cessation had raised BMI from 25.7 to 
27.7 in women and from 26.5 to 27.5 in men to 
never smokers 28.3 (women) and  27.6 (men) 
 Mean 
(SD) 
increase 
in BMI 
(kg/m2) 
Quit after 
study entry 
0.99(0.18) 
Quit before 
study entry 
0.19(0,1) 
Never 
smokers 
0.07(0.06) 
 
Mean (SD) increase in 
weight (kg) 
Quit < 1yr 7.3 
(0.63) 
Quit 1-2 yrs 8.8 
(0.77) 
Quit 2-5yrs 7.9 
(0.61) 
Quit 5-10yrs 7.7 
(0.73) 
Quit >10yrs 6.2 
(0.72) 
Never 
smokers 
3.9(0.1) 
 
Mean (SD) 
increase in 
BMI (kg/m2)  
men women 
Recent 
quitters 
(<5yr)  
2.6(0.30) 2.4(0.34) 
Sustained 
quitters > 
5 year 
1.9(0.22) 2.1(0.22) 
Never 
smokers 
1.6(0.15) 1.8(0.15) 
No significant differences between 
long term quitters and never smokers 
BMI 
(kg/m2) 
from 
Quitters  Never 
smokers 
Baseline 
to 
25.70 
(3.64) 
26.96 (3.56) 
<4 years 
post quit 
27.13(3.64) 27.08(3.60) 
> 5 years 27.46(3.90) 27.12(3.64) 
>9 years 27.61(3.64) 26.97(2.86) 
 
Attrition 
adequately 
addressed?  
No Yes Yes No Yes 
Table 5. Critical appraisal of cohort studies comparing change in weight and BMI in quitters with never smokers 
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1.2.3. What characteristics are associated with this 
weight gain? 
Although it has been reported that 80% of quitters gain weight (USDHHR, 1990), this 
leaves a potential 20% who do not, and there is a wide variation in the amount of 
weight gained. Several studies that follow biochemically validated continuous 
abstainers identify “supergainers”, quitters who gain an excessive amount. In a meta-
analysis of one year follow-up of trial data (Aubin et al., unpublished) 13% of quitters 
gained more than 10kg. In a four year cohort, 7% gained more than 18kg (Daughten 
et al., 1999) and in a 5 year cohort 4% gained in excess of 20kg (O‟Hara et al., 
1998).  
 
It is important to identify characteristics that are associated with greater weight gain 
for a couple of reasons. Firstly, on an individual level, preparing quitting smokers with 
realistic expectations of weight gain may be an important element of success. We 
know from weight loss interventions in obese participants that many people set 
themselves unrealistic expectations of weight loss, become disheartened when they 
fail to reach their target, and so give up (Foster et al., 1997). Also, there is some 
evidence that those who are counselled to accept weight gain have an increased 
chance of stopping smoking in the medium term. Increased abstinence rates were 
shown at 6 months (but not at 12 months) in a randomised controlled trial comparing 
cognitive behavioural therapy (CBT) to accept weight gain with usual care (Perkins et 
al., 2001). But a later study could not replicate these findings (Levine et al., 2010).  
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Secondly, those who put on the most weight will have a greater increase in health 
risks associated with weight gain such as diabetes and cardiovascular disease than 
those who gain less. Therefore, although smoking cessation independently reduces 
these risks, they rise again, although to a lesser extent, with post cessation weight 
gain. Therefore, in a climate of limited NHS resources, those who gain the most 
weight are the ones for who weight control interventions should be targeted.   
 
Three of the reviews described in previous sections (Klesges et al., 1989, Froom et 
al., 1998, Pistelli et al., 2009) also examined factors associated with greater weight 
gain.  They included cross sectional and longitudinal studies. We chose to pull out 
from these the longitudinal studies which measured weight change between two time 
points, rather than the cross-sectional studies, which may have recalled weight 
inaccurately. We did not include those factors, such as physical activity and dietary 
intake, which change over time following a quit attempt, as they are not fixed 
characteristics, identifiable at the time of quitting. Combining the findings showed the 
most consistent evidence, found in nine of 14 studies, was that higher smoking rates 
were associated with greater weight gain. The association between weight gain and 
age, baseline BMI and gender were all inconclusive (Table 6).  
 
As discussed previously these reviews were not exhaustive, they did not appraise the 
studies they included or classify them according to those which relied on point 
prevalence or continuous abstinence.  There is need for an updated systematic 
review of prospective studies to examine the characteristics associated with post 
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cessation weight gain. Such a review would need more inclusive search criteria, 
considered inclusion and exclusion study criteria, critical appraisal of studies and 
appropriate addressing of heterogeneity than the reviews to date.  There is a need 
for more long term prospective studies with accurate classification of abstinence to 
contribute to such a review. 
 
1.2.4. Our contribution to this knowledge 
In the 1990s an influential randomised controlled trial examined the effects of nicotine 
patch versus placebo patch as an aid to smoking cessation within 19 general 
practices in Oxfordshire. Participants were treated for three months, followed up at 
six months, one year and eight years later. At these time points smoking status was 
verified by expired CO concentration and salivary cotinine (ICRF GPRG, 1993, ICRF 
GPRG,1994, Yudkin et al., 2003). Weight was recorded at baseline and at 8 years. 
We used these data (which we will refer to as the „Oxford patch data‟ hereafter) to 
investigate weight change over this time by smoking status. We investigated the 
associations of baseline characteristics, recorded at the time of quitting in the Oxford 
patch data, with weight gain over eight years. These investigations are reported in 
chapter two of this thesis. 
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Baseline Characteristics Associations with weight gain Number of supporting cohort studies   
Age  No association/inconsistent association 
Negative (older gain less e.g. greater if under 55 years old) 
 
4 
3 
 
 
Genetic disposition        Greater concordance of weight among monozygotic than dizygotic twins 1   
Self-rated health             
 
Lower weight gain in quitters with lower self-rated health 1  
Alcohol  Lower weight gain among social drinkers compared to those who do not drink alcohol at baseline 1  
BMI  Positive (higher weight gain in quitters with higher baseline BMI) 
No association 
Negative (lower weight gain in quitters with higher baseline BM)  
 
1 
3 
2 
 
Smoking rate  Positive (greater weight gain in those who smoke more (e.g. greater than 25 cigs/day)  
n-shaped association with moderate smokers gaining most weight after smoking cessation  
No difference in weight gain with baseline smoking rate  
9 
2 
3 
 
Socioeconomic status (SES)  Lower weight gain in quitters with higher SES  
 
2  
 
 
Gender Greater weight gain in women 
No association 
Greater weight gain in men 
 
3 
2 
2 
  
Ethnicity Greater weight gain in African-Americans than European-Americans 2   
Table 6. Baseline characteristics associated with weight gain 
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1.3. What causes post cessation weight gain? 
Quitting smokers are faced with a number of weight promoting challenges 
associated with nicotine withdrawal, that tip the energy balance equation in favour 
of weight gain. As we have previously discussed (section 1.2.2) whether this 
means that weight exceeds that which would have been reached, if quitters had 
not smoked, or individuals reach their „set point‟ is not entirely clear. Perkins in 
1993 postulated the „set-point‟ hypothesis in this context whereby smoking may 
suppress an individuals‟ set point; a homeostatically regulated predetermined 
weight regardless of whether this weight is in the ideal BMI range or not. Although 
we cannot confirm or refute this with current evidence, it does not detract from the 
health risks that post cessation weight gain poses. These are discussed in later 
sections of this chapter (section 1.4).  
 
The reviews described previously and a number of narrative reviews have 
discussed potential causes of post cessation weight gain. They cited research 
ranging from metabolic studies which measure metabolic rate in laboratory 
conditions to cohort studies measuring processes such as dietary change and 
change in physical activity levels. This has led to a variety of biologically plausible 
theories; each of which could be a contributing factor. However, the body of 
evidence shows findings that are inconsistent or samples that are too small to be 
conclusive. However, we have summarised the possible mechanisms below. 
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1.3.1. Reduced basal metabolic rate and energy 
expenditure during physical activity 
A reduction in basal metabolic rate on smoking cessation has been seen in some 
but not all human laboratory studies. A pooling of these studies in the narrative 
review reported that metabolic rate may drop by 4% to 16% with smoking 
cessation, and could account for up to 40% of this weight gain (Filozof et al., 
2004). From meta-analysis of weight gain in the controlled arms of smoking 
cessation trials (Aubin et al. 2011, unpublished) we know that there is 
approximately a 5kg increase in weight by one year post cessation. Therefore, if 
there was no other change, and quitters continued to eat and exercise at their pre-
quitting level, they could expect to gain 2kg (40% of 5kg) in the first year after 
stopping smoking (solely as a result of a fall in metabolic rate). The fall in 
metabolic rate is thought to arise primarily from reduced excitation of the 
sympathoadrenal pathway due to withdrawal of nicotine (Perkins, 1992). Nicotine 
is a cholinergic agonist, which enhances the effects of acetylcholine on nicotinic 
receptors.  
 
There is fairly consistent evidence from cohort studies as described in section 
1.2.3 that those who smoke more cigarettes a day gain more weight on cessation 
(Table 6). One explanation could be that excitation of the sympathoadrenal 
pathway is greater in these smokers and withdrawal reduces metabolic rate further 
in those who smoke more. This dose response relationship may explain why 
different studies have shown different levels of change in metabolic rate (Perkins, 
1992). However, empirical evidence refutes this. A laboratory study has shown 
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those who smoke less have a greater rise in energy expenditure after smoking 
than those who smoke more; who seem to exhibit tolerance (Arcavi et al., 1994). 
Smoking also affects energy expenditure during physical activity.  A laboratory 
study has shown that when 24 hour periods of equal physical activity and dietary 
intake are compared within individuals in abstinent and smoking states, total 
energy expenditure reduces in the abstinent state; but basal metabolic rate stays 
constant (Hofstetter et al., 1986). Another laboratory study showed that the energy 
expending effect of nicotine more than doubled during periods of physical activity 
than during periods of rest (Perkins et al. 1989). Therefore, energy expenditure 
during activity may be reduced further with nicotine withdrawal, than it is when at 
rest.  
 
In summary, nicotine withdrawal may reduce basal metabolic rate, but it is unclear 
how this relates to smoking rate. Alternatively, energy expenditure during physical 
activity may be affected more than basal metabolic rate by nicotine withdrawal. 
The latter would suggest that those who are habitually more active would 
experience greater weight gain, but we are not aware of any epidemiological 
evidence to support this. 
 
1.3.2. Increased fat storage 
Smoking cessation may reduce fat oxidation leading to increased storage of body 
fat. A small study has shown that fat oxidation, measured by indirect calorimetry 
was positively associated with 24 hour urinary cotinine excretion in smokers 
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(Jensen et al., 1995).  Yet another small study that measured fat oxidation 
(lipolysis) in adipose tissue did not find it reduced in quitting smokers. However, 
this study did show increased activity in the fat storage enzyme, adipose tissue 
lipoprotein lipase, in gluteal (but not abdominal) adipose tissue which was 
associated with four week post cessation weight gain (Fererra et al., 2001). 
Therefore, increased storage of fat may be a factor contributed to post cessation 
weight gain. However, the metabolic mechanism and the adipose tissue sites 
involved are unclear.   
 
1.3.3. Increased energy intake 
Laboratory studies in rats have shown that nicotine suppresses food intake 
(Myiata et al., 2001) and hunger is well established as a withdrawal symptom from 
cigarette smoking (Hughes et al., 1986). Two human studies measured food 
intake in quitters after the first two to three months after stopping smoking and 
found daily energy intake increased. The mean value was shown as no more than 
230kcal/day. This may account for 69% of post cessation weight gain (Stamford et 
al., 1986, Moffart and Owens, 1991). However, an increase in energy intake has 
not been found in all studies (Rodin et al., 1987).  
 
An increase in food intake could arise from a number of mechanisms. We can 
group these loosely into a homeostatic response to food deprivation and a 
hedonic response to food reward (Saper et al., 2002, Blundell, 2006).  
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The first response is commonly perceived as an abdominal sensation and 
described as emptiness in the stomach. This occurs through feedback 
mechanisms acting in response to a starved state. For example, low levels of 
leptin (released from adipose tissue in the fed state) allow Neuropeptide Y (NPY) 
to bind to receptors in the hypothalamus and trigger the sensation of hunger.  
There is some evidence from altered activity of NPY in rat studies to suggest that 
increased energy intake during nicotine withdrawal may be due to increased 
homeostatically regulated hunger (Li et al., 2000) but the mechanism is unclear. A 
few studies in humans have measured leptin levels in quitting smokers but the 
evidence shows no consistent decrease in leptin after cessation (Filozof et al., 
2004).   
 
There is also evidence that eating based on sensory properties may increase on 
cessation.  A systematic review shows consistent evidence that during smoking 
cessation the rewarding value of food increases (Berlin, 2009). Studies in rats 
(Schroeder et al., 2001) and several studies in humans also suggest that both 
nicotine and food increase dopamine through activation of the ventral tegmental 
area (Volkow et al., 2008). It has been suggested that food used as a 
“substitutional reinforcer” for smoking may contribute to weight gain (Audrain-
McGovern & Benowitz, 2011). Hedonistic eating and food craving is described in 
more detail in section 3.1.2. However, we are unaware of any empirical studies 
that have examined whether hedonistic eating increases during nicotine 
withdrawal and how this contributes to post cessation weight gain.  
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Thus, while there is consistent evidence that hunger increases during smoking 
cessation and increased energy consumption may account for a significant 
proportion of weight gain. There is no strong evidence that this is mediated by 
changes in neuropeptides or that hedonistic eating is responsible. 
 
1.3.4. Decreased physical activity post cessation 
A reduction in physical activity has been considered as another factor for smoking 
cessation related weight gain, however a review of cohort studies shows a similar 
number of studies report a rise in post cessation physical activity as those that 
report a fall (Chiolero et al., 2007). Thus, the evidence suggests that changes in 
physical activity after cessation are unlikely to be an important cause of post 
cessation weight gain.   
 
1.4. The impact of the weight gain associated with 
smoking cessation  
In this section we examine the impact that smoking related weight gain may have 
on attempts to quit smoking, relapse to smoking and the risks of chronic diseases. 
 
1.4.1. Association of smoking related weight gain with 
quit attempts and relapse to smoking 
Anecdotally, weight gain is a common reason reported in clinical practice for 
relapse to smoking. Some individuals report they cannot tolerate the weight they 
gain when they stop smoking and relapse to smoking in an attempt to return to 
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their previous weight. Others do not attempt to quit for fear that they will gain 
unwanted weight. However, the evidence is less clear.  
 
1.4.1.1. Is concern about anticipated weight gain positively 
associated with reduced attempts to quit?  
The UK Office of National Statistics 2008/9 report showed only 3% of smokers 
claim anticipated weight gain is the main reason not to quit (ONS, 2009). Given 
that 21% of adults in the UK smoke (ONS, 2010), this is approximately 32,000 
people. Whether these claims are in fact associated with lower quit rates, in those 
who are weight concerned, needs to be explored independently in epidemiological 
studies. In our searching of the literature, described at the beginning of this 
chapter, we found one review (French & Jeffrey, 1995, Table 7) which addressed 
the influence of weight concern on attempts to quit. The authors reported that 
studies suggest greater smoking related weight concern was associated with 
fewer attempts to quit. However, this evidence came from cross-sectional studies 
showing higher prevalence of weight concern in current smokers than former 
smokers. While this might suggest that weight concern is associated with fewer 
quit attempts, other explanations are possible.  Perhaps former smokers became 
less concerned about weight after they quit smoking as a response to having put 
weight on but were equally concerned beforehand. Without prospective evidence 
showing a temporal relationship we cannot suggest causality.  
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1.4.1.2. Is concern about anticipated or concern about actual 
weight gain positively associated with relapse?  
The UK Office of National Statistics 2008/9 report showed 5% of smokers claim 
weight gain was the reason they relapsed in their last quit attempt; this is 
approximately 53,000 people. In our searching of the literature we found two 
reviews of studies addressing this (Klesges et al., 1989, French and Jeffery, 1995 
(Table 7)). These both concluded that fear or concern about post cessation weight 
gain was positively associated with relapse. As described above, the cross 
sectional evidence for this was limited by comparing weight concern in current 
versus former smokers. Where relapsed smokers were compared with former 
smokers it was unclear whether weight concern preceded quitting or was a 
consequence of post quit weight gain (Table 7).    
 
Klesges et al. reported on two prospective studies examining prequit weight 
concern, they found that in both of these higher weight concern prequit was 
associated with higher relapse rates in those enrolled in smoking cessation 
programmes. However, it is unclear whether these studies adjusted for the impact 
of actual weight gain on weight concern. Without concurrent exploration of 
changing attitudes to changing weight during smoking cessation we cannot make 
conclusions regarding the effects of weight concern on relapse. 
 
A more recent review (2010) of prospective studies, carried out as a masters 
dissertation that I supervised, reported four out of nine studies showed a positive 
association of weight concern with relapse and five found no association. 
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However, the heterogeneity between these studies means these findings are hard 
to interpret. Four of the studies measured weight concern prequit, and two 
identified weight concern post quit, as a reason for relapse.  
 
1.4.1.3. Is actual weight gain associated with relapse back to 
smoking?  
Klesges et al. reviewed three prospective studies measuring actual weight gain 
and found a negative association between weight gain and relapse. This was 
determined largely by the observation that greater weight gain was seen in those 
achieving abstinence rather than in those that relapsed.  
 
The masters dissertation reviewing more recent studies found two out of seven 
reported a negative association.  Four of the seven studies reported a positive 
association, where greater weight gain was associated with a higher relapse rate 
and one reported no association. Therefore, findings are inconclusive; some of 
this may be accounted for by differences between the studies and sub group 
analysis of these is needed. For example, in two of the seven studies these data 
were derived from placebo controlled trials of bupropion, an effective cessation 
aid. Bupropion may also temporarily delay weight gain.  Therefore lower relapse 
rates in those who gain less weight may be confounded by bupropion use. 
   
So what can we conclude? Weight gain is not consistently associated with higher 
relapse rates. Where it is, it may be due to weight concern at the amount gained 
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or it may be due to other factors. The opposite may also be true, weight gain may 
be associated with lower relapse rates, this may reflect less concern about weight 
in those who quit or it may simply be a consequence of abstinence.  
 
Return to smoking is often a response to cravings for cigarettes, an impulsive 
desire when faced with smoking cues. Whether a reasoned response dependent 
on weight gain can result in the same impulsive action is questionable, although it 
could undermine motivation to resist smoking urges.  Weight gain may be an 
excuse given for returning to smoking or it may be an underlying factor 
contributing to relapse, but more research is needed before we can be certain.  
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 Table 7. Appraisal of systematic reviews that examine associations between weight concern and weight gain with quit attempts 
and relapse 
Study Klesges et al.,1989 French & Jeffrey, 1995  Masters Dissertation, 2010 
Was the question addressed? Yes. Although the article did seek to answer several 
questions at once. We have taken the ones relevant to 
our discussion separately  
Yes Yes 
Is it likely that important 
relevant studies were missed? 
Unclear. No method was described, although a large 
number of studies were identified 
Possibly due to database  
search limited by search 
engines of the time  
No, thorough search terms 
Was inclusion criteria for 
studies appropriate? 
Not defined Yes, cross sectional  Yes, prospective only 
Was validity of included 
studies addressed? 
To a degree. Narrative discussion mostly as an 
explanation for those which did not provide consistent 
results. No evidence of each study being formally 
assessed or excluded on the basis of its validity 
Yes Yes 
Were the results 
homogeneous or was 
heterogeneity adequately 
addressed? 
Discussed e.g. gender difference,  but not adequately 
addressed e.g. no sub-analysis 
Unclear Heterogeneity was discussed in the narrative but little attempt was made to unpick 
it e.g. results not presented according to homogenous categories. 
What were the 
results/conclusions? 
Investigations finding a positive relationship between 
weight gain and relapse have assessed beliefs, concerns, 
and fears regarding post cessation weight gain, 
Investigations finding a negative relationship have 
assessed actual weight gain. 
Actual weight gain may have little relationship to 
participants' perceptions of their weight status. 
High degree of concern regarding post cessation weight 
gain and  a small weight gain after cessation may confirm 
the fear and prompt relapse. 
Conclusions predominantly based on cross-sectional 
studies 
Weight concerns specific to 
smoking may have a 
negative influence on both 
cessation and relapse. 
General weight concerns do 
not appear to have this 
influence 
Seven prospective studies on actual weight gain.  Four were found to be positively 
associated with relapse. Two negatively associated with relapse. One found no 
association.  The positive association in one of the studies was valid in males but 
not in females. These associations were weakened by differing time points for 
assessment of the relationship, and by varying lengths of follow up for the studies.  
Nine studies identified regarding weight concern. Four studies found it to be  
positively associated with relapse. No study was identified where weight gain 
concern was associated with less relapse. Five studies showed no significant 
association between post cessation weight gain concern and relapse to smoking.  
Four studies presented the relationship between weight concern and relapse as the 
weight gain which participants identified prequit as the amount they would  
tolerate before relapsing. A range of 10 – 20 pounds was found to be the tolerable 
weight range, with women willing to tolerate less than men, and higher weight 
concerns correlating with less tolerable weight gain.  
Two studies reported the proportion of subjects who mentioned weight gain after 
quitting as a reason why they would relapse to smoking. Women were more likely 
to relapse for this reason than men, and higher weight concerns predisposed to the 
naming of weight gain as a potential reason for relapse.  
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1.4.2. Impact on risks of chronic diseases 
 
To examine recent evidence that smoking cessation may have an adverse risk on 
chronic disease we searched Medline, Embase and PsycINFO from 1989 to 
present day for review articles. We did a title search and used the following MeSH 
terms „smoking cessation‟ AND „lung function OR diabetes OR metabolic OR 
cardiovascular OR blood pressure OR waist OR body composition‟. We limited our 
search to articles in English. We excluded reviews where authors made no 
attempt to describe how they searched the literature and selected articles. Where 
there was no review article available we searched for observational studies.  
 
1.4.2.1. Changes in body composition 
Abdominal obesity is independently associated with an atherogenic profile and 
increased risk of type 2 diabetes (Berlin, 2008). Most studies looking at post 
cessation weight gain have not measured change in waist circumference, waist to 
hip ratio, or body fat distribution. Therefore, it is not yet clear whether the usual 
pattern of post cessation fat deposition is gluteal or intra-abdominal. If intra-
abdominal it carries a greater health risk than gluteal fat. The Berlin review (2008) 
indentified one prospective study that found waist circumference increased in 
quitting compared to continuing smokers. This was a nine year prospective study 
in 16,587 men (Koh-Banerjee et al., 2003). It reported a mean 2.0cm (SD 0.3) 
increase in quitters and a reduction of 0.7cm (0.3) in continuing smokers. These 
values were after adjustment for confounders at baseline and changes in diet and 
physical activity levels during the study. When change in BMI was also adjusted 
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for, waist circumference was still shown to have increased in quitters and reduced 
in smokers, but by a smaller amount, 0.8(0.3) and 0.4(0.2) respectively. However 
this study relied on self reported recall of smoking abstinence, and the group of 
abstainers contained those who had been quit for variable lengths of time.   
 
We know of one study which has measured change in waist circumference in 
validated quitters. Mean difference (SD) in waist circumference between quitters 
and continuing smokers was 3.5cm (0.5) in men and 4.5cm (0.6) in women 
(Pisinger et al., 2007).  
 
One cross sectional study using computerised tomography scanning has shown 
ex-smokers to have higher visceral fat area (124.0–132.0 cm2) than nonsmokers 
(123.1 cm2) and current smokers (120.4 cm2)1.Categorising these ex-smokers by 
length of reported abstinence showed that recent ex-smokers had higher visceral 
fat area than ex-smokers of longer duration (Matsushita et al. 2011). Prospective 
studies, using such precise measures of visceral fat, would help to confirm 
whether smoking cessation leads to the accumulation of visceral fat and its 
associated adverse health consequences.    
 
Given there are few studies investigating post cessation fat distribution we 
included measurement of waist to hip ratio and percentage body fat assessed by 
                                            
1
 Visceral fat areas from a single scan obtained at the level of the umbilicus are accepted as 
highly correlated with the total visceral fat volume (Yoshizumi et al., 1991) 
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bioelectrical impedence analysis (BIA) in our feasibility trial, but due to limited 
resources were unable to use more advanced BIA or imaging techniques to 
differentiate between visceral and subcutaneous fat.    
 
1.4.2.2. Impact on type two diabetes mellitus 
A review article by Tonstad in 2009 cited two population studies investigating the 
association between smoking status and the risk of type two diabetes. However, 
the search terms used to identify and include or exclude studies for this review 
were unclear. We considered the two cited articles together with another three 
prospective studies identified from our own reference library to examine the 
relative risk of developing type two diabetes associated with smoking cessation.  
 
All five studies showed a higher relative risk of developing type two diabetes in 
recent abstainers (quit for less that 5-8 years) than in continuing smokers 
(reference category: never smokers) (Table 8). In comparing these relative risks, 
the risk of type two diabetes increased by 6% to 73% in quitting compared to 
continuing smokers. In one of these studies this was not seen in heavy smokers 
(smoking 2 or more packs per day) (Will et al., 2001). Three of the five studies 
investigated whether weight gain mediated this association. The evidence 
suggested that some but not all the increased incidence of type two diabetes was 
mediated by weight gain. (Wannamathee et al., 2001, Davey-Smith et al., 2005, 
Yeh et al., 2010). The incidence of type two diabetes in long term ex-smokers was 
investigated in three of the five studies. The incidence of diabetes in smokers who 
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had been abstinent for more than five , 10 and 12 years was similar to that of 
never smokers in three separate proespective studies (Wannamethee et al., 2001, 
Will et al., 2001 and Yeh et al., 2010).  
 
Therefore prospective studies show consistently that risk of type two diabetes is 
elevated in the first five years post cessation beyond that of continuing smokers, 
and this may be explained in part by post cessation weight gain. These findings 
can be further confirmed with long term prospective studies using biochemically 
validated abstinence. To begin to collect some data on this we measured fasting 
blood glucose at the start and end of our feasibility trial, where continuous 
abstinence was measured by expired carbon monoxide of less than 10ppm. 
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Cohort study Wannamethee et al., 2001 Will et al., 2001 Davey-Smith et al., 2005 Hur et al., 2006 Yeh et al., 2010 
Representative 
sample? 
 
Men 
N=7,124 
Yes 
N=709,827 
Men 
N=11,827 
Men 
N=27,635 
Yes 
N=10,892 
Common 
starting point? 
Ex-smokers variable duration of 
abstinence at start 
Ex-smokers variable duration of abstinence at 
start 
Smoking cessation any point during 
follow-up 
Smoking cessation any point 
during follow-up 
Ex-smokers at baseline 
categorised by self report length 
of abstinence 
Adequate 
follow up             
(mean)? 
16.8years 13years 6-7years 8years 9years 
Objective 
exposure? 
Self reported recall of smoking 
status 
Self reported recall of smoking status Self reported smoking status Self reported smoking status Self reported smoking status 
Objective 
outcome?  
Yes (diabetes incidence self report 
confirmed by medical records or 
death certificate) 
Self report and death certificates Measured glucose, on anti-diabetic 
medication 
Uncontrolled DM only (fasting 
blood glucose >7mmol/l) 
fasting blood glucose, self report 
of diagnosis and on anti-diabetic 
medication 
Adjustment for 
confounding? 
Yes Yes Yes Yes Yes 
Results & 
precision of 
results? 
Ref: never 
smokers 
Relative risk (95% CI) 
Smokers 1.74(1.24, 2.43) 
Ex- smokers 1.33 (0.92, 1.90) 
<5 yr quit 1.89 (1.16, 3.06) 
5-10 1.20 (0.67, 2.15) 
11-19 1.42 (0.87, 2.31) 
>20 0.95 (0.54, 1.67) 
 
Ref: never 
smokers 
Incidence density  
ratio IDR (95%CI) 
 
 Men Women 
Smoker < 
1pack/d 
1.05 (0.98, 1.12) 0.98(0.93, 1.03) 
Smoker 1-
2 pack/d 
1.19(1.13, 1.26) 1.21(1.14, 1.29) 
 
Smoker 
>2pack/d 
1.45(1.34, 1.57) 1.74(1.49, 2.03) 
Ex-smoker 1.07(1.02, 1.13) 1.07(0.99, 1.15) 
<5yr quit 1.20(1.09, 1.32) 1.19(1.04, 1.37) 
5-10yr quit 1.12(1.03, 1.21) 0.99(0.86, 1.13) 
>10yr quit 0.99(0.92, 1.07) 1.02(0.91, 1.15) 
 
 
Hazard ratio  
(95%CI) 
smokers 1.27(1.10-1.46) 
Quit in 
intervention  
1.21(0.99, 1.47) 
Quit in usual care 1.35(1.06, 1.72) 
 
Ref: never 
smokers 
Risk Ratio (95%CI) 
Smoker < 
10cig/d 
1.23(1.86*, 1.77) 
Smoker 10-
20cig/d 
1.60(1.28, 2.00),  
Smoker 
>20cig/d 
1.75(1.35, 2.27) 
Ex-smoker 0.95(0.72, 1.25) 
<6yr quit 1.44(0.96, 2.15) 
6-8yr quit 2.13(1.51, 3.00) 
* CI appear to be in error 
 
Ref: never 
smokers 
Hazard Ratio (95%CI) 
Smoker  1.31(1.04, 1.65) 
Ex-smoker 1.22(0.99, 1.51) 
<3yr quit 1.73(1.19, 2.53) 
<6yrs quit 1.80(1.44, 2.25) 
<8yrs quit 1.54(1.10, 2.14) 
<12yrs quit 1.21(0.89, 1.65) 
>12yrs quit 1.16(0.99, 1.36) 
 
 
Was risk 
attenuted by 
post cessation 
weight gain? 
Partially Not investigated Partially Unclear Partially 
Attrition 
adequately 
addressed?  
99% follow-up achieved Unclear Did not compare characteristics 
between analysed and excluded 
individuals 
Did not compare characteristics 
between analysed and excluded 
individuals 
Did not compare characteristics 
between analysed and excluded 
individuals 
Table 8.Review of prospective cohort studies assessing relative risk of type two diabetes in quitting smokers  
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1.4.2.3. Impact on lung function 
Systematic review evidence of prospective studies consistently shows that compared 
to continuing smokers, smoking cessation halts the accelerated decline in lung 
function in those susceptible to COPD (Gratziou, 2009, Willemse et al., 2004). This 
benefit can be seen within one year after cessation (Gratziou, 2009).   
 
Both these reviews showed evidence that weight gain limited this benefit.  One large 
prospective study was cited and, from our own reference library, we knew of one 
more that followed smokers and quitters for 5 years and investigated the association 
between post cessation weight gain and change in lung function.  Wise et al. (1998) 
found that FEV1 decreased by a mean 2.2ml/year in men and 1.1ml/year in women 
for every 1kg/year increase in post cessation weight. Chinn et al. (2005) found it 
decreased by 11.5ml/kg/year in men and 3.7ml/kg/year in women. In these models 
weight gain and decline in lung function was averaged over the five years with no 
detail of the trajectory of lung function decline. We might expect lung function to 
decline by a greater extent initially, given that weight gain is highest during the first 
year post cessation (O‟Hara et al. 1998). Knowing this could help with monitoring and 
thus more rigorous management of pulmonary disease.  With a view to adding to this 
knowledge we measured lung function at baseline and at follow-up in our feasibility 
trial.   
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1.4.2.4. Impact on cardiovascular risk and hypertension 
A review of studies has concluded that the reduction in cardiovascular risk in quitters 
to that of never smokers takes between 2 and 20 years (Bolego et al., 2002). 
Differences between the time it takes for this risk to reduce may be due to different 
baseline characteristics between the studies and it may also depend on post 
cessation weight gain. 
 
A systematic review examined the association between smoking cessation and the 
incidence of hypertension (Gratziou, 2009). Three of four prospective studies found 
the incidence of hypertension was higher in quitters compared to continuing smokers 
(relative risk was 80-350% higher and a greater risk was seen with longer duration of 
abstinence). In all three studies there was evidence that the increased incidence of 
hypertension was mediated by weight gain. One of these studies also showed 
increased risk regardless of weight gain (Lee et al., 2001). Nonetheless, given that 
weight gain is an independent risk factor for hypertension it seems reasonable to 
suggest that greater reduction in cardiovascular risk, through a reduced risk of 
hypertension, would be seen if post cessation weight gain could be prevented.  To 
add to this knowledge we measured changes in blood pressure in our feasibility trial. 
1.5. How can we prevent this weight gain? 
1.5.1. Pharmacotherapies 
The most comprehensive evidence to date comes from a Cochrane review 
investigating interventions to prevent weight gain during smoking cessation (Parsons 
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et al., 2009). This found that fluoxetine, bupropion, nicotine replacement therapy 
(NRT), naltrexone and varenicline all had a small significant effect, and this meant 
between 0.4-1.3kg less weight was gained at the end of treatment compared to 
placebo. This is a prevention of between 14% and 46% of the mean weight gain 
known to occur at this time (2.8kg at three months post quit, Aubin et al., 2011). 
None of these pharmacotherapies had a long term effect on weight gain, by 12 
months there was no significant difference in weight gain between those who had 
received these treatments at quitting and those who had not.  
 
There is some evidence from observational studies that NRT use for 12 months 
prevents almost half the expected weight gain at 12 months (Hajek et al., 1988, 
Sutherland et al., 1992). One study also showed that after 10 months of gum use, a 
gradual reduction did not result in rebound weight gain (Hughes et al., 1991). 
However, evidence of increased insulin resistance in long term users of NRT 
(Eliasson, 1996) limits its use for this purpose. 
 
The Cochrane review found no evidence of a dose response relationship with those 
allocated to higher doses of NRT not significantly less likely to gain weight. However, 
there is some observational evidence that people actually using more gum gain less 
weight. Three prospective studies were identified in the Klesges review (Klesges et 
al., 1989) and one more recently (Ferguson et al., 2011) showed this. However, 
another study showed no difference in weight gain according to the amount of gum 
used (Hajek et al., 1988). Therefore, although we cannot be certain, the evidence 
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does suggest that the amount of NRT actually used, rather than the amount people 
are told to use, may be important for weight control. 
 
1.5.2. Cognitive behavioural therapy (CBT) to accept 
weight gain 
One early trial showed a paradoxical finding. CBT to encourage people to accept 
weight gain was associated with 5.2kg less weight gain at one year compared to 
standard care (Perkins et al., 2001).  However, a replication study by the same 
research team found no evidence that CBT to appease weight concern reduced 
weight gain (Levine et al., 2009). Therefore, an effect is doubtful. 
 
1.5.3. Exercise 
Results from the Cochrane review showed that exercise does not appear to help 
prevent weight gain during the actual period of smoking cessation, although by 12 
months post quit there was less weight gain in those who had received exercise 
interventions than those who had not (-2.07kg (-3.78, -0.36)) (Parsons et al., 2009).  
The inconsistencies between these findings at these two time points create 
uncertainty of the effects of these exercise intervention of preventing post cessation 
weight gain.  
1.5.4. Dietary interventions 
Dietary intervention at the time of quitting holds the most promise for preventing post 
cessation weight gain, although it is controversial. The main reason quit attempts fail 
is due to quitters succumbing to their cravings to smoke. Evidence suggests that 
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hunger increases urges to smoke. Laboratory studies have shown that participants 
on a low calorie diet (700kcal/day deficit) smoked 8% more cigarettes than those on 
a normal-calorie diet (2000-2800kcal/day) (Cheskin et al., 2005). Smokers abstinent 
for 18 hours when in a fasted state were more likely to smoke sooner than those who 
had not fasted (Leeman et al., 2010). Observational studies have shown that people 
who gain most weight are more likely to succeed in quitting smoking (Hall et al., 
1992) and use of glucose tablets during smoking cessation has been shown to 
reduce cigarette cravings (McRobbie & Hajek, 2004). All these findings suggest that 
avoiding hunger and feeding cigarette cravings with food may enhance smoking 
abstinence. Therefore current smoking cessation advice is to avoid hunger and not to 
diet during a quit attempt.   
 
However the hypothesis that dieting while quitting increases hunger and thereby 
increases urges to smoke in the early phases of a quit attempt has not been tested in 
smokers who are attempting to quit. Results from a Cochrane review (Parsons et al., 
2009) suggested that not all types of dietary intervention were effective and some 
may affect quit rates differently. The reviewers reported that general dietary 
education to reduce energy intake through eating a low fat, healthy diet did not 
prevent weight gain compared to standard smoking cessation behavioural support. 
Furthermore, there was a statistically significant reduction in abstinence at 12 months 
(Table 9). An individually tailored dietary plan to reduce energy intake; with regular 
monitoring and adaptation of individual goals, reduced weight gain at 6 and 12 
months; without a statistically significant reduction in abstinence rates (Table 9). 
Intermittent use of a very low calorie diet (VLCD) provided the greatest effect on 
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preventing weight gain at end of treatment, but the effect was no longer statistically 
significant at 12 months although the mean point estimate remained clinically 
important. The use of the VLCD showed a statistically significant increased 
abstinence rate to nearly double that of controls at end of treatment and long-term 
follow up (Table 9). 
 
These findings left a number of questions unanswered; firstly, although the effect of 
the individually tailored dietary plan to prevent post cessation weight gain looked 
promising, there was insufficient power to allow us to conclude it did not reduce 
abstinence. A larger trial to do so was required. 
 
Secondly, although the VLCD might have a neutral effect on post cessation weight 
gain in the long term, it might have the benefit of improving abstinent rates. To 
explore whether this is a causal finding, it helps to understand plausible mechanisms 
by which this may occur.  
 
Thirdly, all these previous trials were run in specialist units, where there was 
considerable dietary expertise, the generalisability of these findings for NHS stop 
smoking clinics is therefore questionable.  
 
Therefore, we designed the Dietary Management in Smokers Trial (DeMiST) to see if 
it was feasible train clinicians and provide these specialist dietary interventions in 
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primary care. If so, this could lead to an adequately powered trial which tests their 
effects on abstinence, in real clinical settings. 
 
Another main objective of DeMiST was to test the hypothesis that hunger increases 
urges to smoke and ketosis reduces urges to smoke. As part of this we developed 
and tested a tool to measure hunger and food craving. We also developed and tested 
a tool to help non dietary experts assess and advise on diet, this tool also aimed to 
measure dietary change as a process by which weight change may have occurred.   
 
Chapter three of this thesis describes the methods of DeMiST. Chapter four 
discusses the measures of feasibility. Chapter five discusses the process measures 
developed and tested for DeMIST. Chapter six describes the effects of dietary 
intervention on urges to smoke and short term measures of weight and other chronic 
disease risk factors.  
43 
 
 
 
 
 
 
Intervention compared to standard smoking cessation Mean difference in weight change  (Kg [95%CI]) Abstinence (RR [95%CI]) 
End of treatment At 12 months End of treatment  At 12 months 
General lifestyle and calorie reducing dietary advice  -0.04 [-0.57, 0.50] -0.21 [-2.28, 1.86] 0.90 [0.76, 1.06] 
 
 0.66 [0.48, 0.90] 
 Individually tailored dietary and lifestyle advice  -1.05 [-2.01, -0.09] 
 
-2.58 [-5.11, -0.05] 1.11 [0.84, 1.46]  0.79 [0.47, 1.33] 
 VLCD compared to general calorie reducing dietary advice  -3.70 [-4.82, -2.58] -1.30 [-3.49, 0.89] 1.40 [1.07, 1.85]  1.73 [1.10, 2.73] 
 Table 9. Effects of dietary interventions on weight change and abstinence during smoking cessation (Adapted from Parsons et 
al., 2009) 
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1.6. Overview of thesis 
1.6.1. Aims of thesis 
There are three aims of this thesis: 
1. To report on the associations of potential predictors at the time of quitting with 
post cessation related weight gain eight years later in a cohort with well defined 
smoking status. 
2. To report on the feasibility of trialling dietary interventions to prevent weight 
gain within NHS stop smoking clinics. 
3. To report on testing the hypothesis that hunger and ketosis affect urges to 
smoke in free-living quitting smokers. 
 
1.6.2. Objectives of thesis 
These aims are met through achieving the objectives described below. Chapter 
numbers are given in brackets beside each objective showing where in the thesis 
these objectives were met. 
1. To summarise and appraise literature to date on the potential predictors of post 
cessation weight gain (Chapter 1). 
2. To discuss the methodology and results of examining potential predictors of 
post cessation related weight gain within the Oxford patch data (Chapter 2). 
3. To discuss the design of a randomised controlled trial (DeMiST) to investigate 
the feasibility of dietary interventions to prevent weight gain within NHS stop 
smoking clinics and examine the effects of these dietary interventions on urges 
to smoke (Chapter 3). 
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4. To report on the feasibility of running DeMiST, including discussion of 
recruitment rates and experiences of the participants (Chapter 4). 
5. To report on the development and validity of a dietary assessment tool for use 
within DeMiST consultations (Chapter 5). 
6. To report on the development of a questionnaire to measure both hunger and 
food craving during quitting smoking (Chapter 5). 
7. To report on the effects of the dietary interventions on urges to smoke and 
whether this is a result of change in desire for food or ketosis (Chapter 6). 
8. To report on the effects of dietary interventions on body weight and chronic 
disease risk factors in quitting smokers (Chapter 6). 
9. To discuss the implications of findings from this doctoral research to advance 
understanding in this field and lead to improved clinical practice. 
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2. ASSOCIATIONS BETWEEN 
POTENTIAL PREDICTORS OF 
WEIGHT CHANGE OVER EIGHT 
YEARS IN A COHORT OF 
CONTINUING AND QUITTING 
SMOKERS 
This chapter fulfils the aim of the thesis to report on weight change over eight 
years according to clearly defined groups of quitting and continuing smokers. It 
reports on associations of potential predictors of such weight change, namely 
baseline BMI, baseline alcohol consumption, patch or placebo use at the time of 
quitting, smoking rate, age, gender and socioeconomic status.  
 
The investigation of baseline BMI was published in Addiction in January 2011 
(Lycett et al., 2011, Appendix 1). An early version of the abstract was presented at 
the 2009 Society for Social Medicine Annual Conference and published in the 
Journal of Epidemiology and Community Health (Lycett et al., 2009, Appendix 2). 
The abstract was also presented at the 2010 Annual Society of Nicotine and 
Tobacco Research.   
 
The investigation of baseline alcohol consumption was published in Nicotine and 
Tobacco Research (Lycett et al., 2011b, Appendix 3). 
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The investigation of placebo or patch treatment during quitting  was published as 
an e-letter in the BMJ (Appendix 4). This was in response to Yudkin et al., 2003 
who reported the odds of continuous abstinence at 8 years increase by 39% in 
those who used nicotine patch over placebo. 
2.1. Introduction 
As discussed in section 1.2.3, there are few studies providing long-term follow up 
of smokers and quitters to examine changes in body weight.  Most are population-
based studies, where smoking status is typically characterised as point prevalence 
abstinence and where the date of quitting is uncertain, usually lying between 
follow up occasions (Klesges et al., 1989).  Using point prevalence abstinence 
underestimates weight gain (Kesges et al., 1997).  The first aim of this study was 
to examine weight gain over eight years in a group with well-characterised 
smoking status. 
2.1.1. Associations of weight gain over eight years with 
baseline body mass index (BMI) 
Reviews of studies that have explored the characteristics associated with greater 
weight gain have found conflicting findings regarding the association between 
body mass index (BMI) at the time of quitting and weight gain (Klesges et al., 
1989, Froom et al., 1998). One study showed higher baseline BMI was positively 
associated with subsequent weight gain. Three showed higher BMI was negatively 
associated with weight gain, and four found no association. No study looked for a 
curvilinear relationship of BMI and post cessation weight gain.  The second aim 
was therefore to examine more fully the relationship of baseline BMI to change in 
weight in those who quit or continued to smoke.   
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2.1.2. Associations of weight gain over eight years with 
baseline alcohol consumption 
Avoidance of alcohol is often advocated in smoking cessation support to reduce 
cues to smoking. People trying to lose weight are often advised to moderate or 
avoid alcohol because alcohol has a combustible energy value of 7kcal/g.  (Fat 
contains 9kcal/g and carbohydrate contains 4kcal/g). However, there is contrary 
evidence on the effect of alcohol on weight gain in general, and very few 
investigations have examined its association with post cessation weight gain.  
 
Laboratory studies of the metabolic effects of alcohol show three important effects 
on energy balance. First, alcohol increases energy intake (Tremblay et al., 1995, 
Westerterp-Plantenga & Verwegen, 1999, Buemann, 2002), particularly when 
consumed in combination with fat (Tremblay & St-Pierre, 1996) and the extra 
energy from alcohol is not compensated for by reducing subsequent food intake 
(Tremblay et al.,1995, Tremblay & St-Pierre, 1996, De Catro & Orozco, 1990, 
Yeomans, 2004). Second, alcohol suppresses fat oxidation, which increases fat 
storage (Suter et al., 1992). Third, alcohol increases 24 hour energy expenditure 
through inducing thermogenesis by up to 30%. Dietary induced thermogenesis 
from alcohol is greater than that from carbohydrate, fat, or protein (Suter et al., 
1994, Raben et al., 2003, Schutz, 2000, Westerterp, 2004). The first two effects 
point towards alcohol promoting weight gain and the last effect works against it.  
So what causes the balance to tip one way or the other? 
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The answer may depend on the pathway by which alcohol is metabolised.  The 
alcohol dehydrogenase (ADH) pathway produces adenosine triphosphate (ATP) 
more efficiently than the microsomal ethanol oxidising system (MEOS). It is 
thought that low levels of alcohol are metabolised by ADH, whereas a high blood 
concentration of alcohol induces MEOS; and it is this that accounts for a higher 
energy expenditure seen in people with alcohol dependence (Suter, 2005, Levine 
et al., 2000).  The threshold level of alcohol for MEOS induction is unknown, but 
individual variation of body weight, smoking status, gender, and genetic variation 
in enzymes metabolising alcohol may explain the different effects of alcohol on 
body weight (Suter, 2005).   
 
Cross sectional studies have shown inconsistent results, although this has been 
explained in part by gender effects, smoking status and drinking patterns. Lower 
alcohol intake has been associated with greater BMI in women, but less so, or with 
the opposite effect, in men (Hellerstedt et al., 1990, Golditz et al., 1991, Breslow & 
Smothers, 2005). This effect in men is not consistently seen among male smokers 
(Mannisto et al., 1996, Cooke & Frost, 1982). More frequent drinking has been 
associated with lower BMI independent of total alcohol consumption (Tolstrup et 
al. 2005, Mannisto et al., 1996, Tolstrup et al., 2008).  
 
Prospective studies have demonstrated increasing alcohol consumption over time 
is not associated with an increase in waist circumference (Tolstrup et al., 2008), 
but it is associated with weight gain (Gordon & Kannel, 1983), particularly in men 
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(Gordon et al., 1986, Wannamethee & Shaper, 2003). These studies have not 
investigated effect modification by smoking status.  Prospective studies in women 
have found a U shaped curve (Wannamethee et al., 2004) and a significant 
inverse relationship on weight gain which was not modified by smoking status 
(Wang et al., 2010).   
 
In the few short-term randomised trials, alcohol consumption did not influence 
weight in obese people (Beulens, et al., 2006), but alcohol reduced weight in lean 
people (Clevidence, et al., 1984). 
 
Three prospective studies have considered the effects of alcohol on body weight 
around the time of quitting smoking; these have all found an inverse effect of 
alcohol consumption and weight gain (Froom et al., 1999; Kawachi et al., 1996; 
Nides et al., 1994). However, these studies did not fully explore the association 
according to smoking status. The weight gain trajectory in quitting and continuing 
smokers is very different; the third aim of this study was to investigate the effect of 
alcohol consumption on post cessation weight gain in both continuously abstinent 
quitters and continuing smokers. 
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2.1.3. Associations of weight change over eight years 
with patch or placebo use during quitting.  
The fourth aim of this study was to examine the association of weight change with 
patch or placebo use at the time of quitting. A Cochrane review (Parsons et al., 
2009) showed nicotine replacement therapy (NRT), compared to placebo, 
significantly reduced weight gain at the end of treatment by a mean difference 
(95% confidence interval)  of 0.46kg (-0.66, -0.27), and the point estimate for the 
effect size was similar at the end of one year: 0.44kg (-1.02, 0.14). However, this 
Cochrane review included no studies that reported weight gain more than one 
year from commencement of a quit attempt. We have used our data to examine, 
for the first time, the association of patch versus placebo use at the time of quitting 
with very long term (over eight years) post cessation weight gain.  
 
2.1.4. Associations of weight change over eight years 
with age, gender, smoking rate and socioeconomic status at 
baseline 
The final aim of this study was to examine the associations of age, gender, 
smoking rate and socioeconomic status (SES) with weight gain in quitters. 
Evidence so far from prospective studies for this is inconsistent and we sought to 
add to this with the results of our analysis.  
2.1.4.1. Age 
As discussed in section 1.2.3 the association between younger age and greater 
post cessation weight gain has previously been shown in three out of seven 
prospective studies, with four showing no association.  
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2.1.4.2. Gender 
Three out of seven prospective studies have shown a greater weight gain in 
women than men. Two studies have shown no association and two studies have 
shown a greater weight gain in men than women (section 1.2.3). 
2.1.4.3. Smoking rate 
The most consistent finding in the literature so far has been that lower smoking 
rate is associated with less weight gain after stopping smoking. Nine out of 14 
prospective studies found a positive association and two studies found a U-
shaped curve (section 1.2.3).   
2.1.4.4. Socioeconomic status 
So far, two prospective studies have found greater weight gain in those with a 
lower socioeconomic status (section 1.2.3).  
 
2.2. Methods 
2.2.1. Participants 
1686 participants, aged between 25 and 65 years, smoking 15 or more cigarettes 
a day enrolled in a clinical trial of a 21mg nicotine patch or placebo in 19 general 
practices in Oxfordshire, UK, between June 1991 and March 1992. They were 
invited to take part in a stop smoking study through a letter from their general 
practitioner (GP). They made an appointment with a nurse, who told them what 
53 
 
the study involved. Then they saw their GP one week later, this was when they 
were recruited, they were expected to quit completely from this day and given 
nicotine patches (ICRFGPRG, 1993). The patch was used for three months then 
stopped and participants were reviewed at four, eight and 12 weeks. Participants 
were followed up six and 12 months later (ICRFGPRG, 1993). Abstinence was 
confirmed by expired CO<10ppm when participants were using the nicotine patch 
and by salivary cotinine <20ng/ml after they had stopped using the patch. Cotinine 
is considered a more reliable measure of abstinence but, as it is a metabolite of 
nicotine, it cannot confirm abstinence during nicotine replacement therapy. An 
unplanned follow up took place eight years later, 1625 participants were living, we 
were able to trace and contact 1532 participants, 840 of these responded. 
Previous examination of this data showed baseline body mass index (BMI) was 
similar between responders and non-responders. However, responders were older 
(43.0 vs. 41.5 years p=0.010), more likely to be female (59% v 52% p<0.005) and 
have stopped smoking during the trial than non-responders (13% v 6% p<0.0001 
quit for 1 year) (Yudkin et al., 2003). Ethical approval for this was granted by 
Anglia and Oxford Multicentre Research Ethics Committee, and 86 local research 
ethics committees (Yudkin et al., 2003). 
 
2.2.2. Measures of height and weight 
Height and weight were measured at trial entry, although this was self-reported in 
19% of participants.  At eight year follow up, weight was self-reported on a 
questionnaire completed by post.  
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2.2.3. Characterisation of smoking status 
Participants completed questionnaires on smoking history and quit attempts that 
spanned the last eight years and smoking status was biochemically confirmed at 
each follow-up visit.  
2.2.3.1. Quitters 
Those who stopped smoking on or around quit day and declared continuous total 
abstinence from three months to one year and were still abstinent eight years later 
were defined as quitters.  Abstinence was confirmed by salivary cotinine 
concentration at three and six months, one and eight years.   
2.2.3.2. Smokers 
Those who were smoking at three months, six months, one year and eight years 
were defined as smokers. People not attending follow up in the first year were also 
classed as smokers. 
2.2.3.3. Relapsers 
Relapsers were those who were biochemically confirmed abstinent at three 
months, six months and one year but relapsed by eight years.  
2.2.3.4. Late quitters 
Late quitters were those who smoked during the first year but were confirmed 
abstinent at eight years.    
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2.2.4. Measure of alcohol intake 
Baseline data on weekly units of alcohol was collected by a trained nurse 
interviewer. Alcohol consumption was assessed by asking participants to report 
daily consumption of beer, lager or cider (pints), wine (glasses), sherry, vermouth 
or port (glasses), and spirits or liqueurs (single tots). Total weekly consumption 
was then converted to UK units (equivalent to 8g ethanol) per week.  
 
2.2.5. Baseline characteristics 
Baseline questionnaires included questions on age, gender, ethnicity, 
socioeconomic status, number of cigarettes smoked per day and the Horne 
Russell score as a measure of smoking addiction. 
 
2.3. Statistical Methods 
2.3.1. Weight change according to smoking status 
All statistical tests were carried out using Statistical Package for Social Sciences 
version 15 for windows software (SPSS 15.0). The characteristics of each of the 
four groups defined by smoking status were summarised with means and SDs or 
proportions. Chi squared tests and one-way ANOVA with Games-Howell post hoc 
testing were used to identify differences between the groups. Differences were 
taken into account in multivariate regression analysis (see below). Means, SDs 
and 95% confidence intervals (95% CI), were calculated for weight change within 
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each smoking status. We compared self reported weight and BMI data with 
measured weight and BMI data. 
 
We calculated the percentage of quitters that gained more weight than the 
average continuing smoker.  We compared the proportion of smokers that were in 
each of the groups defined by the World Health Organisation (WHO) categories of 
BMI (underweight <18.5kg/m2, ideal 18.5 to 24.9, overweight 25 to 29.9, and 
obese 30kg/m2and above (WHO, 2000) at baseline and at eight years using 
Mann-Whitney-U tests.   
 
Linear regression analysis was used to investigate the differences in weight 
change (from baseline to eight year follow-up) according to the four groups 
defined by smoking status. This was adjusted for potential confounders using 
multiple linear regression. Potential confounders were identified from the reviews 
on predictors of post cessation weight gain weight gain. These have been 
discussed in section 1.2.3. Categorical variables (treatment allocation, gender, 
ethnic group (white European/non-white European), and socio-economic status 
measured by the Registrar General‟s classification of occupational status (Drudy, 
1991) were recoded into dummy variables. Continuous variables (BMI, height, 
age, number cigarettes/day, smoking dependence measured by the Horn Russell 
(HR) score (Russell et al., 1974) and weekly units of alcohol consumed at baseline 
(1 unit defined as 8g of ethanol) were centred around the mean. These were 
entered stepwise (to avoid overfitting the model) and considered potentially 
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important if the association between them and the outcome had a p value of <0.2 
(Rothman & Greenland, 1998). 
 
2.3.2. Association with baseline BMI 
To investigate whether the effect of BMI depended upon smoking status linear 
regression was carried out in the combined sample of smokers and quitters. This 
analysis was conducted on smokers and quitters only for simplicity (excluding late 
quitters and relapsers). Terms indicating smoking status, baseline BMI in kg/m2 
and a multiplicative interaction term between the two were included.  Potential 
confounders were added as above.   
 
There was evidence that the association of BMI with weight change was 
dependent on smoking status and so separate models for quitters and smokers 
examined these relationships further.  In both models, we looked for curvilinear 
relations between BMI and weight change by sequentially adding linear, quadratic, 
and cubic terms for BMI. Ninety five percent prediction intervals were calculated 
from the best fitting models to estimate the likely weight gain of most quitters or 
smokers.  In sensitivity analysis, the analysis was repeated including relapsed 
smokers within the smokers group and late quitters within the quitters group.  
Outliers defined by extreme baseline BMI and extreme weight change were 
removed and the models re-run to examine whether the coefficients changed.  
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2.3.3. Association with baseline alcohol intake 
To investigate the effect of baseline alcohol intake on weight change linear 
regression analysis was used first with the combined cohort of smokers and 
quitters. We used higher order terms to investigate curvilinear relationships.  We 
investigated effect modification by gender, baseline BMI and smoking status using 
these terms and the appropriate multiplicative interaction terms.  As smoking 
status modified the effect of alcohol on weight change, separate regression 
equations were used for smokers and quitters.  In both sets of equations 
confounding was controlled as described above. We used Cook‟s distance as a 
measure of influential cases; if Cook‟s distance exceeded one we considered that 
outliers had the potential to influence our findings. 
 
2.3.4. Associations of weight change over eight years 
with patch or placebo use during quitting; age, gender, 
smoking rate and socioeconomic status at baseline 
We calculated mean difference in weight change (kg) and 95% confidence 
intervals (CI) between quitters who had received nicotine patch and those who 
had received placebo.  
 
We carried out a regression analysis of weight change over eight years in quitters. 
We forced age, gender, heaviness of smoking (measured here in cigarettes per 
day and as a measure of addiction using the Horne Russell score) and 
socioeconomic status, along with treatment group, alcohol consumption and 
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baseline BMI into a multivariable model. We did not use a stepwise analysis here 
as we were interested in the size of the coefficients of all these variables, 
regardless of their statistical significance. We did not include ethnicity as there 
was no ethnic variation within our quitters. We included a quadratic term for 
cigarettes per day and Horn Russell score, given that some studies have 
previously demonstrated a U-shaped association with smoking rate and weight 
gain (see section 1.2.3). 
  
2.4. Results 
2.4.1. Baseline characteristics 
Baseline characteristics of the smoking status groups differed modestly and 
significantly in age, treatment allocation, and Horn Russell Score (p<0.05) (Table 
10). Baseline weight data did not differ much or significantly between those whose 
weight was measured and those who self-reported. A t-test showed a mean 
difference of -0.58kg (-2.91, 1.75).   
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Variable smokers quitters relapsed Late quitter 
N* 613 85 26 116 
SES   (%)     
  I  (professional) 3 1 0 4 
  II (managerial/technical) 31 33 54 34 
  III (skilled, non-manual) 22 17 19 27 
  III (skilled, manual) 21 27 15 15 
  IV (partially skilled) 17 16 8 16 
  V (unskilled) 6 5 4 5 
Horn Russell score 
#$
(mean(SD))
 
15 (5) 14 (4) 16 (3) 14 (4) 
Cigs per day 24 (7) 23 (7) 27 (12) 23 (7) 
Weekly units alcohol 10.1 (13.0) 9.2 (9.6) 13.6 (19.9) 11.8 (11.6) 
Height (cm) 168 (9) 169 (9) 171 (9) 168 (9) 
Age
#&
(mean(SD)) 42 (10) 46 (11) 43 (11) 43 (11) 
BMI (mean(SD)) 25 (4) 24 (4) 25 (4) 26 (5) 
Ethnicity (%):     
White 98.2 100 100 100 
Asian 1.0 0 0 0 
South East Asian 
Afro-caribbean 
Other 
0 
0 
0.7 
0 
0 
0 
0 
0 
0 
0 
0 
0 
Not stated 0.2 0 0 0 
Active patch treatment (%)
#  
49 58 65 41
 
Women (%) 59 59 50 60 
*
data was not available in all categories for every person.  
#
ANOVA/Chi p<0.05 
$
Post hoc analysis: smokers v 
quitters p=0.089, relapsed v quitters p=0.067, smokers v late quitters p=0.093. 
&
Post hoc analysis: smokers v 
quitters p=0.057  
 
Table 10. Baseline characteristics by smoking status 
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2.4.2. Weight change over eight years 
Weight change in those who self reported at both points in time did not differ 
significantly from those who were measured at baseline and self reported at 8 
years. The mean difference (95% confidence interval) was -0.40kg (-1.67, 0.87). 
There was no significant difference between measured or self-reported baseline 
BMI. The mean difference was 0.47kg/m2 (-0.15, 1.09).  Eighty three percent of 
quitters gained more weight than the average smoker (Figure 1).  Over the eight 
years, 15% of quitters became obese compared to 2% of smokers, while 18% of 
quitters became overweight compared to 5% of smokers (Figure 2). 
 
2.4.3. Mean weight and BMI change according to 
smoking status 
Quitters gained 8.79kg (SD 6.36) and BMI increased by 3.26kg/m2 (SD 2.94). This 
was 6.55kg more than smokers; who gained on average 2.24kg (SD 6.65) in 
weight and a 0.94kg/m2 (SD 2.92) in BMI. Late quitters, who were not continuously 
abstinent during the first year but quit before eight years had a mean weight gain 
of 8.33kg (SD 8.84), and this was not significantly different to those who had been 
quit from the end of treatment. Those who had quit smoking for the whole of the 
first year and subsequently relapsed gained a mean of 3.28kg (SD 7.16); this was 
not significantly different to smokers.  Adjustment for potential confounders did not 
change these estimates (Table 11). 
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Figure 1 Percentage Frequency of Weight Change over 8 years according to 
Smoking Status
 
Figure 1. Percentage frequency of weight change according to smoking status 
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Figure 2. Percentage of smokers and quitters in BMI categories at baseline and at 
eight years 
 
 
2.4.4. Weight Change and Baseline BMI 
There was evidence that the association between BMI and weight change was 
modified by smoking status, with a p value for the interaction term being 0.002 
both with and without adjustment for potential confounders. Accordingly, separate 
regression models in quitters and continuous smokers were examined. 
quitters quitters 
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Smoking Status Unadjusted 
regression 
coefficient  
95%CI 
Lower 
 
Upper 
P value R
2
 Adjusted* 
regression  
coefficient  
95%CI 
Lower 
 
Upper 
P value R
2 
Constant
#
 2.245 1.692 2.797  0.133     0.182 
Quitters 6.576 4.992 8.161 <0.001  6.810 5.232 8.389 <0.001  
Relapsed 1.047 -1.694 3.788 0.454  1.064 -1.655 3.783 0.442  
Late quitters 6.108 4.722 7.494 <0.001  6.324 4.943 7.705 <0.001  
*Adjusted for confounding variables of baseline height, BMI, Horn-Russell Score, daily number of cigarettes, weekly units of alcohol, age in years, 
socioeconomic status and ethnic origin, gender and treatment group. 
#
In the unadjusted model, the constant can be interpreted as the weight gain in 
smokers (the reference group), but has no useful meaning in the adjusted model. 
 
Table 11. Regression analysis for weight change over eight years according to four groups of smoking 
status, smokers were used as the reference category 
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2.4.5. Association between BMI and weight change in 
quitters 
Regression modelling showed a significant linear association between BMI and 
weight gain in quitters.  Adding a quadratic term improved the fit (p for R2 change 
= 0.015), but the cubic term did not improve this further.  The quadratic model 
accounted for 11% of the variability in weight change (Table 12) and the 
coefficients changed only slightly on adjustment for potential confounders (Table 
12). This model estimated mean weight change over eight years in quitters of 
+9.8kg, +7.8kg, +10.2kg, +19.4kg where BMI was 18, 23, 29 and 36 respectively 
(Table 13, Figure 3). 
 
2.4.6. Association between BMI and weight change in 
smokers 
There was a significant, negative, linear association between BMI and weight 
change in smokers (p<0.001) and the fit was not improved by adding higher order 
terms (Table 14). The negative association remained largely unchanged when 
adjusted for confounders (p=0.002), (Table 14). This model estimated mean 
weight change smokers of +3.9kg, +2.6kg, 1.0kg and -0.8kg where BMI was 18, 
23, 29 and 36 respectively (Table 13, Figure 3). 
 
2.4.7. Sensitivity Analysis 
Late quitters were added to the quitters who had been abstinent for the entire 
eight years while relapsers were added to the smokers who had smoked for the 
entire eight years. The regression models on these combined groups gave similar 
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models and estimates to those derived from the smokers and quitters only (Table 
13).  
 
Excluding participants with higher baseline BMIs, extreme weight gain, and 
excluding outliers judged by visual inspection of a plot did not really change the 
findings (Table 13). 
 
2.4.8. Estimating weight change in individuals 
Although the estimates for mean weight change differed according to BMI, there 
was overlap in the estimates for individuals. Calculating 95% prediction intervals in 
quitters using the quadratic model gave values of -3 and 22kg for a BMI of 18, -4 
and 20kg for a BMI of 23 and -2 and 22kg for a BMI of 29 and 5 and 33kg for a 
BMI of 36.   
 
Calculating 95% prediction intervals in smokers using the linear model gave 
values of -9kg and 17kg for a BMI of 18, -10kg and 16kg for a BMI of 23, -12kg 
and 14kg for a BMI of 29 and -14kg and 12kg for a BMI of 33. 
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Figure 3. Predicted mean and confidence intervals for weight change according to BMI in smokers and abstainers.
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Figure 3. Predicted mean and confidence intervals for weight change according to 
BMI in smokers and quitters 
 
 
BMI terms 
Unadjusted 
regression 
coefficient  
95%CI 
Lower 
 
Upper 
P 
value 
R2 Adjusted* 
regression  
coefficient  
95%CI 
Lower 
 
Upper 
P value 
R2 
Constant 
BMI-linear# 
8.972 
0.382 
7.619 
0.008 
10.339 
0.757 
 
0.045 
 
0.047 
     
Constant 
BMI-linear#  
BMI-quadratic# 
7.947 
0.177 
0.071 
6.360 
-0.225 
0.014 
9.514 
0.578 
0.128 
 
 
0.015 
 
 
0.114 
 
0.217 
0.062 
 
-0.175 
0.006 
 
0.609 
0.118 
 
 
0.030 
 
 
0.172 
*Adjusted for confounding variables of baseline height, BMI, Horn Russell Score, daily number of cigarettes, weekly units of 
alcohol, age in years, socioeconomic status and ethnic origin. # Re-centred around the whole sample mean. 
Table 12. Regression model for the effect of BMI on weight gain in quitters 
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Baseline BMI Mean weight (95% CI) gain estimated from regression models containing:   
 Smokers Smokers 
Combined with 
relapsers 
Quitters Quitters excluding 
BMI>30kg/m
2
 
Quitters excluding 
BMI >30kg/m
2
 
and weight gain 
>20kg 
Quitters 
combined with 
late quitters 
Quitters combined 
with late quitters 
excluding  
(BMI>40kg/m
2
) 
18 3.9 (2.9, 4.9) 4.0 (3.0, 5.1) 9.8 (6.1,13.5) 10.9 (6.4, 15.7) 10.3 (6.3, 14.4) 10.6 (7.9, 13.5) 11.9 (8.6, 14.7) 
23 
29 
2.6 (2.0, 3.1) 
1.0 (0.2, 1.8) 
2.7 (2.2, 3.3) 
1.1 (0.3, 1.8) 
7.8 (6.4,9.3) 
10.2 (7.9,12.5) 
7.4 (5.6, 9.1) 
12.2 (5.7, 14.7) 
7.2 (5.7, 8.9) 
10.2 (7.5, 16.8) 
8.6 (7.5, 9.7) 
7.6 (6.2, 9.1) 
8.4 (7.3, 9.6) 
7.6 (6.3, 8.8)  .  ( . , . ) .  ( . , . ) .  ( . , 12.5) .  ( . , . ) .  ( . , . ) .  ( . , . ) .  ( . , . ) 
36 -0.8 (-2.4, 0.8) -0.8 (-2.4, 0,7) 19.4 (12.7,26.0)   8.3 (7.2, 9.3) 11.2 (8.5, 13.9) 
40 -2.6 (-5.1, -0.3) -2.8 (-5.2, -0.3)    9.6 (7.8, 11.2)  
*outliers are BMI>30kg/m
2
, weight gain >20kg and BMI>40kg/m
2
 
Table 13. Estimated mean weight gain according to BMI for „smokers‟, „quitters‟ and „quitters without potential 
outliers*‟, „smokers combined with relapsers‟, and „quitters combined with late quitters‟ 
 
Smoking 
Status 
Unadjusted 
regression 
coefficient  
95%CI 
Lower 
 
Upper 
P value 
R
2 
Adjusted* 
regression  
coefficient  
95%CI 
Lower 
 
Upper 
P value 
R
2 
Constant 2.206 1.673 2.738  0.155     0.243 
BMI
#
 -0.265 -0.401 -0.128 <0.001  -0.222 -0.358 -0.087 0.002  
Age in years
#
      -0.131 -0.186 -0.076 <0.001  
*Adjusted for confounding variables of baseline height, BMI, Horn Russell Score, daily number of cigarettes, weekly units of 
alcohol, age in years, socioeconomic status and ethnic origin.
 #
 Re-centred around the whole sample mean  
 
Table 14. Regression model for the effect of BMI on weight gain in smokers 
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2.4.9. Baseline alcohol consumption as an effect 
modifier of weight change according to smoking status 
In the model including smokers and quitters, baseline alcohol consumption was 
not associated with weight change.  However, there was a significant interaction 
between smoking status and alcohol consumption before (p=0.019) and after 
(p=0.010) adjustment for confounding variables.  
 
2.4.10. Association between alcohol consumption and 
weight change in smokers 
Separate linear regression modelling in smokers found no association between 
alcohol consumption and weight gain (regression coefficient: 0.005, 95% CI-0.037, 
0.046; p=0.827). There was no evidence that this effect differed by gender, (p for 
interaction term 0.728) or baseline BMI (p for interaction term 0.911). Cook‟s 
distance did not exceed one (min <0.001, max 0.03). 
2.4.11. Association between alcohol consumption and 
weight change in quitters 
There was a significant, negative linear relationship between weight change and 
alcohol consumption in quitters (p = .015, r2 = .070). For every additional unit of 
alcohol consumed per week at time of quitting, mean weight change over eight 
years was −0.174 kg (95% CI: −0.315 to −0.034) p=0.015 (unadjusted) (Figure 4) 
(adjusted: −0.180 kg (95% CI: −0.318 to −0.043) p = 0.011). Fit did not improve 
with higher order terms and effect did not differ by gender (p for interaction was 
0.91). Cook‟s distance did not exceed one (min <0.001, max 0.087).  
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2.4.12. Variability of weight change in quitters according 
to baseline alcohol consumption and BMI  
We have previously demonstrated that 11% of the variability in weight gain in 
quitters (Table 12) was accounted for by a J-shaped curve with baseline BMI 
(Figure 3). There was no evidence that the association between alcohol and 
weight gain was modified by baseline BMI; p for interaction was 0.290. The effects 
of BMI and alcohol consumption were therefore independent, together they 
account for 17% of the variability of weight gain in quitters (Table 15).  The 
regression lines for mean population weight gain according to BMI at different 
levels of alcohol consumption are plotted (Figure 5). 
 
 
 
Figure 4. Weight change over 8 years in quitters (n=84) according to baseline 
alcohol consumption in quitters 
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Figure 5. Weight change according to BMI and baseline alcohol consumption in 
quitters 
 
 
 
Variable Regression 
coefficient* 
Lower 95%CI 
 
Upper 95%CI p value r
2
 
Constant 
BMI
#
  
BMI
2
 
# 
Alcohol units/week
#
 
7.886 
0.217 
0.062 
-0.161 
6.360 
-0.175 
0.006 
-0.296 
9.412 
0.609 
0.118 
-0.026 
<0.001 
0.274 
0.030 
0.020 
0.172 
*Stepwise adjustment, using p=0.2 cut-off for confounding variables of baseline height, BMI, Horne Russell Score, 
daily number of cigarettes, weekly units of alcohol at baseline, age in years, socio-economic status and ethnic 
origin. # Re-centred around the total sample mean. 
Table 15. Regression Analysis of weight change according to baseline BMI and 
alcohol consumption in quitters 
 
 
 
BMI (kg/m
2
) 
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2.4.13. Weight change over eight years with patch or 
placebo use during quitting  
On active patch treatment, there were 49 people who remained abstinent for eight 
years and they gained a mean (standard deviation) of 8.84kg (5.82) while the 36 
smokers using placebo patches, who remained abstinent for eight years gained 
8.73 (7.11)kg.  The mean difference (95% confidence interval) was 0.11kg (-2.68, 
2.90). 
 
2.4.14. Associations of weight change over eight years 
with age, gender, smoking rate and socioeconomic status at 
baseline 
Age, gender, cigarettes per day, Horne Russell score, socioeconomic status and 
treatment group were not significantly associated with weight change over eight 
years in our group of continuous quitters (Table 16), although the point estimates 
required further discussion to examine their clinical importance. The coefficients 
provide a mean point estimate of these associations (Table 16). 
2.4.14.1. Age 
For age, the coefficient represented a 20g increase over eight years for every 
additional year of age at baseline.  This means a 25 year age difference in 
baseline age would be required before an associated 0.5kg difference in weight at 
eight years was seen.  
2.4.14.2. Gender 
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The coefficient for gender showed women gained approximately 1.8kg more than 
men at the end of eight years of abstinence. In unadjusted analysis this was a 
difference of 1.69kg (-1.09, 4.48). 
2.4.14.3. Smoking rate 
For every additional cigarette smoked daily at baseline, there was an associated 
mean weight increase of 50g eight years later. So 20 cigarettes (1 pack) extra a 
day would need to be smoked to see an associated increase of 1kg eight years 
later.  An increase in the level of addiction to smoking, as measured by an 
increase of 1 in the Horne Russell score, increased weight by 0.2kg after 8 years 
of abstinence. The mean (SD) HR score in our sample was 14(4) and scores 
ranged between 4 and 23. Therefore, those who were more addicted, for example 
scoring 7 points higher on the HR score, had an associated weight gain of 1.4kg 
more after 8 years of abstinence than those who were less addicted.  
2.4.14.4. Socioeconomic status 
The coefficients for socioeconomic status (SES) categories were large, but the 
95% confidence intervals were very wide and outside of the range of weight 
change within our sample. To get an idea of the overall effect of SES rather than 
individual effects of smaller categories we examined whether the model without 
adjustment for SES was improved significantly by adding in all the SES 
categories. The improvement in fit was not significant (p=0.18). 
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Unstandardized 
Coefficients 95% Confidence Interval for B 
Sig. B Lower Bound Upper Bound 
(Constant) 12.13 2.39 21.88 0.015 
SES II (managerial/technical)* -3.88 -13.77 6.01 0.437 
SES III (skilled, non-manual)* -3.72 -13.97 6.52 0.471 
SES III (skilled, manual)* -3.36 -13.17 6.45 0.496 
SES IV (partially skilled)* -3.79 -13.90 6.33 0.457 
SES V (unskilled)* -4.26 -15.77 7.26 0.463 
Age
# -0.02 -0.16 0.12 0.788 
Cigarettes smoked per day
# 0.05 -0.25 0.35 0.728 
(Cigarettes smoker per day
#
)
2 0.00 -0.02 0.01 0.945 
Horn Russell score
# 0.21 -0.23 0.66 0.340 
(Horn Russell score
#
)
2
 0.01 -0.07 0.08 0.884 
Weekly baseline alcohol consumption
# -0.17 -0.35 0.00 0.051 
Treatment group* -1.33 -4.42 1.75 0.391 
Gender* 1.83 -2.56 6.22 0.409 
BMI
# 0.49 0.07 0.91 0.023 
*reference category for SES was I (professional), for treatment group was placebo, for gender was male 
#
values were re-
centered around the mean 
 
Table 16. Coefficients with 95% confidence intervals for potential explanatory 
variables of weight gain in continuous quitters over eight years 
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2.5. Discussion 
2.5.1. Findings 
2.5.1.1. Weight change according to smoking status 
In a cohort of people trying to stop smoking, those who failed and continued 
smoking for eight years gained about 2kg. Those who abstained from smoking for 
eight years gained nearly 9kg.  People who stopped smoking for a whole year but 
then resumed smoking had a weight gain that was similar to and not significantly 
different from smokers.  Some quitters gained much more weight than average 
with only a quarter of long-term quitters being a healthy weight after eight years. 
 
2.5.1.2. Association with baseline BMI 
Quitters who were underweight or overweight on cessation were more likely to 
gain more weight than those in the healthy BMI range. These findings were robust 
to sensitivity analyses. 
 
2.5.1.3. Association with baseline alcohol intake 
For every unit of alcohol quitters consumed at baseline they weighed 0.17kg less 
eight years later than those who did not drink. This equates to people drinking 
alcohol at the maximum UK recommended weekly intake for women (14 units or 
112g ethanol/week) weighing a mean 2.4kg less than those who did not drink. 
This association was not significantly different in females and males. The effect 
was independent of baseline BMI.  
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2.5.1.4. Associations of weight change over eight years with 
patch or placebo use during quitting; age, gender, smoking rate and 
socioeconomic status at baseline 
We found no evidence of a statistically significant association between weight gain 
over eight years of abstinence and placebo or patch treatment at baseline, age at 
quitting, baseline smoking rate, gender or socioeconomic status. 
 
2.5.2. Strengths and limitations of this study 
2.5.2.1. Characterisation of smokers and quitters  
In a cohort of smokers followed for eight years, many smokers will try to quit and 
many quitters relapse.  All quitters were biochemically verified as abstinent four 
times over the eight year follow up. Likewise although some smokers tried to quit, 
they were smoking at each follow up point.  The strength of this study therefore 
lies in its accurate characterisation of both these groups, which leads to more 
precise estimates of weight change. There is evidence that post cessation weight 
gain is under-estimated when smoking status is measured by point prevalence or 
by self-report because self-reported point prevalence will classify intermittent 
smokers and recent quitters as abstinent (Klesges et al., 1989, Klesges et al., 
1997).  
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2.5.2.2. BMI investigation robust to sensitivity analysis 
The cohorts of late quitters and relapsers are less well characterised as the time of 
individuals quitting and relapsing is variable, these events could occur at any time 
after year one and before year eight. However, these groups showed similar 
estimates of weight change and weight change in relation to baseline BMI, 
indicating that for most their relapsed or quit state was sufficiently well established 
for weight change to reflect that of long term quitters and smokers.  In support of 
this, other studies have shown that the greatest weight change associated with 
smoking status occurs rapidly (O‟Hara et al., 1998). 
 
2.5.2.3. Reporting bias 
This study is limited by use of self-reported weight and BMI data at eight year 
follow-up. However, sensitivity analysis showed no differences in mean baseline 
weight, BMI or weight change when measured and self-reported data was 
compared. The validity of self-reported weight data has also been demonstrated in 
other epidemiological studies (Spencer et al., 2002), suggesting that reporting bias 
is not a likely explanation of our results.  
 
To explain the J-shaped association of baseline BMI with post cessation weight 
change in quitters by reporting bias the pattern of misreporting weight would have 
to vary in a particular way. Either it would have to vary by baseline BMI such that 
people with a low or a high BMI eight years previously would over estimate their 
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current weight or people with an ideal BMI eight years ago would underestimate 
their current weight. This seems unlikely.  
 
Similarly, alcohol consumption may have been underreported. However, 
underreporting of both measures could not account for the association we 
observed. For underreporting to explain the association, those who underreported 
weight would have had to over-report alcohol consumption and/or vice versa and 
this seems counterintuitive.  
   
Alcohol was measured by careful questioning at baseline only. There is evidence 
that a single measure of alcohol consumption is a reasonable estimate of average 
alcohol consumption over several years.  The Nurses‟ Health Study shows a high 
correlation between alcohol intake at a single point in time and alcohol intake over 
the following 6 years (r=0.75) (Giovannucci et al., 1991). Also there is evidence 
from a large cohort that alcohol consumption does not change as a consequence 
of quitting smoking (Murray et al., 1996).   
 
2.5.2.4. Response bias 
Only 52% of the living participants enrolled in the original trial responded at eight 
year follow up, with success at quitting in the trial being the factor most strongly 
associated with response.  However, non response is an unlikely explanation of 
our findings and it is reassuring that baseline weight and BMI did not differ 
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between responders and non responders. The study participants enrolled in a 
smoking cessation study and responded to a questionnaire on smoking status at 
follow up, with only a single question on weight.  It is unlikely therefore that 
whether individuals gained weight or their pattern of weight change in relation to 
BMI was associated with failure to respond.  For non-response to explain the 
association between BMI and weight change, weight change in non responders 
would have to have been the reverse of what we observed in responders.  That is 
among non-responding quitters weight gain would have resulted in an inverted-J 
shaped relation with baseline BMI, with those of a healthy BMI gaining the most 
weight.  There is no plausible reason for such an association.  
Similarly, if non response were to account for the association of weight change 
with baseline alcohol intake non-responders would have gained more weight the 
more alcohol they consumed at baseline. While this remains a possibility, as this 
was primarily a smoking cessation study, there is no reason to believe that a 
participant‟s perception of weight gain or alcohol consumption influenced their 
decision to complete the questionnaire.  
 
2.5.2.5. The role of confounding 
It is possible that confounding explains the association of weight change with 
baseline alcohol intake.  As this was a smoking cessation trial analyses on weight 
change were not planned; consequently behaviours such as diet and physical 
activity were not assessed.  It is possible that those who drank more alcohol at 
baseline also had better dietary behaviour and did more physical activity than 
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those who drank less. There is cross sectional evidence which shows a positive 
correlation between moderate alcohol intake and habitual physical activity (r=0.41 
p<0.01) (Westerterp et al., 2004), but prospective studies have reported higher 
alcohol consumption is associated with lower weight gain after adjustment for 
physical activity and diet (Wannamethee & Shaper, 2003, Wannamethee et al., 
2004, Wang et al., 2010).   To explore this in an ex-smoking population we carried 
out regression analysis on data from the Health Survey for England (HSE).   
 
The HSE generates a cross sectional dataset from annual surveys on the health 
and lifestyle of a large number of people in England.  For maximum compatibility 
with our own data set of quitters we carried out our analysis on a subset of white 
ex-smokers. The distribution of socioeconomic class was similar between both 
sets of data.  We used the 1998 HSE dataset as this was the nearest year to our 
cohort which contained comprehensive data on alcohol intake, physical activity 
and dietary patterns in over 4000 ex-smokers. We excluded those classified as 
problem drinkers. 
 
We found in unadjusted analysis that an extra unit of alcohol drunk per week is 
associated with an average increase in 2.6 minutes of activity each week, 
including an extra 0.03 days a month doing 20 minutes or more, moderate to 
vigorous physical activity. So someone consuming 14 units of alcohol a week 
compared to no alcohol may be doing an extra 36 minutes of activity each week, 
including an extra 0.4 days a month doing 20mins of moderate or physical activity. 
If we consider a 68kg person walking briskly for one hour would burn 
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approximately 320kcal, an extra 36 minutes of similar intensity exercise each 
week would burn an extra 192 kcal or theoretically an extra 27kcal each day. A 
daily deficit of 550kcal is required for a 0.5kg weight loss over one week. So an 
extra 27kcal expended daily could account for a theoretical weight change of 
0.02kg each week. Based on this reasoning over 8 years one might expect an 
8.3kg difference in weight to be seen, but this is not born out in epidemiological 
studies. Current available evidence suggests that even the recommendation of 30 
minutes physical activity a day for cardiovascular fitness, is insufficient to prevent 
weight gain and 45 to 60 minutes moderate intensity activity each day is 
considered necessary (Saris et al., 2003, Wareham et al., 2005). Given this, the 
extra 36 minutes of activity a week associated with moderate alcohol consumption 
is unlikely to account for the impact of alcohol on weight. 
 
We analysed nine indicators of a healthy diet from food frequency questions. 
There was a statistically significant association with all of these, although the sizes 
of these associations were too small to be meaningful and the directions of these 
associations were inconsistent. Some indicators showed alcohol consumption was 
associated with a less healthy diet, namely more frequent salt use, red meat and 
fried food consumption, a greater amount of total fat and less frequent fruit and 
vegetable consumption. Other indicators found alcohol consumption was 
associated with a more healthy diet, namely more fibre and less frequent 
consumption of chocolate/crisps/biscuits and cakes. The largest association was 
seen for cake consumption, which was equivalent to one additional unit of alcohol 
resulting in an odds ratio of 0.987 for eating less cake.  
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Therefore although we did not measure physical activity and diet in our cohort, 
these findings suggest that they are unlikely to be confounding the association we 
found. However further studies which measure and adjust for these within the 
same study population are needed before we can be certain. 
 
Our measure of alcohol consumption gave an estimate of total quantity of alcohol 
consumed on a weekly basis but no detail on the pattern of drinking. As 
mentioned in the introduction consideration of drinking pattern may have helped to 
explain our findings further.  
 
2.5.2.6. Lack of a never-smoker category 
Our cohort did not contain never-smokers so we have been unable to compare 
weight change in smokers and quitters to never smokers. However data from 
other cohorts allows some comparison which helps us to consider the impact this 
weight gain has on the population‟s weight as a whole. The OXCHECK  cohort 
(Tang et al., 1997) and the Caerphilly male cohort (Munafo et al, 2009) show 
weight gain in quitters during the first five years after stopping is greater than in 
never smokers. Cross sectional analysis of these cohorts show never smokers 
and ex-smokers have a similar BMI in the longer term. However cross sectional 
studies show the BMI of ex-smokers exceeds that of never smokers, particularly in 
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men, suggesting that post-cessation weight gain has public health importance 
(Klesges et al., 1989, Akbartbartoori et al., 2005, section 1.2.2). 
 
2.5.2.7. Lack of ethnic diversity 
Our cohort included predominately white European people living in Oxfordshire, 
UK.  There is evidence that weight gain varies by ethnic group.  For example, 
African Americans have greater weight after stopping smoking than European 
Americans (Williamson et al., 1991, Klesges et al., 1998).  It is therefore possible 
that other ethnic groups might have a different pattern of weight gain in relation to 
baseline BMI or alcohol intake than we observed in this cohort.  
 
2.5.3. Comparison with other literature 
2.5.3.1. Weight change according to smoking status 
We know of only two other prospective studies that have reported on weight gain 
over the long-term in biochemically confirmed quitters.  The Lung Health Study 
found quitters gained 8.2kg over five years whereas smokers gained 1.6kg, a 
difference of 6.6kg (O‟Hara et al., 1998), almost identical to that we reported here.  
A smaller study of 45 quitters showed a mean weight gain of 8.9kg over 4 years 
but did not report weight change for continuing smokers (Daughton et al., 1999).    
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2.5.3.2. Association with baseline BMI 
No other studies have looked for a curvilinear relationship of weight gain 
according to BMI, although some studies have hinted that such a relationship 
might exist. Froom et al. reported weight gain was lowest in those with a BMI 
between 25.8-27.7kg/m2 and higher in those with a BMI above or below these 
values (Froom et al, 1999). Caan et al. found that lighter and heavier women 
gained more weight than those of intermediate weight, but this pattern was not 
seen after adjusting for confounders (Caan et al., 1996).  Other studies have 
reported no association with baseline BMI (Rabkin, 1984, Rodin et al, 1987) some 
have found a negative linear association (Flegal et al., 1995, Bosse et al., 1980, 
Nides et al., 1994) and some a positive linear association (Dale et al., 1998, 
Kawachi et al., 1996). This may be explained because these studies modelled a 
linear relationship between BMI and weight gain. A linear model would tend to 
show no association or a weak positive linear association if the true association 
was U- or J-shaped.  Re-evaluating data from the Lung Health Study and the 
Caerphilly cohort using polynomial modelling would be useful to confirm or refute 
our results.  
2.5.3.3. Association with baseline alcohol intake 
In a cohort study of smokers and quitters, spanning two to four years, quitting 
smoking was associated with an increase in BMI, higher alcohol consumption, 
measured at one point in time, attenuated this rise in BMI. When investigated 
there was no evidence of effect modification by smoking status.  However smoking 
status was self reported and quitting date was variable (any time after study entry), 
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so a smaller weight gain may have diluted the results. That study may also have 
lacked power to detect an effect modification because there were only 65 quitters 
and alcohol consumption was a binary variable (Froom et al., 1999).   
 
A two year cohort found a small but significant inverse effect of alcohol 
consumption at the time of quitting and subsequent weight gain in female smokers 
and quitters. This effect was seen after adjustment for physical activity (Kawachi et 
al. 1996). There was no investigation of interaction by smoking status. Abstinence 
was measured by point prevalence which may have underestimated weight gain 
and accounted for the small effect size seen.  
 
Our findings are similar to the results from the Lung Health Study (Nides et al., 
1994) which followed biochemically validated continuous quitters for 5 years.  The 
data showed that for each standard US drink per week consumed at baseline, the 
regression coefficient was -0.098 (p=0.02) in men and -0.234 (p=0.02) in women. 
(Although the Lung Health Study team reported these coefficients separately for 
each gender, there is no statistically significant difference between them according 
to our calculations).  Equating these to UK units gave regression coefficients of -
0.083 and -0.132 for men and women respectively. These values fit within the 
95% confidence intervals our mixed sample but suggest a slightly lower effect than 
we found.  The Lung Health Study also measured self reported alcohol 
consumption at baseline only and did not measure or adjust for physical activity or 
diet. 
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2.5.3.4. Weight change over eight years with patch or placebo 
use during quitting 
Our data showed no evidence that active NRT has a long-term effect on reducing 
weight gain but are too imprecise to exclude this possibility.  However, the data 
from one year follow up in a Cochrane review (Parsons et al, 2009) also showed 
no sign of efficacy for nicotine patch to prevent weight gain, with a mean 
difference of -0.15kg (-1.04, 0.74).  The possible effect of NRT seen at one year (-
0.44kg (-1.02, 0.14) was generated by three trials of nicotine nasal spray where 
spray use was allowed for up to one year and 21% of abstinent smokers 
continued to use it. These trials had a combined effect of -1.55kg (-3.09, -0.00) 
compared to placebo. Therefore it seems unlikely that patch use at the time of 
quitting has a long term effect on attenuating post cessation weight gain.   
 
2.5.3.5. Association with age 
As described in the introduction to this chapter the association between younger 
age and greater post cessation weight gain has previously been shown in three 
out of seven studies, with four showing no association. Our study adds another 
which shows no significant association and again our mean point estimate, of a 25 
year difference associated with 1kg difference in weight gain after eight years, was 
minor compared to other studies. One previous study showed a mean difference 
in baseline age of one year between those who lost weight and those who gained 
excessive amounts over 15 years (Swan et al., 1995). Another found the chance 
of a 5kg further weight gain, in more than one year of abstinence, almost doubled 
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in those under 55 years compared to those over 55 years old (Williamson et al., 
1991). However, our mean estimate again had wide confidence intervals which 
included larger estimates so we cannot be certain of no association. 
 
2.5.3.6. Association with gender 
We also found no significant association with gender; however, the coefficient was 
large enough to be of clinical importance, with an unadjusted estimate of mean 
weight gain of 1.69kg more in men, after eight years cessation, than women.  As 
described in the introduction to this chapter three out of seven studies have shown 
a greater weight gain in women. Two studies have shown no association and two 
studies have shown a greater weight gain in men. Our study continues to leave us 
with inconsistent results.  
 
2.5.3.7. Association with smoking rate 
Of all the explanatory variables we included in our regression analysis on weight 
change in continuous quitters, we expected lower smoking rate to be associated 
with less weight gain, as this has been the most consistent finding in the literature 
so far (section 1.2.3). However, we did not find evidence of this in our quitters 
despite a wide range of smoking rates from 15 to 60 cigarettes per day. Instead, 
we found a non statistically significant mean difference that showed an extra 
packet of cigarettes smoked daily was associated with 1kg difference at eight 
years. However, the confidence intervals were wide and extended to include the 
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possibility of a larger estimate, so we cannot be certain that no association exists. 
The magnitude of weight change in those who were more addicted to smoking 
was a little larger, with an increase in Horne Russell score of seven being 
associated with an increase of 1.5kg, eight years after quitting. These differences 
although important from a public health perspective are smaller than previous 
estimates.  Previous estimates have found the increased chance of a further 5kg 
increase, in more than one year of abstinence, is associated with smoking 10 
cigarettes per day more at baseline (Williamson et al., 1991).   As discussed in 
chapter one, three of 14 studies also found no association, and we have now 
added a fourth, although our study was too small for us to be certain.   
 
2.5.3.8. Association with socioeconomic status 
We also found no association with socioeconomic status; this is in contrast to two 
studies so far which have found greater weight gain in those with a lower 
socioeconomic status. However, the number of individuals split between the 
categories was small with the majority being between socioeconomic class two to 
four so there was little scope to allow for differences to be examined accurately.  
 
2.5.4. Implications for clinical practice 
Patients in a smoking cessation clinic want to know how much weight they might 
gain on cessation.  The mean and 95% confidence intervals give information 
about average or population effects, but do not give individuals a range in which 
their weight is likely to lie. These are better defined by prediction intervals. Our 
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models showed that someone with a BMI of 22kg/m2 who quits smoking and 
maintains abstinence can expect to lose up to 2kg or gain up to 20kg.  Therefore 
the 95% prediction intervals were wide, however, at higher BMIs, the prediction 
intervals were more useful with a 95% chance that someone with a BMI of 36 
would gain between 5kg and 33kg.  
 
Adding alcohol consumption at baseline into the equation enabled us to explain a 
further 6% of the variability in weight change in quitters, but again the confidence 
intervals were wide and estimates imprecise.  Therefore predicting weight change 
on these baseline characteristics is currently too imprecise to be used in clinical 
practice and further analysis in larger datasets is required.  
 
Moderate drinking, with the potential to prevent a weight gain of 2.4 kg over eight 
years (0.3 kg/year), in a population of ex-smokers could have a significant public 
health impact. An increase of 0.7 kg/year has been shown to increase the risk of 
developing diabetes by 86% in those with impaired fasting glycaemia (Gautier et 
al., 2010). Those who quit smoking are at increased risk of developing diabetes for 
about five years after cessation, which is unexplained by weight gain alone (Hur et 
al., 2007, Wannamethee et al., 2001, Yeh et al., 2010). There is also consistent 
systematic review evidence that shows moderate alcohol consumption is 
associated with the lowest risk of developing diabetes (Baliunas et al., 2009, 
Koppes et al., 2005). However, evidence is currently insufficient to recommend 
quitters increase alcohol intake to moderate levels as a means to prevent weight 
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gain. Such recommendations would also need to be carefully balanced against the 
harmful effects of increasing alcohol intake. 
 
2.5.5. Implications for research 
If the association between BMI and weight gain on cessation is causal, we would 
need to delineate behavioural or physiological mechanisms.  Nicotine suppresses 
appetite and increases metabolic rate (Hofstetter et al., 1986).  Underweight 
smokers might gain more weight than ideal weight smokers because they are 
particularly susceptible to these effects and, when they are removed by stopping 
smoking, greater weight gain results. Those who are already obese while smoking 
may have a cluster of unhealthy behaviours if, for example, they also eat a high fat 
diet, this may be accentuated without nicotine to restrain their appetite. This may 
result from an increased appetite for sweet and fatty food (Caan et al., 1996). 
Alternatively those who are obese while smoking might be those who are 
genetically predisposed to obesity, perhaps through poor expression of appetite 
regulatory hormones (Cummings & Schwatz, 2003, Wynne et al, 2005) and, once 
the appetite suppressing effect of nicotine is removed, weight increases more than 
in healthy weight counterparts.  
 
If the association between alcohol intake and post cessation weight gain was 
causal  it is plausible that MESO induction in quitters may play a role in increasing 
metabolic rate. We did not measure changes in metabolic rate, energy intake or 
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physical activity, and studies which do so are required to understand the 
mechanisms which might account for the associations we found. 
 
2.6. Conclusions 
Smokers who quit smoking gain 7kg more than if they had continued smoking, 
while those who quit for a substantial period and then resume smoking seem to 
resume their „smoking weight‟. This study is the first to look for and find a J-
shaped relation between baseline BMI and weight gain in quitters.  If confirmed, 
this has important implications for the treatment of tobacco addiction. Knowing that 
underweight and obesity predicts greater weight gain on cessation helps clinicians 
plan interventions with their patients and guides epidemiological and physiological 
investigations into causes of weight gain on smoking cessation.  
 
A complex relationship exists between alcohol consumption and weight gain. We 
have found a dose response relationship in quitting smokers, which is consistent 
across studies. It is plausible that MESO induction may play a role in this. 
Therefore, advice to reduce alcohol consumption in this population may promote 
rather that prevent weight gain. Studies are needed to investigate the mechanisms 
of alcohol metabolism in quitting smokers and weigh the adverse health 
consequences of increasing alcohol against the benefit of smaller weight gain. 
Increasing alcohol should not currently be advised for preventing weight gain dur-
ing smoking cessation.   
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We found no evidence of an association between weight gain over eight years of 
abstinence and treatment group, age at quitting, baseline smoking rate, gender or 
socioeconomic status. However, our estimates were imprecise so we cannot be 
certain and larger prospective studies in biochemically validated continuous 
quitters are required. 
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3. TRIAL PROTOCOL: DIETARY 
MANAGEMENT IN SMOKERS TRIAL 
(DeMiST) 
Chapters three to six report on DeMiST. A CONSORT checklist for the reporting of 
this trial is included in Appendix 5. 
Chapter three meets objective three of this thesis, to discuss the design of the 
Dietary Management in Smokers Trial (DeMiST), a randomised controlled trial to 
investigate the feasibility of dietary interventions to prevent weight gain within NHS 
stop smoking clinics and examine the effects of these dietary interventions on urges 
to smoke.  
 
This protocol was published in the journal Trials (Lycett et al., 2010, Appendix 6). The 
original present tense of the publication has been changed to past tense to fit better 
with the thesis and some details on statistical analysis have been added. 
 
3.1. Introduction 
As discussed in section 1.5.4 a Cochrane review (Parsons et al, 2009) showed some 
evidence that both an individiually tailored dietary plan and a very low calorie diet 
(VLCD) reduced weight gain and the VLCD increased abstinence.   
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The effect of the VLCD on improving abstinence was unexpected. One hypothesis is 
that the VLCD induced ketosis, which actually suppressed hunger (Johnstone et al., 
2008) and therefore reduced urges to smoke. This hypothesis is supported by data 
supplied by Danielsson (personal communication), which showed a statistically 
significant reduction of urges to smoke and a smaller increase in appetite during the 
weeks on the VLCD diet than those in the control intervention. There was a 50% 
reduction in urges to smoke after one week on the VLCD diet compared to a 27% 
reduction after one week in the control group (P<0.0001). There was a 4-fold 
increase in hunger in the control group after one week compared to only a 50% 
increase in hunger in the VLCD group (p<0.0003). 
 
We compared three dietary interventions. A VLCD, and an individual dietary and 
activity plan (IDAP) which included a modest energy restriction, using a low fat diet 
that meets the energy requirements of an individual‟s BMR. The third was a control 
condition where general healthy eating advice was provided, but with an emphasis of 
avoiding hunger, this is typical of the current advice given in NHS stop smoking 
services.  
 
Feasibility was the trial‟s primary outcome and we assessed this by measuring 
recruitment and attrition rates. We also assessed acceptability through seeking the 
views of the participants and clinicians who took part.  
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We developed and tested a tool to help non dietary experts assess and advise on 
diet, this tool also aimed to measure dietary change as a process by which weight 
change may have occurred. 
 
The other main objective of DeMiST was to test the hypothesis that hunger increases 
urges to smoke and ketosis reduces urges to smoke. We thought we could include 
this within the feasibility trial as a small sample provided adequate power to test this 
association. We developed and tested a tool to measure hunger and food craving for 
this purpose. 
 
3.1.1. To maximise the difference in hunger between trial 
arms 
The VLCD trial (Danielsson et al., 1998) reviewed in the Parson‟s et al Cochrane 
review used a VLCD intermittently. This may have underestimated the potential effect 
of the VLCD on nicotine withdrawal symptoms. Moving into and out of a ketotic state 
may influence mood and hunger, both symptoms of nicotine withdrawal.  
 
We expected hunger to be greatest in the IDAP group where a moderate energy 
restriction creates a negative energy balance. Appetite then increases in response to 
the usual physiological and neurological mechanisms that work to restore energy 
homeostasis (Wynne et al., 2005). In the control condition, we expected hunger to be 
alleviated by eating freely. 
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We began the VLCD one week before quit day to ensure participants were in ketosis 
before they quit (verified by the presence of urine ketones) and continued, 
uninterrupted, for a further four weeks when nicotine withdrawal would be at its peak. 
The IDAP also began one week before quit day to establish an energy deficit and 
increase the likelihood of hunger in this intervention before the quit date. The control 
group were advised to eat as usual. Therefore, at the time of quitting we expected to 
see the maximal differences in hunger scores between the three groups. 
 
3.1.2. To measure hunger and food craving 
To measure a change in appetite, when food is restricted we cannot rely on a 
measurement of food intake. Rather we need a measure to capture motivation to eat. 
As discussed in section 1.3.3 motivation to eat which is affected by nicotine can 
broadly be described as two main responses. A homeostatic response to food 
deprivation and a hedonic response to food reward (Saper et al., 2002, Blundell, 
2006). 
 
The first response we called „genuine hunger‟, derived predominantly from a 
physiological need for food, commonly perceived as an abdominal sensation and 
described as emptiness in the stomach. When hungry, a wide variety of foods will 
satisfy.  
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The second motivation we termed „food craving‟, this is most commonly described in 
the scientific literature as „an intense desire to eat a specific food‟ (Pelchat et al., 
2004). Food craving can occur irrespective of hunger, although hunger and food 
cravings have been shown to be interdependent (Gibson & Desmond, 1999).  
 
The precise mechanism of food craving has been much debated. Some studies have 
demonstrated that like tobacco addiction (Balfour, 2004), dopamine is released in the 
nucleus accumbens in response to eating the desired food (Martel & Fantino, 1996, 
Pelchat et al., 2004).  Others have suggested endogenous opioid peptides (Mercer & 
Holder, 1997) or a central serotonin deficit (Wurtman & Wurtmen, 1986) trigger food 
cravings. However the serotonergic hypothesis has been questioned in later studies 
(Christensen, 1997). Food craving has also been hypothesied as a learned response 
(Gibson and Desmond, 1999) and a response to food related cues (Christensen, 
2007). 
 
Measurement of hunger and food craving has also been debated. The subjective 
nature of these terms makes them hard to standardize although several scales have 
been developed which have shown good internal consistency. The Food Craving 
Inventory (FCI) measures craving for specific foods (White et al., 2002). The Trait 
and State Food-Cravings Questionnaires, and modifications of these, measure 
cravings in general, in terms of preoccupation with food, anticipation of positive effect 
and loss of control (Cepeda-Benito, 2000, Nijis etal, 2007). The Questionnaire on 
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Craving for Sweet or Rich Foods (QCSRF) measured both and this was designed to 
specifically measure food cravings during smoking cessation (Toll et al., 2008). 
 
However no scales have sought to capture both hunger and craving or distinguish 
between the two outside of laboratory conditions. There is a need to do so, as their 
nature is different so the strategies needed to control them will be different. None of 
the scales developed so far are brief enough or designed to capture cravings on a 
daily basis.  
 
3.1.3.  DeMiST dietary assessment 
As described in section 1.3.3 an increase in food and nutrient intake, energy from fat 
and sugar, in particular has been suggested to account for 69% of weight gained 
following smoking cessation (Stamford et al., 1986). Change in energy expenditure is 
thought to account for less than 40% (Filozof et al., 2004). The goal of dietary 
interventions to prevent weight gain in smoking cessation aim to restrict energy 
intake both prevent this increase in consumption and balance intake with lowered 
energy expenditure.  
 
To measure this process to check adherence and see whether dietary change 
explained change in weight we needed a measure for dietary intake and dietary 
change that could be easily used and assessed in a clinical setting.  
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The accepted gold standard measure for nutrient intake is the seven day weighed 
intake diary although validation studies with doubly labelled water have shown that 
underreporting is common (Livingstone et al., 1990). Data collection and analysis 
from a weighed intake diary is burdensome and the slightly less burdensome seven 
day food diary is now most widely used. Portion sizes are estimated using household 
measures or natural unit sizes (e.g. slices of bread). Individuals can choose to weigh 
food, but the main purpose of using this method is to avoid the burden of weighing. A 
comparison of methods in the UK arm of the European Prospective Investigation into 
Cancer (EPIC) showed that the seven day estimated record, agreed most closely to 
16 days of weighed intake (Bingham et al., 1997) and this is now considered the gold 
standard field measure.  
 
However, frequent recording of food intake even using the estimated seven day food 
diary is extremely burdensome for trial participants and extremely laborious to 
analyse. Even when it is done well, its accuracy is still only an estimate and it is 
prone to misreporting.  Food frequency questionnaires (FFQ) and 24 hour dietary 
recalls are the next best dietary assessment methods correlated to biomarkers 
(Bingham et al., 1997). However, FFQ are designed to measure average 
consumption patterns over a long period so are unsuitable for detecting change over 
short periods in a clinical trial. Twenty-four hour recalls are most accurate by using a 
multiple pass method. This is a five step method, first a participant lists food and 
drinks consumed, second frequently forgotten foods are probed, third time and eating 
occasion are probed, fourth, descriptions and quantity of foods are probed and fifth is 
a final probe of anything else that can be recalled (Conway et al., 2003, Conway et 
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al., 2004). However this technique is time consuming requires considerable training 
and several assessments to take into account day-to-day variability. Diet histories are 
most commonly used in clinical practice, these take into account habitual intake and 
24 hour recall but require lengthy training of clinicians. They provide the basis on 
which dietary advice is given. We searched the literature for a brief, simple and 
reliable tool, which could help clinicians not trained in detailed dietary assessment 
and therapeutic diets, to assess, advise and monitor dietary change. We did not find 
a tool suitable for this purpose so we designed our own and tested its validity against 
the gold standard field measure.   
 
3.1.4. Meeting the needs of trial participants 
As the aim of DeMiST was to inform a study large and long enough to assess long 
term effects on dietary change, weight, cardiovascular risk, lung health and smoking 
abstinence, the design extended beyond the initial quitting stage into a second 
treatment stage where both the VLCD and the control group received individual 
dietary and activity planning.  
 
The reason for this in the VLCD group was to provide participants with conventional 
support to establish long term healthy habits. The greatest criticism of VLCDs in 
current clinical practice is that they may not establish long term healthy eating habits, 
although a review by NICE reported that a 5% reduction in body weight is maintained 
over two years in those following a VLCD plan (NICE, 2006). 
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The reason for this in the control group was two-fold. Firstly, we wanted to compare 
the long term effects from IDAP, which restricts energy intake at the time of quitting, 
with the „control‟ group which restricted it after they quit. There is preliminary 
evidence to suggest that the latter may be more successful than the former, although 
this has not been tested with an adequately powered trial (Spring, 2004).   
 
Secondly, because the control was unblinded we hoped that by providing IDAP after 
quitting this group would not feel „short changed‟ and abandon their quit attempt 
prematurely. We investigated this quantitatively investigating the association between 
belief in trial arm and attrition.  
 
We also asked participants to tell us of their experience in each of the DeMiST trial 
arms, we did this qualitatively using semi-structured interviews. We chose this 
method above others for several reasons. Firstly we considered whether a 
satisfaction survey or an acceptability scale would suffice, this has traditionally been 
used to measure acceptability of interventions. However, the argument to use more 
insightful methods is strong (Finn and Sladczek, 2001), these offer the opportunity to 
discover more than might be predicted and included in preconceived surveys. In 
other words qualitative research it allows us to develop inductive rather than 
deductive reasoning.  It allows us to embrace subjectivity of the participant and the 
interviewer (Swift and Tischler, 2010). What this meant in our research is that we 
were able to take a relativist ontological position, expecting different participants to 
experience the same trial arm differently. We considered that there may not be one 
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real experience of trial arm, but rather many which are perceived differently; with 
perceptions and opinions having been shaped by an individual‟s life experiences. We 
were also able to take a reflexive epistemological approach and considering how our 
own background and interest may have steered the conversation in one particular 
direction or another. 
 
3.2. Methods 
3.2.1. Participants 
Overweight (BMI>25Kg/m2) smokers listed on the databases of participating general 
practices were invited to take part by a letter from their General Practitioner (GP) 
(Appendix 7). All participants were from practices in Birmingham East and North 
Primary Care Trust (PCT) and Worcestershire PCT, in the UK (see Appendix 8, 
Appendix 9, Appendix 10  for practice recruitment documentation).  
 
Interested participants telephoned the trial office at The University of Birmingham for 
further information; they provided verbal consent to initial telephone screening for 
eligibility (Appendix 11, Appendix 12, Appendix 13). If considered eligible they were 
given an appointment with a trial nurse for full screening where they were invited to 
give informed consent for participation (Appendix 14, Appendix 15). The trial office 
sent out participant information sheets (Appendix 16) so that they were received at 
least 24 hours before their first appointment. The clinics were run at local GP 
practices. Daytime appointments were offered from 8.30am until 7pm. 
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3.2.1.1. Inclusion criteria 
Participants had to: 
 Be aged over 18 years 
 Smoke cigarettes daily, and have an exhaled CO of at least 10ppm at least 15 
minutes after last smoking 
 Have a BMI of at least 25kg/m2 
 Be willing to be randomised to any of the three arms and willing and able to 
comply with the intervention and all study procedures. 
 
We recruited only those with a BMI greater than or equal to 25 for the following 
reasons: 1) the rate of weight loss on a VLCD is approximately 2kg/week so anyone 
entering the trial would need to be able to lose 10kg. For example, a woman 1.64m 
tall weighing 68kg with a BMI of 25.2 could potentially lose 10kg and reach a healthy 
BMI of 21.6kg/m2. VLCDs have been shown to be as safe in those with a BMI > 
25kg/m2 as in those with a BMI>30kg/m2 (RTSC, 2007). 2) Research shows that 
those who are overweight or obese are likely to gain more weight than healthy weight 
smokers and so they are an appropriate target for weight gain prevention (Chapter 
two, Lycett et al., 2011a). 3) The smoking population has a lower mean BMI than the 
non-smoking population (Klesges et al., 1989) so we could potentially struggle to 
recruit only those with a BMI >30kg/m2. 
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3.2.1.2. Exclusion criteria 
Individuals could not take part if they: 
 Had any of the absolute or relative contraindications to VLCD use. These 
include situations in which rapid weight loss would be unsafe: pregnancy, 
breastfeeding, myocardial infarction/unstable angina/acute coronary syndrome 
in the past 6 months, cerebrovascular accident /transient ischaemic attack 
/stroke in the past 3 months, major surgery in the last 3 months, severe 
cardiac arrhythmias, severe hepatic impairment, severe renal impairment (i.e. 
GFR ≤ 29mls/min), active carcinoma, untreated gallstones, past history of 
anorexia nervosa or bulimia nervosa, type 1 diabetes, those aged over 70 
years with a BMI<30kg/m2. A large energy deficit alters metabolic rate and so 
anyone with unstable thyroid function was also excluded.  Sudden weight loss 
may cause fainting or precipitate gout in those who are susceptible so those 
with regular blackouts or fainting, and untreated gout were also excluded. The 
VLCD formula is made from milk so is unsuitable for anyone with a milk allergy 
or intolerance.                                                                                                                                                                                                                                                                       
 Had uncontrolled hypertension and type two diabetes treated with medication. 
Although these are not contraindications to the VLCD they are excluded as 
adjusting the medications in these conditions would require specialist advice  
beyond the scope of the research nurses in this trial (diet controlled type two 
diabetics were included). 
 Were on oral anticoagulants, digoxin, phenytoin and lithium due to likelihood 
of increased drug absorption if on a VLCD. Specialist advice beyond the 
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scope of our research nurses is needed to reduce and monitor these 
medications. 
 Were on diuretics for diuresis were excluded as a VLCD can potentiate 
diuresis and increase the risk of hypokalaemia. Those on low dose diuretics 
for treatment of hypertension were not excluded as the risk of hypokalaemic 
complications on these are low (Franse et al., 2000, Peters et al.,1989). The 
effects of combining a VLCD with low dose thiazides has not been well studied 
and may be unpredictable therefore serum potassium was to be monitored 
weekly and the VLCD discontinued if levels fell below 3.1mmol/l.  (Appendix 
17 contains the full list of excluded medications and clinical protocol of this 
developed for study nurses). 
 Had previous severe adverse reaction to nicotine patches (which precluded 
further use). 
 Had active phaeocromocytoma as this combined with use of NRT may 
increase the risk of hypertension and tachycardia. 
 Were concurrently using smoking cessation medication i.e. (NRT), vareniciline 
or bupropion or medication (e.g. nortriptyline) that is known to help smokers 
quit. 
 Were taking weight loss medication e.g. orlistat, sibutramine. 
 Were suspected of abuse of alcohol or other drugs as this might confound our 
measure of cravings. 
 Were using smokeless tobacco 
 Were concurrently participating in other therapeutic clinical trials.  
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3.2.1.3. Removal of participants from therapy 
Participants would discontinue therapy if: 
 A contraindication to treatment became apparent. 
 An adverse event occurred making it inadvisable to continue treatment. 
 Serum potassium fell below 3.1mmol/l in those taking thiazides, the VLCD 
would be discontinued. 
 The person ceased to continue to quit smoking and wished also to abandon 
the weight management programme. If a person failed to stop smoking they 
could continue with the dietary treatment intervention, likewise if a person 
abandoned the dietary treatment they could continue with their quit attempt. 
Keeping participants like this in the trial would help us to explore the reasons 
why a treatment was abandoned. We will find out whether abandonment of 
one treatment ultimately leads to abandonment of both and how these 
participants have decided to tackle their smoking or weight.  
 
3.2.2.  Dietary Interventions 
Week 0 was quit week, negatively numbered weeks were the weeks before quit week 
and positively numbered weeks were the weeks after quit week. Week -3 was 
baseline, three weeks before quit week. Participants were seen and briefed at 
baseline and a quit day was set for three weeks time. Participants were randomised 
into the dietary interventions, VLCD, IDAP and Control (SBS), one week prior to 
quitting (week -1). Each intervention contained two treatment stages. Stage 1 lasted 
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from week -1 to week +4 and treatment stage 2 lasted from week +4 to week +12 
(Figure 6). 
 
3.2.2.1. Treatment Stage 1 – VLCD 
The VLCD formula we used was called Lipotrim. This was provided for the study at 
cost price from the manufacturers, Howard Foundation Research Ltd. It was 
purchased by participating Primary Care Trusts (PCTs) and provided free to 
participants (Appendix 18). Participants were instructed to take 2-3 shakes each day 
and drink a minimum of 4 pints of water, but not in excess of 4 litres. Black tea and 
black coffee could be drunk but no other food or drink could be consumed, as any 
additional carbohydrate or citric acid may suppress ketone production (Appendix 19).  
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Figure 6. Treatment stages for DeMiST 
 
 
The female formula was 425kcal/day and the male formula was 559kcal/day, it 
contained all essential nutrients and complied with the EU codex standard for VLCDs 
(RTSC, 2002). This diet began one week before quitting, by which time the dieter 
would be in ketosis. The diet continued during the first four weeks after quitting when 
nicotine withdrawal symptoms would be at their worst. The rationale for this is that 
dieters should be comfortably in ketosis when they quit and experience acute 
nicotine withdrawal. It takes approximately 3 to 4 days to get into ketosis on a VLCD, 
during which time the side effects of a VLCD are most apparent. After these first four 
days individuals usually gain a feeling of wellbeing that accompanies ketosis and so 
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we wanted to coincide this period of ketosis exactly with the time of quitting to 
maximise any attenuating effects it may have on urges to smoke.  
 
Every effort was made to get the participants to adhere to the VLCD by using 
behavioural change techniques as defined by Abraham and Michie in 2008 
(Appendix 20). These included an explanation of the role of ketones and the 
necessity for strict adherence in order to remain in a ketotic state. (Providing 
instruction and providing information on consequences of action are behavioural 
change techniques 2 and 8.)  Ketosis is usually achieved by the third or fourth day on 
the diet and so participants were advised that they would feel better after this time. 
Encouragement (technique 6) and prompting of self-encouragement (technique 22) 
was used e.g. suggestions for self talk: „today was difficult but if I keep going I will 
feel better in 2 days‟, „if I can stick this out, I can lose weight and stop smoking in 
time for my birthday‟. Support to identify and overcome barriers to adherence 
(technique 5) was also given.  
 
3.2.2.2.  Treatment Stage 1 – Individual Dietary and Activity 
Planning (IDAP) 
This contains dietary, activity and behavioural elements. Assessment of current 
behaviours and food choices was made by using the Health Choice Index (HCI) (the 
development and validity testing of the HCI is discussed in chapter seven). This is a 
multiple choice questionnaire designed to get participants to score their food choices, 
weekly food frequency, eating behaviours and activity. From this, both the participant 
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and the healthcare professional were able to identify areas for improvement and 
agreed goals for progress. Typically three goals were decided, one focusing on food 
choice e.g. I will buy skimmed milk instead of full fat milk; one on eating behaviour 
e.g. „I will prepare a packed lunch the night before to take to work so that I don‟t miss 
lunch‟. And one activity focused goal e.g. „I will park the car a block away from work 
and take a brisk walk at lunchtime so that I fit in three ten minute exercise breaks 
during my working day. Prompting specific goal setting is technique 10 in the 
behavioural change taxonomy. These goals were reviewed regularly and adjusted as 
necessary (behaviour change technique 11). Helping the participant to identify and 
overcome barriers to achieving their goals, discussing time management to 
incorporate these changes into their daily lives, helping them to plan relapse 
prevention strategies and general encouragement all formed part of this intervention 
(behavioural techniques  5, 26, 23 and 6 respectively).  
 
As well as identification of specific goals instructions were given (technique 8) for 
following a moderate calorie restricted diet plan tailored to the individual‟s energy 
requirements. This provided a structure to help consolidate the goals identified and 
ensure that the participants had the right tools to achieve a sufficient energy deficit 
for weight control.   
 
The energy prescription used in previous studies to prevent weight gain on smoking 
cessation has varied. Pirie et al. advised generally to reduce energy intake by 150 to 
300kcal/day (which was considered to equate to metabolic slowing upon nicotine 
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withdrawal, the level of which depended on number of cigarettes smoked) (Pirie et 
al., 1992). Perkins et al. used a 500kcal deficit tailored to individual energy 
requirements (Perkins et al., 2001). Hall used a 500kcal deficit tailored to individual 
requirements should weight increase by 1kg (Hall, 1992). Spring used a 150kcal 
deficit based on individual food diaries (Spring et al., 2004). Danielsson used a 
1600kcal diet compared with a very low calorie diet (419kcal/day) (Danielsson et al., 
1999).  
 
We decided to advise an approximate energy deficit of 600kcal, based on individual 
requirements. This is recommended by NICE for weight loss of 0.5kg/week (NICE, 
2006). This is sufficient to counter the mean rate of post-cessation weight gain and 
promote modest weight loss which is desirable for our population with a 
BMI>25kg/m2. Dietetic consensus considers a usual maximum energy prescription of 
1800kcal. Anecdotally advising above this appears to be ineffective at achieving 
weight loss, this may be due to people misunderstanding the volumes of food 
recommended for larger portion sizes.  
 
To calculate energy prescription in individuals we have assumed all participants will 
have a physical activity level (PAL) of 1.4, which is consistent with a sedentary 
occupation and leisure activities. The PAL is the factor by which BMR is multiplied to 
give an estimate of total energy expenditure. For simplicity in clinical practice we 
wrote dietary plans that equate to energy intakes of 1200kcal, 1500kcal or 1800kcal.  
An individual is allocated the closest energy prescription to their BMR (as calculated 
 112 
 
by the Tanita body composition analyser) (Appendix 21). Calculating total energy 
requirement from a PAL of 1.4 and BMRs of 1200kcal, 1500kcal and 1800kcal, 
shows energy requirement is an increase of 500kcal-700kcal above BMR. This 
means we can approximately achieve the 600kcal deficit by using BMR alone for the 
prescription of energy. The energy level advised was translated into the appropriate 
number of portions from each of the food groups: complex carbohydrates, fruit and 
vegetables, meat, fish and alternatives, dairy foods, sugar and fatty foods. The 
proportion of food coming from these food groups make up a healthy diet with 15-
30% of energy from fat, 10-15% of energy from protein, 55-75% of energy from 
carbohydrate and 0-5% energy from alcohol. Therefore, the diet is low in fat and 
sugary foods which studies have shown significantly increase in the diets of smokers 
when they quit (Perkins et al., 1990, Rodin, 1987, French et al., 1996, Hall et al., 
1989). The dietary plan was a „pick and choose‟ format, where individuals choose 
from a list of items within different food groups at each meal.  The food portions were 
defined in American cup sizes and participants were given measuring cups to 
measure out their portions (Appendix 22 for example).  
  
3.2.2.3. Treatment Stage 1 –  Control (Step by Step (SBS)) 
The control group received healthy eating advice when participants mentioned weight 
concern. This is standard in smoking cessation interventions. Advice was given not to 
„diet‟ but instead to avoid hunger by eating healthy, low fat foods. This is because it is 
thought that hunger may lead to urges to smoke, and may make relapse more likely. 
Tips for avoiding hunger include: 
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 Regular meals, including breakfast (which is often missed in smokers 
(Nishiyama et al., 2009)  
 Handy, healthy snacks e.g. fruit or chopped vegetables (carrot, celery sticks) 
 Drink plenty of water, particularly before meals, this helps fill the stomach and 
satisfy „oral cravings‟. 
There is evidence that glucose tablets satiate urges to smoke within minutes, so 
these can be used (McRobbie & Hajek, 2004). Avoidance of total alcohol for the 
immediate post-cessation period was advised. This was to avoid lapsing due to 
disinhibition and the „cue‟ which alcohol provides, rather than to control weight. 
Participants were advised to increase daily activity, e.g. including a 30 minute walk in 
their day. Advice in the control group was given as general instruction and general 
encouragement (behavioural techniques 6 and 8) but individual goal setting and 
energy prescription was not included. 
 
3.2.3.1. Treatment Stage 2 - VLCD 
This spaned from week +4 to +12 and included four visits (Figure 6). The same 
number of visits has been included in each of the intervention arms so that number of 
consultations with a nurse was not a confounder. 
 
The VLCD was discontinued at week +4, participants were weaned back onto food. 
This weaning took one week. During this week the Lipotrim formula was reduced and 
replaced by low fat meals with increasing amounts of carbohydrate until healthy 
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proportions were achieved (Appendix 23). Gradual reintroduction of carbohydrate is 
necessary to avoid rapid replenishing and storage of muscle glycogen, which could 
result in a rapid increase of body water weight (up to 5kg over the week). At week +5 
lifestyle goals were set and energy prescription was given as described in treatment 
stage one of IDAP. Behavioural support continued at reduced frequency to week 
+12. The reason for this second stage of treatment is to cultivate the development of 
long term healthy habits as explained in the introduction to this chapter (section 
3.1.4). 
 
3.2.3.2. Treatment Stage 2 – Individually Tailored Diet and 
Activity Plan (IDAP) 
This behavioural support continued to week +12 and visits became less frequent. 
 
3.2.3.3.  Treatment Stage 2 – Control (Step by Step (SBS)) 
Participants in the control arm, received IDAP from week +8 to week +12. This 
allowed them time to become established quitters before they embarked on weight 
control. 
 
3.2.3. Smoking Cessation Interventions for all 
Participants 
All participants had identical treatment to stop smoking. This was the treatment which 
is available on the NHS. It is withdrawal orientated such that behavioural strategies 
(examples in Appendix 24) and nicotine replacement are given to relieve withdrawal 
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symptoms. This has been shown to be an effective model for stopping smoking 
(Hajek, 2006). Individuals are seen over seven consecutive weeks, weeks -3 and -2 
prepare them for quitting, they quit at week 0, weeks +1, +2, +3 and +4 support them 
during the first four weeks after quitting when withdrawal symptoms are at their 
strongest. The sessions incorporate a variety of behavioural change techniques:  
 pre-quit sessions prompt intent formation (technique 4) by setting a quit date, 
 they prompt barrier identification (technique 5)  
 and relapse prevention (technique 23) when participants identify times or 
places when it will be particular hard for them to resist smoking, they discuss a 
strategy to help them to deal with these circumstances; for example, changing 
routine so the usual smoking cues are removed.  
Quit week and the weeks that follow provide instruction (technique 8) in the use of 
nicotine replacement, review of and further planning of strategies (technique 11) to 
deal with withdrawal symptoms and general encouragement (technique 6). Self-talk 
(technique 22) is encouraged such that participants are asked to see and describe 
themselves as a „non-smoker‟ and to frequently bring to mind the benefits of quitting 
that they are looking forward to. 
 
3.2.4. Nicotine replacement therapy (NRT)  
Nicorette 25mg transdermal 16 hour patches were provided for 8 weeks followed by 
a 15mg patch and a 10mg patch each for 2 weeks. Patches were supplied free of 
charge by McNeil Products Ltd. Other forms of NRT, such as gum or nasal spray or a 
combination of NRT was not used to avoid the possibility that the amount of NRT 
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taken would differ by arm. This could confound effects of hunger or ketosis on urges 
to smoke that we are trying to discover. We used a nicotine patch as it delivers a 
consistent amount of nicotine to avoid this confounding. As no other NRT products 
could be used in combination to help with acute cravings we used the 16 hour, 25mg 
patch which has been shown to yield better abstinence than other available patches 
(Tonnesen et al., 1999).  
 
3.2.5. Training and supervision 
Treatment was provided by trained practice nurses. Practice nurses were trained by 
NHS stop smoking services (2 days), a research nurse, a general practitioner (GP) 
(0.5 days), and a registered dietitian (1.5 days). Nurses were given the clinical 
protocol to read before training sessions (Appendix 25). Training included 
explanation of dietetic and behavioural interventions and practicing the interventions 
on each other. The clinical protocol was clarified where needed and questions 
answered. The aim of the training was to equip the nurses so that, once they had 
completed it, they felt confident to deliver the interventions according to the clinical 
protocol. 
 
After the training, „hands on‟ supervision was available for the first few clinics. 
Immediate telephone access to the dietitian and GP were available for all clinical 
queries throughout the rest of the trial.  
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Medical history and any medication used or altered during the trial was monitored. 
Any significant changes in clinical condition of individual participants, as measured 
on a weekly basis, was discussed with the supervising GP and action taken, e.g. 
clinically significant fall in blood pressure in participants on the VLCD taking anti-
hypertensives would require adjustment of anti-hypertensive medication (Appendix 
26). The participant‟s own GP was kept informed.  
 
3.2.6. Fidelity checking and monitoring 
Fidelity to the clinical protocol and record keeping was assessed and monitored 
against the clinical protocol by the principal investigator every few months; 
consultations were audiotaped for this purpose. Any deviations were recorded, 
discussed and corrected either immediately or at following clinics. The trial was 
potentially subject to audit by the appropriate regulatory authorities and therefore 
participants were asked to consent to allow their records to be viewed. 
 
3.3. Objectives 
3.3.1. Primary objectives 
To investigate the feasibility of running this three-armed dietary intervention study as 
part of the NHS stop smoking services using primary care nurses. This included the 
feasibility of measuring and monitoring of physiological and biochemical risk factors 
for cardiovascular disease, diabetes and chronic obstructive pulmonary disease 
(COPD).  It explored the acceptability of the interventions to participants. 
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3.3.2. Secondary objectives 
To investigate whether smoking cessation advice and a nicotine patch in combination 
with: a very low calorie diet (VLCD), or individually tailored dietary planning (IDAP), or 
usual support affected urges to smoke, through hunger or ketosis in overweight 
smokers trying to quit.  
 
3.3.3. Tertiary objectives 
To investigate the extent to which changes in smoking status, diet and activity 
achieved during the treatment stages were maintained at the end of treatment and at 
six and 12 months in each of the intervention arms. To investigate associations 
between hunger, abstinence, early and late weight gain. 
 
3.4. Outcome Measures 
3.4.1. Acceptability 
Participant acceptability was measured qualitatively by semi-structured interviewing 
and quantitatively by response and attrition rates as described below:  
 Semi-structured telephone interviews were conducted after the participant had 
completed treatment or dropped out of the programme. Participants who were 
happy to do so gave their consent to this at the start of the trial. To help them 
remember their thoughts and feelings „of the moment‟ they were given the 
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questions they would be asked at the start of the trial, with space to jot down 
notes, during the trial. We aimed to interview participants until theoretical 
saturation of responses was reached. We aimed to purposively sample 
interviewees to encompass the full range of attrition characteristics, for 
example, those who completed the trial, and those who dropped out of 
quitting, dieting or both in each of the three trial arms. Interviews were audio 
recorded and transcribed verbatim. Participants were asked what they found 
helpful and unhelpful and their reasons for dropping out.  
 Rates of response to participant invitation letters and posters. 
 Rates of recruitment at telephone screening, at first consultation. 
 Rates of drop out before randomisation. 
 Rates of drop out after randomisation in each treatment arm.  
 Rates of attendance at each session. 
 Rates of participant adherence to treatment. 
 Quality of life measure, a scale on which the participant can score general life 
satisfaction and well being at baseline, weeks +4, and +12. 
 
3.4.2. Feasibility 
Feasibility of running the trial within the primary care practice was measured 
qualitatively as described below:  
 A focus group of participating nurses to investigate experiences of delivering 
intervention, e.g. how easy was it to carry out the interventions, was training 
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sufficient, was consultation time adequate, what difficulties were encountered 
taking the trial measurements. 
 
 Principal investigator‟s reflections on their experiences of primary care 
involvement e.g. ease of GP practice recruitment, willingness for PCTs to 
participant, obstacles encountered. 
 
3.4.3. Measurement of urges to smoke and hunger, 
Degree of smoking addiction was measured at baseline using the Fagerstrom Score 
(Fagerstrom & Schneider, 1999). Urge to smoke was measured by the Mood & 
Physical Symptoms Combined Scale (MPSS-C) (West & Hajek, 2004). Hunger and 
food craving was measured by the Hunger and food Craving (HCS) score (discussed 
further in chapter five). MPSS-C and HCS were recorded daily in a diary over the first 
four weeks of quitting and weekly thereafter. The primary outcomes of interest were 
over the first 24 hours and the first week of quitting; this is where the largest effects 
are likely to be seen as withdrawal symptoms are at their peak during this time. 
Comparisons between measures were made for all those who continued in their quit 
attempt until they decided to abandon quitting, and adjusted for those who lapsed, 
were point prevalent abstinent at 24 hours, 7 days or continuously abstinent at 4 
weeks. Although it is standard practice in smoking trials to primarily analyse those 
who are abstinent, our interest was in the effects on cravings and we cannot assume 
that those who did not achieve abstinence did not experience cravings as they tried 
to do so. Piasecki showed that cravings were heightened in both smokers who were 
 121 
 
attempting to quit and lapsed, as well as in smokers who succeeded in quitting. He 
found that more cigarettes, smoked on more occasions did reduce cravings 
(presumably as these have served to treat nicotine withdrawal acutely) but also that a 
few cigarettes increased cravings (100 vs 56 cigarettes p<0.001) (Piasecki, 2003). 
Perhaps this reflects a greater struggle to cope with cravings before a cigarette is 
finally smoked out of desperation.   
   
3.4.4. Ketosis  
The presence or absence of ketones was measured using ketostik test strips dipped 
into urine samples. This was done weekly during the first six weeks of dietary 
intervention, to check those in the VLCD were in ketosis throughout the five weeks 
and come out of ketosis during the re-feeding week. It was also measured during this 
time in IDAP and control arms to verify the absence of ketosis in these groups or 
identify any participants which might be self-imposing excessive dietary restriction, 
(unless undiagnosed diabetes presented itself). 
 
3.4.5. Measurement of smoking status 
Twenty-four hour point prevalence abstinence was measured by participants 
achieving 24 consecutive hours of abstinence that was verified by exhaled 
CO<10ppm. Seven day point prevalence abstinence was defined as those reporting 
not smoking over the last seven days, and this was verified by exhaled CO < 10ppm. 
Participants achieving one, six and 12 month abstinence were to be defined using 
the Russell Standard which states that no more than five cigarettes have been 
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smoked since week +2, this was verified by CO<10ppm at each consultation (West et 
al., 2005). Participants who have not achieved abstinence but were still attempting to 
quit were termed „lapsed‟. Smokers who abandoned their quit attempt, such that it 
was no longer their intention to quit, were considered „relapsed‟. 
 
3.4.6. Measurement of Disease Risk Factors 
These were measured as described below. The schedule of measurements is 
contained in Table 17 . 
 Weekly weight, waist to hip ratio, body composition and  blood pressure. 
 FEV1 and FVC post 200mg salbutamol as is recommended by the American 
Thoracic Society 2005 standards for measuring lung function (Miller et al., 
2005) at baseline, three, six and 12 months. 
 Fasting blood glucose, Total cholesterol (TC), low density lipoprotein (LDL) 
cholesterol, high density lipoprotein (HDL) cholesterol, TC/HDL ratio, 
triglycerides, haemoglobin, white blood cell count, platelet count, mean cell 
volume and c-reactive protein (CRP). 
 
Full details of how these measurements were taken are referred to in the trial clinical 
protocol (Appendix 25) as standard operating procedures (SOPs) and work 
instructions (WIs) (e.g. Appendix 26). The nurses were trained in these procedures 
so that they are carried out consistently at each trial site. The nurses were assessed 
in practice against these SOPs and WIs, every couple of months, by the principal 
investigator. 
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3.4.7. Measurement of diet and activity 
Food choices, eating behaviour and activity were measured at baseline, end of 
treatment, 6 and 12 months using the HCI. Validity between this simple, quick 
measure of diet quality as an assessment of nutrient intake was investigated by 
statistical analysis against an estimated seven day food intake diary which was also 
completed at baseline (discussed further in chapter five). Participants were 
encouraged to weigh their food when completing the seven day food diary, but 
portion sizes could also be estimated using household measures or natural food 
units. As discussed in the introduction to this chapter (section 3.1.3) despite 
underreporting weighed diaries are considered the most accurate way to record 
dietary intake and only an estimated food diary comes close to this level of accuracy 
(Bingham et al., 1995, Bingham et al., 1997). Diaries which reported less than 1.2 x 
BMR energy intake or were incomplete were discounted. Where necessary the 
Goldberg cut-off was used to evaluate the mean population bias in reported energy 
intake (Black, 2000). The seven day diaries also estimated physical activity levels 
using the method which determined dietary references values for energy in the UK 
(DRV, 1991).  
 
Those on a VLCD who did not produce ketones or achieve the expected 2kg weekly 
weight loss were considered non adherent. We expected any weight gain in the IDAP 
group to be a result of poor adherence, although weight maintenance was acceptable 
in this group.  
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3.4.8. Confidence in trial arm 
Due to the unblinded nature of the trial, participants were asked prior to 
randomisation to rate their confidence of each treatment arm being successful. From 
this we were able to determine whether expectation of success in treatment 
allocation was associated with attrition rates.  We planned to measure this again at 
weeks +4 and +12 to see if this changed over time.  
 
3.5. Sample Size 
Acceptability and feasibility was measured qualitatively through interviews and by 
recording of recruitment and attendance rates. These outcomes were descriptive and 
not analysed using statistical tests and so a power calculation for them was 
inappropriate. 
 
Instead, we based our sample size on the secondary objective to identify whether 
dietary interventions affect cravings for cigarettes. In the trial by Danielsson 
(Danielsson et al., 1999) the difference in cravings for cigarettes at week +2 was 
mean 1.6 in the control and mean 1.1 in the VLCD group with a standard deviation of 
0.7.
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Table 17. Schedule of measurements during DEMIST 
Treatment week -2 -1 0 1 2 3 4 5-7  8 - 10 12 26 52 
Baseline Questionnaire (with Fagerstrom 
Score) 
 
 √            
Seven day food diary                          √               
Weight  √ √ √ √ √ √ √ √ √ √ √ √ 
Waist/Hip ratio  √ √ √ √ √ √ √ √ √ √ √ √ 
Blood Pressure  √ √ √ √ √ √ √ √ √ √ √ √ 
Smoking Status   √ √ √ √ √ √ √ √ √ √ √ √ 
Urinary ketones 
 
 √ √ √ √ √ √       
Fasting Blood test √          √ √ √ 
Lung function √          √ √ √ 
Russell Standard         √  √ √ √ 
QOL measure 
 
 √     √    √   
Confidence in trial arm 
 
√      √    √   
Body composition 
 
 √ √ √ √ √ √ √ √ √ √ √ √ 
Daily Diaries (MPSS & HCS) 
 
 √ √ √ √ √ √       
Weekly Diaries (MPSS & HCS) 
 
       √ √ √ √ √ √ 
HCI 
 
 √         √ √ √ 
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 The control in the Danielsson trial was a standard (not individualised) 1600kcal 
diet, a moderate energy restriction, likely to lead to increased hunger. We were 
looking to detect a difference of the same magnitude between our hungry (IDAP) 
and not hungry (control) or hunger suppressed (VLCD) groups. Using Epicalc with 
80% power and a type one error rate of 5% we needed 30 participants in each 
group and 90 in total to detect a significant difference between them. For sufficient 
power to detect a difference in an abstinent subgroup, assuming a 60% abstinent 
rate in the first few weeks, we aimed to recruit 42 in each group.   
 
Such a trial would be large enough to differentiate between dietary changes that 
reflect a poor to a healthy diet using a dietary index, this is based on the figures by 
Freisling et al. in 2009 who validated a food frequency index using values of <32 
and >39 for a poor and very good diet respectively. With a standard deviation of 
5.7, 10 people were needed in each arm of our trial to detect a similar difference.  
 
Running a larger trial to identify long term effects on abstinence and weight was 
premature at this stage, although we carried out all the measurements that would 
be needed in such a trial to assess feasibility.  
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3.6. Randomisation 
Randomisation was computer generated by an independent statistician within the 
Primary Care Clinical Research and Trials Unit (PCCRTU) using  random 
permuted blocks of length 6, stratified by practice.  The numbers were entered into 
the trial database by an independent computer programmer within the trials unit. 
The database concealed randomisation until after participants were screened and 
entered into the trial. At week -3 the nurses clicked on the randomisation tab in the 
database and this revealed the arm to which the participant was allocated. The 
database was set up so that the randomisation „tab‟ would not work until all data 
from week -2 was complete. Therefore, it was impossible for anyone to see 
treatment allocation beforehand. This greatly minimised any risk of the trial 
randomisation being undermined.  
 
3.7. Analysis and statistical methods 
Semi-structured interview and focus group transcripts were coded according to 
content. Common themes regarding acceptability and feasibility were identified.  
 
Quantitative measures of acceptability were presented as descriptive statistics.  
 
Outcomes (including smoking abstinence, weight, dietary change) between the 
three arms of the study were compared using statistical tests on adequately 
powered measures. Descriptive statistics (mean, SD and 95% CI) were presented 
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on underpowered measures. Analysis of completer data allowed us to determine 
efficacy of interventions if they were taken as planned. Intention to treat analysis 
allowed us to determine pragmatic effects of these interventions if they are used in 
clinical practice. 
 
Multilevel modelling based on the Piasecki model of cigarette withdrawal (Piasecki 
et al., 2003) was used to investigate the effects of the dietary interventions on 
urges to smoke during the first four weeks of quitting. We investigated whether 
these effects were mediated by hunger and food craving score (HCS) and ketosis. 
We adjusted for confounding variables e.g. active treatment for depression. 
Analysis was carried out on all those who continued to try to quit regardless of 
lapses to smoking and this was adjusted for in the model as described above.  
 
Significance was set at the 5% level, 95% confidence intervals and exact p values 
were given where appropriate. 
 
Analysis of data from treatment stage 1 was undertaken once every participant 
has completed this stage. Analysis from treatment stage 2 and follow-up at 6 
months and one year was planned to be undertaken once participants had gone 
through each of these stages.   
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Trajectory of change in outcomes, e.g. weight change over time, was investigated 
using multi-level modelling and the effects of trial arm and smoking status were 
tested.  
 
3.7.1. Data Validation 
Data cleaning took place by a series of logical checks on the electronic data. (For 
example, a person cannot be recorded as prolonged abstinent smoker at six 
months if they were not in such a state at 8 weeks). Discrepant records were 
checked with the source documents and the database amended as necessary.  
 
3.8. Trial schedule  
One Doctoral researcher was principal investigator and supervising dietitian. Part-
time support was provided by practice research nurses and research 
administrators.   
 
Recruiting was planned to continue over a period of one year until sufficient 
participants were treated in each trial arm. Follow up took place as described and 
it was estimated that the trial would be complete two years from the start.   
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3.9. Definition of end of trial  
The end of the trial was defined as the final 12 month follow-up where the last 
measurement was taken from the last participant and the last participant 
undergoing the trial was debriefed.   
 
3.10.  Value of results 
The results from this study were to provide new information about dieting during 
smoking cessation. Their aim was to inform the design of a multi-component 
intervention that tackles both smoking cessation and its related weight gain in a 
way which can be rolled out into the NHS.  
 
3.11.  Assessment of safety 
Potential participants‟ safety was ensured by screening for eligibility using a 
structured form completed by the trial nurses. This recorded evidence of eligibility 
and that the person did not have any exclusion criteria. In addition, the nurses 
took a general medical and drug history to assess for other complicating diseases. 
Any queries remaining as a result of this process were resolved by discussion 
between the trial nurse, chief investigator and the relevant physicians providing 
routine medical care, usually the participant‟s GP. Such concerns are unusual but 
not rare. Typically, they arise from a participant‟s hazy knowledge or 
understanding of their past medical history and are usually readily resolved. No 
blood or further medical testing was necessary to ensure safety.  
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3.11.1. VLCDs 
Very low calorie diets are a recognised treatment for obesity. They form part of the 
NICE (2006) guidelines for the management of adult obesity and are advised for 
up to three months of continuous use in people with a BMI>30. We used it for 5 
weeks only in people with a BMI>25. Weekly monitoring of weight meant that if 
BMI fell below a healthy level treatment was be discontinued.  VLCDs have been 
used safely for many years including in people with a BMI between 25 and 30 
(RTSG, 2002). Since 1987 they have been subject to the regulations of the 
Committee on Medical Aspects of Food (COMA, 1987). This is an extensively 
researched evidence based document detailing the formulation of VLCDs to 
ensure safety. The product used in this study complied with these standards. 
Thus, there was every reason to expect that treatment in this trial was safe. 
 
Participants were warned about the side-effects of VLCDs and could contact the 
trial team to discuss any concerns. To this end, all participants were given a credit-
card-sized card with the trial team‟s contact details, this allowed participants to 
receive advice on the VLCD or report perceived serious adverse effects and 
receive advice as required. They were asked to carry this card with them at all 
times so that it could be used to notify medical personnel of a participant‟s 
treatment (and the likely presence of urinary ketones) and trial involvement in case 
of emergency. Participants recorded the occurrence of side-effects of VLCDs as 
specified by completing a checklist. The checklist was given to the trial nurse who 
enquired about recorded adverse events, to determine the severity of any adverse 
event and ensure that appropriate advice was given for its management (e.g. 
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drinking appropriate amounts of water to treat symptoms of mild dehydration.) 
Minor adverse reactions were monitored and managed in this way. For each 
known side effect listed in the checklist, the trial nurse had a definition of clinical 
severity. Any side effect that was classified as moderate or severe was reported to 
and discussed with the principal investigator. A decision on stopping therapy was 
made with the participant, attending nurse, principal investigator and other 
relevant parties as appropriate (Appendix 27).  
 
3.11.2. Dietary and Lifestyle Advice 
Healthy dietary and lifestyle advice was individually tailored to create a mild 
energy deficit and gentle increase in activity. Appropriately trained nurses gave 
this advice. It is usual practice and considered very safe. In the unlikely event of 
side effects participants could contact the trial team to discuss any concerns. To 
this end, all participants were given a credit-card-sized card with the trial team‟s 
contact details to allow participants to report perceived serious adverse effects 
and receive advice as required.   
 
 
3.11.3. NRT Patches 
NRT has been investigated in several hundred previous clinical trials and is widely 
prescribed worldwide and subject to safety monitoring. It was replacing a product, 
nicotine, which the participants were already consuming and will have consumed 
for many years in cigarettes. Thus, there is every reason to expect that this 
treatment in this trial is safe. Participants were warned about the side-effects of 
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NRT and advised not to stop taking the medication without consulting with the trial 
team or an NHS professional if the trial team were unavailable. Participants 
recorded the occurrence of side-effects of medication as specified on the 
summary of product characteristics (SPC) for all relevant NRT preparations, by 
completing a checklist. The checklist was given to the trial nurse who enquired 
about recorded adverse events, to determine the severity of any adverse event 
and ensure that appropriate advice was given for its management (such as 
rotating the patch site or use of emollients for skin reactions). Minor adverse 
reactions were monitored and managed in this way. For each known side effect 
listed in the SPC, the trial nurse had a definition of clinical severity (Appendix 28). 
For example, a mild skin site reaction to the patch was defined as burning 
sensation that did not interfere with normal activities, redness or swelling at the 
site of application, or mild blistering. Any reaction beyond that was classified as 
potentially moderate or severe and was reported to and discussed with the 
principal investigator. A decision on stopping therapy was then made with the 
participant, attending nurse, principal investigator, and other relevant parties as 
appropriate. Nicotine has a short half-life (2 hours), meaning that the blood 
concentration does not build up during the course of treatment so that new side-
effects were not expected after the first few weeks. In addition, reactions to it 
relate to local use, such as skin discomfort from patches and people become 
accustomed to the side-effects after a short time of using the preparation. The 
advice given depended upon the severity of the reported reaction and those with 
moderate reactions were invited to an ad hoc consultation.  
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The SPCs for the relevant NRT products contain no warnings about serious 
adverse reactions except rare allergic reactions, such as angioedema, and cardiac 
arrhythmias, occurring in less than 1/1000 users. Thus we expect no or very few 
suspected unexpected serious adverse reactions (SUSARs) in this trial.  
 
3.11.4. Salbutamol  
Salbutamol has been thoroughly investigated in clinical trials and is widely 
prescribed worldwide and subject to safety monitoring. Thus, there was every 
reason to expect that its use in this trial was safe. Common side effects to 
salbutamol are mild (e.g. headache, tremor) and rare with small doses; severe 
reaction is very rare. Any reaction tends to be immediate. Participants were 
warned about the side-effects of salbutamol and asked to give verbal consent to 
taking it. They took a small dose (200mcg) in the company of a nurse and were 
given a contact number should they experience any adverse events in the hours 
that followed. This was administered four times during the year, at baseline, 12 
weeks, six months and one year. For each known side effect listed in the SPC, the 
trial nurse had a definition of clinical severity (Appendix 29). Any reaction beyond 
that was classified as potentially moderate or severe and was reported to and 
discussed with the principal investigator. If a person had side-effects potentially 
related to salbutamol then they were not given salbutamol at the next visit. 
 
3.11.5. Reporting of adverse events  
The long history of use in and outside of trials for NRT and salbutamol meant that 
SUSARs were unlikely. On the reverse of the trial card giving the contact number 
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for advice on side-effect management, there were instructions for reporting of 
serious adverse events (SAEs) (Appendix 30). Through direct contact from the 
participant or contact from their attending physician, we became aware of serious 
adverse events. When any member of the trial team became aware, they informed 
the principal investigator within 24 hours. The principal investigator assessed the 
seriousness, causality, expectedness and severity of the adverse effects. An 
immediate decision was made on the interim use of medication for that participant. 
If an event was judged severe, it was reported to the trial sponsor, who report the 
event to the research ethics committee (REC). Definitions of adverse events (AEs) 
are contained in Appendix 30.   
 
Participants were asked weekly to report intercurrent illnesses and the response 
was recorded. If any of these intercurrent illnesses contra-indicated salbutamol, 
NRT, VLCD or healthy dietary advice, this was immediately reported to the 
principal investigator and a decision made about continued use.  
 
3.12.  Ethics and Research Governance 
The trial was conducted in compliance with the principles of the Declaration of 
Helsinki (1996), the principles of the International Conference on Harmonisation 
(ICH) - Good Clinical Practice (GCP) and run in accord with EU Clinical Trials 
Directive and all of the applicable regulatory requirements. The study protocol and 
other documentation was approved by South Birmingham Research Ethics 
Committee (Appendix 31), Birmingham and Black Country Comprehensive Local 
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Research Network and West Midlands South Comprehensive Local Research 
Network (example in Appendix 32). Protocol amendments were submitted to the 
REC for approval and the other bodies when necessary (example of approval in 
Appendix 33). We complied with ICH-GCP Guidelines over the reporting of 
adverse events (AEs), serious adverse events (SAEs) and suspected unexpected 
serious adverse reaction SUSARs. In addition, we provided the REC with progress 
reports as well as a copy of the final study report. 
 
3.13. Data management, protection and 
confidentiality 
The trial was run as part of the portfolio of trials in the Primary Care Clinical 
Research and Trials Unit (PCCRTU), NIHR accredited trials unit number 33, in 
Primary Care Clinical Sciences at the University of Birmingham. The data 
management was run in accord with the standard operating procedures (SOPs), 
which are fully compliant with the Data Protection Act and ICH GCP. The trial was 
registered with the Data Protection Act website at the University of Birmingham. 
Participant identifiable data was shared only within the clinical team on a need-to-
know basis to provide clinical care and ensure good and appropriate follow up. 
Participant identifiable data was shared with their general practitioner and 
approved auditors from the REC or NHS Research & Development (R&D) as was 
necessary. Otherwise, confidentiality was maintained and no one outside the trial 
team had access to either the case report forms (CRFs) (Appendix 34) or the 
database. The source documents for the trial were CRFs which were stored in a 
locked cabinet at the participating practice. The trial database was securely held 
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and maintained by the PCCRTU. On completion of the trial and data checking, the 
CRFs were transferred to Modern Records, a secure archiving facility at the 
University of Birmingham, where they are held for 15 years and then destroyed. 
The database was anonymised and a secure compact disk containing the link 
between ID number and participant identifiable information was stored in Modern 
Records. 
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4. FEASIBILITY AND ACCEPTABILITY 
OF THE DeMiST TRIAL 
4.1. Introduction 
The primary objective of DeMiST, as described in chapter three, was to investigate 
the feasibility of running a trial to investigate the most promising dietary 
interventions identified in a Cochrane review (Parsons et al., 2009) to prevent 
smoking cessation related weight gain. These were individual dietary and physical 
activity planning (IDAP) and a very low calorie diet (VLCD) which we compared 
with a control intervention of usual care; this was Stage 1 of the trial. Stage 2 
included delivery of IDAP to both the control arm and the VLCD arm for reasons 
discussed in section 3.1.4. 
 
The main reason for a feasibility trial was to prepare for a trial large enough to 
provide evidence of beneficial effects on weight and smoking abstinence in these 
interventions compared to usual care. No trial has yet compared all three options 
and no trial has examined the feasibility of these specialist interventions in nurse 
led clinics, typical of NHS stop smoking services. A commentator on the 
Danielsson trial of VLCD doubted that the intervention could be delivered in usual 
clinical settings (Jones K, 1999). 
 
We measured the response and recruitment rates. We assessed the acceptability 
of each of these interventions to participants and investigated attrition rates and 
reasons behind these. We explored the feasibility of training nurses to deliver 
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these interventions in primary care clinics. For clarity we have dealt with each of 
these aspects of feasibility in three separate sections each with their own 
methods, results and conclusions.  This chapter therefore meets objective four of 
the thesis: to report on the feasibility of running DeMiST, including discussion of 
recruitment rates and experiences of the participants (Chapter 4). 
 
4.2. Response and recruitment rates 
4.2.1. Methods  
As described in chapter three, (section 3.4.1) we measured rates of response to 
participant invitation letters and posters, we measured rates of recruitment at 
telephone screening, and at first consultation. This included a count of drop out 
prior to and post randomisation in each trial arm, which reflected attendance rates 
at visits.  
 
In an effort to improve our recruitment rates we amended our recruitment 
strategies in several ways. However, we had to consider the following limitations:  
Location 
We had to stay within Birmingham East and North (BEN) and Worcestershire 
Primary Care Trusts (PCTs) to run the trial as they had funded the excess 
treatment cost of the VLCD formula up front. 
Timescale 
We only had another six months in which to meet our recruitment target in order to 
complete the trial in time 
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Finance 
We had only budgeted to run one training course for our research nurses. 
4.2.1.1. Recruitment improvement strategy 1 
Therefore, we first tried to increase recruitment within BEN PCT, as there was one 
of our trained nurses available to cover this. We needed to target more people 
from more general practices to boost our recruitment rates quickly. The general 
practice participating in the trial refused to allow our research nurse to see 
participants from other practices on their premises for insurance reasons. 
However, we were able to use a room at the PCT run health centre, and one of 
our trained nurses had spare capacity to work locally as a bank nurse here. We 
did not have the facilities to run routine blood tests at the PCT so we amended our 
protocol and obtained further ethical approval to use skin prick measures instead.  
We also amended our protocol to allow us to advertise more widely, which we did 
by placing flyers and adverts in local newspapers (Appendix 35). Flyers inside 
newspapers were distributed to 9000 homes and an advert in a newspaper went 
to another 2000 homes.  
 
In addition to widening the geographical area for recruitment we also widened the 
inclusion criteria. We no longer excluded those who were unsuitable for a VLCD 
and we opened the trial to all smokers, regardless of BMI, this meant we were 
effectively running two trials, side by side. DeMiST 1, which used the original 
exclusion criteria, and randomised participants into three arms and DeMiST 2 
which independently randomised participants into either the SBS or the IDAP arm. 
Although we would not increase recruitment into the VLCD arm by doing this, we 
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hoped to increase numbers in the other two arms sufficiently to meet the sample 
size to compare those two arms. Without the strict exclusion criteria, this trial was 
now suitable for most smokers regardless of their BMI, energy prescription 
protocols were amended to prevent weight gain without achieving weight loss in 
those with a BMI <25kg/m2 (Appendix 36). Broadening the inclusion criteria made 
it more suitable to advertise the trial to the general public. We anticipated a large 
response and so fewer screening criteria also improved the ease of initial of 
telephone screening.  
 
4.2.1.2. Recruitment improvement strategy 2 
Our final attempt to boost recruitment was to adapt a method previously used in 
Nottingham. This had demonstrated recruitment into the NHS stop smoking 
service could be enhanced from 5% to 30% by first offering a telephone 
consultation with a stop smoking advisor (Murray et al. 2008).  We amended our 
protocol to do this and sent out the first 100 letters containing a questionnaire, 
stamped addressed envelope and an offer of a consultation (Appendix 37).  
 
4.2.2. Results 
4.2.2.1. Original recruitment strategy 
Three family practices in the West Midlands (Bromsgrove, Redditch and Sutton 
Coldfield) identified 1892 potential participants through electronic searching of 
their databases using search criteria of „current smoker‟ and „BMI above 25kg/m2 
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or BMI unrecorded‟ as per protocol. After the research nurses and general 
practitioners (GPs) checked these records for exclusion criteria, 68% were 
suitable and invited to participate in the trial. Of those unsuitable no specific 
reason was given by the practice in 44% of cases, although most of these were 
from one practice which reported significant difficulties searching their database. 
The other practices reported that 37% of participants were medically unfit to follow 
the VLCD or on medication that would require adjustment, beyond the scope of 
our research nurses (Figure 7).  
 
It took nine months to negotiate with the PCTs, obtain NHS permission to run the 
trial at these sites. It took a further five months to recruit the three general 
practices and train our research nurses. Over the following six months these three 
practices yielded 32 respondents, of which 14 were randomised into the trial. Most 
of the other responders did not enter the trial because they dropped out without 
giving a reason or they were not willing to be randomised to the VLCD (Figure 7). 
 
4.2.2.2. Recruitment improvement strategy 1 
We had two responses (Figure 7) and one new recruit from advertising with flyers 
through the newspaper. The cost of advertising in this was £1000. 
 
Widening our exclusion criteria allowed us to carry out a second more inclusive 
search of the general practice databases. However, after initial poor recruitment 
only one of our practices was willing to carry out a second search, we sent out 100 
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more letters and received one response. Therefore, overall 33 out of 1282 (2.6%) 
potential participants who received a letter (original recruitment strategy plus 
improvement strategy one) telephoned the research office. With  
the addition of newspaper advertising we were able to bring the total of 
responders up to 35 (2.7%) (Figure 7). 
 
4.2.2.3. Recruitment improvement strategy 2 
We received two responses both of whom were unsuitable for recruitment as they 
had already stopped smoking. 
 
At this point, it was apparent that we could no longer recruit our original target 
sample size within the timeframe of writing up this PhD, so we closed trial 
recruitment.   
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Figure 7. Flowchart of participants through demist from identification of potential 
participants to numbers who completed trial 
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4.2.3. Discussion 
It took us 15 months to recruit two PCTs, three general practices and randomise 
16 people into DeMiST. The response rate from GP letters was 2.6% and the 
overall recruitment rate from all our efforts was 1.2%. This recruitment rate was 
less than our estimates which were based on a local weight loss trial which 
recruited 10% of those invited to take part by GP letter (Jolly et al., 2011).  
 
Based on our recruitment rate to meet our minimum sample size of 90 we would 
have needed another 15 months, 17 general practices, with two full time nurses to 
travel and cover these clinics. This was beyond our resources.  
 
We have demonstrated that recruiting into a trial which offers help to control 
weight together with smoking cessation is very difficult. This was unexpected 
given the anecdotal evidence that many smokers are concerned about weight gain 
and ask stop smoking advisors for help control it.  
 
4.2.3.1. Potential reasons for poor recruitment 
Our results show that at least 37% of those who were identified as smokers with a 
BMI over 25Kg/m2 could not be invited to take part because of the exclusions due 
to using a VLCD in this clinical environment. In addition, 16% of those who wanted 
to take part, when it came to signing up, were unwilling to be randomised to the 
VLCD. Therefore, use of a VLCD, a drastic weight loss measure, was one reason 
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that limited our ability to recruit but it did not account for all of the difficulty we 
experienced.  
 
The poorest response to recruitment seemed to occur at the point of GP invitation 
and newspaper advertisement. It seemed that there was very little interest in this 
particular study and this may have been for the following reasons:  
 
4.2.3.1.1. Poor marketing 
We need to consider whether the invitation letter and flyers were insufficiently 
captivating to generate interest. However, we modeled our invitations on materials 
that had previously resulted in good recruitment into stop smoking trials. The main 
difference was the added element of weight control.  
 
4.2.3.1.2. Weight control during smoking cessation 
Perhaps weight control during smoking cessation is more of an excuse for not 
quitting rather than a true obstacle. This may mean that when smokers are offered 
this help they do not accept it and choose to continue smoking. Indeed evidence 
from trials and cohort studies suggests that the impact of weight concern on quit 
attempts is conflicting as we have discussed in chapter one (section 1.4). 
 
Perhaps smokers consider weight control during smoking cessation too 
insurmountable a task to attempt it. Perhaps the message from the NHS, that 
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smokers should stop smoking first and not tackle weight at the same time, 
overrides the desire to do so. However, surveys of smokers do not seem to 
support this. In addition, other studies in other countries, such as those cited in a 
Cochrane review (Parsons et al, 2009), have had a good recruitment form 
advertising for such studies. 
 
4.2.3.1.3. The target population 
The problem may therefore lie in the population from which we were trying to 
recruit. We were „cold calling‟ in an area with easy access to stop smoking 
services, so many of those keen to take such an opportunity may have already 
done so. The resulting population may have been the „hardened smokers‟ who are 
either complacent about their smoking and weight or, after repeated failures, have 
given up attempting to change their habits.  
 
4.2.3.2. Potential solutions to poor recruitment 
We did try to widen our inclusion criteria by running a trial without the VLCD 
element and this remains an option to improve recruitment, however by the time 
we did this some of our practices had become so disillusioned with the poor 
recruitment rates that they pulled out of the trial. However knowing the difficulty of 
recruiting into a VLCD trial means this may mean it is not feasible to use in a 
future trial within stop smoking clinics.  
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Engaging individuals with research is notoriously difficult and ways to improve 
recruitment be it through marketing strategies or tailoring it to specific „hard to 
reach‟ communities has been the subject of much research. A Cochrane review 
(Treweek et al, 2010) reviewed studies investigating ways to improve recruitment 
into randomised controlled trials. It reported that the most effective strategies were 
telephone reminders to discuss the trial with those who had not responded to the 
original invitation to participate. This increased the chance of recruitment more 
than 2 ½ fold (RR 2.66 95% CI 1.37, 5.18). Secondly using an „opt out‟ rather than 
an „opt in‟ procedure, for example, notifying participants that they will be called 
regarding the invitation to take part unless they request otherwise, increased 
recruitment by 37% (RR 1.37, 95% CI 1.07, 1.84). However an „opt out‟ procedure 
is ethically controversial.  
 
If we used telephone reminders to GP letters in a future trial we could potentially 
increase the number we randomised into this trial, over the same time period, from 
15 to 40 individuals. This would come at the additional cost and labour of making 
at least 1249 phone calls, but this is likely to be considerable less cost per 
participant than the rate of recruitment we got from the newspaper flyers.  
 
We still need to bear in mind the added challenge of attempting to engage 
smokers in changing two health behaviours simultaneously. This may mean that 
realistically we cannot achieve a better recruitment rate than this. One option is to 
accept that recruiting for such a trial will yield a smaller return for the time, 
advertising costs and labour required than other trials. Budgeting for this 
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adequately in future trials would be one solution but with scarce resources of 
funding bodies this may not prove possible. 
 
Another option is to recruit from a population who were already planning a quit 
attempt. For instance, we could attempt to recruit on entry to the stop smoking 
services, rather than cold calling from the GP population of eligible smokers.  A 
trial in Scotland in stop smoking groups successfully randomised 90% of their 
smokers entering the service into a nutrition education programme that ran 
alongside it (Hankey et al., 2010).   
 
In designing DeMiST we had considered running group sessions to maximise 
recruitment in a short space of time, this was contained in an earlier version of the 
protocol (Appendix 38) for which we gained ethical approval. However this was 
labour intensive and required further funding. We applied to the NIHR Research 
for Patient Benefit stream for this. However, our application was rejected and the 
feasibility of running groups was questioned (Appendix 39) and so, in 
consideration of reviewers comments, we substantially amended our protocol and 
ran the trial as reported in this thesis. 
 
4.2.4. Conclusion 
Recruitment from GP invitations and newspaper flyers into a three armed 
randomised controlled trial of dietary interventions to prevent weight gain during 
quitting smoking was poor in a population with easy access to NHS stop smoking 
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services. Recruitment may be improved somewhat by avoiding the use of a VLCD, 
and offering telephone reminders, but the additional time and resources that would 
be needed may prove too expensive to be feasible. However recruiting from those 
already intending to quit and attending the stop smoking services offers a 
potentially viable alternative. 
 
4.3. Acceptability to participants 
4.3.1. Methods 
We investigated participant acceptability of trial arm qualitatively by semi-
structured interviews. The interviews were conducted by telephone; evidence 
suggests that well planned telephone interviews can gather the same material as 
those held face to face (Sturges et al, 2004, Taylor et al, 1998). They are less 
intrusive, which may be particularly useful to engage with those who dropped out 
of the programme, and they do not require payment of travel expenses.  
 
Interviews were conducted after the participant had completed treatment or 
dropped out of the programme. Participants could not be interviewed before this 
time point in case the interview influenced their views of the trial or the intervention 
being delivered.  
 
Participants were asked to discuss what they found helpful and unhelpful with 
regard to the intervention they received. What did they attribute to their success or 
abandonment of an intervention? To draw this out we asked the following open 
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ended questions: What did you expect to get from taking part? What did you 
actually get from taking part? What, if anything disappointed you? How would you 
have liked things done differently? If you needed to try things again what would 
you do? How did you get on with quitting? (What worked well? What was hard?) 
How did you get on with the dietary side of things? (What worked well? What was 
hard?) How do you feel about your smoking status now? How do you feel about 
your weight now? If you pulled out of the trial early, why was this?  (Appendix 40 
contains the interview schedule) To help participants remember their thoughts and 
feelings „of the moment‟ they were given the questions they would be asked, with 
space to jot down notes, during the trial. Interviews lasted 10 to 20 minutes.   
 
With participant consent, the interviews were audio recorded and transcribed 
intelligent verbatim (words such as „um‟ were not transcribed). Audiofiles were 
outsourced for transcription to Type Research, a recommended transcription 
service for qualitative research.  The data was analysed thematically, as 
discussed below, so that comparisons could be made within and across the 
interviews, and the views participants held towards particular issues, e.g. the 
intervention they received or preventing weight gain whilst quitting smoking, were 
highlighted. 
 
4.3.1.1. Sampling 
We had hoped, as described in the protocol (chapter three, section 3.4.1), to 
obtain a wide set of experiences within each trial arm. We wanted to include all 
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aspects of attrition, for example, those who completed the trial, and those who 
dropped out of quitting, dieting or both. We wanted gain maximum variation in 
relation to gender, age, socio-economic background, ethnicity, smoking rate and 
research site. We wanted to sample until theoretical saturation was reached and 
to do so purposively. However due to the small sample size and the unwillingness 
of some people to be interviewed, we interviewed all those who were willing, and 
ended up with a convenience sample. 
 
4.3.1.2. Analysis 
We carried out a thematic analysis that was informed by the five stage framework 
approach described by Pope et al in 2000. However, it was not a full framework 
analysis as we did not want to test an „a priori‟ concept or framework. We wanted 
to deduce solely from the participants themselves the experiences they found 
helpful and those they did not. As described by Lacey and Luff in 2007 there is no 
one way to analyse qualitative data but rather a considered approach which best 
answers the research question must be taken (Lacey & Luff, 2007). 
 
Our analysis contained the following steps: 
 
4.3.1.2.1. Familiarisation  
We immersed ourselves in the data by listening to the audio recordings, reading 
and re-reading transcripts (Pope et al, 2000). 
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4.3.1.2.2. Coding/Indexing 
We reassembled fractured discourse by pulling together scattered responses to 
questions from wherever they came in the transcripts. For example where an 
earlier question was expanded on later in the conversation, this was cut and 
pasted together as an expanded chunk of conversation. Then we coded the 
content of these responses, our codes were identified predominantly from „in vivo‟ 
words, group of words, sentences, or paragraphs from the transcripts (Lacy and 
Luff , 2007) that described a particular positive or negative experience of the trial. 
Each new code was highlighted using a different coloured pen (Lacy and Luff , 
2007). 
 
We included both literal and interpretative coding and considered reflexively 
whether interviewer prompting or empathy could have led the response or 
changed it over time (Swift and Tischler, 2010).  
 
We did not carry out a discourse analysis (coding for signs to latent meanings), 
this went beyond the scope of the PhD. Instead we noted where content appeared 
particularly emotive, or aspects were stressed repeatedly and it was intuitively 
clear that opinion was strong or contradicting of itself. 
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4.3.1.2.3. Identification of themes 
We then grouped our codes into broader themes and sub themes (Lacy and Luff, 
2007). We did this in Microsoft Word by cut and pasting quotes and/or their codes 
into sub themes under the heading of a broader theme. We took care to keep the 
quote linked to the participant identifier. An example of the worksheet for the 
development of negative themes and subtheme from quotes/codes is contained in 
appendix 41.  
  
4.3.1.2.4. Charting themes by trial arm 
We then developed a matrix of themes and subthemes according to trial arm to 
observe the similarities and differences between them. We took note of the 
presence or absence of any links to trial outcomes. Throughout the process we 
kept the data of responses linked to the individual who gave them.  
 
4.3.1.2.5. Interpretation 
Finally we considered whether the most acceptable and least acceptable aspects 
could be defined by trial arm or by the characteristics or typologies of participants 
(Lacy and Luff, 2007). 
 
A selection of codes and themes were peer reviewed for credibility purposes. A 
colleague reviewed a transcript and comparsion was made between the two sets 
of codes identified by different researchers from the same transcript. Ongoing 
discussion with other qualitative researchers regarding the development of 
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themes, particularly given the context in which codes were identified within 
transcripts, also took place.  
 
4.3.2. Results 
4.3.2.1. Baseline Characteristics 
We carried out semi-structured interviews on 13 participants, baseline 
characteristics are shown in Table 18. 
 
 
 
 
 
 
 
 
 
4.3.2.2. Hindering factors  
Seven main themes, each with subthemes, emerged which described what 
participants found unhelpful or hindered their success at weight control or stopping 
smoking. These are listed in Table 19 and how these were developed can be 
found in  Appendix 41. , some aspects were common to all trial arms and others 
were specific to individual trial arms. We have expanded key themes in the text 
below and substantiated these with quotes. 
  Mean (SD) 
n 13 
 Age (years) 50 (11) 
Cigs/day 24 (8) 
Fagerstrom score 5.3 (1.7) 
Weight (kg) 83.2 (10.8) 
BMI (kg/m
2
) 30.80 (5.41) 
SBS 46% 
 IDAP 23% 
 VLCD 31% 
 Gender (% female) 77%   
Table 18. Baseline characteristics of 
DeMiST participants engaging in 
semi-structured interviews 
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Theme  Trial arm 
 Sub theme VLCD IDAP SBS 
Displeased with trial arm allocation Unreasonable* X   
Did not address weight adequately*   X 
Diet fell below expectations  Taste* X   
Food choice*  X X (Stage 2 only) 
Thought knew better*  X X (Stage 2 only) 
Hunger X X  
Portions   X (Stage 2 only) 
 Feeling unwell X   
Perceived lack of support Not frequent enough*   X 
 Negative rather than a positive approach*  X  
 Feeling alone*   X 
 Wanting peer support*  X X 
 Wanting more psychological therapy*  X X 
Disappointed with self Low self-worth* 
 
  X 
 Inability to stop smoking* X  X 
Socially difficult For diet X  X 
 For smoking X  X 
Personal circumstances Inconvenient appointments* X X X 
 As a reason for limited success X X X 
Difficulty of task A sense of loss of coping mechanism* X X X 
 Tackling both smoking and weight at the same time* X X  
 Could only focus on diet X   
 Could only focus on smoking X  X 
 Stopping smoking X X  
 Getting out of the habit/changing routines X X X 
 Mood changes* X   
 Something to do with your hands   X 
 A sense of loss of identity* X X X 
*some participants who reported these difficulties also dropped out of the trial early 
 
Table 19. Themes and sub-themes of difficult experiences during DeMiST, according to trial arm 
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4.3.2.2.1. Displeased with trial arm allocation 
There was dissatisfaction with trial arm allocation in both the VLCD and SBS 
arms. The VLCD evoked an emotive response: 
  “I was allocated in to that stupid powder stuff...I think it is totally unreasonable 
 to ask somebody to...eat that stuff” Male on VLCD,  abandoned VLCD after 3 
 days, stopped smoking for 5 weeks, did not complete programme. 
 
 
this was linked to the taste of the Lipotrim formula  
 “ surely in this day and age somebody can make that food taste better than it 
 tasted...” Male on VLCD, abandoned VLCD after 3 days, stopped smoking for 5 
 weeks, did not complete programme. 
   
 
In the SBS arm participants expressed both mild disappointment  
 “I would have preferred...” Female, quit, weight gain in Stage 1, weight loss 
 in Stage 2. 
 
and strong objections  
 “I was absolutely gutted...” Female, SBS, left at week +9 smoking no weight 
 loss. 
 
to being allocated the SBS arm. This was because weight was not being 
addressed adequately or soon enough, some even felt cheated  
 “that was one of my major reasons…was the weight as well and to be told that oh 
 no, just carry on as you are for a few…more weeks,”  Female, SBS, left at week 
 +9 smoking no weight loss. 
 
 “I found it a bit of a misnomer really thinking I was going to give up smoking I 
 mean I understand with the trial but I did honestly expect some sort of assistance 
 with the diet side I didn‟t really expect to be just left to get on with it.... I think I was 
 a little misled on that score.” Female, SBS, temporarily stopped smoking, dropped 
 out of programme before diet given in Stage 2. 
 
One particular participant was so dissatisfied that they could not adhere to the 
programme: 
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 “I didn‟t really fully go with the trial if you like, because I did start cutting back on 
 some sort of food in that first 8 weeks because I was not prepared to put a stone 
 on.” Female quit smoking, resorted to dieting during SBS Stage 1. 
 
 
No participants reported any dissatisfaction with being randomised into the IDAP 
intervention.  
 
Therefore although at the time of consent participants agreed to randomisation, it 
was clear that while participants were willing to take a chance, they had strong 
individual preferences, and these were linked to acceptability of the programme. 
 “ I know the programme said you haven‟t got a choice...I was hoping and praying 
 that I, on which one I would be allocated to and when, when I got one I was 
 disappointed anyway but when I tried eating it, crikey, you know, it went downhill 
 after that.” Male on VLCD, abandoned VLCD after 3 days, stopped smoking for 5 
 weeks, did not complete programme. 
 
 
4.3.2.2.2. Diet fell below expectations 
In all the trial arms, there were those for whom the diet fell below expectations, 
this was caused by difficulty in a number of areas. Firstly, in the VLCD arm the 
taste and smell of the formula was a problem. For some this led to them 
abandoning the diet  
 “Absolutely vile it was – I couldn‟t...I even like I was nearly sick just even smelling 
 it” Male on VLCD, abandoned VLCD after 3 days, stopped  smoking for 5 weeks, 
 did not complete programme. 
 
Whereas others continued despite this, when probed as to whether it improved 
one response was: 
  “No, every single one of them was revolting!”  Male, VLCD, lost weight, reduced 
 smoking, did not quit, did not complete programme. 
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Initial hunger and feeling unwell was also a problem in the VLCD arm. The 
reasons behind continued adherence despite these difficulties are explored in 
section 4.3.2.4.  
 
In the IDAP arm and Stage 2 of the SBS arm diet fell below expectations of some 
with respect to food choice, 
  “I mean, I thought... the options that were recommended were clearly restrictive 
 and not very imaginative [interviewer probed further]... more or less the same the 
 everyday”. Female in IDAP, stopped smoking for 8 days, lost weight, did not 
 complete programme   
 
 
Hunger was also a problem in the IDAP arm. Other participants did not like to be 
told what to do, they thought they knew how to do these things better themselves: 
  “I won't lie, I love pasta and rice [large portions] and I don‟t particularly like 
 measuring cups of vegetables, you know if I want a plate full of vegetables I 
 like a plate full of vegetables. I have to say...” Female in SBS, quit, weight 
 gain in Stage 1, weight loss in Stage 2. 
 
 
It is important to note that these themes ran through IDAP and SBS (where IDAP 
was received in Stage 2), but there was no dissatisfaction with IDAP in Stage 2 of 
the VLCD arm. It is possible that disgruntlement was due to disappointment in trial 
arm allocation and not just to the nature of IDAP. In particular, it was interesting to 
note that one individual who initially was rather angry with both allocation to SBS 
and the Stage 2 diet on further probing did in fact change her mind: 
 “I probably will [use the cups], I'd use them for like, cos I was amazed when I did 
 go on the diet that the nurse gave me after 8 weeks that the portions are really, 
 really small so I'm trying, I am aware of the portion size because of what you've 
 given me.  It has been quite positive yeah there's only that little minor negative 
 that, about the whole situation.” Female quit smoking, resorted to dieting during 
 SBS Stage 1. 
 
Whether probing encouraged the participant to reflect on opinion and establishing 
a rapport dissipated anger such that a reasoned opinion was reached; or whether 
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the initial reaction is more in keeping with true opinion is hard to tell. Researcher 
belief in IDAP, coupled with clinical skills, which encourage a reasoned, well 
informed response to treatment, may have biased this response.   
 
4.3.2.2.3. Perceived lack of support 
In the IDAP and SBS arms, but not in the VLCD arm, there was a perceived lack 
of support for some, which was related to the desire for peer support: 
 “I thought I would have liked to have listened to how other people were getting on 
 with their different things, you know and that you know, I think that would‟ve been 
 good.” Female SBS, temporarily stopped smoking, dropped out of programme 
 before diet given in Stage 2. 
Also some participants felt they should have received further psychological 
support:  
 “Well something about you know [helps with] feelings of deprivation, if you have 
 any, feelings of not being who you were, feelings of loss...trying to  balance that...” 
 Female in IDAP, stopped smoking for 8 days, lost weight, did not complete 
 programme.   
Some of these needs may have stemmed from underlying issues which went 
beyond dealing with withdrawal symptoms and this was expressed as another 
theme about how participants felt about themselves as described below. 
 
4.3.2.2.4. Disappointed with self  
For one participant this seemed related to low self-worth: 
 “I just think I am so stupid and then I get annoyed with myself and then you 
 just think „Oh have a fag‟...the way you think about yourself...you‟re not really that 
 important, so what if you overeat and smoke and pop your clogs, you know.” 
 Female, SBS, temporarily stopped smoking, dropped out of programme before 
 diet given in Stage 2. 
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In the VLCD and SBS arms participants were disappointed in their own ability to 
quit smoking: 
  “I just, just so disappointed you know, I don‟t, no, I can‟t tell you how much 
 disappointed that I couldn‟t stop smoking, you know.” Male on VLCD, abandoned 
 VLCD after 3 days, stopped smoking for 5 weeks, did not complete programme. 
 
 
4.3.2.2.5. Socially difficult 
Participants in the VLCD and SBS arms reported on the social difficulties of 
following the diets and those encountered when stopping smoking: 
 “[I] didn't sit at the table...normally [I] sit and talk.” Female on VLCD, 
 successfully controlled weight and then quit smoking. 
 “Sticking to it [the diet] because my neighbour across the road bakes cakes, 
 that was hard.” Female in SBS, left at week +9 still smoking, no weight loss. 
 “So my friend at work who smokes I wasn‟t going outside with her so I wasn‟t 
 speaking much” Female on VLCD, successfully lost weight and then quit smoking. 
 
4.3.2.2.6. Difficulty of task 
Many participants in the VLCD and SBS arms described the most difficult thing as  
 “the giving up”, 
this is one participant‟s account  of his preoccupation with cigarettes as he tried to 
live without them: 
 “It was just on me mind 24 hours a day and I just could not shake it off, I could not.  
 I couldn‟t wake up in the morning without thinking about cigarettes, I couldn‟t go to 
 sleep at night without thinking of cigarettes and it – I mean, I was, I was just 
 cracking up, I actually couldn‟t, you know, I  needed something to block me brain 
 out and, you know...” Male on VLCD, abandoned VLCD after 3 days, stopped 
 smoking for 5 weeks, did not complete programme. 
 
The difficultly of changing diet and stopping smoking at the same time was also 
apparent: 
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 “there was a difficult period with no food and no cigarettes... it was just almost 
 unbearable.” Female on VLCD, successfully lost weight and then quit 
 smoking. 
 
For some this meant that they concentrated on the weight loss attempt and for 
others they focused on smoking cessation: 
 “that [VLCD formula] started to show effect...I think I put all the effort into that” 
 Female, VLCD, abandoned quit attempt first and so later gave up on diet too and 
 pulled out of programme. 
 “And to be perfectly honest, because I wasn‟t smoking I thought, well, you know, 
 that‟s what I want [whole tubs of Haagan Das ice cream]...have it”  Female in 
 SBS, quit, weight gain in Stage 1, weight loss in Stage 2. 
Stopping smoking was perceived as being difficult for a number of reasons, these 
were changing moods, which were most apparent in the VLCD arm, and 
aggression: 
 “I felt slightly miserable and like let down with myself” Female VLCD, did not stop 
 smoking or lose weight or complete programme.  
 
 „my aggression, I was just so aggressive...”  Male on VLCD, abandoned VLCD 
 after 3 days, stopped  smoking for 5 weeks, did not complete programme. 
 
One person in the SBS arm mentioned the difficulty of not  
 “having something to do with my hands.”  Male SBS, lapsed intermittently, weight 
 maintained during Stage 1, lost weight in Stage 2. 
In all trial arms trying to change habits and routines were difficult: 
 “the hardest thing has been the habit, routine of having a cigarette,” Female in 
 SBS, quit, weight gain in Stage 1, weight loss in Stage 2. 
 
And there was a sense of loss, a loss of identity:   
 “...feelings of not being who you were...” Female in IDAP, stopped smoking 
 for 8 days, lost weight, did not complete programme.  
  
And a loss of support:  
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 “... feels like a crutch...kind of lost without that”  Female on VLCD,  successfully 
 controlled weight and then quit smoking. 
 
This loss of support was linked to no longer having a coping mechanism when 
circumstances were difficult: 
 “it was just pressure of work, pressure of life, you know...the pressure of 
 everything just...the pressure really” Male on VLCD, abandoned VLCD after 3 
 days, stopped  smoking for 5 weeks,  did not complete programme. 
 
Therefore, despite the dietary interventions, it seems that for many the stopping 
smoking that was the main difficulty. For a few this was compounded by being 
hungry or trying to control food intake.  
 
4.3.2.2.7. Personal circumstances 
In all trial arms there was evidence that personal circumstances made it difficult to 
keep appointments (see next section) and achieve outcomes:  
 
 “...from a personal point of view I actually found myself in extremely difficult 
 circumstances just after I started and that was the main reason for failure…”  
 Female in SBS, quit smoking, no weight gain (resorted to dieting during Stage 1) 
 did not complete programme. 
 
  
4.3.2.3. Reasons for and links with attrition 
Both participants who did not abandon the treatment programme early and those 
who did reported the problems described above (Table 19). Some attributed their 
lack of adherence to the insuperability of these problems. When participants were 
specifically questioned about their reason for drop out two key themes emerged 
(Table 20).  
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4.3.2.3.1. Difficulty in keeping appointments 
In all trial arms personal circumstances changed which made keeping 
appointments difficult, both the time and frequency of appointments were no 
longer convenient.  Then once an appointment had been missed participants 
became embarrassed to go back to see the nurse or they lost motivation.  
  “Ahh, I had so much crap at home and also I wasn‟t able to get up to the doctor‟s 
 at half past nine...” Female in SBS, left at week +9 still smoking, no weight loss. 
 “But it was that that stopped me going back it wasn‟t that it wasn‟t working, it 
 wasn‟t that it wasn‟t very good or that I felt it wasn‟t worth it; it was purely work 
 and hospital commitments...” Male, VLCD, lost weight, reduced smoking, did 
 not quit, did not complete programme. 
 
 “I popped into the surgery the other day and [she] gave me a wry smile, and I just 
 sort of hid!” Male, VLCD, lost weight, reduced smoking, did not quit, did not 
 complete programme. 
 
The associated loss of motivation may be a key theme here as the inconvenience 
of appointment time could have been overcome by changing the appointment 
schedule, if motivation was high enough to do so. 
 
4.3.2.3.2. A sense of failure 
In all trial arms a participant‟s sense of failure in their own ability to stop smoking, 
or their inability to both stop smoking and control weight were also reported as 
reasons for leaving the trial early.  
 “....but I think, as I say, once I knew that I wasn‟t going to quit the smoking then 
 obviously it went downhill pretty quickly...” Female, VLCD unable to maintain 
 weight loss or quit smoking . 
  “Yeah, I ended up smoking again and I wasn‟t sticking to the diet” Female, IDAP 
 temporarily stopped smoking, lost weight after pulled out of trial. 
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However no one reported abandoning the programme just because they were 
unable to control their weight.  
 
 
Table 20. Themes and subthemes of reason for not completing the trial 
 
 
 
Theme  Trial arm 
 Sub theme VLCD IDAP SBS 
Difficult to keep  appointment Personal circumstances  X  X 
Time was inconvenient   X 
Frequency of visits was inconvenient X X  
Embarrassment X   
Lost motivation  X X 
Sense of failure  Quit smoking only X  X 
 Unable to do both X X  
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Theme  Trial arm 
 Sub theme VLCD IDAP SBS 
Pleased with trial arm Enthusiasm/excitement X   
 Satisfaction  X X 
Weekly support Seeing someone /accountability X  X 
CO monitoring  X X 
 Weight/fat mass/blood pressure monitoring X  X 
Clear instructions   X 
Discussions, tips to tackle cravings   X 
Peer support Support from partners/friends X  X 
NRT Patches Controlled cravings   X 
Dietary aspects Portion control using cups 
 
 X  
 Cups simple to use  X X (Stage 2 only) 
 Structure   X (Stage 2 only) 
 Increase of fruit and vegetables   X (Stage 2 only) 
 Variety of food   X (Stage 2 only) 
 Lack of hunger X  X 
 Mood stability X   
 Replacing cigarettes with healthy snack   X 
 Able to continue dietary plan after end of trial X (stage 2)   
Evidence of success* Rapid, dramatic weight loss X   
 Moderate weight loss   X (Stage 2 only) 
 More money X   
 Smell of smoke gone   X 
 Improved taste and smell X  X 
 Reduction in number of cigarettes smoked X   
 Eating more healthily 
 
X   
 Feelings of being in control of smoking X   
 Feelings of being in control of eating X   
 Sense of achievement on behalf of family    
 Sense of achievement for self    
Feeling good about self* Encouraged by own success X  X 
 Motivation/determination X  X 
Timing Lose weight at same time X X  
 Lose weight after quit   X 
 Preference to lose weight before quit X X X 
*strongly overlapping themes 
Table 21. Themes and sub-themes of helpful experiences during DeMiST, according to trial arm 
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4.3.3.4. Helpful factors 
Eight themes with sub-themes emerged that participants found helpful in DeMiST 
(Table 21). 
 
4.3.3.4.1. Pleased with trial arm allocation 
In all trial arms there were participants that were happy with their allocated 
intervention, a quiet satisfaction characterised responses in the IDAP and SBS 
arms whereas there was notably more enthusiasm and excitement for some of 
those allocated the VLCD: 
 “I knew that diet was right for me! ...I just knew that that was the only thing 
 that was going to work!” Female, VLCD, lost weight then quit smoking. 
 
4.3.3.4.2. Weekly support  
In all trial arms participants said they found the weekly support helpful. Particularly 
helpful aspects were accountability (SBS and VLCD) and carbon monoxide (CO) 
monitoring (IDAP and SBS),  
 “...seeing [the nurse] every week knowing that I was gunna have to blow  into a 
 thing, knowing that she'd know whether I'd had a fag or not huh, just gave me the 
 incentive to keep going. I mean I did slip a couple of times but I find it a lot easier 
 to get back into stopping smoking knowing that I was being monitored every 
 week.” Female, SBS, quit smoking, gained weight. 
Monitoring of CO, weight, fat mass and blood pressure (VLCD and SBS) were 
also helpful, not only for reasons of accountability but also, for motivation arising 
from fear and shock at health status: 
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 “I was actually told exactly what my weight was, my BMI and all those things you 
 know, and I think that‟s quite helpful when you… to look at  your… to actually find 
 out what, oh I forget what they called it now, but the volume of … basically in your 
 body.  It‟s sort of a bit scary actually when you‟re told that a certain percentage of 
 your body is…[fat] I know it kind of makes you sit up and think.”  Female, SBS, 
 initially motivated then could not quit so abandoned diet and programme.  
Monitoring was also a source of encouragement: 
 “[I] saw my blood pressure come down, my carbon monoxide level, the weight 
 come off...” Female on VLCD, lost weight, then quit smoking. 
 
Other helpful aspects of support were the clarity of instructions and the opportunity 
to discuss how to resist urges to smoke  
 “The discussions were very helpful; she was giving me useful tips on how to get 
 around the cravings and getting over the willpower side of things.” Male, SBS, 
 lapsed intermittently, weight maintained during Stage 1, weight lost in Stage 2. 
 
4.3.3.4.3. Peer support  
As well as clinical support, support from others was also an important aspect, if 
the venture was acceptable to those around the participants then it seemed to be  
acceptable to them too:   
 “Yeah it was a bit hard during the first few days but because I had sort of told all 
 my work colleagues what I was doing, but it wasn‟t „oh where is your food today 
 and why have you got?‟ they were really, really supportive.” Female, VLCD, 
 initially enthusiastic then couldn‟t quit, abandoned diet and programme. 
 
4.3.3.4.4. NRT Patches  
Several participants in the SBS arm mentioned the usefulness of the NRT patches 
to help control cigarette cravings. 
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4.3.3.4.5. Dietary aspects  
In all trial arms, there were various aspects attributed to the diets that participants 
found helpful. In the VLCD arm participants were surprised by their lack of hunger 
and mood stability 
  “and I‟ve got to be honest, it did really fill you up, I mean I‟ve been on one of these 
 for… but this, it did fill you up and, you know, I was amazed at that” Female VLCD, 
 lost weight then quit smoking. 
 “the lack of food...it worked far better than the patches. There were many  days 
 when I didn‟t put the patches on at all...[my mood] was more controlled, yeah, it 
 was more even.” Male, VLCD, lost weight, reduced smoking, did not complete 
 programme. 
 
In the IDAP arm and Stage 2 of the SBS arms, simple control of portion size using 
the measuring cups were reported as useful, 
 “...cups were the most helpful. I cut my portion sizes down...” 
as was the structured nature of the diet 
 
 “Well, she just – what, what she did was give me, erm, a list of what I could 
 have, breakfast, dinner, tea which was far better, saying you can have that 
 off that list, that off that list and that off that list. [probed: what sort of advice 
 have you had in the past?] “Make your own really.” Female, SBS, left at week +9 
 smoking, no weight loss despite being pleased with diet, as abandoned 
 programme due to personal circumstances. Also, initially very disappointed with 
 allocation to SBS. 
 
And advice to eat a greater variety of food  
 
 “It [Stage 2 food plan] did point out that I wasn‟t eating as varied a diet 
 maybe...Yeah it was very good.” Male, lapsed intermittently, weight maintained 
 during Stage 1, lost in Stage 2. 
 
and increase fruit and vegetables; this was in contrast to others described 
previously who felt that the variety of the diet was poor. 
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4.3.3.4.6. Evidence of success  
The main aim of the programme was to assist cessation and control weight; 
however, participants also measured success in several other ways, some of 
which were a result of stopping smoking e.g. having more money, improved taste 
and smell, the smell of smoke gone. 
 “when I'm driving behind somebody now that's smoking in their car I can smell it 
 coming into mine, you know and you can smell people in the supermarket and I 
 think oh god did I used to smell like that?” Female, SBS, quit smoking, gained 
 weight. 
Some success was related to feelings of being in control, of both food and 
smoking; this was linked to a sense of achievement. This seemed important as 
participants were able to do what they felt was right for themselves, and pleasing 
to their families. 
 “and having tried before...one thing I will say, it made me very, very grouchy and 
 very irritable. I didn‟t find comments from my family, this time, so obviously this 
 was... (Laugh). My wife has just chipped in with “yeah, you‟re just grumpy some of 
 the time instead of all of the time” Male, VLCD, lost weight, reduced smoking, did 
 not complete programme.  
  
 “I‟m not eating as many fatty foods, I mean, I read all my leaflets and stuff 
 like that and, you know, I‟m trying well, the whole family‟s trying to eat more 
 healthily anyway so ...” Male on VLCD, abandoned VLCD after 3 days, stopped 
 smoking for 5 weeks, did not complete programme. 
 
Initial successes spurred participants to further success, making them more 
determined to persevere through difficulties. This was particularly noticeable in the 
VLCD arm where weight loss was rapid and dramatic, and a sense of 
achievement came at considerable cost. For example 
 “...if I hadn‟t had lost nine pounds or something like that in the first week I  wouldn‟t 
 have carried on that was the incentive, that's why I knew that diet  was right for 
 me.  Having gone through all of that torment and then found it would have 
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 been 2 lbs I would have gone to the chip shop or got a packet of cigarettes...” 
 Female on VLCD, successfully controlled weight and then quit smoking. 
 “It‟s instant, you do start to notice within days and that‟s the good thing, and of 
 course, when you get that buzz and when your clothes start feeling loose so 
 quickly.  Obviously it‟s so very planned and very boring but you get over that first 
 stage, you know, it‟s like any diet isn‟t it, once you see the results, but because 
 that‟s a bit quicker” Female, VLCD, unable to quit smoking and so later gave up on 
 diet too and pulled out of programme. 
 “giving up the food the week before, you‟re to question whether you really 
 needed something... it got me used to saying no to myself ....so then when it came 
 to the cutting out the smoking it was well, „do I really need that?‟ ... I began to take 
 control of my smoking instead of having them out of habit  or of them controlling 
 me; telling me when I wanted them, so it was good, it was very good.” Male, 
 VLCD, lost weight, reduced smoking, did not quit, did not complete programme 
 
 [So what made you really...persevere though every time they tasted awful?] 
 “Because I didn‟t think I would and actually thought it was a very… it was a good 
 opportunity to try and control if not give up smoking.  I then saw the benefit of the 
 weight loss…[I thought] Hey! This is really cool...” Male, VLCD, lost weight, 
 reduced smoking, did  not quit, did not complete programme. 
 
However early evidence of success or early positive experiences were not always 
associated with clinical outcomes of long term weight loss maintenance or 
smoking cessation, as shown by the outcomes labelled beside the participants‟ 
quotes. 
 
4.3.3.4.7. Feeling good about oneself 
As well as a sense of achievement and doing what is right for oneself and others, 
becoming self motivated was valued highly: 
 “I was very motivated, I was absolutely determined I was going to do it. I  was, I 
 was very… my mindset was right and I felt that talking to the nurse and getting sort 
 of the health checks and things kind of made me think.” Female quit smoking, 
 resorted to dieting during SBS Stage 1. 
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4.3.3.4.8. Timing  
In all trial arms the timing of the dietary intervention in relation to the quit attempt 
was important. For some in the SBS arm they were pleased to tackle weight after 
the stopping smoking, others would have preferred to have tackled it at the same 
time. In the IDAP and VLCD arm some were pleased to tackle weight at the same 
time, others wanted to have tackled it before, but none in these arms wanted to 
wait till afterwards.  
 “I think you probably would‟ve been better to get used to being on the diet first. 
 And then like slowly, maybe cutting, maybe I don't know which is the best way to 
 do it maybe cut down on the cigarettes but such a drastic diet and then you feel 
 that there is just nothing, you can‟t do anything really.” Female on VLCD, 
 successfully controlled weight and then quit  smoking. 
 
 I‟d have probably started the diet a month before…got used to it and then stopped. 
 Lose weight first, but you know, quite a bit of weight. Female, IDAP 
 temporarily stopped smoking, lost weight after pulled out of programme. 
 
4.3.4. Interpretation and Discussion 
4.3.4.1. Poor acceptability 
4.3.4.1.1. When the trial did not meet participants’ perceived needs   
Participants described several main themes that they believed hindered their full 
participation in, and successful outcome from, DeMiST. We saw in DeMiST when 
participants were allocated to the SBS arm they were disappointed because it did 
not address their weight from the start. All our participants were overweight, and 
so some felt the desire for weight loss keenly, some participants particularly 
wanted rapid and dramatic weight loss. Both disappointment with allocation to 
control arms (Lindstrom et al., 2010) and unfulfilled high expectations of weight 
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loss (Foster et al., 1997) have been previously shown to be a source of 
considerable disappointment. 
 
Disappointment in trial arm allocation was also seen in the VLCD arm by those 
who found it too unpalatable and too drastic a dietary restriction to continue with.  
Therefore poor acceptability may be due not only to allocation to control but to 
whichever arm did not meet participants perceived needs. Systematic review 
evidence shows that whether participants feel they will personally benefit from a 
programme is closely linked to their preferences within a clinical trial (King et al., 
2005) and their decision to participate (Edwards et al., 1998). 
 
In addition, many studies have shown that many participants do not understand 
randomisation (Kerr et al., 2004, Moffat et al., 2006) which can cause participants 
to feel their needs are not met. There can be an expectation that even in trials, 
clinicians will do what is of most benefit to the individual (Kerr et al., 2004). This is 
considered a therapeutic misconception, where the goals of research, which are 
for the benefit of future patients, are confused with the goals of clinical care of the 
individual. It is proposed that this can result in participants misplacing their trust in 
research as though it were clinical care and this creates a barrier to the 
acceptability of research (de Melo-Martin & Ho, 2008). We found evidence to 
suggest mistrust of this kind as some of our trial participants felt cheated.  
 
Once participants received the dietary intervention in Stage 2 of SBS, some were 
satisfied, but others continued to feel hard done by. Initial disappointment may 
have contributed to a negative appraisal of the dietary intervention in Stage 2 of 
 174 
 
the SBS arm. People allocated to IDAP initially were generally more positive about 
it than those who received it later. As discussed in chapter three (section 3.1.4) we 
included IDAP in a second stage of SBS with the aim of avoiding such 
disappointment, but for some this was not enough as they were not prepared to 
wait.  
 
Support, in particular lack of peer support and psychological help, also fell below 
expectations. Although some of this may have been due to underlying 
psychological issues. Such issues are known to be prevalent among smoking and 
obese populations, but whether they are caused by or an effect of smoking and 
obesity is unclear (Strine et al., 2008). 
 
We explored whether allocation to the trial arm that participants thought would 
work was associated with time until drop out, but we found no evidence of this 
(Chapter five). However, our sample was too small to be conclusive.  
 
4.3.4.1.2. When participants are ‘expert’ 
Dietary intervention also fell below the expectations of some participants allocated 
to the IDAP arm, who received this from the beginning. The participants with these 
views tended to be seasoned dieters who felt they had received better dietary 
advice in the past and were experts themselves.  This is in line with studies 
showing tensions between „expert‟ or self-reliant patients and their acceptance of 
medical advice. These individuals consider medical advice highly reflexively, in the 
light of their own experiences (Fox et al., 2005).  
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4.3.4.1.3. When problems become in surmountable 
 
Participants found it difficult to stop smoking because of mood changes and the 
loss of a „coping mechanism‟, particularly if personal circumstances were difficult. 
Many smokers experience these problems on trying to quit (Hughes et al., 1991, 
Shiffman, 1982). Participants who were unable to quit were disappointed and felt 
they had failed.  
 
4.3.4.2. Acceptability 
4.3.4.2.1. When trial met participants’ perceived needs 
What some participants found helpful others found a hindrance. Some people 
were happy at concurrent weight management and dieting, while others preferred 
to tackle both of these sequentially. Participants also found helpful the same 
aspects of the same interventions that others perceived as poor. For example, in 
contrast to the lack of support described by some, others praised nurse support 
highly and considered it an important source of advice, motivation and 
reassurance.  
 
Some in the VLCD arm were particularly excited and enthused by this intervention. 
They found that the rapid effects of weight loss and improved sense of self-control 
provided a sense of achievement from which they took tremendous 
encouragement.  In the VLCD arm, this achievement came at considerable 
personal cost, but the evidence of their success motivated them to persevere in 
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spite of difficulties. This process is very much in line with the theory that behaviour 
change is prompted by self-efficacy (Bandura, 1977). However, despite early 
success, excitement and enthusiasm this was not always sustained or associated 
with retention in the programme or long term successful clinical outcomes. It 
seemed that, for some, early success was overtaken later by the inability to stop 
smoking or the demands of other life circumstances. 
 
Emotive responses of excitement and disappointment were not so apparent in the 
IDAP arm which may have resulted from quiet satisfaction that both smoking and 
weight were being handled sensibly. 
 
4.3.4.3. How can we improve acceptability? 
We can make steps to improve the acceptability of SBS based on these findings. 
For example, future trial arms involving a sequential weight control element after 
quitting smoking could reduce the delay in receiving this from eight to four weeks. 
However, different views were held on what was acceptable within each trial arm.  
 
To be able to randomise individuals so that they accept their allocation whatever it 
is we need to consider how an individual may view or respond to it, rather than just 
the inherent properties of that particular intervention. In other words, acceptance 
may depend on whether properties of each intervention meet participants‟ 
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individual needs and expectations, which may have been shaped by their previous 
experiences of treatment.  
 
Where participants experience the benefit of their needs being met, this may have 
lead to potentially unacceptable treatments being tolerated despite the cost. This 
seemed to continue until the cost became too high because the demand of life 
circumstances took priority. Therefore to provide effective interventions we need to 
design programmes which are not just well received initially, but stand the test of 
time when things get difficult. We need to explore further what elements will help 
participants to persevere and keep them motivated. Given that both stop smoking 
and weight loss interventions have a high degree of non attendance, a larger 
sample size would be needed to evaluate attrition, this then becomes a question 
which needs answering quantitatively.  
 
So how can we address the issues raised by our trial participants to make the 
clinical trial experience more positive and prevent them abandoning interventions 
in the future. Perhaps we need to preempt some of these challenges and prepare 
participants on an individual basis to deal with them. This could be done in the first 
visit where not only is the understanding of the trial checked and consent taken, 
but time is taken to explore an individual‟s response to events during the trial 
which might sabotage it. For example embarrassment at unachieved goals or 
missed appointments; disappointment in trial arm allocation, or treatment falling 
short of expectations. Helping participants to prepare for these events and plan 
how to deal with them at the outset may alleviate disappointment and reduce 
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emotional distress which can undermine self control and self regulation (Tice et 
al., 2001). Discussing participant needs and how far the trial is able to fulfill these 
would be an important aspect of this. A qualitative study has shown that treatment 
preferences within a randomised controlled trial are dynamic and exploration of 
these can help participants accept other treatment options (Mills et al., 2011). Both 
lowering expectations and investing extra effort in obtaining an outcome are two 
key strategies used to avoid disappointment (Van Dijk et al., 2003). We could build 
on these principals to improve acceptability of randomisation and the interventions 
offered in clinical trials.   
 
Additionally, are there ways in which we could design a trial that will allow us to 
better tailor interventions to individual needs?  A number of trial designs have 
considered this. Pragmatic trials randomise participants to either usual care or a 
package of care in which participants are given the intervention which best suits 
their needs (Thorpe et al, 2009). However, these may still contain dissatisfied 
participants in the usual care group. Trials with a Zelen design randomise 
participants to usual care or intervention prior to consent. They are only told about 
the intervention if they are randomised to it; this is when they are asked if they will 
consent. Analysis is carried out as intention to treat (Zelen, 1979). This means that 
those in usual care may not know there is an alternative treatment to which they 
could have been randomised and as such, there is less chance that they will 
object to usual care. However, post randomisation consent trials have raised 
ethical concerns. Preference trials ask participants if they have a treatment 
preference and randomise those with no preference to either intervention or 
control; those which have a preference are allowed to chose the intervention 
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which they feel will best suit their needs (Brewin & Bradley, 1989). This is a design 
that theoretically would fit best with the findings from our participant interviews. 
However a systematic review of patient level data compared attrition of those who 
did not received their preference to those who did showed there was no significant 
difference (Odds ratio 1.35, (95% confidence interval 0.78 to 2.33) P=0.29 
(n=1583)). A number of trials included in the review contained behavioural 
interventions, so there is little reason to suggest findings from our type of 
interventions would be any different.  
 
4.3.4.4. Methodological strengths and limitations 
4.3.4.4.1. Strengths 
We used semi-structured interviews to understand participants‟ views on the 
acceptability of the DeMiST treatment programmes. This revealed a response to 
experiences which we could not have predicted. If we had carried out a survey, 
with a set agenda, we may have missed some of these.  For example, considering 
the clinical priority for this population was smoking cessation, we may have asked 
participants if they would have preferred to tackle weight when they stopped 
smoking or afterwards. We may not have discovered that some wanted to lose 
significant weight before quitting.  
 
Immersion in the interview data provided a depth of insight  which we could not 
have gained otherwise. This has led to new ideas for how we can work to make 
clinical trials more acceptable to participants, for example, by pre recruitment 
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counselling which explores participants needs and expectations as described in 
the previous section.  
 
We took a reflexive approach to our analysis, we reflected on the effect of our own 
bias where this seemed to occur as in the example of exploring the influence of 
clinical skills which may have led to one participant changing their opinion (section 
4.3.2.2,2 ). This meant we could identify instances that may not have yielded a 
true perspective of the experience at the time. For the same reason we also tried 
to avoid leading questions or suggestive lines of enquiry during the interview.   
 
4.3.3.4.2. Limitations 
There were several limitations to our interviews and qualitative analysis which we 
have discussed in turn below.  
4.3.3.4.2.1. Sample size 
As described above we did not have enough people to „purposely sample‟ all 
those we wanted to or reach theoretical saturation of responses in each of the trial 
arms. This means at best our data can only describe some of the experiences of 
our trial participants, which have led to suggestive interpretations, but we cannot 
infer that these are typical of all those who will enter such a trial. Therefore we 
cannot be certain of our conclusions. Acceptability to interventions may for 
example differ according to gender or social group and our sample was too small 
to explore the responses within these different groups.   
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4.3.3.4.2.2. Data collection and interview skills 
With hindsight from analysing the data, we could have probed responses further to 
gain a greater understanding of the balance of driving forces which made 
participants decide to drop out or remain in the programme. We could have 
explored further what may have helped them to stay in. Where we did probe, we 
were cautious to avoid making assumptions about the meaning behind a 
response, by asking respondents to explain what they meant and to confirm our 
understanding of their response. However, there seemed to be a fine line between 
probing sufficiently and not leading a response, this is a qualitative interview skill, 
which is likely to improve with experience. The interviewer was relatively 
inexperienced in qualitative research and this may have accounted for the limited 
understanding we gained on some issues.  
 
4.3.3.4.2.3. Organising data 
Much of the organising of data for analysis, for example, the tagging of who said 
what within which theme was carried out manually. This became difficult to keep 
track of, particularly as new themes and links rapidly emerged. Therefore, despite 
a relatively low volume of data, if we had had the resources  it may have been a 
worthwhile investment to use a qualitative analysis software package such as 
NVivo.   
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4.3.3.4.2.4. Method of analysis 
We have previously justified our choice of thematic analysis, but we are aware that 
opinions on how best to analyse qualitative data will vary. With hindsight, we 
appreciate there were issues for which we could have collected further data, and 
these may have warranted an analysis based on grounded theory methods. For 
example, as mentioned above, the balance of driving forces leading to attrition 
could have been further explored. In addition, the reasons why participants 
prioritised weight loss over quitting and vice versa would have been an interesting 
exploration. However, these are wider questions requiring further studies to 
answer them fully. Such studies are important as they may lead to the 
development of theories regarding attrition in clinical trials such as this one and 
why individuals chose to change one health behaviour over another. 
  
4.3.3.4.2.5. Validation of findings 
We did not return our analysis of an individual‟s response to them for confirmation 
of meaning. Doing so might have added credibility to our findings. However, it may 
also have allowed a participant to reflect and change their responses from a 
reactive to a more reasoned one. This would have lost some emotion that was an 
important component in understanding reactions to the interventions. 
 
Also considering the time constraints and the resources available we were unable 
to peer review the analysis of all transcripts, so as we have previously described 
only a selection were discussed and interpretation agreed upon.   
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4.3.4. Conclusion 
Individual responses to the DeMiST interventions did not seem to depend on the 
trial arm to which they were allocated, but rather on whether the trial arm met their 
individual needs. As we were unable to purposely sample or reach theoretical 
saturation our analysis can only offer preliminary findings and suggestive 
conclusions. Further studies are required with adequate sampling and further 
„probing without leading‟ interview techniques to answer fully how acceptable 
these dietary interventions are to quitting smokers and what leads to attrition. A 
grounded theory approach may be helpful to explore the theory of attrition more 
fully. Our effort to reduce disappointment in the control arm by offering IDAP 
intervention after the initial treatment stage (Stage 1) was not successful. It may 
be worth exploring whether more in-depth counselling prior to randomisation might 
reduce disappointment with random allocation to a non-preferred trial arm, and 
help participants remain in the trial arm when difficult circumstances arise. 
 
4.4. Feasibility of trial delivery  
4.4.1. Methods 
4.4.1.1. Fidelity checking  
We visited sites to assess how well the behavioural interventions were being 
delivered and assess adherence to other aspects of the protocol. These were 
formative visits in that we used them to identify where nurses needed further 
training. The visits were audio recorded with the participant‟s permission and an 
assessment form was completed during the visit. The form audited, against the 
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clinical protocol, how many of the required behavioural change techniques were 
used and how many of the required procedures were carried out during the 
consultations (Appendix 42). 
 
We also entered the trial database on an ad hoc basis to assess the quality of 
data management and identify any problems which needed addressing. 
 
4.4.1.2. Nurses debriefing 
Our protocol (chapter three, section 3.4.2) stated that we would carry out a focus 
group with our nurses at the end of the trial. However, with poor recruitment and 
the changes in protocol we decided to hold a debriefing session, six months into 
the trial, instead. Debriefing sessions are becoming increasingly recognised for 
their value in the evaluation and education of medicine practice (Rudolph et al., 
2008, Raemer et al., 2011). A debriefing session rather than a focus group 
provided the opportunity for reflective learning of both the research nurses and 
investigator, which we considered was a more appropriate way to evaluate and 
resolve issues with trial delivery that were apparent at the time.  
 
The debriefing session lasted two hours, and the discussion was semi-structured 
to ensure all aspects were covered (Appendix 43). The session was audio 
recorded so an accurate record was kept. We reported on the factual content of 
the debriefing, i.e. what went well and what did not go well with running the trial, 
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the discussion of potential solutions and action points to be carried out. We did not 
intend to analyse this discussion as qualitative data. The objective here was to 
understand descriptively what worked and what did not, rather than explore 
nurses opinion. 
 
4.4.2. Results 
4.4.2.1. Fidelity checking  
Eight trial consultations were assessed, in five of these there was no deviation 
from either the clinical or the research protocol. In the other three, the following 
issues needed addressing. With each the nurse was prompted and helped at the 
time to avoid deviation from the protocol. The issues were noted for inclusion of 
additional training in these areas: 
 A reminder that participants must have bare feet on the Tanita scales, tights 
should not be worn. 
 There was difficulty in measuring waist and hip circumference particularly 
for individuals who had a large amount of adipose tissue which hid the 
exact location of the inferior margin of the last rib and the crest of the ilium. 
 Avoiding hunger in the SBS arm needed greater emphasis.  
 Dietary goal setting needed to be more participant-centred and less 
prescriptive. 
 
Thirteen consultation entries were reviewed in the trial database. One of these 
had no data recorded and a problem with the save function was identified. Data 
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was re-entered from the case report form (CRF). There were two other queries. 
One was missing the date of stopping a medication. This was checked with the 
participant and completed on the database. The other was a missing CO reading, 
which was missed when data was transferred from the CRF to the database and 
was subsequently filled in.  
4.4.2.2. Nurses debriefing 
Several aspects of the preparation and practical working out of the trial were 
discussed (Table 22 and Table 23). For each of these there were positive aspects, 
difficulties, and suggestions of improvements which could be made. Some of 
these suggestions were implemented with immediate effect for the remainder of 
the trial; others were unsuitable for incorporation at the time, but noteworthy for 
consideration in the management of future trials in this field.   
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Issues  Positive aspects Difficulties Suggested Solutions Action taken 
Training and 
support 
 
Initial supervision by 
research nurse 
Complicated study, especially with three arms  
Dietary interventions were most difficult to 
grasp  
Delay between some of the training and use of 
skills e.g. spirometry meant their confidence 
waned for some procedures. 
Interpreting body composition and providing 
feedback on diaries and clinical measures in 
response to participants questions 
How to deal with those who include their own 
dieting strategies, how much flexibility is 
allowed within the protocol? 
Expanded training sessions 
Back ground session with incentive i.e. those on bank being paid hourly rate to 
read and become thoroughly familiar with protocol, to practise filling in diaries 
to gain a participants perspective. 
More opportunity for role play, to run through first two or three sessions and 
practice the following 
Explaining the trial and gaining consent 
Giving the dietary advice  
Consolidating training on new clinical procedures  
 
To consider in nurse 
training session for future 
trial in this field 
Logistics and data 
management  
Database entry 
encouraged a double 
check that everything had 
been completed 
The volume of VLCD formula created storage 
difficulties 
Some equipment was very heavy if it needed 
transporting to different clinic rooms e.g. Tanita 
scales 
Accessing the Citrix database was sometimes a 
problem depending on clinic room 
Data entry was time consuming  
Starting pack of equipment and products 
Central storage space possibly at the university stock could be ordered and/or 
collected 
Extra time to set up and wrap up each clinic and enter data  
Consider for future trials 
Recruitment 
 
Worked well where 
practice had an expert 
who could search GP 
database 
Difficulties with some appointments booked 
centrally while others booked by the nurse  
Problems with identifying and excluding 
potential participants from GP databases 
 
Nurses preferred to be responsible for booking all participants, 
Step by step guide with list of read codes (although not all practices use the 
national read codes ranking 
Identify and agree who will carry out searches at a planning meeting involving 
everyone who will be dealing with the trial 
Changes made to 
appointment booking 
process 
 
Other suggestions to be 
considered in the future 
Table 22. Nurses report of training and support, logistics, data management and recruitment. Improvements made during DeMiST 
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Issues Positive aspects Difficulties Suggested Solutions Action taken 
Clinical aspects 
 
Some appointments were 
an appropriate good 
length of time 
 
Gaps in clinics between 
participants were useful 
for overrunning 
appointments 
Some appointments needed more time: the initial appointment and 
appointment to provide dietary advice especially if giving quit advice at 
the same time. 
Keeping participants focused when keen to talk about food 
Apprehensive with regard to some clinical measures e.g. spirometer (but 
actual procedure was easier than expected) 
Consistent measures of waist and hip circumference were difficult due 
to clothing, overhanging fat and embarrassment.  
Logistics of carrying out fasting blood tests were difficult in some 
surgeries 
Some practices acted on blood test results which went through their 
system e.g. participant in control arm was advised by practice nurse to 
follow a low fat diet 
 
Training on managing consultation time, how to 
redirect clinical conversations but maintain 
rapport 
Pre-clinic practice session on spirometry  
The necessity of all the measures were queried, 
is waist to hip necessary when we have a 
measure of body fat? 
Further planning and discussion regarding blood 
tests needed with some surgeries and what to 
do if trial participants need treatment 
Alternative skin prick testing may be suitable for 
some measures 
 
Appointment times amended 
financial implications of this 
considered for future trials 
Clinical measurements to be 
added to further training and 
considered further for future 
trials 
Protocol 
 
Everything needed was 
within the clinical protocol 
 
Summary sheet was 
particularly helpful 
Difficult to see when forms have to be completed or given out.  
Reasons behind protocol changes not always clear  
Some abbreviations were not clear 
Some diaries contained typographical errors 
 
Packs made up for different visits, for each trial 
arm 
Checklist for each consultation 
 
These suggestions were 
implemented  
 
Improved system of proof 
reading required 
Interventions 
 
 
Healthy choice Index was 
useful guide for nurses 
 
Portion guide easy to 
explain 
Ketotic effect of VLCD hard to explain 
Resetting goals was quite difficult as participants felt they had achieved 
them when it was obvious they had not  
IDAP 8 weeks after quitting smoking seemed too long a wait in the SBS 
arm*. 
Participants seemed keen to quit sooner than fourth visit 
So many visits seemed too long a commitment to some. 
Consider four week gap before given dietary 
help 
Simplified explanation of VLCD 
given 
 
Number and timing of visits to 
be considered in the future 
 
Further training on goal setting 
needed in the future 
Dealing with 
failure to attend 
 Hard to get hold of participants for follow up phonecalls, suspected 
embarrassed to discuss* 
Should an independent person do these 
phonecalls? 
For consideration in future 
trials 
*These perceptions were born out in interviews with participants 
Table 23. Nurses report of the clinical aspects, protocol, delivery of interventions and dealing with failure to attend. Improvements 
made during DeMiST 
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4.4.3. Discussion 
Despite lack of confidence expressed in the nurses debriefing, fidelity checks within 
clinics showed that they delivered the intervention competently and collected data 
appropriately as described in the protocol. We have demonstrated that we were able 
to train nurses to provide specialist dietary interventions within NHS stop smoking 
clinics.  
 
The nurses debriefing session and fidelity checks provided us with suggestions to 
increase nurses‟ confidence in delivering the interventions and to streamline the 
practicalities of doing so. The nurses appreciated the debriefing session and such 
opportunities are important for their job satisfaction and morale which positively 
influences their job performance (Kennedy et al., 1990) so they should not be 
underestimated. 
 
There were several technical difficulties encountered with the Citrix onsite trial 
database. These were resolved but this emphasised the value of completing a paper 
copy in clinic, so that trial data is not lost.  
 
 
4.4.4. Conclusion 
We found that it was feasible to train nurses to provide each of the DeMiST 
interventions according to a randomised controlled trial protocol within primary care 
stop smoking clinics typical of the NHS. 
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5. DEMIST: PROCESS MEASURES 
5.1. Introduction 
Chapter five is concerned with the measures of underlying processes, which may 
have led to changes in outcomes in DeMiST. To capture the processes of change we 
designed a number of questionnaires, some of which needed to be tested to examine 
their reliability and validity. This chapter meets objective five: to report on the 
development and validity of a dietary assessment tool for use within DeMiST 
consultations,  and objective six of the thesis: to report on the development of a 
questionnaire to measure both hunger and food craving during quitting smoking. 
 
However as we were unable to recruit our sample size to test the reliability and 
validity of these questionnaires with any degree of certainty  we have analysed the 
data using the same methods, as we would have done if we had been able to recruit 
full numbers. The reasons for this were two-fold. Firstly, they allowed me to show that 
I can carry out such analyses for the purposes of the PhD and secondly allowed us to 
identify large effects that may provide preliminary evidence on which further research 
may be developed. 
 
The healthy choice index (HCI) (chapter three, section 3.4.7), was developed as a 
simple tool to identify and be used to promote change in eating pattern and physical 
activity; to explore how much this influenced change in body composition. We tested 
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the validity of HCI as a nutritional assessment tool against the gold standard field 
measure of the estimated seven day food diary. 
 
The hunger and food craving score (HCS) (chapter three, section 3.4.3 ), was 
developed to measure hunger and food craving to explore whether changes in these 
mediated changes in cigarette cravings (this mediation analysis is covered in chapter 
six). We tested the reliability of this questionnaire using factor analysis. 
 
We also asked participants which trial arm they thought would be most successful 
(chapter three, section 3.4.8). We did this to explore whether there was greater 
attrition in those who were allocated a treatment which they did not think would work. 
This helped us to understand the influence that the unblinded nature of the study had 
on retaining trial participants.   
 
This chapter provides further background, it describes the methods, results and 
discusses the findings concerning each of these process measures in turn. 
 
5.1.1. The healthy choice index (HCI) 
5.1.1.1. Introduction 
As described in chapter three (section 3.1.3), a gap exists for a dietary assessment 
tool that is brief, reliable, and can be used in routine clinical practice as a prompt for 
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behaviour change.  We developed the Healthy Choice Index (HCI) to do this 
(Appendix 44). This multiple-choice questionnaire required participants to score their 
usual eating patterns, level of physical activity and usual choices of key foods known 
to contribute a large proportion of the intake of a particular nutrient in a typical British 
diet. For example, we know from national surveys that the major contributors of fat in 
the population‟s diet are dairy produce, fatty meats and cereal products (FSA and 
DOH, 2009). Therefore, our questions relating to fat asked about the type of these 
foods eaten, the portion size and the frequency of consumption. Depending on the 
participant‟s answer, they were scored one to three, one being the score for the least 
healthy and three for the healthiest answer.  From this the clinician, led by the 
participant, set guided goals to increase healthy choices and decrease unhealthy 
choices.  This was part of the IDAP intervention where these dietary goals were 
consolidated with individual energy prescriptions (chapter three, section 3.2.2.2). 
 
There were 25 questions designed to capture some of the assessment, and prompt 
discussion of key behaviour change needed for weight loss, that would typically be 
contained in a dietitian‟s initial consultation. This was a simple approach to enable 
non-dietitians to provide similar advice without the need for lengthy training and 
detailed dietary history taking. Questions covered: 
 eating pattern and response to hunger (questions 1 and 2),    
 portion size (questions 4, 7 and 12) 
 fat (questions 9, 10 , 11, 12, 13, 14, 15, 16 and 20) 
 carbohydrate (questions 3, 4, 6, 8, 10, 16, 17 and 18) 
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 energy (question 2 and questions for fat and carbohydrate) 
 non-starch polysaccharide (NSP) (dietary fibre) (questions 5 and 8) 
 calcium (question 10) 
 sodium (questions 11, 19 and 20) 
 alcohol (questions 23 and 24) 
 vitamin C (questions 6 and 7) 
 time spent being active (question 25) 
We measured HCI at baseline and at the end of treatment (week +12). The food 
diary was completed at baseline only. So, how valid was the HCI as an assessment 
of nutrient intake? Did it serve as a sufficiently accurate method to determine whether 
diets were high or low in particular nutrients?  
5.1.1.2. Methods 
We investigated agreement between baseline measures of nutrient intake from the 
HCI and the widely accepted seven day estimated food diary (Chapter three section 
3.4.7, Appendix 45). We analysed the nutrient values from the food diaries using the 
WISP version 3 dietary analysis package (Tinuviel software, based on the McCance 
and Widdowson‟s food tables). This provided data on the DeMiST sample to 
compare with population and recommended dietary intakes.  We estimated the 
nutrient values from the HCI from representative food items described by each 
question (using McCance and Widdowson‟s food tables FSA, 2002). We estimated 
portion sizes of these foods from standard tables (MAFF, 1994), participants answers 
to the proportion of the plate a food covered, and the frequency of consuming these 
foods daily or weekly.  
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We assessed correlation between the nutrient intakes from the food diary and the 
HCI using Pearson‟s regression coefficients. We calculated the limits of agreement 
between these two assessments using the Bland–Altman technique. Where there 
was evidence of a relation between the difference and the mean, we log transformed 
the data to base e for improved accuracy of the limits of agreement (Bland and 
Altman, 1986).   
 
We applied the limits of agreement for the HCI to the mean, minimum and maximum 
nutrient values of our sample to see whether the HCI could differentiate between the 
higher and lower intakes.  
 
Where limits of agreement were acceptable we compared the change in HCI scores 
and the reported behaviour changes by trial arm and investigated their effect as 
mediators on change in body fat. 
 
5.1.1.3. Results 
5.1.1.3.1. Baseline nutrient intakes from food dairy 
 
The food diary data showed a mean energy intake of 2053kcal/day, 2666kcal/day in  
men (n=3) and 1942kcal/day in women (n=10) (Table 24). This may represent an 
underreporting of about 8% in men and 13% in women. These are the values by 
which the actual intakes differ from the expected intakes. Expected intakes are 
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calculated from using the Schofield et al. (1985) energy prediction equation based on 
the average weight in the male and female participants (Table 24), and using the 
mean physical activity level of 1.5 (2896kcal/d and 2228kcal/day respectively).  
5.1.1.3.2. HCI Scores 
Scores could potentially range from 25 to 75. Mean HCI score was 52. Minimum and 
maximum HCI scores in the DeMiST sample were 40 and 66 respectively.  Minimum 
scores were generated from the least healthy food choices and eating behaviours 
described, and maximum scores from the most healthy. 
 
5.1.1.3.3. Correlation and agreement between mean nutrient values 
measured by the food diary and HCI  
Correlation was significant between the two measures for total energy, carbohydrate 
and alcohol, but not fat, fibre, sodium, calcium, vitamin C or protein (Table 25) 
(Figure 8). The Bland-Altman plots for alcohol (Figure 9), calcium (Figure 10), fat 
(Figure 11), energy (Figure 12), carbohydrate (Figure 13) and vitamin C (Figure 14) 
showed a relation between the difference and mean which was partially improved 
with log transformation of these data. Log transformation of the Bland-Altman plots 
for fibre, sodium and protein (Figure 15) were not appropriate. 
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Table 24. Baseline nutrient intake and physical activity level for all participants and by 
trial arm (Mean (SD)) 
 
Trial arm All SBS IDAP VLCD 
Nutrient Intake and physical activity 
level at baseline (7 day diary) 
    
N 13 5 5 3 
Energy (kcal/day) 2053(552) 1891(513) 1937(401) 2517(745) 
        Men only (kcal/day) 2666(256) 2485 - 2847 
        Women only (kcal/day) 1942(520) 1743(451) 2353(974) 2353(974) 
Total Fat(g/day) 89(24) 84(24) 70(16) 105(32) 
Fat (% Energy) 39% 40% 33% 38% 
        Of which saturated fat (g/day) 34(12) 36(15) 30(10) 38(10) 
        Saturated fat (% Energy) 15% 17% 14% 14% 
Carbohydrate(g/day) 220(58) 218(82) 217(41) 228(57) 
Carbohydrate(% Energy) 43% 46% 45% 36% 
NSP (g/day) 10(2) 10(2) 10(3) 11(1) 
Protein (g/day) 79(22) 70(16) 70(16) 100(34) 
        Protein (% Energy) 15% 15% 14% 16% 
Sodium(mg/day) 2896(976) 2397(583) 2720(807) 4022(1065) 
       Salt(g/day) 7.4(2.5) 6.1(1.4) 6.9(2.0) 10.2(2.7) 
Alcohol (g/day) 17(26) 3(4) 13(15) 45(44) 
       Alcohol(% Energy) 6% 1% 5% 13% 
Calcium (mg/day) 882(238) 847(234) 739(73) 1170(185) 
Vitamin C (mg/day) 78(80) 127(107) 59(50) 27(1) 
Physical Activity Level (PAL) 1.5(0.3) 1.4(0.2) 1.3(0.2) 1.8(0.3) 
HCI 52(7) 54(4) 53(1) 47(3) 
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The range of agreement for the nutrient values for raw data and log transformed data 
showed that the HCI overestimation or underestimation of food diary values was too 
wide ranging for differentiation between high and low intakes of most of the nutrients 
measured. The one exception was dietary fat, after log transformation the range of 
agreement was 32% (4% above to 28% below) the mean food diary value (Table 26). 
Applying these limits to the minimum, mean and maximum values of our sample 
showed that the limits of agreement did not overlap and the HCI could detect 
between high, medium and low intakes in our population (Table 27).
Nutrient 
Pearsons correlation 
coefficient 
 
 Energy (kcal) 0.77*  
Fat (g) 0.51   
Carbohydrate (g) 0.74*   
NSP (fibre) (g) 0.26   
Sodium (mg) 0.42   
Alcohol 0.57*   
Calcium (mg) 0.37   
Vitamin C (mg) 0.13   
Protein (g) 0.26   
*p<0.05 
Table 25. Correlation coefficients for nutrients measured by food 
diary and HCI 
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 Figure 8. Scatter plots of nutrient intake (energy (kcal), carbohydrate (g), alcohol (g), fat(g), fibre (g), sodium (mg), calcium 
(mg) and vitamin C (mg))  from food diary compared to HCI with lines of best fit 
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Mean difference (solid line) and upper and lower limits of agreement are plotted (dashed lines) 
 
Figure 9. Bland-Altman plot of mean alcohol intake from food diary and HCI with difference in alcohol between food diary and HCI 
(graph on the left hand side). Bland-Altman plots of log mean alcohol intake from food diary and HCI with difference of log alcohol 
intake between food diary and HCI (graph on the right hand side).  
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Mean difference (solid line) and upper and lower limits of agreement are plotted (dashed lines) 
 
Figure 10. Bland-Altman plot of mean calcium intake from food diary and HCI with difference in calcium between food diary and 
HCI (graph on the left hand side). Bland-Altman plot of log mean calcium intake from food diary and HCI with difference of log 
calcium intake between food diary and HCI (graph on the right hand side).  
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 Mean difference (solid line) and upper and lower limits of agreement are plotted (dashed lines) 
Figure 11. Bland-Altman plot of mean fat intake from food diary and HCI with difference in fat between food diary and HCI (graph 
on the left hand side). Bland-Altman plot of log mean fat intake from food diary and HCI with difference of log fat intake between 
food diary and HCI (graph on the right hand side).  
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Mean difference (solid line) and upper and lower limits of agreement are plotted (dashed lines) 
 
Figure 12. Bland-Altman plot of mean energy intake from food diary and HCI with difference in energy between food diary and HCI 
(graph on the left hand side). Bland-Altman plots of log mean energy intake from food diary and HCI with difference of log energy 
intake between food diary and HCI (graph on the right hand side).  
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Mean difference (solid line) and upper and lower limits of agreement are plotted (dashed lines) 
 
Figure 13. Bland-Altman plot of mean carbohydrate intake from food diary and HCI with difference in carbohydrate between food 
diary and HCI (graph on the left hand side). Bland-Altman plot of log mean carbohydrate intake from food diary and HCI with 
difference of log carbohydrate intake between food diary and HCI (graph on the right hand side).  
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Mean difference (solid line) and upper and lower limits of agreement are plotted (dashed lines) 
 
 
Figure 14. Bland-Altman plot of mean vitamin C intake from food diary and HCI with difference in vitamin C between food diary and 
HCI (graph on the left hand side). Bland-Altman plots of log mean vitamin C intake from food diary and HCI with difference of log 
Vitamin C intake between food diary and HCI (graph on the right hand side).  
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Figure 15.  Bland-Altman plot of mean protein and fibre intakes and 
sodium from food diary and HCI with difference in nutrient between food 
diary and HCI
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Nutrient Mean 
difference 
SD LLA ULA Range of 
agreement 
Mean  
difference 
(log 
transformed 
data) 
SD (log 
transformed 
data) 
LLA (log 
transformed 
data) 
ULA(log 
transformed 
data) 
Antilog 
LLA 
Antilog 
ULA 
% range HCI over or 
under estimates 
nutrients from food 
diary 
Range of 
agreement 
(%) 
Energy(kcal) -1114 366 -1831 -396 1435 -0.4428 0.16222 -0.76 -0.12 0.47 0.88 212 113 99 
Fat(g) -20.1 26.0 -71.1 30.9 102.0 -0.1993 0.26511 -0.72 0.32 0.49 1.38 104 72 32 
Carbohydrate (g) -188.8 65.6 -317.5 -60.2 257.3 -0.6347 0.18980 -1.01 -0.26 0.37 0.77 270 130 140 
NSP (g) -2.1 3.9 -9.8 5.5 15.3 -0.1598 0.39384        
Sodium(g) 1096 1189 -1235 3426 4661 1.4039 3.09456        
Alcohol (g) -6.3 21.3 -48.0 35.5 83.4 -0.5706 0.90124 -2.34 1.20 0.10 3.31 1000 30 970 
Protein (g) -7.0 22.0 -50.1 36.1 86.2 0.8325 0.42315 0.00 1.66 1.00 5.27 100 19 81 
Calcium(mg) 454 254 -43 952 995 -0.0583 0.77128 -1.57 1.45 0.21 4.28 476 23 453 
Vitamin C (mg) 16 77 -135 168 303 -0.1093 0.25436 -0.61 0.39 0.54 1.48 185 68 117 
Table 26. Mean (SD), lower, upper and range of agreement of raw and log transformed data for difference between food diary 
and HCI measurements. Also shows interpretation of antilogs as a percentage of nutrient values. 
Nutrient Minimum 
FD 
values 
HCI range Mean 
FD 
values 
HCI range Maximum 
FD 
values 
HCI range 
Lower 
HCI  
Upper 
HCI  
Lower 
HCI  
Upper 
HCI  
Lower 
HCI  
Upper 
HCI  
          
Fat(g) 51 37 53 86 62 89 132 95 137 
Table 27. Mean, minimum and maximum values of fat intake from food dairies and the 
corresponding range identified by the HCI 
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5.1.1.3.4. Change in fat intake, HCI score and health behaviours  
The HCI was completed at baseline and at the end of treatment. By the end of 
treatment all arms had been given the intervention to develop long term healthy 
eating patterns through IDAP. So we would expect some improvement in all arms, 
although perhaps less in the SBS group who had only received IDAP in the last four 
weeks of the trial. 
 
As an assessment of nutrient intake, the HCI was only reliable for measuring dietary 
fat within the margins of error described above. Questions that did not relate to 
dietary fat, or were not sensitive enough to measure other specific nutrients, 
described healthy food choices and behaviours only.  
 
5.1.1.3.5. Change in fat intake 
Fat intake reduced by an amount that was measureable by the HCI in the IDAP and 
the VLCD arms (39% and 31% reduction in IDAP and VLCD respectively). The 
difference between the rise in the SBS arm and the reduction in the IDAP and VLCD 
arms was also measurable by the HCI and of a clinically important amount (63g/day 
and 57g/day fat respectively)(Table 28).  
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5.1.1.3.6. Change in HCI score 
HCI score increased most in the IDAP arm. An increase of one shows a move from a 
less healthy to a more healthy choice or behaviour on a scale of one to three. A 
mean increase of 11 represents a moderate improvement in 11 food choices or 
lifestyle behaviours, or a more dramatic improvement in five to six of these. This was 
an increase of 21% from baseline HCI score (Table 28).  
 
5.1.1.3.7.  Change in health behaviours 
Based on the percentage frequency of each of the answers to the multiple choice 
questionnaires. The following change in behaviours were reported in our sample as a 
whole: 
 More regular meals, including breakfast (Table 29),  
 increased fruit and vegetable intake (Table 30) 
 more high fibre food choices (Table 30) 
 more high calcium food choices (Table 30) 
 greater daily fluid intake (Table 30) 
 more low fat food choices (Table 31), 
  reduced use of sugar and salt (Table 32),  
 reduced alcohol intake (Table 32), 
 and increased frequency of activity (Table 32).    
Participants began to choose more high fibre food and fewer convenience foods, 
these changes were similar in all arms (Figure 17, Figure 18).  
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Participants ate more breakfast (Figure 16), calcium rich foods on a daily basis 
(Figure 17) and more oily fish on a weekly basis. They ate fewer fatty snacks on a 
daily basis (Figure 18) and increased their daily fluid intake. These changes were 
most apparent in the SBS arm (Figure 18).  
 
Choosing to consume fewer fatty meats (Figure 18) and fewer high sugar foods 
(Figure 19) was reported most in the IDAP arm. Increasing daily fruit and vegetables 
consumption (Figure 17), adding less oil when cooking (Figure 18) was reported 
most in both the SBS and IDAP arms. Changing to lower fat choices of dairy food 
and spreading fats was reported most in the IDAP and VLCD groups (Figure 18).  
Daily alcohol consumption and reduced mealtime salt use was reported most in the 
VLCD arm (Figure 19). Weekly activity levels increased most in the SBS and VLCD 
arm (Figure 19). 
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Whole sample SBS IDAP VLCD SBS-
IDAP 
SBS-
VLCD 
IDAP-
VLCD 
Change in fat intake (g) (mean (SD)  -15 (35) +16 (16) -47 (6) -41 63 57 6 
HCI score 4 (8) 1 (6) 11 (1)  -1 10 0 12 
* between trial arms p<0.05 (ANOVA) but sample too small for post hoc tests. 
 
   
Table 28. Change in fat intake and HCI score from baseline to week +12 according to trial arm and between 
trial arm 
 
 
 
 
 
                                    All        
 
SBS   IDAP   VLCD   
  
Baseline 
End of 
treatment Baseline 
End of 
treatment Baseline 
End of 
treatment Baseline 
End of 
treatment 
Daily miss breakfast & lunch       7   20           
Sometimes miss breakfast & lunch      64 50 20 33 83 50 100 100 
Daily breakfast and 3 meals a day       29 50 60 67 17 50     
Eat even if feel full 21 13 20   17   33 100 
Sometimes eat  when not hungry 29 50 
 
67 33 50 67 
 Eat when hungry & stop when full        50 38 80 33 50 50     
Eat similar foods and meals every day of 
week     14 13     33 25     
Eat similar foods and meals several times a 
week  29 38 60 34 
 
25 33 100 
Eat different foods and meals every day   57 50 40 67 67 50 67   
Table 29. Percentage frequency of response to multiple-choice questions on eating behaviours in the 
whole sample and by trial arm at baseline and end of treatment. Inside borders differentiate between 
questions. 
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Figure 16. Percentage frequency of response to multiple-choice questions on 
eating behaviours by trial arm at baseline and end of treatment. Dashed lines 
differentiate between questions 
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  All SBS   IDAP   VLCD   
  Baseline 
End of 
treatment 
Baseline 
End of 
treatment 
Baseline 
End of 
treatment 
Baseline 
End of 
treatment 
Eat white cereal products        36 13 40   17 25 67   
Eat wholemeal cereal products     50 38 40 33 66 25 33 100 
Eat seeded cereal products     14 50 20 67 17 50     
Hardly ever eat fruit and vegetables     7 13         33 100 
Eat 1 - 4 portions fruit or veg/day     86 50 80 33 100 75 67 
 
Eat 5 or more portion fruit or veg/day   7 38 20 67   25     
Eat 0-1 dairy portions/day     57 50 80 33 50 50 33 100 
Eat 1-2 dairy portion/day    29 25 
 
33 33 25 67 
 
Eat at least 3 dairy portions/day   14 25 20 33 17 25     
Drink less than 3 glasses fluid a day         7 13 20 20       100 
Drink 3-5 glasses fluid a day   29 
 
20 20 33 
 
33 
 
Drink 6-8 glasses fluid a day   64 88 60 60 67 100 67   
Table 30. Percentage frequency of response to multiple-choice questions on food choice behaviours in the whole 
sample and by trial arm at baseline and end of treatment. Inside borders differentiate between questions. 
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Figure 17. Percentage frequency of response to multiple-choice questions on 
food choice by trial arm at baseline and end of treatment. Dashed lines 
differentiate between questions  
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  All SBS   IDAP   VLCD   
  Baseline 
End of 
treatment 
Baseline 
End of 
treatment 
Baseline 
End of 
treatment 
Baseline 
End of 
treatment 
Eat full fat dairy products    21       33   33   
Eat reduced fat dairy products      50 63 60 67 33 50 67 100 
Eat virtually fat free dairy products   29 38 40 33 33 50     
Eat fried or fatty meats regularly 64 25 40 33 67   100 100 
Occasionally eat fried or fatty meats   7 13 20 33 
    
Eat lean meats only       29 63 40 33 33 100     
Meat portion covers half of plate         7       17       
Meat portion cover 1/3 of plate  50 38 60 67 33 
 
67 100 
Meat portion covers 1/4 of plate        43 63 40 33 50 100 33   
Eat fried fish each week 36 13 60   17   33 100 
Eat plain white fish each week      21 13 
  
33 25 33 
 
Eat plain white fish and oily fish each week     29 50 40 100 17 25 33   
Pour oil freely         36 13 20 33 40       
Measure out oil         50 38 60 
 
60 50 67 100 
Use oil spray   7 38 20 67   25 33   
Use butter or margarine     50 25 40 67 50   67   
Reduced fat spreads     21 25 20 
 
17 25 33 100 
Low fat spreads  29 50 40 33 33 75     
Eat 3 or more fatty snacks a day       7   20           
Eat 2-3 fatty snacks a day 
        
Eat fatty snacks once a day or less    93 100 80 100 100 100 100 100 
Table 31. Percentage frequency of response to multiple-choice questions on sources of dietary fat in the whole sasmple and 
by trial arm at baseline and end of treatment. Inside borders differentiate between questions.  
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Figure 18. Percentage frequency of response to multiple-choice 
questions on dietary fat by trial arm at baseline and end of treatment. 
Dashed lines differentiate between questions. 
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                                                          All  
 
SBS   IDAP   VLCD   
  Baseline 
End of 
treatment 
Baseline 
End of 
treatment 
Baseline 
End of 
treatment 
Baseline 
End of 
treatment 
Always add sugar        29 13 20 33 17   67   
Sometimes add sugar     29 
 
40 
 
33 
   
Never add sugar         43 88 40 67 50 100 33 100 
Eat sweets every day    7       17       
Eat sweets most days    14 13 20 33 17 
   
Eat sweets less than once a week        79 88 80 67 67 100 100 100 
Add salt to cooking and food    36 22 40 33 33   33   
Add salt either to cooking or food      50 36 40 33 50 75 67 
 
Use herbs and spices  instead of salt  14 53 20 33 17 25   100 
Use processed foods often       21   20   17   33   
Choose reduced fat salt & sugar 
varieties         
Rarely use convenience food     79 100 80 100 83 100 67 100 
Drink alcohol daily     14 13     17 25 33   
Drink alcohol 1-5 times a week  57 50 40 33 67 50 67 100 
Don't drink alcohol     29 38 60 67 17 25     
Drink more than 2-3 units alcohol/day       57 13 20   83 25 67   
Drink less than 2-3 units alcohol/day      14 50 20 33 
 
50 33 100 
Don't drink alcohol     29 38 60 67 17 25     
Spend most of spare time sitting 
down      
43 13 60 
 
33 25 33 
 
Exercise on 2-3 day of the week     29 38 20 67 33 25 33 
 
Exercise 30 minutes or more each 
day     
29 50 20 33 33 50 33 100 
Table 32. Percentage frequency of response to multiple-choice questions on sucrose, salt alcohol and activity for the whole 
sample by trial arm from baseline to end of treatment. Inside borders differentiate between questions. 
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Figure 19. Percentage frequency of response to multiple-choice questions on 
sucrose, salt alcohol and activity by trial arm from baseline to end of treatment. 
Dashed lines differentiate between questions 
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5.1.1.3.8. Change in fat intake and HCI score as mediators of change in body 
fat 
We investigated whether change in dietary fat intake or HCI score mediated the 
effect of dietary intervention on fat mass. This is reported, together with other multi-
level models, in chapter six.  
 
5.1.1.4. Discussion 
5.1.1.4.1. Baseline nutrient intake 
In comparison with the Department of Health dietary reference values (DRV) for 
nutrients (DOH, 1991), mean intake data showed the participants exceeded 
recommendations for total fat, saturated fat, alcohol (although only the VLCD group 
exceeded alcohol recommendations) and salt (again only the VLCD group notably 
exceeded this). The participants met the recommendations for protein and calcium 
intake. They met the reference nutrient intake (RNI2) for vitamin C, but not quite for 
vitamin C in smokers; those in the VLCD group only met the estimated average 
requirement (EAR3) for vitamin C. The participants fell short of the requirement for 
carbohydrate and non-starch polysaccharides (fibre) (Table 33). These aspects of 
the participants‟ diets were also poorer than the general population as determined by 
the national diet and nutrition survey (NDNS) (FSA and DOH, 2010) (Table 33). 
 
                                            
2
 The RNI is the level of intake considered to be sufficient to meet the requirements of 97.5% of the population 
3
 The EAR is the level of intake considered to be sufficient to meet the requirements of 50% of the population. 
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This is in line with a meta analysis of cross-sectional studies by Dallongville et al in 
1998 that also showed smokers have a higher intake of total and saturated fat and a 
lower intake of fibre than non smokers (Dallongville et al., 1998). The meta analysis 
also provided evidence of higher intakes of energy and alcohol, lower intakes of 
polyunsaturated fat, vitamin E and β-carotene. The authors showed that protein and 
carbohydrate intakes did not differ between smokers and nonsmokers. 
 
Comparing DeMiST measures of energy intake with estimated energy requirements 
showed that the underreporting in our sample might have been below that previously 
observed in overweight populations (Kretsch, 1999, Hill and Davies, 2001). The food 
diary was very similar to others used in the field and there is no reason to expect its 
format led to more accurate reporting. However, participants were advised that if they 
were to take part fully in the trial they had to demonstrate their commitment to it by 
Nutrient Participants DRV (DOH, 1991) General Population (FSA and 
DOH, 2010) 
Total fat (% energy) 39 33 33 
Saturated fat (% energy) 15 10 12 
Total Carbohydrate (% energy) 43 47 45 
Alcohol (% energy) 6 5 6 
Protein (% energy) 15 15 16.5 
Salt (g/day) 7.4 6 6.1 
NSP (g/day) 11 18 14 
Calcium (mg/day) 882 RNI: 700mg 824 
Vitamin C (mg/day) 78 RNI: 40mg (Smokers: 80mg) 94 
Table 33. Baseline nutrient intake in comparison to the dietary reference values 
and current intakes of the general population 
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completing the food diary accurately. This incentive may have resulted in more 
careful self reporting. Secondly, there was a potential source of personal bias. I 
carried out the analyses of the food diaries and I am keenly aware of underreporting, 
so where there was ambiguity I tended to over rather than underestimate.  
 
5.1.1.4.2. The Healthy Choice Index (HCI) 
Despite good correlation between measures of nutrient intake from the food diary 
and the HCI, investigating the levels of agreement between these two measures 
showed that the HCI could not provide a valid estimate to determine high or low 
intakes of energy, carbohydrate, fibre, sodium, alcohol, calcium, vitamin C or protein. 
The risk in accepting any new clinical measure to replace a gold standard measure 
through considering only correlation between the measures rather than their limits of 
agreement has been well documented since the 1980s (Bland & Altman, 1986). 
However, some studies that do so continue to be published (Paxton et al., 2011).   
 
The HCI was able to estimate fat intake reasonably accurately, giving limits of 
agreement from 28% below to 4% above the value obtained from food diary data. 
This was accurate enough to differentiate between high, medium and low intakes of 
our population. Changes in the frequency of responses to food behaviours, food 
choice and physical activity were captured by the HCI. The sample was too small to 
look for statistically significant changes between arms and over time. However, it did 
show worthwhile improvements in eating behaviours, for example daily breakfast 
eating and fruit and vegetable consumption increased and participants chose to eat 
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foods that were high in sugar and fat less frequently. Improvements, that are all 
necessary, in the diets of smokers (Stefanikova et al., 2009, Margetts and Jackson, 
1993).  
 
However, we have assumed that a reported change in HCI score reflected a change 
in behaviour. But, it is possible that after help and support to change behaviours 
participants scored what they had learnt they ought to do or what they had agreed 
they would do, rather than what they actually did.   
 
The HCI was not a good indicator of whether diets were high or low in many 
nutrients, but it may identify large changes in dietary fat and improvements in food 
choices and eating behaviours. Future efforts could focus on refining questions to 
improve sensitivity to detect smaller changes in fat intake and change in the other 
nutrients discussed. It could then be used in an adequately powered sample to test 
its validity. Before it can be used as a nutrient assessment tool within clinical trials its 
repeatability and sensitivity to dietary change associated with a change in clinical 
outcomes is needed. 
5.2. The hunger and food craving score (HCS) 
5.2.1. Introduction 
As discussed in chapter one, there are no scales which capture both hunger and 
craving for food or distinguish between these two motivations. In addition, no current 
food craving scales are brief enough or designed to be administered daily. We 
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needed such a scale to identify day-to-day change in hunger and food craving, which 
may differ by dietary intervention, to show whether hunger and/or food craving is 
associated with urges to smoke. 
 
We mirrored the questions on craving for food on the mood and physical symptoms 
scale (MPSS) which has been shown to be a reliable measure of cigarette withdrawal 
(West, 2004). The MPSS is brief and asks two questions to measure cigarette 
cravings: “How much of the time have you felt the urge to smoke in the last 24 
hours?” and “How strong have these urges been?” Answers are chosen from a six 
point rating.  
 
To capture the amount of time craving food and the strength of food craving we 
asked analogous questions. Food craving was broken down into desire for sweet 
food, sweet and fatty food, and savoury and fatty food. These categories were 
chosen as previous studies have shown an increase in the intake of sweet foods 
(Rodin, 1987, French et al., 1996), sucrose and fat (Hall et al., 1989) after smokers 
quit. Women typically crave sweet, and sweet and fatty foods. Men typically crave 
savoury foods (Pelchat, 1997).  The questionnaire also included a question on 
hunger and a desire for healthy food, which aimed to assess genuine food need or 
hunger (Figure 20). 
 
We measured hunger and food craving at baseline and daily for the first four weeks 
after quit day. So how well did the HCI capture different components of food desire 
and food need? Was it possible to reduce the data for ease of analyses?  
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Figure 20. Hunger and food craving score (HCS) 
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5.2.2. Method 
We checked whether the data from the HCS was suitable for principal components 
analysis by doing two tests (UCLA ATA, 2011). Firstly, the Kaiser-Meyer-Olkin 
Measure of Sampling Adequacy should have a minimum cut off value of 0.6. 
Secondly, Bartlett's Test of Sphericity should show that the correlation matrix is 
significantly different from an identity matrix (an identity matrix consists of all the 
diagonal elements being one and all off diagonal elements being zero).  
 
We then extracted the main components this questionnaire sought to address, using 
principal components analysis with a direct oblimin rotation in SPSS 17. This is the 
standard method when the factors are allowed to correlate (a non-orthogonal/oblique 
solution). As discussed in chapter three (section 3.1.2) hunger and food craving have 
been shown to be interdependent. Components were included using the Kaiser 
criterion i.e. if they had an Eigenvalue greater than one.  
 
We reduced the data by creating a „component score‟ from the mean scores of 
answered questions showing good internal consistency (r > 0.8). These mean scores 
were used in further analyses. 
 
To confirm the internal consistency of component 1, the measure of craving for sweet 
or fatty foods, we calculated Cronbach‟s alpha. We did this for one day‟s data each 
week, to see if the internal consistency of the questionnaire changed over time. 
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5.2.3. Results 
The Kaiser-Meyer-Olkin Measure of Sampling Adequacy and the Bartlett's Test both 
met the criteria for suitability to perform a principal components analysis (Table 34). 
There were two principal components identified, which together accounted for 80% of 
the variance (Table 35, Figure 21). 
 
The first component had a high correlation (>0.8) on all the questions relating to 
cravings for sugary or fatty foods both in the pattern (Table 36) and structure matrix 
(Table 37). I called this component „food desire‟, the score of which was a mean of 
answers to questions 2a, 2b, 2c, 3 and 4 (Figure 20).  The second component was 
most highly correlated with a desire for healthy food (r=0.9) both in the pattern and 
structure matrix. It was also more weakly correlated with „genuine hunger‟ (r=0.7). I 
called this component „food need‟ and it was scored solely on healthy food desire as 
the plot in rotated space showed „genuine hunger‟ to be midway between component 
1 and 2 (Figure 22). 
 
There was good internal consistency of the elements that made up food desire at 
various point in time (Table 38). 
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Kaiser-Meyer-Olkin Measure of Sampling Adequacy 0.6 
Bartlett's Test of Sphericity Approx. Chi-Square 63.0 
df 21.0 
Sig. <0.001 
Table 34. Kaiser-Meyer-Olkin and Bartlett‟s Test for the HCS 
 
 
 
 
   
 
 
  Component 
  1 2 
Hunger 0.542 0.730 
Sweetcraving 0.875 0.167 
Sweetfatcraving 0.864 0.251 
Sweetsavourycraving 0.788 0.037 
Timecravingsugarandfat 0.972 0.156 
Strengthofcraving 0.969 0.173 
Healthyfoodcraving -0.002 0.899 
Table 36. Pattern matrix for components 1 and 2 
 
 
Component 
Initial Eigenvalues 
Rotation 
Sums of 
Squared 
Loadings
a
 
Total 
% of 
Variance 
Cumulative 
% Total 
1 4.3 62.1 62.1 4.3 
2 1.2 17.6 79.7 1.5 
3 0.7 10.4 90.1 
 
4 0.5 7.2 97.3 
 
5 0.1 2.0 99.3 
 
6 0.0 0.6 99.9 
 
7 0.0 0.1 100.0   
Table 35. Total variance explained by 
component extraction from the HCS 
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 Component 
 
 1 2 
Hunger 0.424 0.653 
Sweetcraving 0.873 0.009 
Sweetfatcraving 0.846 0.097 
Sweetsavourycraving 0.808 -0.109 
Timecravingsugarandfat 0.976 -0.020 
Strengthofcraving 0.970 -0.003 
Healthyfoodcraving -0.170 0.930 
Table 37. Structure matrix for components 1 and 2 
 
 
 
 
Figure 21. Scree plot of components in the HCS 
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       Figure 22. Component plot in rotated space using oblimin rotation 
 
 
          
 
 
 
 
Day since quit date cronbach's alpha 
1 0.9 
7 0.9 
14 0.9 
27 0.8 
Table 38. Cronbach‟s alpha for 
Component 1 „food desire‟ over 
time 
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5.2.4. Discussion 
The HCS captured two different motivations to eat, the first was a craving for sweet 
or fatty foods and the second was desire to eat healthy foods. The high correlation 
between the elements in the first component, lent itself well to data reduction. This 
suggests that it may not be necessary to capture craving for sweet, sweet and fatty 
or sweet and savoury foods separately as discussed in Toll‟s paper (Toll et al., 2008). 
Rather, grouping the desire for these foods together may be just as reliable measure. 
The second component was unexpected; it did not fit well with the notion of genuine 
hunger. Although hunger can be differentiated from craving as a drive for any food 
type and the healthy foods defined here were in direct contrast to the fatty and 
sugary foods usually craved (White, 2002). However, the expected defining question 
on hunger was strongly correlated to both components so we are still some way from 
defining this as a separate entity from food craving.  
 
One limitation of developing a brief questionnaire, such as this, was that we could not 
measure all dimensions of food craving such as perceived positive affect (Toll et al., 
2008, Nijis et al., 2007), loss of control, preoccupation and emotional craving (Nijis et 
al., 2007). Instead, we focused on intensity of craving, the feeling most likely to lead 
to impulsive behaviour rather than preoccupation; the behavioural aspects were left 
to speak for themselves as outcomes on smoking and weight. In addition, we used 
the words „crave and want‟ in contrast with „genuine and need‟ without further 
explanation of their meaning, so they were open to interpretation. For some people 
the distinction between the two may have been unclear.   
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Future efforts to differentiate between hunger and food craving require us to 
backtrack a little. We need to expand our questionnaire further before reducing it to 
the brief tool that we needed. Our questions and definitions need to incorporate more 
dimensions of hunger and craving which clarify the differences between the two. It 
would be helpful to start with a qualitative study to understand whether and how 
people conceptualise, express notions of craving or desire for food, and differentiate 
these from more physiological notions of hunger.   
 
The value of developing this tool goes beyond smoking cessation studies; measuring 
food craving is being developed for research into the causes and treatments of 
obesity, mood disorders and addictions. However, none of these have sought to 
differentiate between physiological hunger and the more impulsive based food 
craving, which could be confused.  
 
5.3. Measure of confidence in trial arm 
5.3.1. Introduction 
Blinding of participants is the usual method to avoid participants‟ expectations 
affecting the apparent response to treatment (Altman et al., 2001).  Participants who 
know the treatment they receive may have favourable or unfavourable expectations 
of it. If they are assigned to a treatment they do not think will work or a control group, 
they may become disheartened and drop out early.  
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It was impossible to blind the different dietary interventions in DeMiST so participants 
were asked, prior to randomisation, which treatment they were most confident would 
be successful. We used this to determine whether expectation of success in the 
allocated treatment was associated with attrition. 
 
 
5.3.2. Method 
We coded participants according to whether they were randomised into the arm 
which they thought would be most successful or not. We then compared the 
association between this and the mean length of retention in the study using 
unadjusted linear regression in SPSS 17.  
 
5.3.3. Results 
Most participants (10/16, 63%) thought the IDAP arm had the greatest chance of 
success, (5/16, 31%) thought the VLCD would be most effective and one participant 
thought the SBS arm would be most successful. Sixty-three percent of participants 
(10/16) received the arm they thought would be successful and 37% (6/16) did not. 
 
Unadjusted linear regression showed no significant association between considering 
a treatment would be successful and length of time staying in the treatment 
programme (Table 40). The mean difference showed those who did not receive the 
allocation they thought would be successful stayed in the study -0.3 weeks [-3.2, 2.6] 
less than those who did. However, confidence intervals around this mean difference 
were large. In addition, semi-structured interviewing revealed some very strong 
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feelings of disappointment in those receiving SBS, which was interpreted as a control 
group, a treatment that they did not feel met their needs (chapter four).  
 
 
 Regression 
coefficient 
Standard 
error 
p value  
95% LCI 95% UCI 
(Constant) 9.3 0.8  7.5 11.1 
Received 
allocation thought 
successful 
-0.3 1.3 0.826 -3.2 2.6 
Reference category: did not receive the treatment thought successful 
 
 
 
Table 39. Unadjusted linear regression coefficient with 95% confidence intervals for 
association between participants who received the allocation they considered to be 
successful and the length of time they stayed in study 
 
 
5.3.4. Discussion 
There was no evidence that participants dropped out of DeMiST early because they 
did not receive the treatment they thought had the most chance of success. As 
discussed previously in section 4.2.3.2  there are many trials which have examined 
the association of receiving preferred treatment on attrition, overall these have not 
found an association.  
 
However, our qualitative findings suggest that participants had strong feelings of 
disappointment when they did not receive their favoured treatment but other reasons 
for attrition were given, for example life circumstances becoming difficult and failure 
to stop smoking (chapter four). 
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6. DeMiST RESULTS: CHANGES IN 
CIGARETTE CRAVING, SMOKING 
STATUS AND PHYSICAL MEASURES 
BY TRIAL ARM 
6.1. Introduction 
The primary objective of DeMiST was to determine acceptability and feasibility of 
running a dietary intervention trial in smoking cessation clinics, which was discussed 
in chapter four.  
 
Chapter six contains the results of the quantitative measurements collected to meet 
the secondary and tertiary outcomes, the measurement of which have been 
described in detail in chapter three. This fulfils objective seven: to report on the 
effects of the dietary interventions on urges to smoke and whether this is a result of 
change in desire for food or ketosis, and objective eight of the thesis: to report on the 
effects of dietary interventions on body weight and chronic disease risk factors in 
quitting smokers. 
   
We have included analysis for data up to the end of treatment. Data was not 
available at all time points, in particular, six month and 12 month follow up data was 
not available at the time of completing this PhD so long term outcomes were not 
included.  
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The outcomes assessed were: 
 The effects of each intervention on cigarette cravings and whether this was 
mediated by hunger or ketosis, 
 Smoking cessation rates in each intervention arm, 
 Weight gain according to treatment arm. In addition, we included a sub-group 
analysis splitting by those who abstained (abstainers) and those who lapsed 
back to smoking but did not abandon their quit attempt (lapsers)?  
 The effects of each intervention on body composition, cardiovascular risk 
factors, blood glucose and lung function.  
 
 
We were unable to recruit sufficient people to test the hypothesis that cravings would 
be worsened by hunger, but would improve with ketosis. Nevertheless, we have 
analysed the data using the same methods, as we would have done if we had been 
able to recruit full numbers. The reasons for this were two-fold. Firstly, they allowed 
me to show that I can carry out such analyses for the purposes of the PhD and 
secondly allow us to identify large effects that may provide preliminary evidence for 
these interventions. 
 
As described in the protocol (section 3.7 ) we analysed data in completers to 
investigate efficacy of interventions if they were taken as planned. Sub-analyses and 
modelling excluded those who were not adherent to the VLCD (verified by the 
absence of urinary ketones).  Then we carried out intention to treat analyses (ITT), 
which accounted for people who began treatment but dropped out.  
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ITT gives a pragmatic estimate of benefit were the intervention to be used in clinical 
practice (rather than the potential benefit in those who receive treatment exactly as 
planned). Without ITT analyses falsely positive results are common, as those with 
poor outcomes may drop out of the intervention and bias the results (Hollis and 
Campbell, 1999). Where there were missing values, we imputed baseline 
observation carried forward (BOCF).This assumed that all those who dropped out of 
the trial early relapsed to smoking and regained lost weight. Where there was 
missing data but participants had not dropped out, a mean of their weight measured 
immediately before and after was imputed. Imputation from available longitudinal 
data for a particular person is considered the most reliable way of dealing with 
missing data (Engels and Diehr, 2003).  
 
As described in the protocol (section 3.7) we focused on outcomes at the following 
key time points.  Firstly we did so regardless of smoking status and then in abstainers 
and lapsers only. Change in anthropometrics (measurements of weight, waist and 
hip) were investigated:  
 From baseline to prequit week, to give an idea of the effects of diet before 
quitting, 
 From baseline to the first week post quit date – when abstinence rates are 
likely to be highest and differences between the trial arms can be most clearly 
seen3.4.3, 
 At four weeks post quit date which defines the end of Stage 1 of treatment 
and the Russell standard of abstinence 
 At the end of Stage 2 of treatment (12 weeks post quit) when the control 
group will have received the IDAP intervention.  
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Multilevel modelling of the trajectory of weight change and change in fat mass used 
all the weekly time points to investigate the effects of trial arm and smoking status. In 
addition we investigated the mediating effects of change in fat intake and HCI score 
on change in fat mass as discussed in the previous chapter . 
We modelled the trajectory of cigarette cravings using daily measures during the first 
four weeks of treatment. We paid particular attention, as per protocol, to the change 
from baseline cigarette craving score in the first 24 hours and during the first week 
when differences between trial arms were expected to be at their highest. In the 
multilevel model this was taken into account using a time*trial interaction. Multilevel 
modelling was carried out using MLwiN 2.20 software. 
 
The most sensitive approach for detecting differences in cravings between trial arms 
is to adjust for baseline cravings as a covariate (West et al., 2006). However as the 
sample size was so small we used change in craving score rather than baseline 
score as a covariate, to minimise the number of variables in the model. Multilevel 
modelling between individuals at level two is limited by the level two sample size and 
follows the same rules as single level regression. 
 
To minimise overfitting we did not test all the explanatory and mediating variables in 
one model, as we would have liked, instead we tested them individually in separate 
models as described in later sections. Even so, in such a small sample we could not  
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Trial arm 
All SBS IDAP VLCD 
N 16 6 6 4 
Age 46(14) 56 (7) 37 (17) 46 (4) 
Fagerstrom Score 5(2) 5 (2) 5(2) 6 (1) 
Number of cigarettes per day 23(8) 21 (7) 19 (6) 30 (8) 
MPSS-C 3.7(0.8) 3.5(0.5) 3.8(0.3) 4.0(2.1) 
Forced Vital Capacity (FVC) (L) 3.6(1.0) 3.3 (0.7) 3.5 (0.7) 4.5 (1.6) 
Forced Expiratory Volume in 1 sec (FEV1) (L) 2.9(0.8) 2.6 (0.6) 3.0 (0.6) 3.2 (1.3) 
FEV1/FVC ratio (%) 80(9) 80 (6) 85 (7) 71 (11) 
Total Cholesterol (TC) (mmol/L) 5.6(1.5) 5.5 (1.4) 5.4 (1.6) 6.2 (2.0) 
HDL-cholesterol (mmol/L) 1.2(0.3) 1.2 (0.3) 1.3 (0.3) 1.0 (0.2) 
LDL-cholesterol (mmol/L) 3.0(1.2) 2.5 (1.2) 3.2 (1.5) 3.5 
TC:HDL ratio 4.8(1.5) 4.8 (1.3) 4.3 (1.6) 6.2 (0.8) 
Triglyceride (mmol/L) 1.3(0.7) 1.6 (0.9) 1.0 (0.4) 1.6 (0.9) 
Glucose (mmol/L) 4.7(0.4) 4.6 (0.4) 4.7 (0.4) 5.1 (0.2) 
White blood cells (WBC) (x10
9
/L)                                                  7.4(2.7) 5.7 (4.1) 7.8 (1.6) 9.3 (0.7) 
Mean Corpuscular Volume (MCV)         92(4) 92 (3) 93 (5) 91 (2) 
Haemoglobin (Hb) g/dl      14.4(1.3) 14.2 (0.7) 14.2 (1.7) 15.5 (1.2) 
Platelets (x10
9
/L) 277(91) 275 (63) 282 (123) 269 (59) 
C-Reactive Protein (mg/L) 4.3(3.6) 6.8 (2.2) 1.8 (1.8) 6.5 (6.4) 
CO (ppm) 22(8) 19 (9) 24 (9) 25 (7) 
Blood pressure (mmHg) 126/79(16/10) 128/82 (13/5) 124/76 (23/13) 123/81 (9/10) 
Weight (Kg) 79.7(13.8) 81.3 (11.4) 73.5 (15.4) 86.7 (14.1) 
      Men (Kg) 91.6(5.5) 91.5 - 91.7(7.7) 
      Women (Kg) 77.0(13.8) 79.3(11.4) 73.4(15.4) 81.6(20.9) 
BMI (Kg/m
2
) 29.52(5.60) 30.3 (4.3) 27.6 (5.3) 31.3 (8.2) 
Hip circumference (cm) 106(12) 107(7) 104 (16) 109 (12) 
Waist circumference (cm) 96(13) 97 (9) 91 (16) 102 (14) 
Fat Mass (Kg) 28.8(9.7) 31.3 (7.5) 27.4 (12.0) 27.3 (10.7) 
Fat Free Mass (Kg) 50.9(10.2) 50.1(10.0) 46.1(4.3) 59.4(13.5) 
Total Body Water (Kg) 37.0(6.9) 36.7 (7.3) 33.7 (3.2) 42.6 (8.5) 
BMR (Kcal) 1573(257) 1515 (236) 1494 (165) 1765 (348) 
Healthy Choice Index (HCI) Score 52(6) 54 (8) 53 (3) 47 (6) 
Food desire 2.1(1.0) 2.3(1.3) 1.8(0.8) 2.3(1.1) 
Food need 1.9(0.8) 1.8(0.8) 2.0(1.2) 2.0(<0.1) 
Table 40. Baseline characteristics of all participants by trial arm (mean(SD)) 
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rule out over-fitting and so conducted the analysis predominately to demonstrate my 
ability to do so and ability to interpret these analyses. Therefore, we interpreted our 
coefficients and model plots cautiously with careful reference to how well the models 
fitted the raw data. 
6.2. Results 
6.2.1. Baseline characteristics 
As we were unable to randomise more than fourteen participants into DeMiST 1 and 
two participants into DeMiST 2 it was not possible to analyse DeMiST 1 and 2 
separately and then combine them in a meta-analysis as we had planned. Instead to 
maximise the data we had we combined the results and adjusted for baseline 
differences.   
 
Participants were overweight (Table 40), white European population in middle age, 
heavy smokers and predominantly female. The majority had a mortgage or owned 
their home, and were in employment. Half were educated up to secondary school 
level and a quarter had a professional qualification (Table 41).   
 
If we had recruited the full sample size, no difference in baseline characteristics 
between the groups would have been expected, as randomisation determined 
allocation into each trial arm. Randomisation, based on the theory of probability, 
generates similar numbers in the three trial arms that have an approximately equal 
distribution of known and unknown potential confounders. Therefore, any differences 
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should be due to chance alone rather than a reflection of selection bias (Altman et 
al., 2001).  
 
Trial arm All SBS ITDA VLCD 
 
Gender     
 
   
   Male    19% 1/6 - 2/4 
   Female 81% 5/6 6/6 2/4 
 
Ethnicity 
    
   White 100% 6/6 6/6 4/4 
   Pakistani  - - - 
   Bangladeshi  - - - 
   Indian  - - - 
   Black-African  - - - 
   Black Caribbean  - - - 
   Black-other  - - - 
   Chinese  - - - 
   Other groups – Asian  - - - 
   Other groups – other  - - - 
 
Car ownership 
    
   No car  - - - 
   I car 69% 2/6 6/6 3/4 
   2 or more cars 31% 4/6 - 1/4 
 
Home ownership 
    
   Owning it/Buying it 56% 5/6 2/6 2/4 
   Renting it 38% 1/6 4/6 1/4 
   Not disclosed 6% - - 1/4 
 
Educational level 
    
   Secondary 50% 3/6 2/6 3/4 
   Sixth Form 6% 1/6 - - 
   
Professional/Technical 
25% 1/6 3/6 - 
   University/Polytechnic 
Degree 
13% - 1/6 1/4 
   Still In Full-time 
Education 
 - - - 
   None f the above 6% 1/6 - - 
 
Employment 
    
   In paid employment 75% 3/6 5/6 4/4 
   Unemployed 13% 2/6 - - 
   Looking after home 13% 1/6 1/6 - 
   Retired  - - - 
   Full-time Student  - - - 
     
Medical history 
 
    
Depression/Anxiety 20% 1/6 1/6 1/4 
Table 41. Baseline characteristics all participants and by trial arm (Frequency) 
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However, with our small sample and combining DeMiST 1 and DeMiST 2 participants 
there were moderate differences between trial arms such as age and gender (Table 
40, Table 41). These may have influenced change in weight so we adjusted for these  
in analyses of weight and body fat changes.  
 
6.2.2.  Cigarette craving 
Baseline MPSS-C in smokers, measured before they attempted to quit was 
approximately four in all trial arms (Table 40), scored from a range of zero to six. 
There was a mean fall after 24 hours post quit date in the SBS arm (-1.1), a rise in the 
IDAP, (0.8) and no change in the VLCD arm. Mean differences between these arms 
was clinically, but not statistically different (Table 42).  After one week, there was a 
reduction in score of approximately two in all arms. After one month, MPSS-C had 
reduced most in the VLCD arm and least in the SBS arm (Table 42).  
 
Trajectories of mean change in daily MPSS-C score varied considerably in each trial 
arm, perhaps less so in the SBS arm. MPSS-C appeared to fall most towards the end 
of the month in those on the VLCD (Figure 23).  
 
We can see from the trajectories in individuals that this variability was not clearly 
associated with 7 day point prevalent abstinence or daily smoking (cigarette smoking 
was recorded daily in individuals: 21, 26, 30, 31, 32) (Figure 24). 
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Table 42. Mean change(SD) in trial arms and mean difference [95% CI] between trial 
arms in MPSS-C  after 24 hours, 7 days and 1 month post quit date (ANOVA with 
Gabriel post hoc tests) 
 
 
 
 
Change from baseline in: SBS (n
=
5) IDAP (n=3) VLCD (n=2) VLCD-SBS IDAP-SBS VLCD-IDAP 
After 24 hours  
MPSS-C  
-1.1 (0.7) 0.8 (1.7) 0.0 (0.7) 1.1[-1.7, 3.9]
 
1.9[-0.6, 4.4] -0.8[-4.0, 2.3] 
After 7days 
MPSS-C 
-1.8(0.8) -2.0(0.9) -2.0(2.1) -0.2[-2.9, 2.5] -0.2[2.6, 2.2] 0.0[-3.0, 3.0] 
After 1month 
MPSS-C 
-1.1(1.0) -2.5 -4.5 -3.4 -1.4 -2.0 
Figure 23. Mean change in MPSS-C score in each trial Arm (1=SBS, 
2=IDAP, 3=VLCD) 
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 1= Abstinent 0=Lapsed 
 
 Figure 24. Trajectories of Cigarette craving for individuals 
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6.2.3. Modelling of trajectories of cigarette craving by 
trial arm 
We used seven random effects models to investigate differences in change in 
MPSS-C score by trial arm, adjust for smoking status, and explored the mediating 
effects of food desire and food need on cigarette cravings. Ketosis characterised 
those adhering to the VLCD. Model one was an unadjusted linear function of 
change in craving score over time, we added trial arm variables to create model 
two. We compared these models using chi squared to see if adjusting for trial arm 
improved the fit of the model. We then created models to investigate the mediating 
effects of food desire (model 3), food need (model 4), and abstinent/lapsed status 
(model 5) on the differences of trial arm.  
 
There was no statistically significant improvement in fit when we included trial arm 
(Model 1 to 2,Table 43). However, the coefficient for trial arm showed that each 
day mean craving score in the VLCD arm was 1.0 less than in the SBS arm (the 
SBS arm was the reference category in which MPSS-C score fell by a mean 0.9 
from baseline) (Model 2, Table 44). If this were the true difference between the 
VLCD and SBS diets then this would be of clinical relevance. By comparison the 
Danielsson trial showed craving score fell by 0.5 in VLCD compared to the control 
arm, which was associated with improved abstinence (Danielsson et al., 
1999)(section 3.1). 
 
Adding food desire (Model 2 to 3, Table 43) and food need (Model 2 to 4, Table 
43) significantly improved the fit of the model. However, including these variables 
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did not mediate/explain the difference in cigarette craving by trial arm. Mediation 
would be shown if the coefficients for trial arm reduced substantially by including 
these terms, but as Table 44 shows this did not happen. The VLCD coefficient 
remained approximately -1.0.  
 
The magnitudes of the coefficients for food desire (0.1 (Model 3)) and food need 
(0.1(Model 4)) were too small to be clinically relevant (Table 44). These 
represented a 0.1 increase in craving score with a one unit increase on a six point 
scale (zero being the least desired and five being the most desired) of food desire 
and a five point scale (zero to four) of food need. 
 
Adjusting for complete abstinence and lapses to smoking a cigarette significantly 
improved the model fit (Model 2 to 5, Table 43), and suggested that total 
abstinence was associated with a reduction in MPSS-C score of 0.4. However it 
did not explain the difference in craving between trial arms as the coefficients for 
trial arm changed very little (Model 2 compared to model 5, Table 44 ).  
 
We allowed the effects of trial arm to vary over time as the plots of the mean 
trajectories by trial arm suggested these might differ (Figure 23). To do this we 
included a time by trial interaction term (model 7). This significantly improved the 
fit of the model (Table 43) and the model fit better with the observed data.  
Piasecki, in 2003, found that the best fitting curve for cigarette cravings was a 
quadratic one, so we added in a trial arm by time squared interaction. This did not 
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significantly improve the fit further (Model 8, Table 43) and including this risked 
overfitting the model. However, visually comparing both the linear model (Figure 
25) and the quadratic model slopes (Figure 26) to the observed mean (Figure 23) 
showed that the quadratic model appeared to fit best. However, these models did 
not capture or explain the dramatic peaks and troughs which varied within and 
between individuals (Figure 24).   
 
 
Model Steps -2LL -2LL Chi df p 
1 to 2 619.49 616.98 2.51 2 0.285 
2 to 3 616.98 504.31 112.68 1 0.000* 
2 to 4 616.98 585.06 31.92 1 0.000* 
2 to 5 616.98 613.08 3.090 1 0.048* 
2 to 6 616.98 606.12 10.86 2 0.001* 
2 to 7 606.12 603.75 2.36 2 0.125 
*statistically significant improvement in fit of model to data p<0.05.  
Model 1: change in craving score, according to linear function of time.  
Model 2: model 1 plus trial arm.  
Model 3: model 2 adjusted for food desire.  
Model 4: model 2 adjusted for food need.   
Model 5: model 2 adjusted for abstinence.  
Model 6: model 2 plus trial arm*time interaction.   
Model 7: model 6 plus trial arm*time
2
 interaction. 
 
Table 43. Difference in fit between models 1 to 7 for trajectory of change in 
cigarette craving 
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*statistically significant improvement in fit of model to data p<0.05. Model 1: change in craving score, according to linear function of time. Model 2: model 1 plus trial arm.  
Model 3: model 2 adjusted for food desire. Model 4: model 2 adjusted for food need.  Model 5: model 2 adjusted for abstinence. Model 6: model 2 plus trial arm*time 
interaction.  Model 7: model 6 plus trial arm*time
2
 interaction. 
 
Table 44. Coefficients of multilevel models 1 to 7 for cigarette cravings 
Model 1 S.E. 2 S.E 3 S.E 4 S.E. 5 S.E. 6 S.E. 7 S.E. 
Fixed Part 
        
      
cons -1.116 0.282 -0.913 0.343 -0.747 0.354 -0.932 0.334 -0.561 0.374 -1.081 0.335 -1.321 0.387 
Days post quit date 
(Time) -0.002 0.009 -0.003 0.009 -0.011 0.008 -0.001 0.009 -0.007 0.009 0.01 0.011 0.061 0.044 
IDAP 
  
-0.007 0.542 0.016 0.640 -0.027 0.526 -0.149 0.523 0.062 0.554 0.466 0.642 
VLCD 
  
-0.994 0.616 -1.022 0.620 -0.912 0.593 -1.282 0.607 -0.098 0.635 -0.106 0.736 
Food desire 
    
0.054 0.108 
  
      
Food need 
      
-0.112 0.096       
Abstinent 
        
-0.388 0.195     
IDAP*Time 
        
  -0.003 0.021 -0.094 0.081 
VLCD*Time 
        
  -0.08 0.024 -0.076 0.088 
Time*time 
        
    -0.002 0.002 
Time*time*IDAP 
        
    0.003 0.003 
Time*time*VLCD 
        
    0 0.003 
Random Part 
        
      
Level: Participant ID 
        
      
cons/cons 0.656 0.314 0.494 0.242 0.501 0.255 0.443 0.22 0.449 0.222 0.421 0.207 0.409 0.202 
Level: Time 
        
      
cons/cons 0.895 0.088 0.896 0.088 0.733 0.077 0.885 0.089 0.883 0.087 0.856 0.084 0.847 0.083 
-2*loglikelihood:  619.491 
 
616.981 
 
504.306 
 
583.057 
 
613.079  606.124  603.766  
Units: Participant ID 10 
 
10 
 
9 
 
10 
 
10  10  10  
Units: Time 217   217   190   206   217   217   217   
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Figure 25. Plot of fixed effects of trial arm dependent on time on MPSS-C from 
model 7 
 
 
Figure 26. Plot of fixed effects of trial arm dependent on time squared on MPSS-C 
from model 10 
 
Trial arm 
             SBS                     
             IDAP 
             VLCD 
Trial arm 
             SBS                     
             IDAP 
             VLCD 
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6.2.4. Change in food desire and food need by trial arm 
In examining whether the effects of trial arm on cravings are mediated by food 
desire and/or food need, we have made two assumptions. One that food desire 
and/or food need is dependent on trial arm and two that cigarette craving is 
dependent on desire and/or food need, but so far, we have not examined these 
independently. We do so in this section with the use of seven models. (Food 
desire and food need were measured using the HCS). 
 
6.2.5. Is food desire and /or food need affected by trial 
arm? 
Model 1 is the change in food desire over time; we tested with chi square whether 
the fit of this model improved by adding in the explanatory variable, trial arm 
(Model 2). We found that the improvement in fit did not reach statistical 
significance (Table 45), but the difference in hunger score between trial arms, as 
shown by the coefficients were quite large. On a scale of 1 to 6, food desire was 
reduced during this time by a mean 0.7 points in the SBS arm. Whereas in the 
IDAP arm its increase was 1.3 points higher than in the SBS arm and in the VLCD 
arm it was 0.7 points higher than in the SBS (Table 46). 
 
Model 3 is the change in food need over time; we tested with chi square whether 
the fit of this model improved by adding in the explanatory variable, trial arm 
(Model 4). We found that the improvement in fit did not reach statistical 
significance (Table 45), but the difference in food need score between trial arms, 
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as shown by the coefficients were again quite large. On a scale of 1 to 6, food 
need increased slightly in the SBS arm (0.4) but it was 1.7 points less in the IDAP 
arm than in the SBS arm and 0.7 points less in the VLCD than in the SBS arm 
(Table 46). 
 
 
 
*statistically significant improvement in fit of model to data p<0.05.  
Model 1: change in food desire, according to linear function of time.  
Model 2: model 1 plus trial arm.  
Model 3:change in food need, according to linear function of time.  
Model 4: model 3 plus trial arm  
 
Table 45. Difference in fit between models 1 to 4 for trajectory of change in food 
desire and food need 
 
  Model 1 S.E. Model 2 S.E. Model 3 S.E. Model  4 S.E. 
Response 
Food 
desire 
 
Food 
desire 
 
Food 
need 
 
Food 
need 
 Fixed Part 
        cons -0.351 0.356 -0.799 0.409 -0.081 0.391 0.371 0.51 
Time -0.007 0.005 -0.007 0.005 -0.024 0.006 -0.025 0.006 
Cigarette craving 
        IDAP 
  
1.317 0.759 
  
-1.017 0.827 
VLCD 
  
0.702 0.756 
  
-0.733 0.946 
Random Part 
        Level: Participant ID 
       cons/cons 1.089 0.521 0.8 0.385 1.465 0.665 1.255 0.571 
Level: Time 
        cons/cons 0.292 0.031 0.292 0.031 0.37 0.037 0.37 0.037 
-2*loglikelihood:  345.989 
 
343.229 
 
423.149 
 
421.599 
 Units: Participant 
ID 9 
 
9 
 
10 
 
10 
 Units: Time 191   191   206   206   
Model 1: change in food desire, according to linear function of time.  
Model 2: model 1 plus trial arm.  
Model 3:change in food need, according to linear function of time.  
Model 4: model 3 plus trial arm  
 
Table 46. Coefficients of multilevel models 1 to 4 for food desire and food need 
Model Steps -2LL -2LL Chi df p 
1 to 2 345.989 343.229 2.76 2 0.097 
3 to 4 423.149 421.599 1.55 2 0.213 
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Therefore this shows that our measure of food craving (food desire) fell in the 
control (SBS) arm where people were allowed to eat freely, but by comparison it 
increased the most in the IDAP arm but was unaffected in the VLCD arm. Our 
measure of hunger (food need) was largely unchanged in the SBS arm, but fell by 
comparison in the VLCD arm and fell the most in the IDAP arm. So it would seem 
that food craving rather than actual hunger becomes the stronger motivation to eat 
and is felt most keenly in the IDAP arm. 
 
6.2.6. Is cigarette craving affected by food desire and 
/or food need? 
The fit of the model of cigarette craving over time was statistically significantly 
improved by adding in both food desire and food need as explanatory variables 
(Table 47). However, the coefficients of food desire and food need seemed too 
small to have any meaningful influence on craving (Table 48). So this lack of 
meaningful association accounts for the lack of evidence we found for food craving 
and hunger mediating the difference in cigarette craving by trial arm, and suggests 
the difference in craving by trial arm is caused by another mechanism. 
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Model Steps -2LL -2LL Chi df p 
5 to 6 619.491 506.875 112.616 1 <0.001* 
5 to 7 619.491 585.359 34.132 1 <0.001* 
*statistically significant improvement in fit of model to data p<0.05. 
Model 5: change in cigarette craving, according to linear function of time.  
Model 6: model 5 plus food desire.  
Model 7: model 5 plus food desire 
 
Table 47. Difference in fit between models 5 to 7 examining 
change in food desire and food need on the trajectory of change in 
cigarette craving 
 
 
 
 
 
 
 
Model 5 S.E. Model 6 S.E. Model 7 S.E. 
Fixed Part 
      cons -1.114 0.285 -0.979 0.303 -1.124 0.271 
time -0.002 0.009 -0.01 0.008 0 0.009 
food desire 
  
0.038 0.108 
  food need 
    
-0.101 0.097 
Random Part 
      Level: Participant ID 
     cons/cons 0.656 0.314 0.688 0.343 0.574 0.279 
Level: time 
      cons/cons 0.895 0.088 0.733 0.077 0.885 0.089 
-2*loglikelihood:  619.491 
 
506.875 
 
585.359 
 Units: Participant 
ID 10 
 
9 
 
10 
 Units: time 217 
 
190 
 
206 
 Model 5: change in cigarette craving, according to linear function of time.  
Model 6: model 5 plus food desire.  
Model 7: model 5 plus food desire 
 
Table 48. Coefficients of multilevel models 5 to 7 for which 
examine food desire and food need on cigarette craving 
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6.2.7. Change in smoking status - time to relapse 
All those in the IDAP and VLCD arms had either relapsed to smoking or dropped 
out and assumed relapsed back to smoking by 12 weeks (Table 49) although we 
know that one person became abstinent later on in the VLCD arm, after initial 
weight loss (ID 31, Figure 32).   
 
The median time to relapse was early at 1 and 2 weeks in the IDAP and VLCD 
arms respectively (Table 49, Figure 27). The hazard ratios from Cox regression 
using the SBS arm as the reference category show those in the IDAP arm were 
almost 4 times more likely to relapse than those in the SBS arm. And those in the 
VLCD arm were 8 times more likely to relapse than those in the SBS arm. These 
differences did not reach statistical significance, but we cannot exclude type two 
error as the sample size was small and confidence intervals wide giving imprecise 
results.  
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Trial Arm Median time to 
relapse (weeks) 
Number of relapses/Total 
number in arm 
HR [95%CI] for relapse to 
smoking 
SBS  2/6 Reference Category 
IDAP 1 6/6 3.7 [0.7 , 18.8] 
VLCD 2 4/4 7.8[1.2, 50.3] 
Table 49. Number of relapses, median time to relapse and hazard ratios of relapse to 
smoking at 12 weeks according to trial arm 
 
 
 
 
 
 
Figure 27. Kaplan Meier curve for survival of abstinence, until relapse to smoking 
within the first 12 weeks post quit attempt in each trial arm 
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6.2.8. Change in anthropometric, body composition and 
disease risk factors: completer analysis 
Statistically significant differences between trial arms were unlikely considering the 
small sample size. The wide 95% confidence intervals (CIs) of many mean 
differences (Table 50) show imprecise estimates, so we cannot conclude these 
effects were due to chance alone. Therefore, we interpreted the findings in light of 
the possible clinical significance of means, bearing in mind the precision of the 
estimates. For example, we decided that a clinically important difference in weight 
change was approximately 0.5kg per week as this is considered a good rate of 
weight loss for the treatment of obesity in the NHS (NICE, 2006, SIGN, 2010).  
 
The exception to this was for change in waist circumference, hip circumference and 
blood pressure; these were highly variable, with little obvious trend (Table 50). The 
95% CIs for the mean differences between trial arms were so wide as to encompass 
biologically implausible changes over a week. In addition, the trial nurses reported 
difficulty obtaining accurate waist and hip measurements (chapter four), which adds 
to this uncertainty. Therefore, it would be unwise to draw any conclusions from such 
data, so although we have presented these measures for completeness, we will not 
discuss them further. 
 
 
6.2.8.1. Prequit change in weight, BMI and body composition  
Over the week prior to quitting, weight, BMI, and fat mass reduced by a clinically 
significant amount in the IDAP and VLCD arms, but by a clinically insignificant 
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amount in the SBS arm (week 0 in Figure 28, Figure 29). There was a fall in fat free 
mass, in particular total body water (which accounted for 82% of fat free mass loss) 
in the VLCD arm (week 0 in Figure 30, Figure 31). The standard deviations of these 
measurements were large, often exceeding the mean, sometimes several times over, 
which indicates that there was wide variation between individuals (Table 50). 
 
The large loss of total body water seen in the VLCD arm is expected; initially 
glycogen stores become completely depleted by such severe energy restriction and 
water is released as glycogen is converted to glucose.   
 
Those in the VLCD arm lost statistically significantly more weight than those in the 
SBS arm. The differences between the VLCD and SBS arm in change in fat mass, fat 
free mass and total body water were of clinical importance. Removing those who did 
not adhere to the VLCD from the analysis increased the difference between these 
two arms (Table 50).There was a clinically important difference in weight change and 
in particular fat mass change between the IDAP and SBS arm (0.4kg and 0.5kg 
respectively).
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Figure 28. Bar chart of mean change in weight by trial 
arm, from baseline to week 0, +1, +4 and +12 
Figure 29. Bar chart of mean change in fat mass by trial 
arm, from baseline to week 0, +1, +4 and +12 
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Figure 30. Bar chart of mean change in fat free mass by 
trial arm, from baseline to week 0, +1, +4 and +12 
Figure 31. Bar chart of mean change in total body water 
by trial arm, from baseline to week 0, +1, +4 and +12 
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Change from baseline in: SBS (n
$
=6) IDAP (n
$
=6) VLCD (n
$
=4) VLCD(a)(n=2) VLCD-SBS VLCD(a)-SBS IDAP-SBS VLCD-IDAP VLCD(a)-IDAP 
Week  0 
 
 
 
 
 Weight (kg) -0.1(0.6) -0.5(1.0) -2.3(1.8) -3.5(1.6) -2.2[-4.1, -0.3]* -3.4[-5.4, -1.5]* -0.4[-2.1, 1.3] -1.8[-3.7, 0.1] -3.03[-4.99, -1.07]* 
BMI (kg/m
2
) -0.01(0.21) -0.18(0.36) -0.84(0.70) -1.25(0.77) -0.83[-1.57, -0.10]* -1.24[-2.04, -0.45]* -0.17[-0.83, 0.49] -0.66[-1.39, 0.07] -1.07[-1.86,-0.27] 
Systolic BP -1(12) -2(8) 4(11) 7(16) 4[-14, 22] 7[-17, 31] -1[-18, 15] 6[-12, 23] 9[-15, 32] 
Diastolic BP -1(6) 0(3) 2(7) 6(6) 3[-7, 12] 7[-3, 17] 1[-7, 9] 2[-7, 10] 6[-4, 16] 
Waist circumference 
(cm) 1(1) -4(6) -2(2) -4 -3[-11,6]  -5[-12, 2] 2[-6, 10]  
Hip circumference (cm) 1(2) 3(7) 0(3) 1.00 0[-11, 11]  2[-7, 11] -2[ -12, 8]  
WHR -0.00(0.02) -0.07(0.13) -0.02(0.27) -0.05  -0.20[-0.22,0.18]  -0.7[-0.24,0.10] -0.05[-0.14, 0.23]  
Fat mass (kg) -0.2(0.7) -0.6(0.5) -0.5(1.5) -0.8(1.1) -0.3[-1.8,1.2] -0.6[-2.0, 0.8]   -0.5[-1.8, 1.2] 0.2 [-1.3, 1.6] -0.2[-1.6, 1.2] 
Fat free mass (kg) 0.1(0.8) 0.1(0.9) -1.8(2.0) -2.7(0.4) -1.9[-4.0, 0.2] -2.8[-4.5, -1.0]* 0.1[-1.9, 2.0] -2.0[-4.1, 0.2] -2.8[-4.6, -1.1]* 
Total body water (kg) <0.0(0.6) 0.2(0.6) -1.7(1.9) -2.8(1.3) -1.8[-3.6, 0.1] -2.8[-4.3, -1.3]* 0.1[-1.5,1.8] -1.9 [-3.7, -0.1] -2.9[-4.4, -1.4]* 
Week +1 
   
 
 
 
  
 
 Weight  (kg) 0.4(0.9) -0.9(0.8) -4.4(3.3) -6.3(0.1) -4.8[-8.1, -1.6]* -6.7[-8.6,-4.9]* -1.3 [-4.0, 1.4] -3.5[-6.6, -0.4]* -5.4[-7.2, -3.6]* 
BMI (kg/m
2
) 0.19(0.36) -0.33(0.29) -1.50(1.18) -2.15(0.48) -1.68[-2.86, -0.50]* -2.34[-3.14, -1.54]* -0.51[-1.50, 0.47] -1.17[-2.30, -0.04]* -1.82[-2.59, -1.06]* 
Systolic BP 3(18) -7(2) -6(5) -1(6) -9[-33,16] -11[-40, 18] -10[-32,11] 1[-23,26] -1[-30,29] 
Diastolic BP 2(8) -2(9) -6(9) -2(6) -9[-26,9] -4[-23, 15] -4[-19, 11] -5[-2, 12] 0[-19, 19] 
Waist circumference (cm) 1(3) -7(9) -5(6) -9 -6[-23, 12]  -8[-21, 2] 2[-14, 18]  
Hip circumference (cm) 2(1) 1(9) 1(4) -2 -2[-25, 21]  -1[-20,18] 0[-19,18]  
WHR -0.01(0.01) -0.09(0.18) -3.00 -0.07 -0.04[-0.49, 0.42]  -0.07[-0.45, 0.30] -0.03[-0.34, 0.41]  
Fat mass (kg) 0.3(1.2) -0.8(0.8) -2.6(1.2) -4.8 -2.9[-5.0, -0.8]* -3.6[-5.3, -1.4]* -1.0[-2.8, 0.7] -1.9[-3.9, 0.1] -2.5[-4.6, -0.4]* 
Fat free mass (kg) 0.2(0.9) -0.2(0.4) -1.8(2.1) -3.0 -1.9[-4.1, 0.3] -3.2[-4.6, 1.7] -0.3[-2.1, 1.5] -1.6[-3.7, 0.5] -2.9[-4.3, -1.5]* 
Total body water (kg) 0.1(0.6) -0.1(0.3) -1.9(2.3) -3.1 -2.0[-4.1, 0.2] -3.2[-4.6, -1.7]* -0.2[-2.0,1.5] -1.8[-3.8, 0.3] -2.9[-4.3, -1.5]* 
#
p<0.05 ANOVA *p<0.05 post-hoc Gabriel. Post hoc tests could not be performed in all cases due to small numbers.  
$
Not complete numbers for all measurements, where no SD, mean is an individual 
measurement. (a)= those adherent to VLCD.  
Table 50. Mean (SD) change in anthropometrics, body composition and blood pressure from baseline to week 0 and to week +1 in all 
completers by trial arm and mean difference [95% CI] in these between trial arm 
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6.2.8.2. Change in weight, BMI and body composition, baseline 
to the end of the first week post quit date 
Weight gain in the SBS arm and weight loss in the IDAP arm was attributed to 
change in fat mass (week 1 in Figure 28, Figure 29) , but a large proportion of 
weight loss in the VLCD arm was due to change in total body water occurring 
during the first week (week 1 in Figure 30) (Table 50). During the second week 
on a VLCD people lose less water because glycogen stores are exhausted. 
Instead fat is metabolized for energy. Loss of body water during the second 
week may have occurred because people find it difficult to drink enough water.  
 
When the SBS arm was compared with those adhering to the VLCD arm, there 
were statistically and clinically significant differences between the change in 
weight, BMI and fat mass (-6.7kg[-8.6, -4.9], -2.34kg/m2[-3.14, -1.54], -3.6kg[-
5.3, -1.4]). Such differences were also clinically important, but not statistically 
significant, between the SBS and IDAP arms (-1.3kg, -0.51kg/m2, -1.0kg 
respectively) (Table 50).  
 
6.2.8.3. Change in weight, BMI and body composition baseline 
to the end of Stage 1  
Weight, BMI and fat mass had increased in the SBS arm and reduced in the 
IDAP and VLCD arms (week 4 in Figure 28, Figure 29). The differences 
between the intervention and control arms were clinically important and in 
favour of both interventions (Table 51). There was an increased loss of fat free 
mass, not explained by body water (-0.9kg) in those adhering to the VLCD 
(week 4 in Figure 30, Figure 31). This indicates an unexpected loss of lean 
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body tissue, although this has been a concern with VLCD formulas in the past, 
current formulas are tailored to minimise loss of lean tissue (section 3.11.1). 
However, useful conclusions cannot be drawn from data on one individual.  
 
6.2.8.4. Change in weight, BMI and body composition, baseline 
to the end of treatment  
No participants in the IDAP arm attended their end of treatment visit (reasons 
behind attrition have been explored in chapter four). One participant attended in 
the VLCD arm and four in the SBS arm. By this point in the trial both the SBS 
and VLCD arm had entered Stage 2 and had received IDAP advice.  
 
In the SBS arm, there was a small further rise in weight (week 12 in Figure 28). 
Most of this was fat free mass, 73% of which was body water indicating some of 
the increase was lean body tissue (week 12 in Figure 30, Figure 31).  Fat mass 
was slightly above baseline at this point (0.2kg) indicating that the gain seen 
after four weeks (0.6kg) had reduced during Stage 2 (week 12 in Figure 29, 
Table 51). In the VLCD arm approximately half of the weight lost was regained 
by the end of treatment, although the amount lost from baseline was still 
clinically significant (-4.6kg). Body composition analysis indicated that most of 
this weight regain was fat mass (+3.0kg) (week 12 in Figure 29) with an 
accompanying loss of fat free mass (-7.6kg) (week 12 in Figure 30) 92% of 
which was body water (-7.0kg) (week 12 Figure 31, Table 51). Changes in 
trends over time are explored more fully using multilevel modelling in section 
6.2.18 .
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Table 51. Mean (SD) change in anthropometrics, body composition and blood 
pressure from baseline to week +4 and to week +12 in all completers by trial 
arm and mean difference [95% CI] in these between trial arm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Change from baseline 
in: 
SBS 
(n
$
=5) 
IDAP 
(n
$
=3) 
VLCD 
(n=1) 
VLCD-
SBS 
IDAP-
SBS 
VLCD-
IDAP 
Week+4       
Weight  (kg) 1.0 (0.8) -1.2 (1.7) -8.6 -9.6
# 
-2.2
# 
-7.4
# 
BMI (kg/m
2
) 0.38(0.31) -0.49 (0.66) -2.54 -2.92
# 
-0.87
# 
-2.05
# 
Systolic BP 4(11) -17(9) 3 -1 -22 20 
Diastolic BP 3(9) -2 (9) 12 9 -5 14 
Waist circumference 
(cm) 
4(<0) -8 (9) -12 -16 -12 -4 
Hip circumference (cm) 1 4 (11) -3 -4 3 -7 
WHR 0.03 -0.12 (0.18) -0.09 -0.12 -0.15 0.03 
Fat mass (kg) 0.4(1.5) -1.2 (1.6) -4.8 -5 -1.6 -3.6 
Fat free mass (kg) 0.6(0.9) -0.1 (0.5) -3.8 -4.4
# 
-0.7
# 
-3.7
# 
Total body water (kg) 0.4(0.7) -0.0 (0.3) -2.9 -3.3
# 
-0.5
# 
-2.9
# 
 
Week +12 
      
Weight (kg) 1.2 (2.2)  -4.6 -5.8 -1.2  
BMI (kg/m
2
) 0.45(0.78)  -1.79 -2.24 -0.45  
Systolic BP 1 (7)  -9 -10 -1  
Diastolic BP -3(18)  12 15 3  
Waist circumference 
(cm) 
-3(6)      
Hip circumference (cm) 2(1)      
WHR       
Fat mass (kg) 0.2(2)  3.0 2.9 -0.2  
Fat free mass (kg) 1.0(0.5)  -7.6 -8.6
# 
-1.0
# 
 
Total body water (kg) 0.7(0.4)  -7.0 -7.7
# 
-0.7
# 
 
#
p<0.05 ANOVA  Post hoc tests could not be performed due to small numbers  
$
Not complete 
numbers for all measurements, where no SD, mean is an individual measurement.  
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6.2.8.5. Change in lung function, blood glucose and cardiovascular 
risk parameters at the end of treatment  
Data on change in lung function was only available for the SBS arm and showed lung 
function reduced by a clinically irrelevant amount over the course of treatment (Table 
52). (Known large intra-individual variability in measured lung function means a 
clinically meaningful change in forced expiratory volume in 1 second (FEV1) should 
exceed 15% (Brusasco, 2009). 
 
Blood glucose rose slightly in SBS and less so in IDAP, where dietary intervention 
had been present in both Stage1 and 2. Plasma lipid profile improved more in the 
IDAP arm than the SBS arm. The differences in change between these arms were 
clinically, although not statistically, significant as calculated as a percentage of the 
baseline value (Table 52) (10% and 18% improvement in TC:HDL ratio and 
triglycerides respectively). Most other markers of cardiovascular risk, elevated CRP, 
WBC, platelets, MCV and Hb (Lloyd-Jones et al., 2006, Libby et al., 2002, Davi & 
Patrono, 2007, Lowik et al, 1992) improved in both arms; generally more so in IDAP.  
Again, the sample size was too small to draw any conclusions from these changes, 
but these differences as a percentage of baseline values were clinically important 
(WBC and platelets improved by at 66% and 27% respectively). CRP reduced in both 
arms by more than 2.4mg/l (CRP above 2.4mg/l is associated with double the 
cardiovascular risk of CRP of 1mg/l (Lloyd-Jones et al., 2006)). 
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Change in: SBS (n
$
=4) IDAP (n
$
=1) IDAP-SBS 
Week +12 
Week +12 
   
Fasting blood glucose (mmol/L) 0.3(<0.1) 0.2 0.1 
Forced Expiratory Volume in 1 sec (FEV1) 
(L) 
-0.1(0.2)   
Forced Vital Capacity (FVC) (L) -0.1(0.2)      
C-Reactive Protein (mg/L) -3.5(0.7) -4.0   0.7[-10.5, 11.5]  
TC:HDL ratio -0.3(0.6) -0.8   0.5[-8.3, 9.3]  
LDL-cholesterol (mmol/L) -0.2 -0.3   0.1  
HDL-cholesterol (mmol/L) 0.2(0.4) 0.3   -0.1[-6.5, 6.3]  
Total Cholesterol (TC) (mmol/L) -0.2(0.6) 0.0   -0.2[-10.1, 9.8]  
Fasting triglycerides (mmol/L) 0.2(0.2) -0.1   0.2[-2.2, 2.7]  
White Blood Cells (WBC) (x10
9
/L) 3.9(6.2) -1.0   4.9[-90.9,100.6]  
Platelets (x10
9
/L) -14(42) -89   75[-585,735]  
Mean Corpuscular Volume (MCV) -1(1) 1   -2[-25, 21]  
Haemoglobin (Hb) g/dl -0.2(<0.1) -0.4   0.2  
$
Not complete numbers for all measurements, where no SD, mean is an individual measurement. 
 
 
 
 
 
 
 
 
 
 
 
Table 52. Mean Change (SD) in lung function and blood test results from 
baseline to week +12 in all completers by trial arm and mean difference [95% CI] 
in these between trial arm 
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6.2.9. Change in weight, BMI and body composition from 
baseline to 1 week post quit, in those achieving 7 day point 
prevalent abstinence 
One, four and no participants fell into this category in the SBS arm, IDAP arm and 
adhering to the VLCD respectively. Comparison of abstainers in the SBS was only 
possible with those in the IDAP arm. A clinically important difference in change in 
weight (1.4kg), BMI (0.53kg/m2) and fat mass (1.2kg) was seen between these 
groups. This was from gains in the SBS arm and losses in the IDAP arm. Fat free 
mass and body water reduced slightly in both groups but values did not represent 
clinically meaningful differences (Table 53). 
6.2.10. Change in weight, BMI and body composition from 
baseline to 4 weeks of continued abstinence 
Weight, BMI and fat mass continued to rise in the SBS arm and fall in the IDAP arm. 
The difference in the measures between the groups was clinically significant (-3.9kg, 
-1.52 kg/m2 and -3.0kg respectively), although this was based on just one individual 
in the IDAP group (Table 53).   
 
6.2.11. Change in weight, BMI and body composition from 
baseline to 12 weeks of continued abstinence 
Twelve week abstinence data was only available for those in the SBS arm. In the 
preceding 4 weeks, participants in the SBS arm received the IDAP intervention. At 12 
weeks participants BMI was the same as that recorded at 4 weeks post quit (Table 
53). Fat mass was less than the 4 weeks post quit values, fat free mass and total 
body water had increased. 
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       *p<0.05 Students‟ t-test 
 
Table 53. Mean Change (SD) in anthropometrics, body composition and blood 
pressure from baseline to week +1, +4 and +12 in completer abstainers by trial arm 
and mean difference [95% CI] in these between trial arm 
 
 
 
Change in: SBS  IDAP  IDAP-SBS 
Week +1 
   n 4 5  
 Weight  (kg) 0.2(1.0) -1.2(0.5) 1.4[0.2, 2.5]* 
BMI (kg/m
2
) 0.11(0.37) -0.42(0.20) 0.53[0.08, 0.98]* 
Systolic BP (mm/Hg) 3(21) -7(2) 10[-24, 44] 
Diastolic BP (mm/Hg) 2(9) -2(9) 3[-11, 17] 
Waist circumference (cm) 1.0(3.2) -6.6(8.6) 7.6[-3.2, 18.4] 
Hip circumference (cm) 2.3(1.1) 1.2(1.1) 1.1[-15.5, 17.6] 
WHR -0.01(0.01) -0.09(0.01) 0.07[-0.27, 0.41] 
Fat mass (kg) 0.3(1.4) -0.9(0.8) 1.2[-0.4, 2.9] 
Fat free mass (kg) -0.1(0.8) -0.2(0.4) 0.1[-0.8, 1.1] 
Total body water (kg) -0.1(0.6) -0.2(0.3) 0.1[-0.6, 0.8] 
 
Week+4 
   n 4 1 
  Weight  (kg) 1.1(0.8) -2.8 -3.9[-6.8, -1.0]*
 
BMI (kg/m
2
) 0.43(0.34) -1.09 -1.52 [-2.70, -0.32]*
 
Systolic BP 6(13) -19 -25 [-69, 20] 
Diastolic BP 4(10) 3 -1 [-36, 35] 
Waist circumference (cm) 4(<0) -9 -13 
Hip circumference (cm) 1 -7 -8 
WHR 0.03 -0.02 -0.05 
Fat mass (kg) 0.8(1.4) -2.3 -3.1[-8.2, 2.0] 
Fat free mass (kg) 0.4(0.9) -0.5 -0.9[-3.9, 2.2] 
Total body water (kg) 0.2(0.6) -0.3 -0.5[-2.7, 1.6] 
 
Week +12 
   n 4 
   Weight (kg) 1.15(2.22) 
  BMI (kg/m2) 0.45(0.78) 
  Systolic BP 1.25(6.84) 
  Diastolic BP -2.50(17.82) 
  Waist circumference (cm) -2.50(6.36) 
  Hip circumference (cm) 
   WHR 
   Fat mass (kg) 0.15(2.18) 
  Fat free mass (kg) 1.00(0.52) 
 
 
Total body water (kg) 0.73(0.43) 
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6.2.12. Change in lung function, blood glucose and 
cardiovascular risk parameters by end of treatment in 
abstainers 
Data on these parameters was only available for the four continuous abstainers in 
the SBS arm. Lung function reduced by a clinically insignificant amount (section 
6.2.8.5). Most cardiovascular risk factors improved (TC:HDL cholesterol ratio reduced 
by 6% of baseline value) but triglycerides (rose by 14% of baseline value) and fasting 
blood glucose rose (Table 54). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 54. Mean Change (SD) in lung function and blood test results from baseline to 
week +12 in SBS abstainers and IDAP lapsers 
 
 
Change in: SBS (A) (n=4) IDAP (L) (n=1) 
Week +12   
Glucose (mmol/L) 0.3(0.00) 0.2 
Forced Expiratory Volume in 1 sec (FEV1) (L) -0.1(0.2)  
Forced Vital Capacity (FVC) (L) -0.1(0.2)  
C-Reactive Protein (mg/L) -3.5(0.7) -4.0 
TC:HDL ratio -0.3(0.6) -0.8 
LDL-cholesterol (mmol/L) -0.2 -0.3 
HDL-cholesterol (mmol/L) 0.2 (0.4) 0.3 
Total Cholesterol (TC) (mmol/L) -0.2(0.6) 0.0 
Triglycerides (mmol/L) 0.2(0.2) -0.1 
WBC (x10
9
/L) 3.9(6.2) -1.0 
Platelets (x10
9
/L) -14(42) -89 
MCV -1.15(1.48) 0.80 
HB -0.2(0.0) -0.4 
A=Abstainers L=Lapsers 
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6.2.13. Change in weight and body composition in lapsers 
from baseline to 1 week post quit date  
There was data on one lapser each in the SBS and IDAP arms and two on the 
VLCD. Weight increased in the SBS arm by a clinically meaningful amount (1.2kg). 
By comparison, weight fell dramatically in the VLCD arm (-6.3kg) and increased 
moderately in the IDAP arm (0.4kg). These accounted for clinically meaningful 
differences in weight between the trials arms but much of these weight changes were 
attributable to body water (67%, 25% and 49% in the SBS, IDAP and VLCD arms 
respectively) (Table 55).   
 
6.2.14. Change in weight and body composition in lapsers 
from baseline to four weeks post quit date (end of treatment, 
Stage 1) 
There was data on one participant in the SBS arm, two in the IDAP arm and one in 
the VLCD arm who were still trying to quit but were not doing so successfully. The 
person in the SBS arm had gained weight (0.5kg) but had lost fat mass (-1.1kg), in 
the IDAP arm weight (fat mass(-0.6kg)) was lost. The individual in the VLCD arm had 
lost a large amount of weight (-8.6kg), which included fat mass (-4.8kg), fat free mass 
(-0.9kg) and total body water (-2.9kg). Differences between the VLCD and SBS arm 
were clinically important, but not between the IDAP and SBS arms (the sample was 
too small to generate confidence intervals for these differences between the trial 
arms) (Table 55).  
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6.2.15. Change in weight body composition and disease 
risk factors in lapsers from baseline to end of treatment  
There were anthropometric data available on one lapsed individual in the VLCD arm 
who gained fat mass by this time (section 6.2.8.4). Data for lung function and blood 
test results were available for one individual who was in the IDAP arm. Lung function 
showed no clinically relevant change (Section 6.2.8.5). Blood glucose rose slightly, 
triglycerides fell by 5% of baseline value, TC:HDL cholesterol fell by 19% of baseline 
value (both LDL cholesterol fell and HDL cholesterol rose). CRP fell by 4mg/L, and 
platelets fell by 27% of baseline value, which are clinically meaningful changes 
(Table 54).    
 
There was a smaller rise in blood glucose and a greater improvement in 
cardiovascular markers in the individual who followed IDAP, but continued to smoke, 
than in the individuals in the SBS arm who stopped smoking. But the sample is far 
too small to draw any meaningful conclusions (Table 54). 
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   $
Not complete numbers for all measurements, where no SD, mean is an individual measurement.
 
Table 55 Mean (SD) change in anthropometrics, body composition and blood pressure from baseline to week +1 
and to week +4 in completer lapsers by trial arm and mean difference [sample to small for 95% CI] in these 
between trial arms
Change from baseline in: SBS (n
$
=1) IDAP (n
$
=1) VLCD (n
$
=2) VLCD-SBS IDAP-SBS VLCD-IDAP 
Week  +1 
   
   
 Weight (kg) 1.2 0.4 -6.3(0.1) -7.5 -0.8 -6.7 
BMI (kg/m
2
) 0.5 0.15 -2.15(0.48) -2.65 -0.35 -2.3 
Systolic BP 4 
 
-1(6) -4.8 
  Diastolic BP 4 
 
-2(6) -6 
  Waist circumference (cm) 
  
-9  
 Hip circumference (cm) 
  
-2   
 WHR 
  
-0.07   
 Fat mass (kg) 0.1 0.1 -4.8 -4.9 0 -4.9 
Fat free mass (kg) 1.1 0.2 -3.0 -4.1 -0.9 -3.2 
Total body water (kg) 0.8 0.1 -3.1 -3.9 -0.7 -3.2 
Week  +4 
   
   
 Weight (kg) 0.5 -0.5(1.5) -8.6 -9.1 -1.0 -8.2 
BMI (kg/m
2
) 0.21 -0.19(0.58) -2.54 -2.75 -0.4 -2.35 
Systolic BP -1 -17(12) 3 4 -16 20 
Diastolic BP -1 -5(11) -4 -3 -4 1 
Waist circumference (cm) 
 
-8(12) -12   -5 
Hip circumference (cm) 
 
9(7) -3   -12 
WHR 
 
-0.18(0.22) -0.09   0.09 
Fat mass (kg) -1.1 -0.6(1.8) -4.8 -3.7 0.5 -4.2 
Fat free mass (kg) 1.6 0.2(0.4) -3.8 -5.4 -1.5 -4.0 
Total body water (kg) 1.2 0.1(0.3) -2.9 -4.1 -1.1 -3 
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6.2.16. Individual trajectories of change in weight and fat 
mass 
The measures of weight and fat mass over time were of most clinical interest here. 
As there are only a small number of participants, we have presented the change in 
weight and fat mass trajectories of all individuals (Figure 32). By doing so  
annotating the time points of abstinence, lapses, dietary change and colour coding 
them by trial arm  we can see these effects within each individual. This helps with 
understanding and interpreting the data in subsequent analyses.  
 
For most participants in the SBS arm weight increased over time (ID 3, 21, 32) and 
slowed or fell following the start of IDAP in Stage 2 (ID 3, 6, 26 32). One individual 
lapsed back to smoking (although their intention was not to abandon their quit 
attempt at this point) and weight began to fall (ID 6).  
 
Weight initially fell (ID 4, 10, 8 and 30) in the IDAP arm and then rose again towards 
the end of treatment (ID 10, 18 and 30).  
 
In the VLCD arm two participants abandoned their diet early and also failed to quit 
and left the programme (ID 7 and 21). Two participants continued the diet and lost a 
lot of weight until re-feeding (ID 12 and 31); Neither had quit by this point. One of 
these two (ID 31) quit after initial weight loss and during the re-feeding stage. 
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The change in fat mass paralleled and largely accounted for the change in weight. 
This was true for all individuals in all trial arms (Figure 33), except for one person. 
This person (ID 31) put on a large amount of fat mass during Stage 2 of the VLCD 
intervention. This coincided with the time that they quit smoking. Therefore, they had 
a greater fat mass at the end of treatment (week +12) than at baseline.  Quitting in 
the other trial arms was not associated with this dramatic increase in fat mass. 
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Figure 32. Individuals‟ change in weight over weeks -1 to +12, annotated by trial arm, 
change in smoking status and dietary change 
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Figure 33. Individuals‟ change in fat mass over weeks -1 to +12, annotated by trial 
arm, change in smoking status and dietary change 
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6.2.17. Change in mean weight and fat mass by trial arm 
In Stage 1 weight and fat mass rose in the SBS arm, fell moderately in the IDAP arm 
and fell dramatically in the VLCD arm. During Stage 2 weight began to fall in the SBS 
arm, rise in the in the IDAP arm and rise dramatically in the VLCD arm. Fat mass 
began to level off in the SBS arm, continued to fall in the IDAP arm and rose 
significantly beyond baseline in the VLCD arm (Figure 34,Figure 35). 
 
6.2.18. Modelling of weight and fat mass trajectories by 
trial arm 
We modelled the effects of trial arm to adjust for the effects of abstinence or lapsing, 
gender and age. We built up the multilevel model in several stages. From the mean 
plots of weight and fat mass over time we could see that the effects of trial arm were 
not linear. So we modelled a quadratic and then cubic function of time. The fit 
significantly improved from the linear to the quadratic model, but not to the cubic 
model for both weight (Model 1-2 and 2-3,Table 56) and fat mass (Model 1-2 and 2-
3,Table 57). 
 
The effects of trial arm, with SBS as the reference category, were interpreted from 
the coefficients for each trial arm in a model containing a quadratic function of time 
and trial arm (Models 4 in Table 58, Table 59). Over the 12 weeks, the mean 
differences for weight and fat mass change between the IDAP and SBS arm were  
-1.3kg and -0.9kg respectively.  Between the VLCD and SBS arm they were -7.1kg 
for weight -3.4kg for fat. 
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 Adjusting for point prevalent abstinence (with lapsing as the reference category) 
significantly improved the fit of the models for both weight and fat mass (models 4 to 
models 5). The coefficients showed weight and fat mass was 0.4kg higher in those 
who were abstinent. But this did not explain the differences by trial arm, the 
coefficients for trial arm hardly changed (Models 5,Table 58 & Table 59).  
 
Adjusting for age significantly improved the fit of the models, such that a one year 
increase in age was associated with a 40g increase in weight and fat mass. 
Therefore, someone who was 60 years old might gain 0.8kg more than someone 
who was 30 years old. But this did not explain differences between trial arms as the 
trial arm coefficients were unaltered (model 6, Table 58 & Table 59). Adjusting for 
gender (female was the reference category) did not significantly improve the fit of the 
model or explain difference by trial arm, but the coefficients suggested that males 
gained 0.7kg more and had 0.9kg more fat mass than females (model 7, Table 58 & 
Table 59).  
 
The mean plots of change in weight (Figure 34) and fat mass (Figure 35) by trial arm 
suggest that rate of change was different within each trial arm, this was expected as 
during Stage two participants received the IDAP intervention at different times (week 
5 in VLCD and Week 8 in SBS). To account for these changes we included a time by 
trial arm interaction, which showed a large, significant reduction in -2loglikelihood and 
hence improvement in the fit of the model (model 8 Table 58 & Table 59). Plotting the 
fixed effects of these models (Figure 36 & Figure 37) showed that they fit the mean 
plots well (Figure 34 & Figure 35). 
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VLCD re-feeding 
Start of IDAP 
Start of IDAP 
VLCD re-feeding 
Figure 34. Mean weight change by trial arm over weeks 
post quit 
Figure 35. Mean fat mass change by trial arm over 
weeks post quit 
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Model Steps -2LL -2LL Chi df p 
1 to 2 294.314 287.966 6.348 1 0.012* 
2 to 3 287.966 287.656 0.31 1 0.578 
2 to 4 287.966 258.986 28.98 2 <0.001* 
4 to 5 258.986 257.891 1.095 1 0.295 
4 to 6 258.986 254.871 4.115 1 0.043* 
4 to 7 258.986 257.765 1.221 1 0.269 
4 to 8 258.986 221.629 37.357 4 <0.000* 
*statistically significant improvement in fit of model to data using Chi-squared test. Model 1: weight change 
according to linear function of time. Model 2: weight change according to quadratic function of time. Model 3: 
weight change according to cubic function of time. Model 4: weight change according to quadratic function of time 
and trial arm. Model 5: weight change according to quadratic function by time, trial arm, adjusted for point 
prevalence abstinence. Model 6: weight change according to quadratic function by time, trial arm, adjusted for 
age Model 7: weight change according to quadratic function by time, trial arm, adjusted for gender Model 8:  
weight change according to quadratic function by time, trial arm, and trial arm by time interaction.  
 
Table 56. Difference in fit between models of change in weight over time 
 
 
 
 
Model Steps -2LL -2LL Chi df p 
1 to 2 311.09 300.862 10.228 1 0.001* 
2 to 3 300.862 300.846 0.016 1 0.899 
2 to 4 300.846 287.133 13.713 2 <0.001* 
4 to 5 287.133 283.265 3.868 1 0.049* 
4 to 6 287.133 283.394 3.739 1 0.053 
4 to 7 287.133 285.014 2.119 1 0.145 
4 to 8 287.133 223.007 64.126 4 <0.001* 
*statistically significant improvement in fit of model to data using Chi-squared test. Model 1:fat mass change 
according to linear function of time. Model 2: fat mass change according to quadratic function of time. Model 3: fat 
mass change according to cubic function of time. Model 4: fat mass change according to quadratic function of 
time and trial arm. Model 5: fat mass change according to quadratic function by time, trial arm, adjusted for point 
prevalence abstinence. Model 6: fat mass change according to quadratic function by time, trial arm, adjusted for 
age Model 7: fat mass change according to quadratic function by time, trial arm, adjusted for gender Model 8:  fat 
mass change according to quadratic function by time, trial arm, and trial arm by time interaction.  
  
Table 57. Difference in fit between models of change in fat mass over time 
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  Model 1 S.E. Model 2 S.E. Model 3 S.E. Model 4 S.E. Model 5 S.E. Model 6 S.E. Model 7 S.E. Model 8 S.E. 
Fixed Part 
                cons -1.206 0.687 -0.858 0.692 -0.793 0.699 0.744 0.42 0.622 0.441 2.575 0.918 0.895 0.421 0.175 0.414 
Time 0.035 0.037 -0.265 0.122 -0.377 0.235 -0.268 0.118 -0.328 0.13 -0.266 0.117 -0.277 0.118 0.172 0.129 
Time*time 
  
0.027 0.011 0.055 0.05 0.028 0.01 0.032 0.011 0.027 0.011 0.028 0.010 -0.011 0.011 
Time*time*time 
    
-0.002 0.003 
          IDAP 
      
-1.323 0.535 -1.294 0.547 -1.738 0.505 -1.417 0.511 -0.736 0.591 
VLCD 
      
-7.133 0.734 -6.988 0.763 -7.312 0.642 -6.950 0.709 -4.585 0.824 
Point prevalence(PP) 
        
0.361 0.345 
      Age (years) 
          
-0.038 0.017 
    Gender 
            
-0.713 0.616 
  IDAP*time 
              
-0.526 0.223 
VLCD*time 
              
-1.787 0.262 
IDAP*time*time 
              
0.054 0.023 
VLCD*time*time 
              
0.148 0.022 
Random Part 
                Level: Participant  ID 
cons/cons 6.078 2.418 5.971 2.367 5.924 2.349 0.582 0.31 0.623 0.326 0.389 0.232 0.490 0.276 0.607 0.284 
Level: Time  cons/cons 1.274 0.22 1.164 0.201 1.16 0.2 1.145 0.197 1.117 0.192 1.139 0.196 1.152 0.193 0.670 0.116 
-2*loglikelihood:  294.314 
 
287.966 
 
287.656 
 
258.986 
 
257.928 
 
254.817 
 
257.765 
 
211.629 
 Units: Participant ID 14 
 
14 
 
14 
 
14 
 
14 
 
14 
 
14 
 
14 
 Units: week from quit 81   81   81   81   81   81   81   81   
Model 1: weight change according to linear function of time. Model 2: weight change according to quadratic function of time. Model 3: weight change according to cubic function of 
time. Model 4: weight change according to quadratic function of time and trial arm. Model 5: weight change according to quadratic function by time, trial arm, adjusted for point 
prevalence abstinence. Model 6: weight change according to quadratic function by time, trial arm, adjusted for age Model 7: weight change according to quadratic function by time, 
trial arm, adjusted for gender Model 8:  weight change according to quadratic function by time, trial arm, and trial arm by time interaction.  
 
Table 58. Coefficients of multilevel models for weight change 
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Model 1:fat mass change according to linear function of time. Model 2: fat mass change according to quadratic function of time. Model 3: fat mass change according to cubic function 
of time. Model 4: fat mass change according to quadratic function of time and trial arm. Model 5: fat mass change according to quadratic function by time, trial arm, adjusted for point 
prevalence abstinence. Model 6: fat mass change according to quadratic function by time, trial arm, adjusted for age Model 7: fat mass change according to quadratic function by 
time, trial arm, adjusted for gender Model 8:  fat mass change according to quadratic function by time, trial arm, and trial arm by time interaction.  
 
Table 59. Coefficients of multilevel models for change in fat mass 
Model 1 S.E. 2 S.E. 3 S.E. 4 S.E. 5 S.E. 6 S.E. 7 S.E. 8 S.E. 
Fixed Part 
                cons -0.962 0.417 -0.415 0.441 -0.397 0.463 0.485 0.430 0.344 0.459 2.201 0.906 0.695 0.423 -0.115 0.408 
Time 0.044 0.044 -0.411 0.143 -0.442 0.281 -0.401 0.140 -0.48 0.155 -0.399 0.139 -0.412 0.140 0.095 0.125 
Time*time 
  
0.041 0.012 0.049 0.06 0.04 0.012 0.046 0.013 0.040 0.012 0.041 0.012 -0.005 0.011 
Time*time*time 
    
0 0.003 
          IDAP 
      
-0.886 0.522 -0.856 0.537 -1.264 0.492 -1.019 0.481 -0.508 0.583 
VLCD 
      
-3.459 0.711 -3.289 0.748 -3.627 0.623 -3.267 0.655 -0.859 0.813 
Point 
prevalence(PP) 
        
0.436 0.405 
      Age (years) 
          
-0.036 0.017 
    Gender 
            
-0.924 0.585 
  IDAP*time 
              
-0.214 0.220 
VLCD*time 
              
-2.178 0.259 
IDAP*time*time 
              
0.006 0.023 
VLCD*time*time 
              
0.208 0.021 
Random Part 
                Level: Participant ID 
cons/cons 1.657 0.784 1.665 0.769 1.66 0.769 0.44 0.288 0.486 0.307 0.263 0.216 0.301 0.233 0.586 0.279 
Level: Time  
cons/cons 1.95 0.334 1.687 0.289 1.687 0.289 1.669 0.284 1.641 0.281 1.667 0.283 1.684 0.286 0.662 0.113 
-2*loglikelihood:  311.09 
 
300.862 
 
300.846 
 
287.133 
 
283.265 
 
283.394 
 
285.014 
 
223.007 
 Units: Participant ID 14 
 
14 
 
14 
 
14 
 
14 
 
14 
 
14 
 
14 
 Units: week from 
quit 82   82   82   82   81   81   81   82   
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Figure 36. Plot of fixed effects of weight change trajectories 
by trial arm (model 8) 
 
 
 
 
 
Figure 37. Plot of fixed effects of fat mass change 
trajectories by trial arm (model 8) 
  
Trial arm 
             SBS                     
             IDAP 
             VLCD 
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6.2.19. Change in fat intake and HCI score as mediators of 
change in body fat 
As described in chapter five we had data on change in fat intake and HCI score for 
some individuals. So we tested these as mediators within a multilevel model of 
change in body fat for these individuals.  
 
The HCI could only detect large differences in fat intake (there was a 32% level of 
agreement). So we classed the guideline daily amount of fat (70g (females)) with 
corresponding lower and upper levels of agreement as a medium level of fat intake, 
anything below and above this was classed as low and high respectively. Change in 
fat intake from baseline to the end of treatment was defined as a move between 
these categories. All our participants either stayed within the same category or 
moved from a high to medium or a medium to a low category of fat intake. 
 
Adding change in fat intake and change in HCI score into the multilevel model for 
trajectory of fat mass did not significantly improve the fit of the models (Table 60) 
but the coefficients were of clinical importance.  A fall by one category of fat intake 
(with no change being the reference category) was associated with a decrease in 
body fat mass of 1.0kg. The change in the coefficients for trial arm showed that this 
explained 22% of the reduction in body fat in the IDAP arm but had a negligible effect 
in the VLCD arm (Table 61). 
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An increase of one point in HCI score was associated with an increase in fat mass of 
0.056kg (56g), or to put it another way an increase of 10 was associated with a 
increase of 0.6kg. But it did not explain the change in fat mass by trial arm, the 
coefficient for the VLCD arm hardly changed and the coefficient for the IDAP arm got 
larger (Table 61). 
 
 
 
Model Steps -2LL -2LL Chi df p 
1 to 2 132.926 131.781 1.145 1 0.285 
1 to 3 132.926 132.444 0.482 1 0.488 
Table 60. Change in fit of models for the trajectory of change in fat mass 
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Table 61. Coefficients for multilevel models for trajectory of change in fat mass 
 
 
 
Model 1 S.E. 2 S.E. 3 S.E. 
Fixed Part       
cons 0.877 0.618 0.969 0.615 0.692 0.669 
week from quit day -0.392 0.246 -0.422 0.243 -0.389 0.244 
Week from quit
2 0.051 0.021 0.052 0.021 0.05 0.021 
IDAP -0.968 0.601 -0.651 0.66 -1.39 0.85 
VLCD -4.623 0.696 -4.64 0.686 -4.385 0.771 
Drop by one fat intake category 
  
-1.013 0.939 
  Change in HCI score 
  
  0.056 0.081 
Random Part 
  
  
  Level: Participant ID 
  
  
  cons/cons 0 0 0 0 0 0 
Level: week from quit day 
  
  
  cons/cons 2.35 0.554 2.277 0.537 2.319 0.547 
-2*loglikelihood:  132.926 
 
131.781  132.444 
 Units: Participant ID 5 
 
5  5 
 Units: week from quit day 36 
 
36  36 
 Models: trajectory of change in fat mass by trial arm (1) adjusted for change in fat intake (2) 
adjusted for change in HCI score (3)  
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6.2.20. Change in anthropometrics and body composition: 
Intention to treat (ITT) analysis 
As described in section 6.1, to get an idea of the pragmatic effects of our trial we 
carried out an ITT analysis. We input BOCF for missing values of those who dropped 
out and means of before and after values for intermittent missing data. 
 
All results are presented in the tables that follow but only the key similarities and 
differences between the results from ITT and completer analysis are described in the 
sections below. 
 
6.2.20.1. Prequit change in weight, BMI and body composition  
No one had dropped out by week 0 so results for the ITT analysis were the same as 
those from completer analysis without removed of those who were not adhering to 
the VLCD (Table 62). 
 
6.2.20.2. Change in weight and body composition from baseline to 
one week post quit date  
Differences in change in weight and fat mass between IDAP and the SBS arm was 
the same for ITT and completer analysis (1.3kg and 1kg respectively). Differences in 
changes in weight and fat mass between VLCD and SBS arms were less marked but 
still statistically and clinically significant (3.7kg and 2.2kg respectively) (Table 62).  
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Table 62. Mean (SD) change in anthropometrics, body composition and blood pressure from baseline to week 0 and to 
week +1 in ITT population by trial arm and mean difference [95% CI] in these between trial arm.
Change from baseline in: SBS (n=6) IDAP (n=6) VLCD (n=4) VLCD-SBS IDAP-SBS VLCD-IDAP 
Week  0 
  
  
   Weight (kg) 0.1(0.6) -0.5(1.0) -2.3(1.8) -2.2[-4.1, -0.3]* -0.4[-2.1, 1.3] -1.8[-3.7, 0.1] 
BMI (kg/m2) -0.01(0.21) -0.18(0.36) -0.84(0.70) -0.83[-1.57, -0.10]* -0.17[-0.83, 0.49] -0.66[-1.39, 0.07] 
Systolic BP -1(12) -2(8) 4(11) 4[-14, 22] -1[-18, 15] 6[-12, 23] 
Diastolic BP -1(5) <-1(3) 2(7) 3[-6, 11] 1[-6, 8] 2[-7, 10] 
Waist circumference (cm) 1(1) -4(6) -2(2) -3[-10, 5]  -5[-11, 1] 2[-5, 10] 
Hip circumference (cm) <0(1) 3(7) <0(2) <0[-8, 8] 2[-5, 9] -2[-10, 5] 
WHR -0.00(0.02) -0.07(0.13) -0.02(0.02) -0.15[-0.16, 0.13]  -0.07[-0.20, 0.06] 0.06[-0.09, 0.20] 
Fat mass (kg) -0.2(0.7) -0.6(0.5) -0.5(1.5) -0.3[-1.8, 1.2] -0.5[-1.8, 0.9] 0.2[-1.3, 1.6] 
Fat free mass (kg) 0.1(0.8) 0.1(0.9) -1.8(2.0) -1.9[-4.0, 0.2] 0.1[-1.9, 2.0] -2.0[-4.1, 0.2] 
Total body water (kg) <0.0(0.6) 0.2(0.6) -1.7(1.9) -1.8[-3.6, 0.1] 0.1[-1.5, 1.8] -1.9[-3.7, -0.1]* 
Week +1 
       Weight  (kg) 0.4(0.9) -0.9(0.8) -3.3(3.5) -3.7[-6.8, -0.5]* -1.3[-4.1, 1.6] -2.4[-5.6, 0.8] 
BMI (kg/m2) 0.16(0.33) -0.33(0.29) -1.12(1.22) -1.28[-2.41, -0.15]* -0.48[-1.50, 0.53] -0.80[-1.93, 0.33] 
Systolic BP 3(17) -6(3) -5(5) -7[-26, 12] -9[-26, 8] 2[-17, 20] 
Diastolic BP 2(7) -1(8) -5(8) -7[-20, 6] -3[-15, 9] -3[-16,10] 
Waist circumference (cm) 1(3) -6(8) -3(5) -4[-15, 8] -6[-16, 3] 3[-9, 14] 
Hip circumference (cm) 1(1) 1(8) <0(2) <0[-9, 8] <0[-8, 8] -1[-9, 8] 
WHR -0.00(0.01) -0.07(0.16) -0.03(0.04) -0.02[-0.20, 0.16] -0.07[-0.23, 0.09] 0.05[-0.13, 0.22] 
Fat mass (kg) 0.2(1.1) -0.8(0.8) -2.0(1.6) -2.2[-4.2, -0.2]* -1.0[-2.8, 0.8] -1.2[-3.2, 0.8] 
Fat free mass (kg) 0.1(0.8) -0.2(0.4) -1.3(2.0) -1.5[-3.4, 0.4] -0.3[-2.0, 1.4] -1.2[-3.1, 0.7] 
Total body water (kg) 0.1(0.6) -0.1(0.3) -1.4(2.1) -1.5[-3.4, 0.4] -0.2[-1.9, 1.5] -1.3[-3.2, 0.6] 
#
p<0.05 ANOVA *p<0.05 post-hoc Gabriel. Post hoc tests could not be performed in all cases due to small numbers.   
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6.2.20.3.  Change in weight, BMI and body composition from 
baseline to the end of Stage 1  
By four weeks post quit date differences in change in weight and fat mass between 
VLCD and SBS arms were less marked but still statistically and clinically significant 
(5.4kg and 1.5kg respectively). Differences in change in weight and fat mass 
between IDAP and SBS arms were less marked but still of some clinical importance 
(1.6kg and 1.0kg respectively) (Table 63). 
 
6.2.20.4.  Change in weight and body composition from baseline to 
the end of treatment  
By the end of treatment, differences in change in weight and fat mass between VLCD 
and SBS arms were again less marked but still clinically significant (1.9kg and 0.7kg 
respectively). Differences in change in weight and fat mass between IDAP and SBS 
arms were small (0.8kg and 0.1kg respectively) (Table 63). However, they arose 
essentially from lack of weight gain in the IDAP compared to the SBS arm. At three 
months post quit we would expect an increase of almost 3kg in untreated abstinent 
smokers (Aubin et al., under review) but the weight gain in the SBS arm was a third 
of this, which may have been due to the IDAP intervention in Stage 2. However little 
weight gain in these both arms may just reflect the weights of many participants who 
dropped out, and were assumed to have relapsed to smoking and their baseline 
weight. Splitting the analysis into abstainers and lapsers helps address this.   
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#
p<0.05 ANOVA *p<0.05 post-hoc Gabriel. Post hoc tests could not be performed in all cases due to small numbers.   
 
Table 63. Mean (SD) change in anthropometrics, body composition and blood pressure from baseline to week +4 and to week 
+12 in ITT population by trial arm and mean difference [95% CI] in these between trial arm
Change from baseline in: SBS (n=6) IDAP (n=6) VLCD (n=4) VLCD-SBS IDAP-SBS VLCD-IDAP 
Week+4 
       Weight  (kg) 0.8(0.8) -0.8(1.3) -4.5(5.2) -5.4[-10.0, -0.7]* -1.6[-5.8, 2.6] -3.7[-8.4, 1.0] 
BMI (kg/m2) 0.32(0.32) -0.30(0.48) -1.56(1.86) -1.88[-3.56, -0.20]* -0.62[-2.13, 0.89] -1.25[-2.93, 0.42] 
Systolic BP 4(10) -9(11) 1(2) -3[-19, 13] -12[-27, 2] 9[-7, 26] 
Diastolic BP 2(8) -1(6) -1(2) -3[-14, 8] -3[-13, 6] <1[-11, 11] 
Waist circumference (cm) 1(2) -4(7) -3(6) -4[-14, 5] -5[-14, 3] 1[-8, 10] 
Hip circumference (cm) <0(0) 2(7) -1(2) -1[-9, 7] 2[-5, 8] -3[-10, 5] 
WHR 0.00(0.01) -0.06(0.13) -0.02(0.04) -0.03[-0.18, 0.12] -0.07[-0.20, 0.07] 0.04[-0.11, 0.19] 
Fat mass (kg) 0.3(1.4) -0.7(1.2) -2.5(2.9) -2.9[-6.0, 0.3] -1.0 [-3.8, 1.8] -1.8[-5.0, 1.3] 
Fat free mass (kg) 0.5(0.9) <0.0(0.3) -1.0(1.9) -1.5[-3.3, 0.4] -0.5[-2.2, 1.2] -0.9[-2.8, 1.0] 
Total body water (kg) 0.4(0.6) 0.1(0.3) -1.9(2.3) -2.3[-4.4, -0.2]* -0.3[-2.2, 1.6] -2.0[-4.1, 0.1] 
Week +12 
       Weight (kg) 0.8(1.8) 0.0(0.0) -1.2(2.3) -1.9[-4.7, 0.8] -0.8[-3.2, 1.7] -1.2[-3.9, 1.6] 
BMI (kg/m2) 0.30(0.65) 0.00(0.00) -0.45(0.90) -0.75[-1.78, 0.28] -0.30[-1.22, 0.62] -0.45[-1.48, 0.58] 
Systolic BP 1(5) 0(0) -2(5) -3[-10,4] -1[-7, 5] -2[-9, 5] 
Diastolic BP -2(14) 0(0) 3(6) -5[-11, 20] -2[-13, 16] 3[-13, 19] 
Waist circumference (cm) -1(3) 0(0) 0(0) 0.1[-3, 4] 0.8[-2, 4] 0[-3, 3] 
Hip circumference (cm) 0(0) 0(0) 0(0) 
   WHR 0.00(0.00) 0.00(0.00) 0(0) 
   Fat mass (kg) 0.1(1.7) 0.0(0.0) 0.8(1.5) 0.7[-1.6, 2.9] -0.1[-2.1, 1.9] 0.6[-1.5, 3.0] 
Fat free mass (kg) 0.7(0.7) 0.0(0.0) -1.9(3.8) -2.6[-5.8, 0.7] 0.7[-3.0, 2.3] -1.9[-5.2, 1.4] 
Total body water (kg) 0.5(0.5) 0.0(0.0) -1.8(3.5) -2.2[-5.2, 0.8] -0.5[-3.2, 2.2] -1.8[-4.7, 1.2] 
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6.2.21. Change in weight and body composition in 
abstainers only:  intention to treat (ITT) analysis  
ITT results for abstainers followed a very similar pattern to the completer analysis for 
changes after one, four (Table 64) and 12 weeks post quit (Table 66) in the SBS and 
IDAP arms. Differences between IDAP and SBS arms were very slightly less marked 
at the end of seven day point prevalence abstinence than in the completer analysis 
(Table 64 vs Table 50).  In the ITT analysis clinically important differences between 
the IDAP and SBS group after four weeks of continuous abstinence were seen for 
weight and fat mass (0.5kg and 0.9kg respectively) (Table 64).  
 
6.2.22. Change in weight and body composition in lapsers 
only:  intention to treat (ITT) analysis  
Differences in change in weight and fat mass between the IDAP and SBS arms in the 
ITT analysis for lapsers did not differ from the completer analysis at the end of one 
week post quit date, and were very similar after four weeks post quit date (Table 65).  
These differences in change in weight and fat mass between the VLCD and SBS 
arms were the same after one week post quit date but approximately half that seen in 
completer analysis at the end of week four (Table 65 versus Table 51) 
 
In lapsers the only change still apparent by 12 weeks was in the VLCD arm which 
showed a smaller, although still clinically important, reduction in weight (-1.3kg) and 
an increase in fat mass (0.8kg) (Table 68). 
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*p<0.05 ANOVA post-hoc Gabriel. 
#
p<0.05 students t test 
Table 64. Mean (SD) change in anthropometrics, body composition and blood pressure from baseline to week +1 and to week 
+4 in ITT abstainer population by trial arm and mean difference [95% CI] in these between trial arm 
Change from baseline in: SBS (n=5) IDAP (n=5) VLCD (n=2) VLCD-SBS IDAP-SBS VLCD-IDAP 
Week +1       
 Weight  (kg) 0.2(0.8) -1.2(0.5) -0.3(0.4) -0.5 [-2.0, 1.1] -1.3[-2.5, -0.2]* 0.9[-0.7, 2.4] 
BMI (kg/m2) 0.09(0.32) -0.42(0.20) -0.09(0.13) -0.18[-0.78, 0.42] -0.51[-0.98, -0.04]* 0.33[-0.27, 0.93] 
Systolic BP 2(18) -8(2) -1(1) -3[-32, 26] -10[-32, 13] -3[-23, 36] 
Diastolic BP 1(8) -2(9) -8(11) -9[-29, 11] -3[-19, 13] -6[-26, 14] 
Waist circumference (cm) 1(3) -7(9) 0(0) -0.80[-15.02, 13.42] -7.40[-18.42, 3.62] 6.60[-7.62, 20.82] 
Hip circumference (cm) 1(1) 1(9) 2(2) 1[-13, 15] <1[-10, 11] 1[-13, 14] 
WHR -0.01(0.01) -0.09(0.18) -0.2(0.03) -0.01[-0.29, 0.26] -0.08[-0.30, 0.13] 0.07[-0.21, 0.35] 
Fat mass (kg) 0.2(1.2) -0.9(0.8) -0.6(0.9) -0.9[-3.2, 1.4] -1.2[-3.0, 0.6] 0.3[-2.0, 2.6] 
Fat free mass (kg) -0.1(0.7) -0.2(0.4) 0.4(0.5) 0.4[-0.9, 1.7] -0.2[-1.2, 0.9] 0.6[-0.8, 1.9] 
Total body water (kg) <0.1(0.5) -0.2(0.3) 0.3(0.4) 0.3[-0.7, 1.3] -0.1[-0.9, 0.7] 0.4[-0.6, 1.4] 
Week+4       
 Weight  (kg) 1.1(0.8) -2.8   -3.9[-6.9, -1.0]
#  
BMI (kg/m2) 0.43(0.34) -1.09   -1.51[-2.71, -0.32]
#  
Systolic BP 6(13) -19     
Diastolic BP 4(10) 3     
Waist circumference (cm) 2(2) -9   -11[-19, -3]
#  
Hip circumference (cm) <1(<1) -7   -7[-9, -6]
#  
WHR 0.01(0.01) -0.02   -0.03[-0.08, 0.2]  
Fat mass (kg) 0.8(1.4) -2.3   -3.1[-8.2, 2.0]  
Fat free mass (kg) 0.4(0.9) -0.5   -0.9[-3.9, 2.2]  
Total body water (kg) 0.2(0.6) -0.3   -0.5[-2.7, 1.6]  
 290 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*p<0.05 ANOVA post hoc tests could not be performed in all cases due to small numbers.   
 
Change from baseline in: SBS (n=1) IDAP (n=1) VLCD (n=2) VLCD-SBS IDAP-SBS VLCD-IDAP 
Week +1       
 Weight  (kg)* 1.2 0.4 -6.3(0.14) -7.5 -0.8 -6.7 
BMI (kg/m
2
) 0.5 0.15 -2.15(0.48) -2.65 -0.35 -2.3 
Systolic BP 
4 0 -8(6) -12 -4 -8 
Diastolic BP 
4 0 -2[6] -6 -4 -2 
Waist circumference (cm) 0 0 -5(6) -5 0 -5 
Hip circumference (cm) 0 0 -1(1) -1 0 -1 
WHR 0 0 -0.03(0.05) -0.03 0 -0.03 
Fat mass (kg)* 0.1 0.1 -3.3(0.1) -3.4 0 -3.4 
Fat free mass (kg) 1.1 0.2 -3.0(0.3) -4.1 -0.9 -3.2 
Total body water (kg) 0.8 0.1 -3.1(1.3) -3.9 -0.7 -3.2 
Week+4       
 Weight  (kg) 0.3(0.4) -0.4(0.9) -4.5(5.2) -4.8[-13.0, 4.5] -0.7[-8.5, 7.2] -4.1[-10.6, 2.3] 
BMI (kg/m
2
) 0.10(0.15) -0.15(0.33) -1.56(1.86) -1.66[-4.60, 1.27] 0.25[-3.06, 2.56] -1.41[-3.71, 0.89] 
Systolic BP -1(1) -7(11) 1(2) 1[-18, 21] -6[-25, 13] 7[-8, 23] 
Diastolic BP -1(1) -2(6) -1(2) -1[-12, 11] -2[-13, 11] 1[-8, 10] 
Waist circumference (cm) 0(0) -3(7) -3(6) -3(-19, 13] -3[-18, 12] 0[-13, 13] 
Hip circumference (cm) 0(0) 4(6) -1(2) -1[-12, 10] 4[-7, 14] -4[-13, 4] 
WHR 0(0) -0.07(0.15) -0.22(0.04) -0.22[-0.29, 0.35] -0.07[-0.29, 0.25] 0.05[-10.57, 2.34] 
Fat mass (kg) -0.6(0.8) -0.4(1.0) -2.5(2.9) -2.0[-6.9, 2.9] -0.7[-4.5, 4.9] -2.2[-6.0, 1.7] 
Fat free mass (kg) 0.8(1.1) 0.1(0.2) -1.0(1.9) -1.8[-4.9, 1.4] -0.7[-3.7, 2.3] -1.0[-3.5, 1.4] 
Total body water (kg) 0.6(0.9) 0.2(0.3) -1.9(2.3) -2.5[-6.2, 1.2] -0.4[-4.0, 3.1] -2.1[-5.0, 0.9] 
Table 65. Mean (SD) change in anthropometrics, body composition and blood pressure from baseline to week 
+1 and to week +4 in ITT lapser population by trial arm and mean difference [95% CI] in these between trial arm 
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Change from baseline in: SBS (n=4) 
Week +12 
  Weight (kg) 1.2(2.2) 
BMI (kg/m
2
) 0.45(0.78) 
Systolic BP 1(7) 
Diastolic BP -3(18) 
Waist circumference (cm) -1(4) 
Hip circumference (cm) 0(0) 
WHR 0(0) 
Fat mass (kg) 0.2(2.2) 
Fat free mass (kg) 1.0(0.5) 
Total body water (kg) 0.7(0.4) 
Table 66. Mean (SD) change in 
anthropometrics, body composition and 
blood pressure from baseline to week 
+12 ITT abstainer population by trial arm 
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Table 67. Mean (SD) change in anthropometrics, body composition and blood pressure from baseline to week +12 in ITT 
lapser population by trial arm and mean difference [95% CI] in these between trial arms 
 
Change from baseline in: SBS(n=1) IDAP(n=1) VLCD (n=2) VLCD-SBS IDAP-SBS VLCD-IDAP 
Week +12   
     Weight (kg) 0.0(0.0) 0.0(0.0) -1.2(2.3) -1.2[-4.4, 2.1] 0[-3.0, 3.0] -1.2[-3.6, 1.3] 
BMI (kg/m
2
) 0.00(0.00) 0.00(0.00) -0.5(0.9) -0.45[-1.72, 0.83] 0[-1.18, 1.18] -0.45-1.41, 0.51] 
Systolic BP 0(0) 0(0) -2(5) -2[-9, 4] 0[-6, 6] -2[-7, 3] 
Diastolic BP 0(0) 0(0) 3(6) 3[-6, 12] 0[-8, 8] 3[-3, 9] 
Waist circumference (cm) 0(0) 0(0) 0(0) 
   Hip circumference (cm) 0(0) 0(0) 0(0) 
   WHR 0.00(0.00) 0.00(0.00) 0.00(0.00) 
   Fat mass (kg) 0.0(0.0) 0.0(0.0) 0.8(1.5) 0.8[-1.4, 2.9] 0[-2.0, 2.0] 0.8[-0.9, 2.4] 
Fat free mass (kg) 0.0(0.0) 0.0(0.0) -1.9(3.8) -1.9[-7.3, 3.5] 0[-5.0, 5.0] -1.9[-6.0, 2.2] 
Total body water (kg) 0.0(0.0) 0.0(0.0) -1.8(3.5) -1.8[-6.7, 3.2] 0[-4.6, 4.6] -1.8[-5.5, 2.0] 
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6.2.23. Change disease risk factors from baseline to end of 
treatment in lapsers 
In contrast to completer analysis, the ITT analysis showed that all changes in the 
disease risk factors we measured were of negligible clinical importance (Table 68). It 
was not possible to examine the difference between arms in abstainers because only 
participants in SBS arm maintained abstinence. In the SBS arm the changes from 
baseline here were less than those seen in completer analysis and were minimal 
(0.2mmol rise in blood glucose, a 6% rise in triglycerides, an 8% rise in HDL 
cholesterol and fall of 4% in LDL cholesterol and TC:HDL ratio (Table 69).  
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Change in: SBS  IDAP   VLCD VLCD-SBS IDAP-SBS VLCD-IDAP 
Week +12  
  
   
Glucose (mmol/L) 0.1(0.2) <0.1(0.1) 0.0(0.0) -0.1[-0.3, 0.1] -0.1[-0.2, 0.1] <0.1[-0.2, 0.2] 
Forced Expiratory Volume in 1 sec (FEV1) (L) -0.1(0.14) 0.0(0.0) 0.0(0.0) 0.1[-0.1, 0.2] 0.1[-0.1, 0.2] 0[-0.2. 0.2] 
Forced Vital Capacity (FVC) (L) -0.1(0.2) 0.0(0.0) 0.0(0.0) 0.1[ -0.1, 0.2] 0.6[-0.1, 0.2] 0[-0.2, 0.2] 
C-Reactive Protein (mg/L) -1.2(1.8) -0.7(1.6) 0.0(0.0) -1.2[-1.5, 3.8] 0.5[-1.9, 2.9] 0.7[-2.0, 3.3] 
TC:HDL ratio -0.1(0.3) -0.1(0.3) 0.0(0.0) 0.1[-0.4, 0.6]  <0.1[-0.5, 0.4] 0.1[-0.3, 0.6] 
LDL-cholesterol (mmol/L) <0.1(0.1) 0.0(0.0) 0.0(0.0) <0.1[-0.1, 0.2] <0.1[-0.5, 0.1] 0.1[-0.3, 0.6] 
HDL-cholesterol (mmol/L) 0.1(0.2) 0.1(0.1) 0.0(0.0) -0.1[-0.3, 0.2] <0.0[-0.2, 0.2] -0.1[-0.3, 0.2] 
Total Cholesterol (TC) (mmol/L) -0.1(0.3) 0.0(0.0) 0.0(0.0) <0.1[-0.3, 0.4] <0.1[-0.3, 0.3] 0.0[-0.3, 0.3] 
Triglycerides (mmol/L) 0.1(0.1) <0.1(<0.0) 0.0(0.0) -0.1[-0.2, 0.1] -0.1[-0.2, 0.1] <0.1[-0.1, 0.1] 
WBC (x10
9
/L) 1.3(3.4) -0.2(0.4) 0.0(0.0) -1.3[-5.0, 2.4] -1.5[-4.8, 1.9] -1.3[-3.5, 3.9] 
 
Platelets (x10
9
/L) -4.7(20.3) -14.8(36.3) 0.0(0.0) 4.7[-40.4, 49.7] -10.2[-50.7, 30.3] 14.8[-30.2, 59.9] 
MCV -0.38(0.89) 0.13(0.33) 0.00(0.00) 0.38[-0.64, 1.41] 0.52[-0.41, 1.44] -0.13[-1.16, 0.89] 
HB -0.1(0.1) -0.1(0.2) 0.0(0.0) 0.1[-0.1, 0.8] 0.0[-0.2, 0.2] 0.1[-0.1, 0.3] 
 
   
          
Table 68. Mean Change (SD) in lung function and blood test results from baseline to week +12 in all ITT by trial 
arm and mean difference [95% CI] in these between trial arms 
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Table 69. Mean change (SD) in lung function and blood test results from baseline to week +12 in ITT abstainers and ITT 
lapsers by trial arm 
 
Change in: 
SBS (A) 
(n=4) 
SBS (L)  
(n=2)  
IDAP (L) 
(n=6) 
VLCD(L) 
(n=4) 
Week +12  
 
  
Glucose (mmol/L) 0.2(0.2) 0.0(0.0) <0.1(0.1) 0.0(0.0) 
Forced Expiratory Volume in 1 sec (FEV1) (L) -0.1(0.2) 0.0(0.0) 0.0(0.0) 0.0(0.0) 
Forced Vital Capacity (FVC) (L) -0.1(0.1) 0.0(0.0) 0.0(0.0) 0.0(0.0) 
C-Reactive Protein (mg/L) -1.8(2.1) 0.0(0.0) -0.7(1.6) 0.0(0.0) 
TC:HDL ratio -0.2(0.4) 0.0(0.0) -0.1(0.3) 0.0(0.0) 
LDL-cholesterol (mmol/L) -<0.1(0.1) 0.0(0.0) -0.1(0.1) 0.0(0.0) 
HDL-cholesterol (mmol/L) 0.1(0.3) 0.0(0.0) 0.1(0.1) 0.0(0.0) 
Total Cholesterol (TC) (mmol/L) -0.1(0.4) 0.0(0.0) 0.0(0.0) 0.0(0.0) 
Triglycerides (mmol/L) 0.1(0.1) 0.0(0.0) <0.1(<0.1) 0.0(0.0) 
WBC (x10
9
/L) 1.9(4.2) 0.0(0.0) -0.2(0.4) 0.0(0.0) 
Platelets (x10
9
/L) -7.0(25.8) 0.0(0.0) -14.8(36.3) 0.0(0.0) 
MCV -0.58(1.08) 
0.00(0.00) 0.13(0.33) 
0.00(0.00) 
HB -0.1(0.1) 
0.0(0.0) -0.1(0.2) 
0.0(0.0) 
A=Abstainers 
L=Lapsers 
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6.2.24. Adverse Events 
There were no serious adverse events during the trial. Most adverse events (7) 
occurred in the SBS arm, 5 of which may have been related to NRT use. There 
was one adverse event in the IDAP arm related to NRT and there were 4 adverse 
events in the VLCD arm, 2 of which were related to the VLCD formula (Table 70).   
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Table 70. Adverse Events (AE) during DeMiST 
AE ID visit 
Trial 
arm 
PARTICIPANT 
ID Diagnosis Syndrome Start Date Stop Date Intensity Serious Cause: Study Med? Action taken (study Med) Outcome  
1 +1 2 27 
Sore/heavy/ inflamed arm 
at site of patch 04/06/2010 08/06/2010 moderate No Yes (NRT) Intervention discontinued Recovered 
2 0 3 29 
unable to tolerate 
lipotrim formula 11/06/2010 13/06/2010 mild No Yes (Lipotrim) Intervention discontinued Recovered 
3 +4 1 21 headache 28/07/2010 29/07/2010 moderate No Possibly (NRT) Reduced patch* Recovered 
4 +4 1 21 central chest pain 29/07/2010 29/07/2010 moderate No Possibly (NRT) Reduced patch* Recovered 
5 +4 1 21 nausea 29/07/2010 29/07/2010 mild No Possibly (NRT) Reduced patch* Recovered  
6 +4 1 21 backache 28/07/2010 29/07/2010 moderate No Unlikely None Recovered 
7 +4 1 21 pain in right forearm 28/07/2010 29/07/2010 mild No Unlikely None Recovered 
8 +4 1 21 visual disturbance 28/07/2010 29/07/2010 moderate No Possibly (NRT) Reduced patch* Recovered 
9 +4 1 21 cold sweating /flushing 28/07/2010 29/07/2010 mild No Possibly (NRT) Reduced patch* Recovered 
10 +1 3 31 Headaches 16/09/2010 23/9/2010 mild No Yes (Lipotrim) None Recovered 
11 +2 3 31 Headache & sore throat 26/09/2010 30/9/2010 mild No Unlikely None Recovered 
12 +3 3 31 Flu-like symptoms. 30/09/2010 2/10/2010 mild No Unlikely None Recovered 
*Unlikely related to NRT as been on patches for 4 weeks by this time, no ECG changes. Med = medication 
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6.3. Discussion 
6.3.1. Limitations  
The greatest limitations for our findings came from the small sample size. Firstly, 
randomisation of few participants led to an unequal balance of characteristics in the 
intervention arm, these presented a possible source of confounding. However where 
it was appropriate and possible we adjusted for these; we adjusted for age and 
gender in the analysis of change in weight and fat mass.  Secondly, there was 
insufficient quantitative data to draw conclusions as lack of statistical significance 
may have been due to type two error rather than lack of real effect. Thirdly, although 
some effects did reach statistical and clinical significance the sample was too small to 
be representative of the population as a whole. Fourthly, a larger sample size is 
needed to overcome measurement error. This may have been the case for 
bioelectrical impedence measures of body fat. We used a standard operating 
procedure and trained nurses to standardise measurements and kept participants 
appointment times consistent. However natural variations in body water throughout 
the day or throughout the menstrual cycle may have increased random error. Also, 
the large variability in waist and hip measurements meant we had to discount these.  
 
6.3.2. Summary and interpretation of cigarette cravings 
by trial arm 
We found no evidence that cravings in people on IDAP were different from the 
control group (Stage 1 of SBS). There was however, evidence that VLCD reduced 
cravings by a clinically relevant degree. This is similar to the findings of Danielsson 
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that also showed a reduction in cravings in those on a VLCD (Danielsson et al., 
1999). 
 
We examined whether the effect of the diets on cigarette cravings was mediated by 
food desire and/or food need. Food desire, in particular, increased in the IDAP arm, 
but there was no evidence that either food desire or food need accounted for the 
difference in cigarette cravings between trial arms. Those adhering to the VLCD were 
in ketosis and this may have explained the reduction in cravings in the VLCD arm.  
 
Periods of abstinence were associated with lower cigarette craving scores. 
Abstinence varied by trial arm, but there was no evidence that these differences in 
abstinence accounted for the difference in cigarette cravings seen between trial 
arms.  
 
The best fitting model of cigarette cravings over time was a quadratic function that 
varied by trial arm but this did not capture or explain the dramatic peaks and troughs 
within and between individuals. This variability in withdrawal patterns among 
individuals has previously been reported by Piasecki in 2003. He described and 
mathematically defined „symptomatic volatility‟ to model the deviations of the 
observed data from an individual‟s predicted quadratic model of craving. He 
suggested that it is these peaks which make an individual suceptible to relapse. He 
also showed that lapsing to smoking can result in either a peak or a trough. We also 
saw that abstinence was associated with drop in cigarette craving. We expected the 
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opposite to be true. But as discussed by Piasecki, higher cravings may be associated 
with lapsing, as desire to smoke may become too great to resist, rather than smoking 
reducing desire. In other words the association may have been due to cause rather 
than effect. To explore this further a time lagged model is needed to differentiate 
between cause and effect, investigating whether an increase in craving preceeds 
lasping and whether lapsing leads to a reduction in craving.  
 
To better explore the relationships between lapsing and cigarette craving, food need 
and food desire with cigarette craving we need a more sensitive measure of cigarette 
cravings, food cravings and hunger over time. This could be done using ecological 
momentary assessment (Shiffman et al., 2002), together with a record of when 
cigarettes are smoked. Then, perhaps the most useful way to model these data 
would be a time lagged model on the symptomatic volatility of cigarette cravings. 
 
6.3.3. Summary of and interpretation of smoking status 
by trial arm 
Participants were 4 and 8 times more likely to relapse in the IDAP and VLCD arms 
respectively, than those in the SBS arm.  These values were not statistically 
significant and the small sample size and wide 95% confidence intervals around the 
means makes the findings uncertain.  
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Cravings may predict relapse, data from an observational study (n=1500), where 
smokers enrolled in a smoking cessation trial assessed withdrawal symptoms four 
times a day over the two weeks prior to and two weeks post quit date, showed a 
postive association between mean craving score and relapse (Piper et al, 2011).  So 
our findings that relapse is higher and cravings are lower in the VLCD arm seem 
contradictory, although our study was not powered to detect difference in abstinence 
rates.  
 
6.3.4. Summary and interpretation of physical measures 
by trial arm  
Weight and fat mass reduced in the IDAP arm and increased in the SBS arm. These 
effects lessened as the intervention continued and the SBS arm went into Stage 2. 
The differences between these trial arms were of clinical importance at all time 
points. Reduction in dietary fat intake explained 22% of the reduction in body fat 
mass. 
 
Weight, fat mass and total body water reduced dramatically in the VLCD arm, by four 
weeks post quit there was also evidence of some loss of lean body mass, which is of 
clinical concern. Most lost weight was regained in Stage 2 of the VLCD but weight 
gain was less than in the SBS arm. Fat mass in the VLCD arm exceeded its baseline 
value at 12 weeks post quit date and this gain was greater than in the SBS arm. 
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Subgroup analysis by abstinence status showed that participants who lapsed or 
relapsed to smoking lost greater weight than those who stopped smoking. This is 
consistent with previous cohort studies (O‟Hara et al., 1998) and our own analysis of 
the Oxford Patch data (section 2.4.3) which shows those who relapse to smoking 
return to their smoking weight.  
 
IDAP showed the most promise of a clinically important effect on weight and body fat 
in particular, and this was greatest when given at the time of quitting. The Cochrane 
review also showed that an individually tailored dietary intervention prevented more 
weight gain compared to usual care 12 months, than did a VLCD or general healthy 
eating education (Parsons et al., 2009).  We found IDAP was not associated with any 
adverse events, but people were more likely to relapse to smoking in this arm, 
however our study was inadequately powered to investigate abstinence rates. The 
Cochrane review showed no significant difference in abstinence rates at 12 months 
between those on this type of intervention and usual care, but the sample size from 
which this was calculated was still too small to be certain.   IDAP now needs to be 
compared to usual care in an adequately powered trial to detect long term change in 
body composition and effects on relapse. 
 
6.3.5. Summary and interpretation of disease risk factors 
by trial arm 
There were no data on these parameters in the VLCD arm. We had some on lung 
function in the SBS arm which showed no important change during the trial.  
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By the end of treatment blood glucose rose slightly in both the SBS and IDAP arms. 
In general, cardiovascular risk factors improved in both these arms but more so in the 
IDAP arm. The exception was triglycerides, these fell in the IDAP arm but rose in the 
SBS arm. It was interesting to note that the data from the IDAP arm was from a 
lapsed individual and the data from the SBS arm was from abstainers, but even so, 
parameters improved most in the IDAP arm. The sample was too small to draw 
conclusions. However, it does draw attention to the benefit:risk ratio of smoking 
cessation on short term increase in disease risk factors that were discussed at length 
in the introduction to this thesis. The investigation of which needs further 
investigation with the aim of targeting and reducing these risks in quitting smokers.  
 
6.3.6. Failure to attend and intention to treat analysis  
This trial, as expected from other smoking cessation trials (Marteau et al., 2010), had 
a large proportion of participants not attending their appointments and assumed 
relapsed to smoking. More participants completed the programme in the SBS arm, 
and they were less likely to relapse to smoking although this was an underpowered 
measure. It is possible that the incentive of weight control support at eight weeks, 
after they stopped smoking, helped to keep them motivated and adhering to the 
programme.  Whereas, by then, the other arms already received most of their 
intervention and incentive to return for visits was reduced. 
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High non-attendance rates meant a large number of missing data had to be imputed 
for intention to treat analysis. Although I used BOCF that assumed no effect (i.e. a 
return to smoking and original weight) this did not allow for the possibility of weight 
gain following relapse after a quit attempt. However, available data suggests that this 
is unlikely as „relapsers‟ return to their smoking weight (Lycett et al., 2011a, O‟Hara et 
al., 1998). Not accounting for this worst case scenario may have made the results 
from the ITT analysis appear more favourable than they were. 
 
The ITT analysis provided a similar pattern of results, but with a diluted effect, on 
physical measures compared to completer analysis. Clinically important differences 
in favour of the IDAP and VLCD interventions compared to the SBS arm were found. 
However, changes in disease risk factors were no longer clinically important in the 
ITT analysis. 
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7. SUMMARY OF CONCLUSIONS. 
REFLECTIONS AND FUTURE 
DIRECTION 
I presented many of the findings of this doctoral research and its implication for 
clinical practice and future research as a plenary at the annual UK National 
Smoking Cessation Conference in June 2011 (Appendix 46).  
 
Chapter seven fulfils objective nine of the thesis : to discuss the implications of 
findings from this doctoral research to advance understanding in this field and lead 
to improved clinical practice. 
 
7.1. The Oxford patch cohort analysis 
We began this thesis by discussing the problem of smoking cessation related 
weight gain. We sought to add to current knowledge by investigating long term 
weight gain in a cohort of smokers and abstainers where abstinence was 
biochemically validated and continuous over eight years. We then investigated the 
baseline characteristics associated with this weight gain. Key points are 
summarised in Table 71 with respect to what was already known at the start of our 
research, what our research has added and reflections on what this means for 
public health, clinical practice and further research. Further detail is discussed in 
the text below. 
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We found that smokers who quit smoking gain, over eight years, 7kg more than if 
they had continued to smoke, while those who quit for a substantial period and 
then resume smoking seem to resume their „smoking weight‟. We were the first 
researchers to find a J-shaped relation between baseline BMI and weight gain in 
quitters.  We also found evidence to suggest that moderate alcohol consumption 
at the time of quitting is associated with less weight gain in quitters over eight 
years. A complex relationship exists between alcohol consumption and weight 
gain and this has long been a source of controversy, so far it has rarely been 
explored in quitting smokers.  
 
Our cohort included well-defined continuous abstainers, over a full eight years, 
however this group of abstainers was relatively small (n=85) and did not measure 
all potential confounders. Therefore, further studies are needed to confirm our 
findings, but if these are confirmed, they have important implications for the 
management of weight during smoking cessation, in particular to identify those 
individuals who are at most risk and at most need of weight control interventions.  
 
From a personal point of view, this cohort analysis helped me develop my skills in 
multiple regression analysis and I learnt to identify the strengths and limitations of 
our data. This was helped by the peer review process when I submitted these 
findings for publication and had to justify the value of my findings despite 
limitations of a high level of attrition, some self reported data and unmeasured 
confounders. All these things I will consider in designing future studies. 
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Area of 
investigation 
Previous Evidence Our method Our contribution to further 
evidence 
Implications for further research  Implications for public 
health/clinical practice  
Risks of post 
cessation weight 
gain 
Some of the benefit of 
smoking cessation such as 
reduced decline in lung 
function, is offset by 
weight gained 
Literature review Several large prospective 
cohort studies show that the 
risk of type two diabetes 
during the first five years of 
quitting exceeds that of 
continuing smokers. 
 
Full systematic review and meta-
analysis of these studies is 
required to quantify the risk of 
diabetes during the years after 
quitting smoking 
Quitting smokers may benefit 
from screening for diabetes 
during this time. 
Extent of post 
cessation weight 
gain 
5kg at one year post 
cessation, 8-9 at four and 
five years post cessation  
Oxford Cohort 
analysis 
9kg at eight years post 
cessation.  Large standard 
deviations of our estimates 
show variable weight gain. 
 
2kg gain in continuing 
smokers, which is similar to 
relapsed smokers over this 
time. 
 
Only 25% of those who quit 
remain a healthy weight 8 
years later. 
 
Further long term prospective 
cohort studies are needed with 
comparison to the continuing 
and never smoking population 
to further determine the extent 
and duration of post cessation 
weight gain  
Mean weight gain over 8 years 
is 7kg above continuing 
smokers, for some it is a lot 
more.  
 
Those who quit smoking are a 
population at risk of 
accelerated weight gain 
Association of 
baseline BMI with 
post cessation 
weight gain 
Evidence is inconclusive  Oxford Cohort 
analysis 
We showed for the first time 
a J shaped relation between 
baseline BMI and weight gain 
which may account for some 
previous inconsistencies. 
 
Confirmatory analysis needed in 
a larger cohort, with more 
potential confounders measured 
and adjusted for. 
If confirmed those who are 
already obese,  should be 
targeted for interventions to 
prevent further weight gain on 
smoking cessation 
Association of 
baseline alcohol 
consumption with 
post cessation 
weight gain 
One study showed weight 
gain is greater at 5 years 
with lower baseline alcohol 
consumption 
Oxford Cohort 
analysis 
Higher baseline alcohol 
consumption is associated 
with less weight gain at eight 
years. 
Confirmatory analysis needed in 
a larger cohort, with more 
potential confounders measured 
and adjusted for. 
If confirmed advice to avoid 
alcohol during smoking 
cessation may need to be 
revised for those at greatest 
risk of weight gain.  
 
Or non drinkers may need to 
be targeted for weight gain 
prevention strategies. 
Table 71. Summary of findings and academic contribution from the analysis of the Oxford patch data 
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7.2. The DeMiST trial 
We considered how we could add to the evidence base to advance clinical 
practice to prevent or treat post cessation weight gain. The Cochrane review 
(Parsons et al., 2009) showed evidence that two separate dietary strategies may 
prevent weight gain and not reduce abstinence and may even increase it. The 
interventions were an individualised dietary and physical activity plan (IDAP) and a 
very low calorie diet (VLCD). We therefore designed a three armed randomised 
controlled feasibility trial comparing these interventions to usual care within NHS 
stop smoking clinics. To do this we used a variety of research methods to answer 
a number of questions. Key aspects of our findings on feasibility, process 
measures and clinical outcomes, and how these contribute to the current evidence 
are summarised in Table 72, Table 73 and Table 74 respectively with some further 
detail described below. 
  
7.2.1. Acceptability  
To investigate the acceptability of the trial to participants we measured response 
and recruitment rates. We found that using a VLCD excluded many potential 
participants. We demonstrated that it is difficult to recruit into a trial which offers 
help to control weight together with smoking cessation, from GP practices and 
advertisement by fliers in newspapers. We were recruiting in an area with access 
to free smoking cessation services, so many of those keen to have stop smoking 
support may have already done so. It may also be that people are not keen to 
tackle weight control and smoking cessation together. 
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Our plan is to move to a full scale trial of the IDAP intervention for weight control 
versus usual care during smoking cessation. To improve recruitment we plan to 
recruit from a population who are already enrolled in an NHS stop smoking 
service. A recent trial in Scotland did so and recruited 90% of smokers entering 
the service into a trial to prevent weight gain through education about healthy 
eating (Hankey et al., 2010).   
 
We carried out qualitative interviews to understand participants‟ views of the 
interventions and trial design. Reasons for acceptability of the IDAP arm seemed 
to be a conservative approach to weight loss, whereas in the SBS lack of 
acceptability was because participants wanted a weight control intervention 
sooner than offered in the control arm.  Participants attracted to this kind of trial 
were not persuaded that tackling this „step by step‟ was appropriate. Acceptability 
seemed also to depend on whether the allocated intervention met participants‟ 
individual needs rather that the inherent properties of a particular trial arm.  
However, our conclusions are tentative as we were unable to meet our purposive 
sample. Nevertheless there are several ways we could incorporate meeting 
participants‟ needs within our future trial design to test these findings. We could 
run a pragmatic trial where participants are randomised into control or a pragmatic 
intervention arm in which participants are offered one of several strategies from 
which to choose and/or swap between. However, this still leaves us with a control 
arm which some might find unacceptable.  We could run a preference trial, where 
participants without preference are randomised into control or intervention and 
those with a preference are allowed to choose.  However, systematic review 
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evidence shows that this does not improve retention within an intervention, 
although it may improve recruitment rates at the outset (King et al., 2005).  
 
We also asked participants prior to randomisation which intervention they thought 
would be most successful. We found no evidence that those who got the 
intervention they believed in followed the programme for longer than those who 
did not. Aside from the small sample, this evidence is clouded because our 
question did not assess whether this was a general belief about the efficacy of the 
intervention in a population, or whether it was a belief that it would work for them 
personally.  
 
Further investigations of ways to improve retention in behavioural treatment 
programmes are needed. One way might be to counsel participants to deal with 
difficulties and disappointments that might arise during a clinical trial. 
 
During the exploration of acceptability, I developed skills in semi-structured 
interview techniques and learnt that there is a fine balance between insufficient 
probing which can lead to false assumption, and too much probing which can 
sway participants‟ opinion. The complexity of analysing qualitative data with its 
many levels of meaning and interlinking themes has reminded me of the necessity 
to keep to a clearly focused research question.  
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7.2.2. Feasibility 
Fidelity checks within clinics showed that nurses were competent to run the trial 
and deliver the clinical interventions according to the protocol. We have therefore 
demonstrated that we were able to train nurses to provide these specialist dietary 
interventions within NHS stop smoking clinics. The nurses debriefing session and 
fidelity checks provided suggestions to increase nurses‟ confidence in delivering 
the interventions and to streamline the practicalities of the full scale trial. In 
particular, we will reduce the number of clinical parameters measured. The nurses 
found some of these clinical measures difficult. Although they performed them 
adequately, the complexity undermined their confidence in their work. In a phase 
three trial, where less supervision is likely, there is the potential that this lack of 
confidence could lead to stress and reduced competence.     
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Area of 
investigation 
Previous Evidence Our method Our contribution to further 
evidence 
Implications for further research  Implications for public 
health/clinical practice  
Recruitment to a 
stop smoking and 
weight control trial 
through invitations 
from GPs 
When we began our 
research this has not been 
tried in an NHS setting 
Demist feasibility 
trial 
Recruitment to such a trial 
through invitation via GP 
practices is difficult  
 
 
We should try recruiting those 
already enrolled in the stop 
smoking services 
If recruitment continues to be 
unsuccessful, we may need to 
question whether there is a 
real need for the development 
and provision of a service 
which combines smoking 
cessation and weight control. 
Acceptability of 
randomisation into 
SBS 
Preference trials have 
shown recruitment can be 
increased if individuals are 
given a choice although 
there is little effect seen on 
attrition. 
Demist feasibility 
trial 
Despite attempts to appease 
those in the control group 
with belated dietary 
intervention participants still 
found randomisation to the 
control arm unacceptable. 
Although there was no 
evidence to suggest that 
those randomised to the 
control arm left the 
programme earlier than the 
other arms.  
 
Further research should 
consider ways to help 
participants prepare for  
difficulties and disappointments 
within clinical trials in order to 
improve retention in these 
 
 
Feasibility of a 
VLCD for quitting 
smokers 
One trial showed a VLCD 
was feasible for us in this 
population in a research 
setting 
Demist feasibility 
trial 
VLCD was not a practical 
option for use in typical NHS 
stop smoking services 
Alternative ketogenic diets could 
be explored 
 
It is unlikely that VLCDs will 
form standard care for 
preventing smoking cessation 
related weight gain.  
Feasibility of 
delivery of IDAP by 
stop smoking 
nurses 
When we began our 
research this has not been 
tried in an NHS setting 
Demist feasibility 
trial 
This was feasible This model could now be trialed  
on a larger scale.  
 
Table 72. Feasibility Findings from DeMiST and their contribution to current evidence
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7.2.3. Process measures 
7.2.3.1. The Healthy Choice Index (HCI) 
We developed the healthy choice index and assessed its validity against a seven 
day food diary where food quantity was estimated but not weighed. We measured 
the limits of agreement for nutrient intake. We found that while the HCI was a 
useful prompt for setting dietary goals within the IDAP intervention it was not a 
valid measure of nutrient intake. The one exception to this was total fat, where it 
was able to distinguish between low, medium and high intakes. Our results 
showed that a fall by one category of fat intake over 12 weeks was associated with 
a decrease in body fat mass of 1.0kg. This explained 22% of the reduction in body 
fat seen in the IDAP arm. 
 
 
The assessment of dietary fat was based on more questions than any of the other 
nutrients which may have influenced the validity of this measure. Future efforts 
should focus on refining the questions in the HCI to improve sensitivity to detect 
change in the other nutrients. It could then be used in an adequately powered 
sample to test its validity. Before it can be used as a full nutrient assessment tool 
within clinical trials, investigating its repeatability and sensitivity to dietary change 
associated with a change in clinical outcomes is also needed. 
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7.2.3.2. The Hunger and Craving Score (HCS) 
We designed the HCS to capture two different motivations to eat, that resulting 
from a homeostatic response to lack of food and the more hedonistic food craving. 
There have been independent measures of hunger and cravings developed before 
(section 3.1.2). Also, laboratory experiments have measured „implicit wanting‟ and 
„explicit liking‟ as a response to food cues before and after test meals (Finlayson et 
al., 2008). However, we know of no questionnaire to distinguish between these 
two motivations in free living conditions.  
 
We carried out principal components analysis on our HCS to reduce our data for 
further analysis. We found that we could distinguish between a craving for fatty 
and sugary food and desire for healthy food, but that the item measuring hunger 
could be perceived as either.  We found no evidence that either of these 
motivations to eat was associated with urge to smoke, but we cannot be sure that 
this did not arise from the limitations of our questionnaire.  
 
More work on this is needed to better differentiate between hunger and food 
craving. A new good starting point would be a qualitative study to understand how 
people conceptualise and express notions of craving or desire for food, in contrast 
to more physiological notions of hunger.  It would have value in investigating not 
only hunger and food cravings during smoking cessation, but also their role in 
obesity development. 
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Area of investigation Previous Evidence Our method Our contribution to further evidence Implications for further research  
 
Hunger and food craving 
in quitting smokers 
No questionnaire available to 
distinguish between food need 
and food craving in the usual living 
conditions 
 
 
Laboratory studies showed that 
hunger may increase cravings for 
cigarettes 
Development of 
Hunger Craving Score 
(HCS) 
It was possible to distinguish between two 
motivations to eat using a questionnaire, but the 
nature of ‘hunger’ was still unclear 
 
Despite cigarette cravings and food craving being 
different between trial arms we found no evidence 
that desire for food mediated cravings for cigarettes 
 
There was considerable overlap of these 
motivations which require further 
exploration before these can be measured 
accurately.  
 
This was a process measure which needs 
confirmation in a larger trial 
Dietary change in 
quitting smokers 
There was no validated tool which 
can be used to assess diet and 
prompt  dietary change in clinical 
practice 
Development of 
Healthy Choice Index 
(HCI) 
The HCI was validated for assessing high, medium 
and low intakes of dietary fat, but not of other 
nutrients. 
 
Change in fat as calculated by the HCI partially 
accounted for reduction in fat mass in the IDAP arm 
 
The nurses found it a useful tool to initiate 
discussion regarding dietary behaviour change 
 
This tool needs revision and further 
investigation of its validity as a dietary 
assessment tool. 
 
 
Its role in helping to prompt and monitor 
change in fat intake needs to be confirmed. 
Table 73. Findings of the investigation of process measures in DeMiST their implication for further research 
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7.3.1. Effects of trial arms on urges to smoke 
We found no evidence that IDAP reduced cravings compared with control (Stage 1 
of SBS) but there was evidence that the VLCD, in which adherent participants 
were ketotic, reduced cravings by a score of one on the MPSS similar to previous 
findings (Danielsson et al., 1998). However, our modelling did not capture or 
explain the dramatic peaks and troughs within and between individuals, which 
may be the most likely cause of relapsing (Piasecki et al., 2003). Also it was not a 
time lagged model to allow us to investigate whether hunger clearly preceeded 
uges to smoke. Our daily measures were also not frequent enough to capture a 
variation in urges over the course of a day. This could be investigated in future 
studies using ecological momentary assessment (Shiffman et al., 2002). 
 
Analysis of our repeated measures data in DeMiST developed my skill and 
confidence in multilevel modelling.  
 
7.3.2. Effects of trial arms on relapse 
Participants were four and eight times more likely to relapse in the IDAP and 
VLCD arms respectively, than those in the SBS arm, but our sample size was too 
small for us to be certain. If cravings predict relpase (Piper at al., 2011) this finding 
does not support our findings or those of Danielsson et al. (1998) that cravings are 
reduced on a VLCD.  The Cochrane review (Parsons et al, 2009) also showed that 
abstinence rates were not statistically significantly worse in an individualised 
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dietary intervention compared to usual care, and abstinence rates were better in 
those receiving a VLCD than a control condition.  
7.3.3. Effects of trial arms on smoking cessation related 
weight gain  
Completer analysis of all those attempting to quit showed weight and fat mass 
reduced in the IDAP arm and increased in the SBS arm. These effects lessened 
as the intervention continued, and the SBS arm went into Stage 2, and received 
their dietary advice. The differences between these trial arms were of clinical 
importance at all time points. Intention to treat analysis showed a similar pattern 
but the differences were smaller.  
 
In those achieving four week continuous abstinence weight rose in the SBS arm 
by 1.1(0.8)kg, this is comparable with weight gain of 1.3kg at four weeks shown by 
meta-analysis of those in control arms of smoking cessation trials (Aubin et al., 
unpublished). By contrast weight fell by 2.8kg in the IDAP arm but this was based 
on one individual.  Two studies have weight data at four weeks in continuous 
abstainers who were given individualised dietary advice, one showed weight 
increased by 0.6(1.6)kg (n=72) (Perkins et al, 2001) and the other showed virtually 
no mean weight increase 0.08(2.4)kg (n=26) (Hall et al., 1992). However, the 
standard deviations for these means were large indicating a wide variability, so 
with more people we may find that mean weight loss in IDAP is not quite so big. 
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There were no continuous abstainers in the VLCD arm at four weeks, but during 
this time participants had quit and lapsed. Overall weight loss was dramatic. 
However, there was some evidence of loss of lean body mass by four weeks and 
excessive gain in body fat by 12 weeks, which is of clinical concern, but our 
sample was too small to be conclusive. Many other studies, in the general 
population, have investigated changes in body composition on a VLCD and these 
have been reassuring (COMA, 1987).  However Danielsson et al. (1998) carried 
out the only trial using a VLCD in quitting smokers and they not measure changes 
in body composition. So more research is needed if a VLCD is to be pursued for 
quitting smokers. However, because of the reasons summarised in the next 
section we do not feel this is a feasible option within typical NHS stop smoking 
services. 
 
We did not have enough abstainers at the end of twelve weeks to compare 
changes in body composition by trial arm. 
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Area of investigation Previous Evidence Our method Our contribution to further evidence Implications for further research  
 
Effect of intervention on 
weight control 
Individual tailored advice  and a 
VLCD looked most promising 
Demist feasibility trial VLCD may have unfavorable changes 
on body composition in this 
population. 
IDAP continues to look promising 
IDAP needs to be trialed on a larger scale in 
comparison to usual care to determine its long term 
effect on weight gain in this population. 
 
Changes in body composition in quitting smokers 
need to be investigated further before a VLCD can 
be recommended in clinical practice 
 
On cigarette cravings VLCD looked promising Demist feasibility trial Cravings reduced in the VLCD arm 
compared to the control but were no 
different between the IDAP and SBS 
arm 
 
See above 
On relapse to smoking VLCD looked promising, individual 
tailored advice looked neutral, 
general healthy eating education 
was identified as potentially 
problematic. 
Demist feasibility trial Those in the SBS arm were least likely 
to relapse, those in the VLCD arm 
were most likely to relapse 
A trial large enough to test the equivalence of IDAP 
compared to usual care on smoking rates is needed. 
 
The evidence from the Danielsson trial (Danielsson 
et al., 1998) of reduced abstinence still stands as our 
trial was so small however the effects on body 
composition would need to be investigated before 
recommendations could be made 
Table 74. Effects of DeMiST interventions on clinical outcomes and the implication for further research 
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7.3.4. What DeMiST means for clinical practice and 
future research  
The sample was too small to draw firm conclusions for clinical practice. However, 
the value of VLCD use within NHS stop smoking clinics appears to be limited for 
several reasons. Firstly, only half of those randomised to the VLCD were able to 
adhere to it. Secondly, adverse events related to the VLCD were reported. Thirdly, 
lean body tissue reduced and fat mass increased beyond that of the control. 
Fourthly, the VLCD contraindications, including necessary monitoring which fell 
outside of the scope of stop smoking clinics, limited recruitment. This translates to 
its limited suitability as a treatment option for quitting smokers. We are therefore 
not keen to pursue further research of a VLCD within this population. However, the 
reduction in mean craving score found here, similar to those in the Danielsson 
study, cited in the Cochrane review (Parsons, 2009), should not be overlooked. It 
may be that there is a more practical, food based, ketogenic diet with the potential 
to reduce cigarette cravings, and we are keen to explore further. 
 
IDAP showed the most promise at promoting weight loss in abstainers. Cravings 
in these individuals were no worse than those who were not actively trying to diet 
in the SBS arm. This goes a little way to alleviate concerns based on laboratory 
studies that dietary restriction leads to an increase in cigarette cravings. However, 
none of the individuals in the IDAP arm achieved 12 week abstinence; and it is not 
possible to tell whether this was an artifact of a small sample or an effect of 
dieting. Qualitative data showed that this was the least resisted arm of the trial. 
The Cochrane review (Parsons et al, 2009) also showed an individually tailored 
approach, with an energy prescription, was effective at preventing weight gain. It 
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also showed that this approach did not significantly reduce abstinence rates at 12 
months, although the estimate was too imprecise to be sure that there is not a 
substantial harmful effect. We are now planning a large equivalence trial to 
investigate the long term effects of IDAP on smoking cessation related weight gain 
to determine whether abstinence rates in IDAP are equivalent to those in usual 
care. 
 
In the meantime how should smoking cessation related weight gain be tackled in 
routine clinical practice? In the 2010 national survey of stop smoking advisors 
(n=484), we asked advisors what advice they give clients regarding preventing 
weight gain. Seventy-six percent reported they encourage healthy food choices 
(Appendix 47). Therefore, education about healthy eating is currently prevalent in 
practice, but it is not supported by evidence. We offered general healthy eating 
messages to those in the SBS arm, but they felt disgruntled and it did not prevent 
weight gain. The Cochrane review showed general healthy eating advice was 
ineffective in preventing weight gain and suggested that such an approach 
reduced abstinence. So, it seems prudent to discourage this practice. 
 
For now, we advocate that smoking cessation advisors encourage patients not to 
embark on a dietary strategy to control weight until a quit attempt is established. 
Advisors can be reassured that there is no clear evidence, from a review of the 
literature, that allowing some weight gain will lead to relapse. However, given the 
evidence that this weight gain was unacceptable to some there is a need to be 
pragmatic.  We would recommend quitting smokers who are keen to control their 
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weight follow the individually tailored dietary advice with an energy prescription. 
Many NHS dietitians currently provide this as a treatment for obesity. It appears 
the most promising and least likely to cause harm when quitting smoking. For now, 
the most expedient way is for a quitter to attend a weight loss service. In the 
future, if abstinence rates prove to be equivalent, stop smoking services could be 
trained to provide this dietary treatment as part of usual care. An alternative model 
is for weight management services to provide smoking cessation support. It need 
not only be an option for the weight concerned, but for all individuals as this weight 
gain attenuates some of the benefits of stopping smoking and may increase 
diabetes risk in the medium term. 
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